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Abstract 
This thesis is divided into two chapters, describing two organic chemistry projects, both 
born from fundamentally different motivations. The main part of this work was application-
driven research, in which a specific “real-world”-problem was approached, targeting a goal 
with a direct impact on our society. In the contrary, the second chapter describes a curiosity-
driven project, based on a simple idea not having a direct application for society that is 
obvious. 
In Chapter 1 the stereoselective total synthesis of the antibiotic, fidaxomicin, is described. 
The chapter starts with an introduction about the history and origin of antibiotics, and the 
increasing threat of multidrug-resistant pathogens. The promising bioactivity of fidaxomicin 
against many pathogens and the shortcomings of the natural product as therapeutic make the 
natural product an interesting synthetic target. The goal of this project was the development of 
a new antibiotic, based on the fidaxomicin lead structure, with improved pharmacological 
profile. Synthetically, six main fragments were prepared and assembled in the end-game, 
leading to a highly convergent and flexible route, required for prospective structure-activity 
relationship studies. The key features of the total synthesis were the first ever β-selective 
noviosylation, a Suzuki cross-coupling of sterically demanding substrates, a ring-closing 
metathesis and a challenging, β-selective rhamnosylation. Furthermore, semisynthetic studies 
were performed, intercepting a late-stage intermediate of the total synthesis. The synthetic 
route is currently used to produce diverse analogues of fidaxomicin for biological evaluation 
in our group.  
 
The genesis of the project in Chapter 2 was created from the idea, to apply methionine 
derivatives as precursors for 1,3-oxazines, making use of the thioether as triggerable leaving 
group. In the course of the studies, the focus of the project changed as we discovered a novel 
methodology for the preparation of isolable iminium lactones from methionine. The synthetic 
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VI   
utility of the methionine-derived iminium lactones as electrophiles was explored. Despite the 
interesting features of the transformation that may find its use in the synthesis of unnatural 
amino acids and peptidomimetics, the method has a major drawback that the cyclisation leads 
to racemic products. To make synthetic use of the methionine-derived iminium lactones, 
future studies will have to address this issue. 
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Zusammenfassung 
Die hier vorliegende Doktorarbeit ist in zwei Kapitel unterteilt, beide beschreiben ein 
organisch chemisches Projekt, denen jedoch eine unterschiedliche Motivation zugrunde liegt. 
Der Hauptteil dieser Arbeit umfasste eine anwendungsorientierte Forschung, in der ein 
spezifisches Problem aus der “realen Welt” angegangen wurde, mit einer direkten 
Auswirkung auf unsere Gesellschaft. Im zweiten Kapitel hingegen ist ein Projekt beschrieben, 
welches von Neugier getrieben war und auf einer einfachen Idee basierte ohne, dass eine 
direkte Anwendung im Vordergrund gestanden hätte.  
In Kapitel 1 ist die erste, stereoselektive Totalsynthese des Antibiotikums, Fidaxomicin 
beschrieben. Das Kapitel beginnt mit einer Einleitung über die Geschichte und Herkunft von 
Antibiotika und die immer grösser werdende Gefahr die von multiresistenten Pathogenen 
ausgeht. Fidaxomicins vielversprechende biologische Aktivität gegen verschiedene 
Pathogene, sowie dessen ausbaufähigen Eigenschaften als Therapeutikum, machen den 
Naturstoff zu einem attraktiven Syntheseobjekt. Das Ziel dieses Projekts war die Entwicklung 
eines neuen Antibiotikums mit verbessertem pharmakologischen Profil basierend auf der 
Fidaxomicin Grundstruktur. Unsere Totalsynthese begann mit der Herstellung von sechs 
Hauptfragmenten die in der Endphase zusammengesetzt wurden, was zu der notwendigen, 
höchst konvergenten und flexiblen Route für künftige Struktur-Aktivitätsbeziehungs Studien 
führte. Die Schlüsselelemente der Synthese waren die erste β-selektive Noviosylierung, eine 
Suzuki Kreuzkupplung sterisch gehinderter Substrate, eine Ringschlussmetathese und die 
anspruchsvolle β-selektive Rhamnosylierung. Weiter wurden semisynthetische Studien 
durchgeführt die Zugang zu einem späten Intermediat der Totalsynthese erlaubten. Unsere 
Route wird momentan für die Herstellung unterschiedlichster Fidaxomicin Analoge 
verwendet, um sie dann auf ihre biologische Aktivität zu prüfen. 
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Der Anstoß zum Projekt im Kapitel 2 war die Idee, Methionin Derivate als 
Ausgangsmaterial für die Herstellung von 1,3-Oxazinen zu verwenden, dabei sollte der 
Thioether als aktivierbare Abgangsgruppe dienen. Während unseren Untersuchungen änderte 
sich der Fokus des Projekts als wir eine neue Methode, um stabile Iminiumlactone aus 
Methionin herzustellen, entdeckten. In der Folge untersuchten wir den synthetischen Nutzen 
der Methionin abgeleiteten Iminiumlactone als Elektrophile. Die gefundene Transformation 
könnte ihre Anwendung in der Synthese unnatürlicher Aminosäuren und Peptidomimetika 
finden. Allerdings hat die Methode den Nachteil während der Zyklisierung zu razemischen 
Produkten zu führen. Der Herausforderung, eine enantioselektive Variante zu entwickeln, 
werden sich künftige Studien stellen müssen. 
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 General Introduction  1 
General Introduction  
Generally, there are two fundamental scientific approaches that thrive science; application-
driven and curiosity-driven research.1 The motivation of application-driven science is a 
defined goal with a concrete utility, having immediate impact for economy and society. 
Curiosity-driven science (also referred as basic or blue skies research) stands in contrast to 
applied science, in that it does not have a defined goal with a specific utility. The uncertainty 
of the output and significance of such projects is expressed in the difficulty to find financial 
support for basic research. The funding of application-driven projects is comprehensibly 
easier, as the output is measurable and a return of investment is anticipated. This leads to the 
pressure to formulate a defined goal, even if a project is purely curiosity-driven at the core.1a 
That aspect is highly controversial. In fact, Prof. Dr. Dieter Seebach’s seminars are often 
covering the conflict between curiosity-driven science and the pressures of the current model 
of publication and funding, which are followed by extensive discussions among scientists. 2 
During my doctoral studies I was involved in two projects, each covering one of the above-
mentioned scientific approaches. In Chapter 1, an application-driven project is described, in 
which we aimed for a new antibiotic to act against the increasing threat of drug-resistant 
pathogens. Antibacterial research was neglected by the free market in the last decades and, 
thus, has become a task for academia. In the second Chapter, a curiosity-driven project was 
approached. At the outset, a purely chemical question was formulated and the project came 
without boundaries. Throughout the studies, an interesting observation shifted our attention 
from the original idea to another, which led to the discovery of a new chemical methodology. 
 
 
 
 
                                                
1  a) B. Linden, J. Biomed. Discov. Collab. 2008, 3, 3; b) P. Balaram, Curr. Sci. 1999, 76, 5–6. 
2 http://inspiringchemistry.reaxys.com/conference2014; accessed: 16.01.2015. 
2   
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1 Total Synthesis of the Antibiotic Fidaxomicin 
1.1 Introduction 
1.1.1 The Antibiotic and the Post-Antibiotic Era 
With the discovery of the antibiotics a new era in medicine began.3 Salvarsan, an arsenic 
compound, was one of the first modern chemotherapeutic agents against syphilis, but suffered 
from difficult administration (air-sensitivity) and severe side effects (Figure 1.1). The 
breakthrough came with the discovery of penicillin (1928, Fleming) and prontosil (1932, 
Domagk), which had much less side-effects. Suddenly, many live threatening bacterial 
infections became curable.4 As a cut with a knife could become a doom due to inflammation, 
it turned that seemingly all bacterial diseases could be defeated. Not least, owing to the 
discovery and development of antibiotics, the life expectancy of humankind increased 
dramatically after World War II.  
      
Figure 1.1: Left: Alexander Fleming the godfather of penicillin. Right: The first marketed antibiotics. 
The huge significance and demand of antibiotics encouraged industrial and academic 
laboratories to discover new antibiotics. As a consequence, a gold rush in antibiotic 
development took place in the following years and decades. Drugs like streptomycin (1944), 
erythromycin (1952), isoniazid (1950`s), tetracycline (1955), vancomycin (1955), 
metronidazole (1960), doxycycline (1966), rifampicin (1967) and ciprofloxacin (1987) are 
                                                
3  A. Fleming, Brit. J. Exp. Pathol. 1929, 10, 226. 
4  J. Li, E. J. Corey, Drug Discovery, John Wiley & Sons, 2013. 
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only a few antibiotics on the WHO model list of essential medicines, which rose from this 
period.5 
Bacteria are the oldest, simplest and most successful live form on our planet and owing to 
their high plasticity, it is not surprising that these microorganisms evolved resistance to our 
antibiotics. Alexander Fleming predicted already in 1948 that no antibiotic would ever be able 
to compete with the power of evolution.6 This phenomenon has been recognized very soon 
after introduction of antibiotic therapy. The first drug resistant strains emerged from hospitals 
– e.g. sulphonamide resistant Streptococcus pyogenes in the 30’s and penicillin resistant 
Staphylococcus aureus in the 40’s.6 It was not until the 50’s that the first multiple drug 
resistant (MDR) bacteria were found, and physicians were faced with a novel, severe 
problem. Ignoring these alarming signs, antimicrobial resistance was enhanced through 
expanding misuse of antibiotics in humans, food animals and crop protection. Nowadays, the 
situation has become a global concern not only in hospitals but also in the society. In the 
WHO report on antimicrobial resistance in 2014, therapeutics with critical levels of 
effectiveness were identified.7 Among the concerned infections are common pathogens like 
Mycobacterium tuberculosis (TB), Plasmodium falciparum (malaria), methicillin resistant 
staphylococcus aureus8 (MRSA) or Escherichia coli9. The swissnoso10 estimated that 70`000 
drug resistant infections cause about 2000 deaths per year in swiss hospitals.11 In the US, the 
FDA stated two million infections of which 99`000 were deadly in 2002.11 Keiji Fukuda 
(assistant director general health security, WHO) paints a dark picture, of a future threatened 
by “a post-antibiotic era – in which common infections and minor injuries can kill”.7 
                                                
5  World Health Organization, 19th WHO Model List of Essential Medicines 2015, April. 
6 a) M. Barber, M. Rozwadowska-Dowzenko, The Lancet 1948, 641–644. b) S. B. Levy, The Lancet 1982, 83–
88. c) S. B. Levy, B. Marshall, Nat. Med. 2004, 10, 122–129. 
7  World Health Organization, Antimicrobial Resistance: Global Report on Surveillance 2014.  
8  MRSA is a main issue in surgery as staphylococcus aureus is the most common cause of postoperative 
wound infections. 
9  E. coli is the most common cause for bloodstream and urinary tract infections as well as foodborne 
infections. 
10  Swissnoso is a group of Swiss medical doctors in leader positions at hospitals and at the Swiss federal agency 
of health (BAG). 
11  S. Gross, Trendwende bei Antibiotikaforschung, in: Tages Anzeiger 2014, Dez. 03. 
 Total Synthesis of the Antibiotic Fidaxomicin  5 
After the golden age of antibiotic drug discovery, the numbers of approved antibiotic 
pharmaceuticals decreased remarkably (Figure 1.2). 12  Many pharmaceutical companies 
ceased their investigations on antibiotic drug development during the 90’s. This is in stark 
contrast to the above-mentioned increasing threat of resistant bacteria strains. The question 
rises why there is such an imbalance between supply and demand. One reason is that research 
on antibiotics is not profitable anymore. Marijn Dekkers from Bayer stated in an interview 
with “Der Spiegel” that a new antibiotic would need to be around six times more expensive 
than an existing one, to have economical relevance.13 In addition, novel anti-infective agents 
should be used as little as possible to prevent resistance and to keep them as a reserve for 
patients suffering from drug resistant pathogens.  
 
Figure 1.2: Approved systemic antibiotics by the US Food and Drug Administration in the recent years.12 
These reasons are preventing profit-oriented institutions to invest in this field. Hence, there 
is an increasing call for political stimulation of antibiotic development. In this context, 
Piddock et al. assessed funding, promoting antibiotic research in the UK,14 and found that 
0.7% (95 million £) of research funding available, was awarded to antibiotic research. 
Compared with the importance and urgency of the global problematic, this is a seemingly 
small amount. To approach the increasing threat, the US launched the so-called GAIN 
                                                
12  H. W. Boucher, G. H. Talbot, D. K. Benjamin, J. Bradley, R. J. Guidos, R. N. Jones, B. E. Murray, R. A. 
Bonomo, D. Gilbert, Clin. Infect. Dis. 2013, 56, 1685. 
13  C. Pauly, F. Dohmen Der Spiegel 2015, 22, 74-76. 
14  E. C. Bragginton, L. J. V. Piddock, The Lancet Infectious Diseases 2014, 14, 857–868. 
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(Generating Antibiotic Incentives Now) programme in 2012, which secures to new antibiotics 
a five-year market restriction of drugs with the same profile. In addition, the FDA approval of 
such pharmaceuticals will be accelerated.11 This topic was also discussed at the G-7 meeting 
in Elmau 2015 and it was agreed to stimulate fundamental research and the development of 
antimicrobials.15 Moreover, the EU has announced that the issue should play a prominent role 
in the agenda of 2016.16  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                
15  Annex to the Leader’s Declaration of G7 Summit 2015, Jun. 06, 1-15. 
16  K. M. Smolka, Wenn kein Antibiotikum mehr hilft in: Frankfurter Allgemeine Zeitung 2015, Sept. 07, 22. 
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1.1.2 Antibiotics – Origin and Development 
Most of the antibiotics available are natural products or natural product derived 
molecules.4 However, the pioneers under the antibiotics were fully synthetic and simple 
compounds. One of the first antibiotics arose from the dye industry. Paul Ehrlich’s search for 
the “magic bullet” 17  together with the company Bertheim, brought up a range of 
organoarsenic compounds, one of which was salvarsan, the first therapeutic against syphilis 
(Figure 1.3). 
 
Figure 1.3: Fully synthetic antibiotics. 
                                                
17  With the magic bullet Paul Ehrlich meant chemical compounds capable to combat pathogens. 
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The sulfa drugs have their origin in the dye industry as well. The company I.G. Farben, 
together with Gerhard Domagk discovered prontosil, to be effective against streptococci.18,19 
Later, it was discovered that prontosil was simply a prodrug, and the active species the 
sulfanilamide. In further elaborative studies, around 5000 variants of sulfanilamide have been 
synthesized and tested of which some, such as sulfapyridine, made it to market. Another 
success story was the discovery of the quionolones, 20 which was isolated as a byproduct 
during a synthetic approach towards the antimalarial chloroquine. Based on this structure, 
four generations of antibiotics have been developed, evolving from gram negative activity to 
broad spectrum activity.21,19 George Hitching and co-workers followed a more rational 
approach in antibiotic development, trying to prevent DNA synthesis by interrupting the 
incorporation of purines in the strand. Thus, they were looking into purine-mimicking 
molecules that would block DNA chain grow. Along this line, trimethoprim, a pyrimidine-
based antibiotic was developed, which is of particular importance in developing countries due 
to its low costs.  
Natural products are a valuable source of inspiration in drug discovery. In contrast to fully 
synthetic anti-infectives they have a very broad spectrum of complexity (Figure 1.4). In some 
cases, the natural products itself made it to market (e.g. penicillin, fosfomycin, streptomycin, 
erythromycin, vancomycin, chlorotetracycline), in others semisynthetic modifications or de 
novo synthesized analogues led to new therapeutics (e.g. 2-nitroimidazole (metronidazole), 
thienamycin (carbapenems), cephalosporin C (cephalosporins), rifamycin SV (rifampicin)).19 
In the following section a few examples from antibiotic drug discovery by 1) semisynthetic 
and 2) fully synthetic means are described. 
                                                
18  J. E. Lesch, The First Miracle Drugs: How the Sulfa Drugs Transformed Medicine, Oxford University Press, 
New York, 2007.   
19  P. M. Wright, I. B. Seiple, A. G. Myers, Angew. Chem. Int. Ed. 2014, 53, 8840–8869. 
20  G. Y. Lesher, E. J. Froelich, M. D. Gruett, J. H. Bailey, R. P. Brundage, J. Med. Pharm. Chem. 1962, 5, 
1063-1065. 
21  V. T. Andriole, Clin. Infect. Dis. 2005, 41, 113–119. 
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Figure 1.4: The beautiful diversity of natural products with antimicrobial activity, serving as lead structures for 
drug development. Dates in brackets refer to the year marketed or isolated. 
A success story of antibiotic development by semisynthetic means, are the simple 
modifications of tetracycline (natural product analogue of chlorotetracycline), which brought 
up a range of new antibiotics (Figure 1.5). It was discovered that removal of the benzylic 
alcohol led to more stable compounds while maintaining their biological activity. Thus, 
modifications under more forcing conditions could be performed, especially, electrophilic 
substitution at the aromatic portion brought up new antibiotics.  
The erythromycin-based anti-infectives are another successful example of semisynthetic 
drug discovery. The ketone in the macrolide is prone to react with the tertiary alcohol in γ-
position to give an anhydrohemiketal. Protection of the alcohol as the methylether 
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(clarithromycin, six steps from erythromycin), or complete removal of the ketone 
(azithromycin, four steps from erythromycin) led to more stable therapeutics (Figure 1.5).  
 
Figure 1.5: Semisynthetically developed antibiotics from the parental natural compounds tetracycline and 
erythromycin. The blue portions highlight the semisynthetic modifications. The figure was adapted from 
reference19. 
Semisynthetically, the variation of the lead structure is limited by the stability of the 
compounds and in addition certain transformations are not doable in a selective manner, and 
for a long time, fully synthetic antibiotics were very simple molecules with no chiral centre. 
With the development of the fully synthetic β-lactams (e.g. cephalosporin, thienamycin) in the 
80’s, a huge step was taken. Suddenly, a wide variety of antibacterial molecules with high 
complexity could be manufactured (Figure 1.6). Non-trivial modifications by semisynthetic 
strategies, like the replacement of the sulphur by oxygen or methylene in cephalosporin 
(Figure 1.4), were achieved fully synthetically and gave rise to new antibiotics. Thienamycin, 
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a very promising broad-spectrum antibiotic, was highly unstable due to intermolecular attack 
of the primary amine on the lactam. Here, semisynthetic studies led to imipenem, which was 
significantly more stable while retaining the high bioactivtity (Figure 1.6). Since the isolation 
and purification of thienamycin was very challenging, imipenem was manufactured using a 
fully synthetic route. Along the successful total synthesis and therapeutic utility of imipenem, 
the antibiotic has been further developed, resulting in meropenem – introduction of a methyl 
group α to the thioether improved the pharmacokinetics – and more recently, ertapenem 
(Figure 1.6). 
 
Figure 1.6: Fully synthetic β-lactams based on the parent thienamycin. The portions in red highlight the fully 
synthetic modifications compared to the lead structure. The figure was adapted from reference19. 
 
Figure 1.7: Top: Fully synthetic approach towards tetracyclines. Bottom: Selected examples of fully synthetic 
tetracycline analogues derived from the approach above. The figure was adapted from reference 19. 
Another example that shows the advantage of fully synthetic versus semisynthetic 
approach was the development of eravacycline and other tetracycline derived antibiotics. Due 
to a lack of possible chemical transformations, semisynthetic changes on tetracycline were 
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limited to only three positions in the molecule (Figure 1.5). The total synthesis of tetracycline 
by Myers and co-workers, contributed an important tool for the synthesis of diverse 
analogues, such as 1.5. In their synthesis, the A-ring is introduced at a late stage of the 
synthesis (Figure 1.7).22 This was of particular interest since modifications at this site is 
widely tolerated for the antibiotic activity. Thereof a huge number of tetracycline analogues 
were synthesized and tested and finally resulted in the discovery of eravacycline, which is 
currently in the phase III clinical trial against urinary tract infections. 
 
1.1.3 Lipiarmycins, Tiacumicins, Clostomicins and Fidaxomicin 
In 1975, Parenti et al. published the isolation of a new compound isolated from a soil 
sample, which was collected in India on the 29th February in 1972, a leap year.23 Thereof the 
isolate from the strain Actinoplanes deccanensis, lipiarmycin. The compound was found to be 
active against Gram-positive bacteria and more interestingly, against strains, resistant to 
commercially available antibiotics (e.g., rifampin, streptomycin, tetracycline, erythromycin). 
It took until 1987 to realize that the isolated sample indeed was a mixture of two compounds 
in a 3:1 ratio, which were termed lipiarmycin A3 and A4.24  
 
Figure 1.8: The antibiotic macrolide fidaxomicin, also known under the names lipiarmycin A3, tiacumicin B 
and clostomicin B1. 
                                                
22  a) M. G. Charest, D. R. Siegel, A. G. Myers, J. Am. Chem. Soc. 2005, 127, 8292–8293; b) C. Sun, Q. Wang, 
J. D. Brubaker, P. M. Wright, C. D. Lerner, K. Noson, M. Charest, D. R. Siegel, Y.-M. Wang, A. G. Myers, 
J. Am. Chem. Soc. 2008, 130, 17913–17927. 
23  C. Coronelli, R. J. White, G. C. Lancini, F. Parenti, J. Antibiot. 1975, 253–259. 
24  A. Arnone, G. Nasini, B. Cavalleri, J. Chem. Soc., Perkin Trans. 1 1987, 1353–1359. 
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Independently, in 1986, the isolation of the clostomicins from a new strain collected in 
Japan called Micromonospora chinospora was reported.25 One of them, clostomicin B1, was 
identified to be identical with lipiarmycin A3. In addition, the group of McAlpine reported the 
isolation of the tiacumicins A-F in 1987, of which “B” was found to be the same compound 
as lipiarmycin A3.26 Despite the early discovery of these antimicrobially active compounds, it 
was not until the end of the 90’s that their therapeutic potential was recognized. The 
investigations on tiacumicin B by Optimer Pharmaceuticals paid off, and the FDA approved 
the antibiotic under its tradename Dificid® and generic name Fidaxomicin in 2011 for the 
treatment of Clostridium difficile infections (CDI).27  
Fidaxomicin consists of a central 18-membered polyketide macrolide with high 
unsaturation and five stereocenters, which is glycosylated at two sides with an unusual D-
noviose and a D-rhamnose. The rhamnose moiety on his part, is linked to a chlorinated 
resorcylate unit (Figure 1.9). It should be mentioned that the assignment of all stereocenters in 
fidaxomicin (and the lipiarmycins, clostomicins and tiacumicins), in particular the 
configuration at C18, remained unclear for a long time. The stereocenters were 
unambiguously assigned by X-ray crystal structure analysis in 2006 for the first time.28 
Optimer Pharmaceuticals presents in the same patent their studies on the isolate (OPT-80) 
from Dactylosporangium auantiacum, containing mainly C18-(R)-tiacumicin B and in minor 
quantities lipiarmycin A4, as well as, what they call “C19-ketone” (clostomicin D). Reduction 
of the C18 ketone in C19-ketone/clostomicin D afforded (S)-tiacumicin B. As the (S)-
tiacumicin B (bearing an ethyl group at resorcylate) appeared spectroscopically identical to 
lipiarmycin A4 (bearing a methyl group at resorcylate), the stereocenter of the latter was 
assigned as (S), too. By that, the C18 configuration of lipiarmycin A3 and its co-identity with 
tiacumicin B was questionable again. Late, in 2014, degradation studies by Serra et al. 
proofed that lipiarmycin A3 is identical to tiacumicin B.29  Though the co-identity of 
tiacumicin B, clostomicin B1, lipiarmycin A3 and fidaxomicin is clear, the configuration of  
                                                
25  S. Omura, N. Imamura, R. Oiwa, H. Kuga, R. Iwata, R. Masuma, Y. Iwai, J. Antibiot. 1986, 39, 1407–1412. 
26   J. E. Hochlowski, S. J. Swanson, L. M. Ranfranz, D. N. Whittern, A. M. Buko, J. B. McAlpine, J. Antibiot. 
1987, 40, 575–588. 
27  W. Erb, J. Zhu, Nat. Prod. Rep. 2013, 30, 161. 
28  Y.-K. Shue, C.-K. Hwang, Y.-H. Chiu, A. Romero, F. Babakhani, P. Sears, F. Okumu 2006, 
WO2006/085838. 
29  A. Bedeschi, P. Fonte, G. Fronza, C. Fuganti, S. Serra, Nat. Prod. Commun. 2014, 9, 237-240. 
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other analogues is still unsure. So far, no unambigious analytical proof of any (S)-configured 
natural product in the fidaxomicin family was given. 
  
Figure 1.9: The isolated natural products having the central macrolactone in common. The configuration at C18, 
shown here as R-configured, is not terminally determined, except for fidaxomicin and synonyms. 
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1.1.4 Fidaxomicin – Biological Activity and Mode of Action 
Fidaxomicin is a narrow-spectrum antibiotic against Gram-positive bacteria with minimal 
systemic absorption. Owing to its potent activity against the Gram-positive bacteria C. 
difficile (MIC = 0.012 µg/mL (0.011 nmol/mL)), it was introduced to the market in 2011 for 
the treatment of Clostridium difficile infections (CDI).30 CDI is a nosocomial (hospital 
acquired) disease, causing diarrhea. Compared to vancomycin, treatment with fidaxomicin 
shows comparable cure rates but decreased recurrence. Further, broad-spectrum antibiotics 
such as metronidazole or vancomycin are prone to promote resistance of Enterococci, which 
is not the case with fidaxomicin.31 Fidaxomicin also showed promising activity against MDR 
strains of Mycobacterium tuberculosis (MTB) (MIC < 0.1 mg/mL (<0.1 nmol/mL)).32 This 
result is especially interesting as MDR-MTB is one of the growing public health concerns 
worldwide.7 For CDI the minimal oral systemic bioavailability is highly advantageous as it 
results in fewer adverse effects. On the other hand, the antibiotic is not suitable as therapeutic 
for systemic diseases like tuberculosis. In addition, fidaxomicin and semisynthetic derivatives 
showed good IC50 values (5.56–4.04 µg/mL) in breast cancer cells, comparable with the 
values of Tamoxifen® (5.50 µg/mL).33  
The RNA-polymerase (RNAP) is essential to all organisms, and responsible for the 
transcription of DNA to RNA. The bacterial RNAP consists of five subunits (αI, αII, β, β’, ω), 
which form a pincer-like structure between the β, β’-subunits. The so formed channel serves 
as the active site where the DNA-strand fits and a Mg2+ ion is complexed (Figure 1.10). The 
β’-subunit plays a special role in this enzyme as it is a mobile part which opens and closes the 
access to the active site and it constitutes the docking site for the σ-cofactor to form the active 
holoenzyme. The σ-cofactor is responsible for the recognition of the promoter in the DNA 
sequence (Figure 1.10). When the holoenzyme-DNA complex is formed, the DNA is opened 
to single strands and the transcription to RNA is started. Once the first ten RNA-nucleotides 
are synthesized the σ-cofactor is released and the transcription goes on until the termination 
                                                
30  A. A. Venugopal, S. Johnson, Clin. Infect. Dis. 2012, 54, 568–574. 
31  W. N. Al-Nassir, A. K. Sethi, Y. Li, M. J. Pultz, M. M. Riggs, C. J. Donskey, Antimicrob. Agents Chemother. 
2008, 52, 2403-2406. 
32  M. Kurabachew, S. H. J. Lu, P. Krastel, E. K. Schmitt, B. L. Suresh, A. Goh, J. E. Knox, N. L. Ma, J. Jiricek, 
D. Beer, M. Cynamon, F. Petersen, V. Dartois, T. Keller, V. Sambandamurthy, J. Antimicrob. Chemother. 
2008, 62, 713–719. 
33  M. C. Wu, C. C. Huang, Y. C. Lu, W. J. Fan, US 20090110718 A1, 2009. 
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signal is reached. Often this terminal signal results in the formation of a β-hairpin in the 
synthesized RNA, which destabilizes the complex to release DNA and RNA.  
  
Figure 1.10: A: Backbone worm diagram of bacterial RNAP. 34 The two α and ω subunits are coloured in white. 
The blue part assigns the β- and the pink the β’-subunit. The complexed Mg2+-ion in the active pocket is in 
magenta. In green, evolutionarily highly conserved regions of the β-units are highlighted. B: The transcription 
cycle of bacterial RNAP. In the first step the σ-cofactor binds to the polymerase forming the holoenzyme. 
Specific bindings between the σ-cofactor and the promoter on the DNA are formed (1) and the double helix is 
unwound (2). Now transcription into RNA starts (3) and the σ-unit is released (4) while the polymerase tightens 
around the DNA. Now transcription goes on until the termination signal on the sequence is reached (6) and the 
RNA and DNA are released from the complex (7). Adapted from reference35. 
Although many compounds have been found to inhibit bacterial RNAP, only a few have 
been approved as antibiotics, e.g., the rifamycins and fidaxomicin. While it was shown that 
the rifamycins bind to the β-subunit and block the elongation of the RNA,36 the mode of 
action of fidaxomicin is not fully understood yet and the published studies are often 
contradictory.  
Already along with the isolation-paper of lipiarmycin, it was found that the inhibition 
pattern was very similar to that of rifampicin.23 The RNA synthesis was completely inhibited 
                                                
34  Illustration used with permission of Elsevier from: S. A. Darst, Current Opinion in Structural Biology 2001. 
35  B. Alberts, A. Johnson, J. Lewis, D. Morgan, M. Raff, K. Roberts, P. Walter, Molecular Biology of the Cell, 
Garland Science 2015, 4th Ed.  
36  E. A. Campbell, N. Korzheva, A. Mustaev, K. Murakami, S. Nair, A. Goldfarb, S. A. Darst, Cell 2001, 104, 
901–912. 
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when the isolate was added prior to the RNAP-DNA association. When added after the 
complex formation, RNA synthesis was only gradually inhibited.37 
The group of Sonenshein showed for B. subtilis, that the inhibition did not result from the 
interaction with the σ-cofactor but more likely with the holoenzyme. 38  Furthermore, 
lipiarmycin resistant strains incorporated mutations in the gene coding for the β-subunit of the 
RNAP.  
Much later, in 2006, the group of Leonetti showed that mutations of the gene in B. subtilis, 
coding for the β’-subunit, led to resistance against fidaxomicin.39 Later, Sambandamurthy et 
al. and Leonetti et al. showed on different strains (M. tuberculosis and E. faecalis), that 
mutations in the genes, coding for the β- and β’-subunits in the region of the RNA-exit-
channel, caused resistance.32,40 Leonetti and co-workers then investigated the mode of action 
of fidaxomicin on E. coli as a model,41 and found that, indeed, two sites are targeted, the σ70 
3.2 region and the switch-2 element on the β’-subunit. The switch-2 unit is responsible for the 
clamping of the promoter DNA in the active pocket of the RNAP, while the σ70-region 
stimulates the RNA synthesis. As the two regions are essential for the DNA fitting into the 
active site, it was reasoned that fidaxomicin blocks this process to inhibit transcription. 
Referring on unpublished results, the group of Ebright, could not verify the interaction 
with the σ-cofactor.42 They located the binding site of fidaxomicin in the switch-2 to switch-3 
region of the β’-subunit (Figure 1.11). The site of binding, strongly suggests fidaxomicin to 
interfere with the RNAP switch-region or the RNA-exit channel or both. 
                                                
37  S. Sergio, G. Pirali, R. White, F. Parenti, J. Antibiot. 1975, 28, 543–549. 
38  a) A. L. Sonenshein, H. B. Alexander, D. M. Rothstein, S. H. Fisher, J. Bacteriol. 1977, 132, 73–79; b)A. L. 
Sonenshein, H. B. Alexander, J. Mol. Biol. 1979, 127, 55–72. 
39  M. Gualtieri, P. Villain-Guillot, J. Latouche, J.-P. Leonetti, L. Bastide, Antimicrob. Agents Chemother. 2006, 
50, 401–402. 
40  M. Gualtieri, A. Tupin, K. Brodolin, J.-P. Leonetti, Int. J. Antimicrob. Agents 2009, 34, 605–606. 
41  A. Tupin, M. Gualtieri, J.-P. Leonetti, K. Brodolin, EMBO J 2010, 29, 2527–2537. 
42  A. Srivastava, M. Talaue, S. Liu, D. Degen, R. Y. Ebright, E. Sineva, A. Chakraborty, S. Y. Druzhinin, S. 
Chatterjee, J. Mukhopadhyay, Y. W. Ebright, A. Zozula, J. Shen, S. Sengutpa, R.R. Niedfeldt, C. Xin, T. 
Kaneko, H. Irschik, R. Jansen, S. Donadio, N. Connell, R. H. Ebright, Curr. Opin. Microbiol. 2011, 14, 532–
543. 
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Figure 1.11: The binding sites in bacterial RNAP of rifamycins (Rif) and fidaxomicin (= lipiarmycin, Lpm). 
Fidaxomicin binds to the switch-2 region of the β’-subunit, the rifamycins on the other hand, bind to the β-
subunit, which is in agreement with no cross-resistance between the antibiotics. The illustration is used with 
permission from reference 42.. 
In 2012, researchers from Optimer Pharmaceuticals published results, showing that 
fidaxomicin inhibits the transcription in C. difficile and E. coli upon holoenzyme formation, 
but necessarily before opening of the complex for DNA fitting.43 They compared the results 
between fidaxomicin in their tests and the results from Leonetti41, using a fermentation 
mixture from A. deccanensis, stated as lipiarmycin (of which the authors believed to have the 
C18-(S)-configuration). In contrast to Leonetti, in their tests, the activity of fidaxomicin was 
not dependant on alterations of the σ-cofactor. Though, they found different results than 
Leonetti, it is declared that this observation might origin from differing analysis methods. 
To sum up, fidaxomicin is a RNAP inhibitor with no cross-resistance to rifamycins (a 
RNAP inhibitor itself) and it inhibits the holoenzyme better then the core RNAP. It is very 
likely that inhibition occurs in the opening of the protein complex for DNA docking, which 
would be a new mechanism of transcription inhibition.  
 
                                                
43  I. Artsimovitch, J. Seddon, P. Sears, Clin. Infect. Dis. 2012, 55, 127–131. 
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1.1.5 Biosynthesis of Fidaxomicin 
The group of Zhang has investigated the biosynthesis of fidaxomicin in the D. 
aurantiacum strain, from which tiacumicin B was isolated originally.44 Extensive DNA-
sequence analysis and knockout experiments resulted in the identification of 31 open reading 
frames putatively involved in the fidaxomicin biosynthesis. Specific genes have been 
inactivated, and the metabolites of the mutants identified. In this way, the functions of a 
halogenase (TiaM), two glycosyltransferases (TiaG1, TiaG2), a sugar C-methyltransferase 
(TiaS2), an acyltransferase (TiaS6) and two cytochrome P450s (TiaP1, TiaP2) were 
identified. Together with bioinformatic comparison of identified enzymes, and established 
knowledge from polyketide biosynthesis, the following pathway was suggested (Figure 1.12). 
 
Figure 1.12: Biosynthetic pathway of the central macrolide of fidaxomicin. Only four of the final five 
stereocenters are introduced, yet. ACP = acyl carrier protein; AT = acyl-transferase; DH = dehydratase; KR = 
keto-reductase; KS = keto-synthase; TE = thio-esterase. The tiaA1 to tiaA4 encode the TiaA1 to TiaA4 modular 
type I polyketidesynthases (PKS).44 
The central aglycon 1.6 is synthesized by a modular type I polyketide synthase (PKS). 
PKS are very large multi domain enzymes, mainly occurring in bacteria, plants and fungi, that 
produce polyketides. Typically, polyketide synthesis starts with the loading module, in which 
step the acyl group is bound to the acyl carrier protein (ACP) domain, in this case  promoted 
                                                
44  a) Y. Xiao, S. Li, S. Niu, L. Ma, G. Zhang, H. Zhang, G. Zhang, J. Ju, C. Zhang, J. Am. Chem. Soc. 2011, 
133, 1092–1105; b) T. Hu, S. Li, Y. Xiao, L. Ma, G. Zhang, H. Zhang, X. Yang, J. Ju, C. Zhang, 
ChemBioChem 2011, 12, 1740-1748. 
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by TiaA1. Successively, acyl-transferase (AT) and keto-synthase (KS) modules are 
responsible for chain elongation and the dehydrogenase (DH) and keto-reductase (KR) 
modules are required for the chain decoration. The sequence is terminated with the cyclization 
and releasing through the thioesterase (TE). 
The biosynthesis of the homo-orsellinic acid unit 1.10 commences with the PKS TiaB, 
which incorporates AT, KS and ACP domains, required for the synthesis of the linear 
polyketide 1.9 from propionyl-CoA 1.7 and three malonyl-CoA 1.8 (Figure 1.13). 
Spontaneous cyclization and aromatization then leads to the non-halogenated resorcylate unit 
1.10. 
 
Figure 1.13: The biosynthesis of the homo-orsellinic acid moiety 1.10. TiaB is a polyketide synthase containing 
active KS, AT and ACP domains. The sequence starts with the rather unusual propionyl-CoA. 
The two carbohydrate units of fidaxomicin are suggested to derive from GDP-mannose 
1.11 (Figure 1.14). Three genes tiaS1, tiaS3 and tiaS4 have been found to share high sequence 
similarity to GDP-mannose-4,6-dehydratase encoding genes (GmD). Although no required 
GDP-4-keto-6-deoxymannose reductase (Rmd) has been found, they propose that at least one 
of the GmD’s is bifunctional as a RmD. Thus, the ketone 1.12 was suggested as an 
intermediate in the biosynthesis before transformation to the GDP-rhamnose 1.13 occurs. 
TiaS2, a C-methyltransferase and TiaS6 an isovaleryltransferase are most probably 
responsible for the biosynthesis of the C4 acylated GDP-noviose 1.14. The TiaS5, an O-
methyltransferase is responsible for the transformation to the 2O-methyl rhamnose 1.15.  
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Figure 1.14: Biosynthesis of the GDP-noviose and the GDP-rhamnose starting from GDP-mannose. TiaS1, 
TiaS3 and TiasS4 are putatively GDP-mannose-4,6-deoxygenases (GmD) of which at least one is supposed to 
contain a GDP-4-keto-6-deoxymannose reductase (Rmd). 
In the final steps of the proposed biosynthesis, TiaP2 and TiaP1 (cytochrome P450 
enzymes) are responsible for the oxidation to the primary alcohol and the C18 alcohol. 
Sequential insertion of the glycosides (TiaG1, TiaG2) renders the fully glycosylated 
macrolide. Further acylation (TiaF) of the rhamnoside with the resorcylate, and chlorination 
(TiaM) finally gives fidaxomicin (Figure 1.15). 
 
Figure 1.15: The final steps of the fidaxomicin biosynthesis. TiaG1, TiaG2 = glycosyltransferases; TiaP2, TiaP1 
= Cytochrome P450 enzymes; TiaF = acyltransferase; TiaM = halogenase. 
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1.1.6  Structure-Activity-Relationship Studies 
So far, there exists only limited knowledge about the structure activity relationship (SAR) 
of fidaxomicin. The available data are often not comparable between different publications 
due to differences in the bioassays, and unsystematic modifications of the compounds. The 
reported biological activities of fidaxomicin analogues so far originate from the isolation of 
similar natural products,23-26 the patents around fidaxomicin and the biosynthesic studies.44 
Nevertheless some statements can be made.  
Results of Zhang et al. 44 as well as from the thesis of Glaus45 in the group of Altmann 
showed that the bioactivity was lost when a carbohydrate or resorcylate moiety was missing. 
This is also in agreement with the low bioactivity of the natural product analogue tiacumicin 
A, which lacks the rhamnosyl-resorcylate unit (Figure 1.9).46 
Modifications on the resorcylate part are to some extend tolerated. The exchange of the 
chlorines against hydrogens led to a small MIC value increase.44 Brominated variants from 
feeding experiments with NaBr, showed higher MIC values for some strains, except for C. 
difficile the activity was mostly preserved (Table 1.1, Entry 13–16).47 Substitution of the 
phenolic groups by methyl was not tolerated at all and showed an 8–16 fold loss of activity.48 
The phenolic groups of fidaxomicin are also responsible for the lower bioyctivity at higher 
pH values (8 to 16 fold increase of MIC, from pH 6 to pH 8.1).49 This can be explained by 
deprotonation of the phenols, leading to a charged molecule, which hinders the permeation 
through bacterial membranes. The alkyl-substituent (ethyl or methyl) on the aromatic ring 
seems to play a minor role for the bioactivity (Entry 1 vs. 5).  
                                                
45  F. D. Glaus, Total Synthesis and SAR Investigations of Natural Products Inhibiting Bacterial RNA 
Polymerase: Ripostatin B and Tiacumicin B. ETH-Zürich 2015. http://dx.doi.org/10.3929/ethz-a-010422569 
online accessed 26.11.2015. 
46  R. J. Theriault, J. P. Karwowski, M. Jackson, R. L. Girolami, G. N. Sunga, C. M. Vojtko, L. J. Coen, J. 
Antibiot. 1987, 40, 567–574. 
47  J. Hochlowski, M. Jackson, R. Rasmussen, A. Buko, J. Clement, D. Whittern, J. McAlpine, J. Antibiot. 1997, 
50, 201–205. 
48  J. B. McAlpine, J. E. Hochlowski (Abbott Laboratories), WO9635702 A1 1996,. 
49  P. Sears, S. L. Miller-Shangle, R. B. Walsh, Y.-K. Shue, F. Babakhani, T. J. Louie (Optimer 
Pharmaceuticals) US 20070105791 2007. 
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The major metabolite of fidaxomicin, OP-1118, is missing the isobutyric ester, which 
results in a dramatic loss of antibiotic activity (Entry 6).50 Also migrations of the ester to 
adjacent alcohols (Entry 17-20) and exchanges with propionic and acetyl esters (Entry 9-11) 
have an adverse effect on the biological activity. 
The impact of the C18 substituent is unclear. From a patent of Optimer Pharmaceuticals, it 
can be depicted that the C18 configuration has a high impact on the activity.51 Their 
fidaxomicin isolate showed around 4-8 fold lower MIC values in C. difficile strains than the 
semisynthetic (S)-tiacumicin B (Entry 2). At the same time, lipiarmycin A4, with the putative 
(S)-C18 configuration and a methyl substituent at the resorcylate, and the C18 ketone 
(Clostomicin D) showed only small changes of the MIC values (Entry 3,5). Compounds 
without substitution at C18 showed also similar biological activities (Entry 4).  
 
 
 
 
 
 
 
                                                
50  Y. Ichikawa, Y.-H. Chiu, Y.-K. Shue, F. K. Babakhani (Optimer Pharmaceuticals), WO 2009070779 2009. 
51  Y. K. Shue, C. K. Hwang, Y. H. Chiu, A. Romero, F. Babakhani, P. Sears, F. Okumu (Optimer 
Pharmaceuticals) US20080269145 A1, 2008. 
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Table 1.1: Biological Activities of Selected Fidaxomicin Analogues. 
 
Ref: 44,51                             R4, R5= Cl; R8,R7=H MIC [µg/mL] 
 R1 R2 R3 R6 C. difficile E. faecalis S. aureus 
1 (R)-OH Me Et iPrCO 0.5 2-4 8 
2 (S)-OH Me Et iPrCO 1 8 64 
3 =O Me Et iPrCO 0.5 – – 
4 H Me Et iPrCO – 4 8 
5  (S)-OH52 Me Me iPrCO 0.5 2 8 
6 (R)-OH Me Et H 4 16-64 >64 
7 (R)-OH H Et iPrCO – 4 16 
8 H Me Et H – 32 128 
9 H H Et iPrCO – 1 2 
10 H H Et EtCO – 2 4 
11 H H Et MeCO – 4 8 
Ref:47 R2= Me; R3=Et; R7=H MIC [µg/mL] 
 R1 R4 R5 R6 R8 C. difficile C. perfringens S. aureus 
12  (R)-OH Cl Cl iPrCO H 0.06-0.12 0.06 0.78 
13 (R)-OH Br Cl iPrCO H 0.06 0.03 6.2 
14 =O Br Cl iPrCO H 0.25-1.0 0.015 50 
15 (R)-OH H Br iPrCO H 0.12-0.5 <0.06 6.2 
16 (R)-OH H Br H iPrCO 0.5-2.0 0.06 50 
Ref:46 R1=(R)-OH; R2= Me; R3=Et; R4,R5=Cl MIC [µg/mL] 
 R6 R7 R8 E. faecium S. epidermis S. aureus 
17  iPrCO H H 6.2 12.5 6.2 
18 H iPrCO H 16.2 12.5 12.5 
19 H H iPrCO 100 25 50 
20 H H EtCO 12.5 12.5 25 
                                                
52  putative and not proven. 
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1.1.7  Synthetic Studies Towards the Total Syntheses of Fidaxomicin 
Despite the interesting biological activity and the unique structure of fidaxomicin, no total 
synthesis of fidaxomicin or related products were published until 2015. The single fragments, 
on the other hand, have been approached before. Grassot and Erb in the group of Jieping Zhu 
described efforts towards the putative lipiarmycin A4 central aglycon in their Ph.D. theses.53 
In addition synthetic studies towards the carbohydrates54,55 and the homo-orsellinic acid,56 
mainly for structure elucidation purposes, have been published (discussed in the respective 
chapters). It took until early 2015, when independently Altmann57 and our group58 published 
the first total synthesis of the fidaxomicin aglycon, back-to-back. At the same time, Zhu and 
coworkers59 reported their synthesis of the C18 epimeric aglycon of fidaxomicin. In the 
following sections the synthesis of Zhu and Altmann are summarized. 
Zhu’s Aglycon Synthesis of Putative Lipiarmycin A4 
Zhu’s approach towards the protected aglycon 1.17 is based on the synthesis of a main 
fragment, incorporating all the stereogenic centers, and a dienoic acid, which are combined by 
Yamaguchi esterification and a ring closing metathesis (Figure 1.16). The main fragment’s 
five stereocenters are defined by a Brown alkoxyallylation, an Evans aldol reaction and a 
Brown allylation.  
                                                
53  J. M. Grassot, Ph. D. Thesis, Université de Paris-Sud XI 2007; W. Erb, Ph. D. Thesis, Université de Paris-
Sud XI 2010. 
54  a) A. Lipták, Carbohydr. Res. 1982, 107, 300–302; b) A. Lipták, I. Czégény, J. Harangi, P. Nánási, 
Carbohydr. Res. 1970, 15, 327–331.  
55  a) A. Klemer, M. Waldmann, Liebigs Ann. Chem. 1986, 2, 221–225; b) E. Walton (Merck & Co), US 
2938900, 1960. 
56  M. Alexy, H.-D. Scharf, Liebigs Ann. Chem 1991, 1363–1364. 
57  F. Glaus, K.-H. Altmann, Angew. Chem. Int. Ed. Engl. 2015, 54, 1937–1940. 
58  H. Miyatake-Ondozabal, E. Kaufmann, K. Gademann, Angew. Chem. Int. Ed. Engl. 2015, 54, 1933–1936. 
59  W. Erb, J.-M. Grassot, D. Linder, L. Neuville, J. Zhu, Angew. Chem. Int. Ed. Engl. 2015, 1929–1932. 
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Figure 1.16: Zhu’s approach towards the putative liparmycin A4 aglycon. RCM = ring closing metathesis. 
The synthesis commences with the stereoselective Brown alkoxyallylation of the PMP 
protected allylalcohol 1.18 to furnish the two first stereocenters in 1.19 (Scheme 1.1). 
Unfortunately, the corresponding TBS-protected allylalcohol was unreactive towards 
acetaldehyde in this reaction. Thus, the benzyl protecting group was installed and the PMP 
group was swopped to TBS. Hydroboration of the terminal alkene and Swern oxidation 
yielded the suitable aldehyde 1.20. A Horner Wadsworth Emmons (HWE) olefination gave 
the trans-enoate ester 1.21, which was transformed to the aldehyde 1.22, by reduction with 
DIBAL-H and oxidation using manganese dioxide. The same sequence, HWE-reduction-
oxidation, gave the α,β-unsaturated aldehyde 1.23. 
 
Scheme 1.1: a) sBuLi, THF, –78°C, 30 min, then (+)-Ipc2BOMe, –78°C, 60 min, then BF3·OEt2, –78°C, then 
acetaldehyde, –78°C, 3 h, then H2O2, NaOH, –78°C to RT, 18 h, 80%, ee 92%; b) NaH, DMF, 0°C, 1 h, then 
BnBr, 0°C to RT, 18 h, 81%; c) CAN, CH3CN, H2O, 0°C, 15 min, 81%; d) TBSCl, imidazole, DMF, RT, 18 h, 
90%; e) Cy2BH, THF, 0°C, 2 h, then H2O2, NaOH, 0°C, 4 h, 73%; f ) (COCl) 2, DMSO, CH2Cl2, –78 °C, 1 h, 
then Et3N, –78°C to RT, 1 h, 99%; g) 1.24, NaH, THF, 0°C, 20 min, then 1.22, 0°C, 2 h, 92%, E/Z=7:1; h) 
DIBAL-H, toluene, –78°C, 1 h, 93%; i) MnO2, THF, RT, 2 h; j) 1.24, NaH, THF, 0°C, 20 min, then 1.23, 0°C, 2 
h, 78%, E:Z = 4:1; k) DIBAL-H, toluene, –78°C, 1 h, 59%; l) MnO2, THF, RT, 2 h.  
An Evans aldol reaction with the oxazolidinone 1.31 and the dienal 1.23 followed by TES 
protection of the secondary alcohol furnished the intermediate 1.25 in good yield (Scheme 
1.2). Cleavage of the auxiliary with the lithium thiolate gave the corresponding thioester 1.26, 
which was then reduced directly to the aldehyde 1.27. Now, another HWE-reduction-
oxidation sequence gave the aldehyde 1.28. Interestingly and fortunately, the TBS-ether was 
chemoselectively cleaved during the reduction with DIBAL-H. Zhu et al. suggest a chelating 
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effect of the adjacent benzyl ether to be responsible for this unexpected chemoselectivity. 
Yamaguchi esterification of the secondary alcohol 1.28 with the dienoate 1.32 then gave the 
advanced intermediate 1.29. The last stereocenter was formed during the following Brown 
allylation. A ring closing metathesis (Grubbs II) between the terminal olefin and the dienoate 
moiety of 1.30 was performed. In this way, the macrolide 1.17 with an E:Z selectivity of 2:1 
was reached with a longest linear sequence of 21 steps. 
 
Scheme 1.2: a) 1.31, nBu2BOTf, Et3N, CH2Cl2, 0°C, 30 min, then 1.23, –78°C to RT, then H2O2, MeOH, buffer 
pH 7.0, 10°C to RT, 1 h, 86% (2 steps); b) TESCl, imidazole, DMF, 0°C, 20 min, 73%; c) EtSH, nBuLi, THF, 
0°C, 5 min, then 1.25, THF, RT, 10 min, 85%; d) DIBAL-H (1.0 M in hexane, 2 equiv), toluene, –78 °C, 20 min; 
e) 1.24, NaH, THF, 0°C, 2 h, then crude aldehyde 1.28, 0°C, 2 h, 65% (2 steps), E:Z = 4:1; f) DIBAL-H (1.0 M 
in hexane, 5 equiv), CH2Cl2, –78°C, 1 h, 71%; g) MnO2, THF, RT, 2 h; h) 1.32, 1,3,5-trichloro-benzoyl chloride, 
Et3N, toluene, RT, 1 h, then 1.29, DMAP, RT, 4 h, 53% (2 steps); i) (–)-Ipc2BAllyl, THF, –78°C, 1 h, then H2O2, 
NaOH, –78°C to RT, 3 h, 42%; j) Grubbs II (20mol%), toluene, 100°C, 43%, E:Z = 2:1.  
It should be mentioned that Zhu et al. first attempted to perform a macrolactonization with 
the linear precursor 1.36 (Scheme 1.3). Thus, a cross metathesis between 1.33 and 1.34 was 
performed, which furnished the protected intermediate 1.35 in low yield (E:Z selectivity not 
given). Unfortunately, the deprotection of the carboxylic acid and TBS ether cleavage gave 
complex mixtures and the product 1.36 could not be isolated.  
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Scheme 1.3: Zhu`s macrolactionization attempt failed due to troublesome hydrolysis of the ester and the TBS 
silyl ether. a) Hoveyda-Grubbs II (25 mol%), toluene, 100°C, µw, 15 min, 38%. 
 
Altmann’s Fidaxomicin Aglycon Synthesis 
In the approach of Altmann57 and Glaus the aglycon is built up through an assembly of 
three fragments via successive cross metathesis, Yamaguchi esterification and a Suzuki cross 
coupling for ring closure (Scheme 1.4).  
 
Scheme 1.4: Altmann's approach towards the central aglycon of fidaxomicin. 
The boronic ester fragment 1.41 was synthesized from the racemic allyl alcohol 1.38, 
which was submitted to kinetic resolution using Sharpless epoxidation and in situ TBS 
protection. Opening of the epoxide 1.39 with propyne and nBuLi gave 1.40, further 
hydroboration furnished the boronic ester 1.41 with high regioselectivity (Scheme 1.5). 
 
Scheme 1.5: a) Ti(OiPr)4, (–)-DIPT, tBuOOH (0.45 equiv), m.s. 3Å, CH2Cl2, –20°C, 39 h; then TBSCl, 
imidazole, CH2Cl2, –20°C to RT; then RT, 16 h, 21%; b) nBuLi, propyne, BF3·OEt2, THF, –78°C, 3.5 h, 75%; c) 
bis(pinacolato)diboron, CuCl (5 mol%), KOtBu (20 mol%), PPh3 (6 mol%), THF/MeOH, RT, 3.5 h, 79%.  
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The western part was synthesized from the known alcohol 1.42 (Scheme 1.6), which was 
transformed to the aldehyde by allylic oxidation with manganese dioxide. Then, an Evans 
aldol reaction with 1.31 furnished the syn-product with high diastereoselectivity (20:1), 
cleavage of the auxiliary with MeONHMe·HCl gave the corresponding Weinreb amide 1.43. 
After TES-protection and direct reduction to the aldehyde, a Peterson olefination with imine 
1.46 was performed to give the enal 1.44 with excellent E:Z-selectivity (20:1). The aldehyde 
1.44 was stereoselectively allylated using Leighton’s silacycle 1.47, and the resulting 
secondary alcohol was protected as TBS silyl ether to give the fragment 1.45. 
 
Scheme 1.6: a) MnO2, m.s. 3Å, CH2Cl2, RT, 75 min; b) 1.31, nBu2BOTf, Et3N, CH2Cl2, –78°C, 2.5 h; then 0°C, 
1.5 h; then pH 7 buffer, MeOH, H2O2, 0 °C, 1 h ; c) MeONHMe·HCl, AlMe3, THF, 0 °C, 2 h, 53% (3 steps); d) 
TESCl, imid, CH2Cl2, RT, 30 min, 94%; e) DIBAL-H, THF, –30°C, 1 h; then –20°C, 1 h, 94%; f) 1.46, sBuLi, 
THF, –20°C, 2 h; then PhSH, –20°C, 2 h; then sat. aq. NaH2PO4, RT, 4 h, E:Z = 20:1, 81%; g) 1.47, Sc(OTf)3, 
CH2Cl2, –35°C to –20°C, 30 min; then –20°C, 2.5 h; then 1M HCl, RT, 7 min, 83%, d.r. > 20:1; h) TBSCl, imid, 
CH2Cl2, RT, 22 h, 93%. 
With all the fragments in hands, the cross metathesis of the terminal olefin 1.45 with the 
dienoate 1.48 (synthesis not shown) was performed (Scheme 1.7). The cross metathesis was 
highly challenging, especially homo-dimerization of the dienoate was a problem. However, 
Altmann and Glaus managed to reach a good yield and high E:Z-selectivity (6.7:1) with the 
Hoveyda-Grubbs II catalyst.  
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Scheme 1.7: a) Hoveyda–Grubbs II (15 mol%), EtOAc, RT, 3.5 h, 56%, E:Z 6.7:1; b) LiOH, tBuOH/H2O 
3:1, 33°C, 48 h, 69%; c) 1.41, 2,4,6-Cl3H2C6COCl, Et3N, DMAP, toluene, RT, 5.5 h, 81%; d) [Pd(PPh3)4] (20 
mol%), TlOEt, THF/H2O 3:1, RT, 25 min, 73%; e) Et3N·3HF, CH3CN/THF 7:3, –15°C, 4 h; then –25°C, 15 h; 
then –15°C, 7 h, 70%; f) Et3N·3HF, CH3CN/THF 6:4, –15°C to 5°C, 2 h; then 5°C, 5 h; then 15°C, 27 h, 54%; 
g) Et3N·3HF, CH3CN, 0°C to RT, 1 h; then RT, 8 h; then 50°C, 86 h, 47%.  
Hydrolysis of the methylester afforded the carboxylic acid precursor 1.49 for the 
subsequent Yamaguchi esterification with the boronic ester 1.41. A rapid intramolecular 
Suzuki coupling of the resulting compound 1.50 affected the macrocyclization to give the 
fully protected macrolide 1.51 in 73% yield. Conveniently, silyl ether cleavage at different 
temperatures gave access to the differently protected macrolides 1.52, 1.53 and 1.37. The TES 
group was found to be the most labile followed by the primary and finally the two secondary 
TBS ethers. This highly efficient and convergent approach furnished the fully deprotected 
aglycon 1.37 in 13 steps (longest linear sequence). 
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1.2 Goal of the Study and Retrosynthetic Considerations 
The aim of this project was to develop a total synthesis of fidaxomicin, in order to enable 
the synthesis of a second-generation antibiotic, based on the fidaxomicin lead structure, with 
improved pharmacokinetics and increased or maintained biological activity against nowadays 
multidrug resistant pathogens. This shall be reached either by semisynthetic or fully synthetic 
means. By the total synthesis of the antibiotic, insights into the chemistry of fidaxomicin 
should be gained. In reference to diversified fully synthetic analogues we aimed for a total 
synthesis, which a) is highly convergent, b) allows a flexible assembly and c) is easily 
modifiable at a late stage.  
The total synthesis of fidaxomicin should derive from four main fragments: 1) the central 
polyketide macrolide, 2) the rare carbohydrate novioside, 3) the 2O-methyl rhamnoside and 4) 
the resorcylate fragment (Figure 1.17). Considering the protecting group-strategy, we aimed 
for orthogonally and easily cleavable hydroxyl-masks. Thus, we planned to protect the 
alcohols on the core macrolide and the rhamnoside C3 alcohol as the TBS ether (Figure 1.17). 
A cyclic carbonate-protecting group seemed to be a convenient protecting group of the cis-
diol in the novioside portion. Importantly, the electron-withdrawing nature of the carbonate 
supports the selectivity of the β-noviosylation (Chapter 1.6.4). For the phenols, we chose an 
allyl ether protection since it offers mild cleavage conditions. In this protecting group-strategy 
the different groups are all orthogonal to each other allowing for a high flexibility in the end-
game of the synthesis. To satisfy the challenges of the total synthesis of the antibiotic 
fidaxomicin we decided to share the tasks between Dr. Hideki Miyatake Ondozabal and me. 
Thus, Dr. Miyatake Ondozabal was approaching the synthesis of the central aglycon, while I 
was engaged in the synthesis of the carbohydrate moieties, the resorcylate unit, as well as the 
demanding cis-selective rhamnosylation and noviosylation. Since the main focus of my work 
was on the carbohydrates, our synthesis of the macrolide is not discussed in full detail in this 
thesis. 
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Figure 1.17: Retrosynthetic strategy leading to four main fragments. 
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1.3 The Synthesis of the Aglycon 
As mentioned before, the studies towards the core aglycon in this chapter were mainly 
conducted by Dr. Hideki Miyatake Ondozabal during his post-doctoral studies in our group. 
The accomplished synthesis of the macrolide was published58 in Angewandte Chemie back to 
back to back with the syntheses of Altmann57 and Zhu59. The key steps of our aglycon 2.53 
synthesis were a ring closing metathesis (RCM), a Yamaguchi esterification, a Stille coupling 
and a vinylogous Mukaiyama aldol reaction (VMAR). Our retrosynthetic analysis led to three 
main fragments, the iodide 2.45, the dienoic acid 2.55 and the stannane 2.56. 
 
Figure 1.18: Retrosynthetic plan towards the protected aglycon. 
The known compound 2.57 (2 steps)60 served as the starting material for our synthesis of 
the fragment 2.45. In the first step, the Mukaiyama aldol precursor 2.58 was synthesized by γ-
deprotonation of 2.57 using NaHMDS and trapping of the enolate with TBSCl (Scheme 1.8). 
A vinylogous Mukaiyama aldol reaction (VMAR) of the silyl ether 2.58 and the aldehyde 
2.63, mediated by TiCl4, gave the trans-product 2.59 in high diastereoselectivity (d.r. > 
20:1).61 To the best of our knowledge, Kobayashi’s VMAR has so far never been conducted 
with a larger substituent than a methyl in γ-position. Nonetheless, the reaction gave 47% yield 
of the desired compound 2.59 and a considerable amount of the desilylated starting material 
2.57 was recovered (35%). The rationale behind the trans selectivity of the reaction is shown 
in Figure 1.19. 
                                                
60  a) K. Ohata, S. Terashima, Chem. Pharm. Bull. 2009, 57, 920-936; b) D. J. Ager, D. R. Allen, D. R. Schaad, 
Synthesis 1996, 1283-1285 
61  a) S.-I. Shirokawa, M. Kamiyama, T. Nakamura, M. Okada, A. Nakazaki, A. Seijiro Hosokawa, S. 
Kobayashi, J. Am. Chem. Soc. 2004, 126, 13604–13605; b) M. Kalesse, M. Cordes, G. Symkenberg, H.-H. 
Lu, Nat. Prod. Rep. 2014, 31, 563–594. 
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Scheme 1.8: Synthesis of the eastern iodide fragment: a) NaHMDS, THF, −78°C then TBSCl, 97%; b) 2.63, 
TiCl4, CH2Cl2, −78°C to −30°C, 47%, d.r. > 20:1; c) p-nitrobenzoic acid, DEAD, PPh3, THF, 0°C, 78%; d) 
NaBH4, THF/H2O; e) MnO2, CH2Cl2, 76% (2 steps); f) (−)-Ipc2B(allyl), Et2O, −78°C then aq. NaBO3, 70%, d.r. 
= 20:1; g) TBSOTf, 2,6-lutidine, CH2Cl2, 93%; h) K2CO3, MeOH/H2O; i) TESOTf, 2,6-lutidine, CH2Cl2, 95% (2 
steps). 
 
Figure 1.19: Stereochemical rational for the vinylougous Mukaiyama aldol reaction. 
The required syn-product 2.60 was achieved by a Mitsunobu inversion under standard 
conditions using para-nitrobenzoic acid as nucleophile (Scheme 1.8). Cleavage of the Evans 
auxiliary was performed selectively over the PNB-ester using NaBH4 and the resulting 
primary allyl alcohol was oxidized successively with MnO2 to give aldehyde 2.61. A Brown 
allylation was chosen to introduce the last stereocenter of this fragment, which gave good 
yield and high diastereoselectivity (70%, d.r. = 20:1). The resulting secondary alcohol was 
protected as the TBS-ether using TBSOTf and lutidine with good yield (93%). Since, the 
Stille-coupling with benzoyl ester 2.62 was not successful, a protecting group swap from the 
ester to the triethylsilyl ether was performed to give the final fragment 2.45.  
The stannane fragment 2.56 was synthesized in only three steps, starting from enantiopure 
epoxide 2.64 (Scheme 1.9).62 First, the TBS-protecting group was installed, then the epoxide 
was regioselectively opened with propynyl lithium and BF3·Et2O. Unfortunately, the 
                                                
62  J. D. White, M. Kang, B. G. Sheldon, Tetrahedron Lett. 1983, 24, 4539–4542. 
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regioselectivity during the following hydrostannylation of alkyne 2.65 was only poor, thus 
stannane 2.56 was isolated in moderate yield (51%).  
 
Scheme 1.9: Synthesis of the stannane fragment: a) TBSCl, imid, CH2Cl2, 93%; b) propyne, nBuLi, BF3·Et2O, 
THF, −78°C to 0°C, 90%; c) Pd(OAc)2, PCy3, Bu3SnH, hexane, 51%. 
The third and final fragment, the dienoic acid 2.55, was synthesized from the commercially 
available β-hydroxy propanoate 2.66 (Scheme 1.10). An aldol reaction with acrolein was 
performed, followed by monoselective silyl ether protection of the primary alcohol mediated 
by dimethyltin chloride, to furnish the allylic alcohol 2.67 in 75% yield over two steps. Next, 
acylation and DBU induced elimination gave the dienoate 2.68 with good E:Z-selectivity 
(5.5:1). As the ester hydrolysis under standard conditions (LiOH, NaOH) was troublesome, 
mainly due to silyl ether cleavage, a reduction-oxidation sequence was performed to access 
the final building block 2.55 in 70% yield. 
 
Scheme 1.10: Synthesis of the dienoate: a) LDA, THF, −78°C then acrolein, −78°C; b) Me2SnCl2 (10 mol%), 
TBSCl, Et3N, 75% (2 steps); c) Ac2O, Et3N, DMAP, CH2Cl2; d) DBU, CH2Cl2, 72% (2 steps), E:Z = 5.5:1; e) 
DIBAL-H, CH2Cl2, −10°C; f) MnO2, CH2Cl2; g) NaClO2, KH2PO4, 2-methyl-2-butene, t-BuOH/H2O, 70% (3 
steps). 
As all the required building blocks have been synthesized, we moved on to their assembly 
(Scheme 1.11). The Stille coupling between the stannane 2.56 and iodide 2.45 was performed 
first. As expected, the reaction was exceptionally challenging due to the bulky nature of the 
two fragments. Nevertheless, we found that Fürstner’s conditions 63  using thiophene-2-
carboxylate Cu(TC), tetrabutylammonium diphenylphosphonate and Pd(PPh3)4 gave the diene 
2.69 in good yield (77%). The secondary alcohol 2.69 was then condensed with dienoic acid 
2.55 using Yamaguchi esterification conditions to furnish the linear compound 2.70. Ring 
                                                
63  A. Fürstner, C. Nevado, M. Tremblay, C. Chevrier, F. Teplý, C. Aïssa, M. Waser, Angew. Chem. Int. Ed. 
2006, 45, 5837-5842. 
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closing metathesis between the terminal olefins of 2.70 was conducted with the second 
generation Grubbs catalyst. This furnished macrocycle 2.51 smoothly even at room 
temperature, although only the Z isomer was formed in this case. By increasing the 
temperature, the E:Z ratio could be optimized in favour of the E-isomer (40°C, 2:3; 100°C, 
2:1). Further E-macrolide 2.51 was obtained by recycling of (Z)-2.51. In this way, after one 
cycle a yield of 80% of the desired fully protected fidaxomicin aglycon 2.51 was reached. The 
final task was the cleavage of the primary tert-butyl dimethysilyl ether and the triethylsilyl 
ether. Thus the macrolide 2.51 was treated with 3HF·Et3N at room temperature. To avoid 
over-deprotection, the reaction was stopped after a certain time to isolate the desired aglycon 
2.53 in 65% and the mono deprotected macrolide 2.52 in 35% yield. 
 
Scheme 1.11: a) 2.56, CuTC, [Pd(PPh3)4], [Bu4N]+[Ph2PO2]-, DMF, 77%; b) 2.55, Cl3C6H2COCl, Et3N, DMAP, 
toluene, 86%; c) Grubbs cat. II (15 mol%), toluene, 40°C (µw), 10 min, E:Z = 2:3, then 100°C, 18 h, E:Z = 2:1, 
90%; d) Grubbs cat. II (15 mol%), toluene, 100°C, 18 h, E:Z = 2:1, 92%; e) Et3N·3HF, THF/MeCN 1:1, 0°C to 
23°C, 2.53:65%, 2.52:32%. 
In this chapter the synthesis of the protected fidaxomicin aglycon 2.51 in a highly 
convergent fashion from three main fragments was described. The longest linear sequence of 
the synthesis from compound 2.57 was only 14 steps. The aglycon 2.53 serves as the 
appropriate precursor for the total synthesis of the glycosylated fidaxomicin. 
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1.4 Synthesis of the D-Novioside – an Unusual Carbohydrate 
1.4.1 Occurrence and Previous Synthetic Contribution 
Fidaxomicin and the related natural products bear a β-linked D-(–)-novioside fragment, 
which is unique in nature (Figure 1.20). So far, the glycosylated macrolide is the only known 
natural source of this enantiomer. Similarly, the L-(+)-antipode is also only sparely occurring 
in natural products. The family of the aminocoumarins (e.g. novobiocin, clorobiocin, 
coumermycin A1, coumabiocin A) are the only natural products incorporating the L-(+)-
novioside, which is exclusively α-linked to a coumarine system and all bear a methoxy 
function at C4 (Figure 1.20). Novobiocin, clorobiocin and coumermycin A1 are potent 
bacterial DNA gyrase inhibitors of the type II topoisomerase.64 Special interest gained 
novobiocin, which was available for a short time as a broad-spectrum antibiotic in 
combination with tetracycline under the tradename Albamycin T.65 Further it was used in 
anticancer therapy,66 and caught attention as an effective compound for MRSA treatment.67 
To the best of our knowledge, eleven different synthetic studies towards the noviose can be 
found in literature. Most of them are targeting the 4-O-methyl L-(+)-novioside, only three 
reports furnished the 4-O-methyl D-(–)-novioside. Except for one publication,68 the entire 
published syntheses target the methylated noviose, and generally the alkyl substituent is 
introduced in an early step. In the following, I want to discuss the key features of the reported 
novioside syntheses in chronological order.  
 
                                                
64  a) D. C. Hooper, J. S. Wolfson, G. L. McHugh, M. B. Winters, M. N. Swartz, Antimicrob. Agent. 
Chemother. 1982, 22, 662–671; b) R. J. Lewis, O. M. P. Singh, S. V. C, T. Skarzynski, A. Maxwell, A. J. 
Wonacott, D. B. Wigley, EMBO J 1996, 15, 1412. 
65  Canadian Medical Association Journal 1960, 82, 30. 
66  M. V. Blagosklonny, Leukemia 2002, 16, 455–462. 
67  T. J. Walsh, H. C. Standiford, A. C. Reboli, J. F. John, M. E. Mulligan, B. S. Ribner, J. Z. Montgomerie, M. 
B. Goetz, C. G. Mayhall, D. Rimland, Antimicrob. Agent. Chemother. 1993, 37, 1334–1342. 
68  A. Klemer, M. Waldmann, Liebigs Ann. Chem. 1986, 2, 221–406. 
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Figure 1.20: The aminocoumarins and the fidaxomicin family constitute the two only natural sources of the 
carbohydrate noviose. 
The earliest synthesis of the noviose dates back to 1964. 69  Spiegelberg’s approach 
commenced with glucose 1.71, which was transformed to the glucofuranose 1.72 having the 
methoxy-function already installed. Hydrolysis and oxidation at the anomeric position served 
the lactone, which was methylated twice using methyl Grignard to give the linear intermediate 
1.73. In the last nine steps elaborate protection/deprotections, an oxidative cleavage using 
Pb(OAc)4 and a base catalysed epimerization at C3 were carried out to furnish the noviose 
1.74.  
 
                                                
69  J. Kiss, H. Spiegelberg, Helv. Chim. Acta 1964, 47, 398–407. 
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Scheme 1.12: The first noviose synthesis by Spiegelberg et al. in 1964 commencing from glucose.69 
In 1975 Achmatowicz and co-workers70 reported the synthesis of the racemic 4-O-methyl 
β-novioside 1.78 from 2-acetylfuran 1.75 (Scheme 1.13). Key to the synthesis is a ring 
expansion – nowadays referred as Achmatowicz reaction – which transforms the furfuryl 
alcohol 1.76 into the dihydropyran 1.77. Subsequent insertion of the 4-O-methyl group and a 
dihydroxylation of the corresponding 1,4-trans intermediate gave the desired (±)-novioside 
1.78 in total seven steps. 
 
Scheme 1.13: Achmatowicz’s synthesis of the β-D,L-novioside.70 a) MeMgBr, Et2O; b) Br2, MeOH, Et2O,          
–35°C, 97%; c) H2SO4 1% aq., 2 h, 98%. 
Up to date, the only synthesis of the unsubstituted L-noviose 1.82 was reported by Klemer 
in 1986 (Scheme 1.14).68 They started with the natural L-rhamnose 1.79, which was 
isomerized to the furanoside 1.80. The C5 hydroxy group was then oxidized and reacted with 
methyl Grignard to give the novio-furanoside 1.81. Aqueous acidic hydrolysis then gave the 
desired L-noviose. This protocol is the shortest (4 steps) and highest yielding (76% over all) 
reported in literature. 
 
Scheme 1.14: Synthesis of the L-noviose by Klemer et al. a) MeOH, 2,2-DMP, pTsOH, 65°C, 8 h, 89%; b) 
CrO3, py, CH2Cl2, 94%; c) MeMgI, Et2O, 35°C, 95%; d) H2SO4 0.5 M aq., 80°C, 2 h, 95%. 
                                                
70  O. Achmatowicz Jr., G. Grynkiewicz, B. Szechner, Tetrahedron 1976, 32, 1051–1054. 
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Kreiser et al. were the first to describe a stereoselective total synthesis of the 4O-methyl-D-
noviose 1.86 (Scheme 1.15). 71  Starting from readily available medion (1.83) a 
desymmetrization approach with lipase gave the enantiopure precursor 1.84 in six steps. Then 
dihydroxylation, acetate hydrolysis, carbonate protection and oxidation served the ketone 
1.85. To finalize the synthesis a Baeyer-Villiger oxidation to the lactone and a reduction using 
DIBAL-H was conducted.  
 
Scheme 1.15: The first stereoselective synthesis of D-noviose. a) mCPBA, CH2Cl2, 3 d, RT, 74% b) DIBAL-H, 
CH2Cl2, –78°C, 78%.  
The synthesis of Musicki72 and co-workers started with L-arabinose 1.87 as the chiral pool 
precursor and followed the strategy of Spiegelberg (vide supra). Their route also goes via 
oxidation of the anomeric position to the lactone 1.88. Then dimethylation using Grignard 
conditions gave the linear diol, which is then oxidized and deprotected to give the desired 
carbohydrate 1.74.  
 
Scheme 1.16: Total synthesis of the 4O-methyl-L-noviose by Musicki.72 a) MeMgBr, THF, 0°C, 86%; (b) PCC, 
CH2C12, RT, 66%; (c) DIBAL-H, THF, 0°C, 63%; (d) H2SO4 aq., 65°C, 95%. 
D-Ribose 1.89 served as precursor in the synthesis by the group of Wilson (Scheme 
1.17).73 In the first four steps the C5 methyl groups were installed. Hydrolysis of the anomeric 
position was undertaken to reductively open up the ring using LAH and protection of the 
                                                
71  a) W. M. Pankau, W. Kreiser, Helv. Chim. Acta 1998, 81, 1997–2004; b) W. M. Pankau, W. Kreiser, 
Tetrahedron Lett. 1998, 39, 2089–2090; c) W. Kreiser, A. Wiggermann, A. Krief, D. Swinnen, Tetrahedron 
Lett. 1996, 37, 7119-7122. 
72  P. Laurin, D. Ferroud, M. Klich, C. Dupuis-Hamelin, P. Mauvais, P. Lassaigne, A. Bonnefoy, B. Musicki, 
Bioorg. Med. Chem. Lett. 1999, 9, 2079–2084. 
73  D. W. Gammon, R. Hunter, S. Wilson, Tetrahedron Lett. 2002, 43, 3141–3144. 
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resulting primary alchohol to give 1.91. An oxidation/reduction sequence of the C4 hydroxy 
group was performed to interconvert the stereogenic center and furnish 1.92. In the final 
steps, the methoxy group at C4 was introduced and the pyranose 1.74 was formed by cleavage 
of the benzyl groups and reoxidation of the C1-carbon.  
 
Scheme 1.17: Wilson’s synthesis of 4O-methyl-L-noviose: a) i. HCl 1M aq., dioxane, 60°C; ii. acetone, H2SO4, 
0°C, 62%; b) LAH, THF, 0°C, 84%; c) NaH, benzyl bromide, THF, RT, 98%; d) (COCl)2, DMSO, Et3N, 
CH2Cl2, 85%; e) K-selectride®, toluene, 0°C to RT, 72%.  
Another synthesis serving 4O-methyl-D-noviose 1.86, via a similar intermediate 1.95 as 
Wilson 1.92, was reported by Blagg et al. (Scheme 1.18). Here, the previously reported 
furanose 1.93 served as the starting material to reach the olefin 1.94 by a Wittig reaction. Key 
to their approach was the dihydroxylation of the olefin to give the right diastereomer 1.95 in 
modest selectivity (d.r. = 2:1). Further standard transformations accomplished the synthesis to 
obtain the D-noviose 1.86.74  
 
Scheme 1.18: Synthesis of 4O-methyl-D-noviose by Blagg et al.74 a) Ph3P+CH(CH3)2, nBuLi, 91%; b) NaH, 
BnBr, 95%; c) OsO4, NMO, 84% d.r.=2:1; d) KOtBu, MeI, 86%. 
The starting point of the synthesis by Reddy et al.75 was the olefin 1.96 (Scheme 1.19). 
Key transformations in their synthesis were a RCM, a stereoselective dihydroxylation and a 
Baeyer-Villiger oxidation to access the target molecule 1.86 in overall 14 steps. This 
synthesis was later further developed, such that both enantiomers could be prepared using the 
same approach.75b 
                                                
74  X. M. Yu, G. Shen, B. S. J. Blagg, J. Org. Chem. 2004, 69, 7375–7378. 
75  a) D. S. Reddy, G. Srinivas, B. M. Rajesh, M. Kannan, T. V. Rajale, J. Iqbal, Tetrahedron Lett. 2006, 47, 
6373–6375; b) B. M. Rajesh, M. V. Shinde, M. Kannan, G. Srinivas, J. Iqbal, D. S. Reddy, RSC Adv. 2013, 
3, 20291–20297. 
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Scheme 1.19: Synthesis of 4O-methyl-D-noviose by Reddy and co-workers. a) (COCl) 2, DMSO, Et3N, –78°C, 
96%; b) CH2CHMgBr, 0°C, 82%; c) Grubb’s catalyst (5 mol%), RT, 91%; d) Jones’ oxidation, 86%; e) NaBH4, 
CeCl3·7H2O, 0°C, 96%; f) TBSCl, imid, 0°C, 83%; f) OsO4, NMO, acetone, H2O, tBuOH, rt, 89%; g) 
triphosgene, 0°C to RT, 92%; h) TBAF, THF, 94%; i) Swern or PDC; j) mCPBA, CH2Cl2, 3 d, RT, 90% (2 
steps); k) DIBAL-H, CH2Cl2, –78 °C, 60%. 
The most efficient synthesis of the novioside 1.74 starting from achiral starting material 
was reported by Hanessian in 2008.76 Within only six steps from 1.99, the 4O-methyl-L-
noviose 1.74 was reached using a CBS-reduction-desymmetrization approach combined with 
an established Baeyer-Villiger, dihydroxylation end-game (Scheme 1.20). Thereby, the C4 
methoxy group is installed at the very beginning of the synthesis. 
 
Scheme 1.20: Synthesis of Hanessian and co-workers.76 a) CBS, borane-N,N-diethylaniline complex, THF, 0°C, 
78%, 96% ee; b) MeI, Ag2O, reflux, 5 d, 88%, c) mCPBA, Sc(OTf)3 (5 mol%), CH2Cl2, 99%; d) LHMDS, 
TMSCl, THF, –78°C, then Pd(OAc)2, MeCN, 0°C to RT, 72%; e) DIBAL-H, CH2Cl2, –78°C; f) OsO4, NMO, 
H2O, acetone, 0°C, 55% (2 steps). 
 
1.4.2 Novel Synthetic Route Towards D-Novioside 
For our total synthesis of fidaxomicin and in respect to the synthesis of analogues we 
aimed to synthesize the novioside fragment 1.102 via the unsubstituted novioside 1.103 
(Scheme 1.21). This approach allows us to the the O4 substituents at a late stage of the 
synthesis, which is of special interest with regard to the decreased biological activity of 
fidaxomicin’s major metabolite (OP1118) – lacking the isobutyric ester at the noviose. We 
planned to use the carbonate-protecting group to reach a high degree of SN2-like character 
during the glycosylation (vide infra). Most of the reported syntheses (Chapter 1.6.4) insert a 
methoxy group at C4 in an early stage. Unfortunately, these strategies are not only 
                                                
76  S. Hanessian, L. Auzzas, Org. Lett. 2008, 10, 261–264. 
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incompatible with an ester substituent but also limit the flexibility of the substitution pattern. 
Furthermore, the rare examples that serve the D-noviose require many synthetic steps. 
However, the synthesis by Klemer et al. would be the most suitable to address our 
requirements (chapter 1.4.1). For us, a simultaneous synthesis was not possible since the 
unnatural D-rhamnose is not commercially available. In addition, we aimed for the sake of 
convenience towards the methyl-novioside 1.103 rather than the noviose. Due to these 
considerations, we decided to developed a new route towards this unusual carbohydrate. We 
figured that the natural and commercially readily available D-mannoside 1.104 would be a 
logical precursor for this purpose as it unites all the required stereochemical information 
(Scheme 1.21). 
 
Scheme 1.21: Retrosynthetic plan towards the desired substituted novioside. 
Our approach commenced with the transformation of the primary C6-alcohol in 1.104 to 
the iodide 1.105 under Garegg-Samuelson conditions and protection of the cis-diol using 2,2-
dimethoxypropan to give the dimethylacetal 1.106.77 A Bernet-Vasella fragmentation gave the 
furanose 1.107. The procedure we used is a variant of the originally applied condtions.78 
Generally, this reaction needs acidic preactivation of zinc or the addition of TMSCl. also 
vitamin B12 was used as activator.79 In our case, the addition of NH4Cl was sufficient to 
initiate the reaction.  
                                                
77  H. Kumamoto, K. Deguchi, T. Wagata, Y. Furuya, Tetrahedron 2009, 65, 8007-8013. 
78  B. Bernet, A. Vasella, Helv. Chim. Acta 1979, 62, 1990–2016; B. Bernet, A. Vasella, Helv. Chim. Acta 1984, 
67, 1328–1347. 
79  a) P. R. Skaanderup, L. Hyldtoft, R. Madsen, Chem. Month. 2002, 133, 467–472; b) M. Kleban, U. Kautz, J. 
Greul, P. Hilgers, R. Kugler, H.-Q. Dong, V. Jäger, Synthesis 2000, 7, 1027–1033; c) A. Fürstner, H. 
Weidmann, J. Org. Chem. 1989, 54, 2307–2311. 
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Scheme 1.22 Garegg-Samuelson iodination and Bernet-Vasella fragmentation: a) I2, PPh3, imid, THF, reflux, 
80%; b) 2,2-DMP, TsOH, acetone, RT, 93% (2 steps); c) Zn (10 equiv), NH4Cl (0.4 equiv), MeOH, 60°C, 91%. 
The oxidative cleavage of the terminal olefin was performed by Marshall’s ozonolysis in 
the presence of sodium hydroxide and methanol which gave direct rise to the desired methyl 
ester (Scheme 1.23).80 It was important to protect the anomeric position first as the furanoside 
1.108 – which has a nice, sweet smell – as otherwise the hemiacetal in 1.107 is oxidized to the 
methylester 1.111 to some extend. After acetal formation, Marshall’s protocol furnished the 
previously reported 81  methylester 1.109, along with a small amount of the known 
corresponding aldehyde 1.110.82 Alternatively, simple ozonolysis to the aldehyde followed by 
bromine-mediated oxidation in methanol gave the ester 1.109 in about the same overall yield 
(66%). The conditions reported by Borhan and co-workers using oxone in methanol83 to 
oxidize aldehydes to esters gave only very poor yield in this case. 
 
Scheme 1.23: Oxidative cleavage of the terminal olefin: a) i. 1.107, O3, 2.5M methanolic NaOH, CH2Cl2, −78°C; 
ii. Amberlyst IR120H+, 2,2-DMP, MeOH, 55°C, 30% 1.109, 10% 1.111; b) 1.108, O3, 2.5M methanolic NaOH, 
CH2Cl2, −78°C, 62% 1.109; c) 1.108, O3, MeOH, CH2Cl2, −78°C, then Me2S, 72% 1.109 d) CSA, 2,2-DMP, 
MeOH, 55°C, quant; e) Br2, NaHCO3, MeOH, H2O, 40°C, 92%. 
Treatment of the methylester with methyl Grignard in ether at reflux inserted the C5 
methyl groups with quantitative yield. At this point, we crossed the synthesis of the L-noviose 
by Klemer et al.68 in which the enantiomeric compound was synthesized and then fully 
                                                
80  J. A. Marshall, A. W. Garofalo, R. C. Sedrani, Synlett 1992, 643–645. 
81  R. R. Schmidt, P. Hermentin, Chem. Ber. 1979, 112, 2659–2671. 
82  J. M. J. Tronchet, B. Gentile, A. P. Bonenfant, O. R. Martin, Helv. Chim. Acta 1979, 62, 696–699. 
83  B. R. Travis, M. Sivakumar, G. O. Hollist, B. Borhan, Org. Lett. 2003, 5, 1031–1034. 
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hydrolysed and isomerized to the pyranose. In contrast, we aimed to keep the anomeric 
position protected as the methyl acetal 1.103. Thus, the hydrolysis of the acetal was 
performed in presence of methanol. Heating the furanoside 1.112 in methanol and Amberlyst 
IR120H+ at 50°C for 2 days gave a 2:1 ratio of the pyranoside (60%) to furanoside (30%). 
This ratio corresponds to the thermodynamic equilibrium and does not change by prolonged 
reaction time. Hence, we decided to recycle the furanoside 1.113 to increase the output. We 
then changed to more forcing conditions, in order to lower the reaction time. Treating the 
tertiary alcohol 1.113 with trifluoroacetic acid in methanol at 100°C in the microwave gave 
the same 2:1 ratio after 1 h. Recycling of the furanoside 1.113 two times served the desired 
methyl-D-novioside 1.103 in good yield (81%) as an inseparable anomeric mixture (α:β = 
2:1). 
 
Scheme 1.24: C5 Methylation and isomerization to the D-novioside: a) MeMgBr (2.4 equiv), Et2O, reflux, 99%; 
b) TFA, MeOH, 100°C (µw), 1 h, 81% (3 cycles), α:β = 2:1. 
The cis-selective protection of the C2,C3-hydroxyl groups was achieved by the addition of 
1,1-carbonyldiimidazole (CDI) (Scheme 1.25). In an initial approach we added CDI (freshly 
recrystallized) portion wise to a solution of 1.103 in DCE at reflux until complete 
consumption. The crude material was then used directly in the acylation step with isobutyryl 
chloride to give the desired product 1.102 in 67% yield over the two steps. Unfortunately, the 
carbonate protection is not easy to control and in certain batches the yield dropped 
dramatically due to over dosing or under dosing of CDI. We thus tried to improve the 
protocol. Triphosgene in dichloromethane and pyridine at –78°C to room temperature, gave 
only poor yield (30%) of the desired carbonate 1.115. On the other hand, treatment of the 
novioside 1.103 with an excess of CDI in THF and subsequent hydrolysis of the intermediate 
1.114 in  aqueous HCl (6M) gave the desired carbonate 1.115 in 88% yield (Scheme 1.25). 
This procedure is significantly easier to conduct, as tedious reaction control is not required 
anymore. In regard to the synthesis of analogues, in particular the natural product tiacumicin 
A, the acetylated novioside equivalent 1.116 was synthesized as well (Scheme 1.25). Acetic 
anhydride/pyridine furnished the desired product 1.116 in moderate yield. 
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Scheme 1.25: Carbonate protection and acylation: a) CDI (3.5 equiv), THF, 50°C, 3 h, then HCl 6M aq., RT 1 h, 
88%; b) from 1.103, CDI, DCE, reflux, 3 h; then iPrCOCl, Et3N, CH2Cl2, RT 67% 1.102 (2 steps); c) Ac2O, 
pyridine, RT, 1 h, 67% 1.116. 
Even though irrelevant to advance further, the anomers were separable by column 
chromatography on the acetylated stages. The α- and β-epimers were isolated in a 2:1 ratio 
and the stereochemistry was assigned by NMR (NOESY) and X-ray analysis. The coupling 
constants and the chemical shifts of the anomers are highly characteristic (Table 1.2). The 
coupling constants of the α epimers are in agreement with a flattened 1C4 ring conformation 
according to the Karplus and Bothner-By equation. The signals of the β-novioside do not 
show distinct coupling patterns and the H2 and H3 signals are superimposed. The most likely 
explanation for this observation is the slow interconversion of one into another ring 
conformation, slower than NMR measuring time scale. Thus, a distinct ring conformation can 
not be assigned to this molecule. Remarkably, the β-H4 (5.8-5.7 ppm) is significantly down 
field shifted compared with the α-H4 (5.1 ppm). These characteristics simplified the 
identification of the anomeric ratio in the later noviosylations substantially (chapter 1.6.4). 
Table 1.2: 1H-NMR chemical shifts of the α- and β-anomers in CDCl3. d = duplet; dd = duplet of duplet; t = 
triplet; m = multiplet. 
 
   
 R = iPrCO R = Ac R = iPrCO R = Ac 
H no. δH/ppm, (J/Hz) δH/ppm, (J/Hz) δH/ppm, (J/Hz) δH/ppm, (J/Hz) 
1 4.85, d (7.7) 4.91, d (3.0) 4.79–4.75, m 4.86–4.82, m 
2 4.62, dd (7.8, 2.9) 4.68, dd (7.8, 3.0) 
4.73–4.70, m, 2H 4.81–4.74, m, 2H 
3 4.72, t (7.7) 4.78, t (7.7) 
4 5.06, d (7.6) 5.11, d (7.7) 5.73–5.66, m 5.80–5.72, m 
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In addition to the NOESY correlation the relative stereochemistry of the β-novioside 1.102 
was confirmed by X-ray crystallographic analysis (Figure 1.21). Remarkably, the compound 
crystallized in a boat conformation (1,4B), placing the anomeric oxygen in the axial position 
and allowing the stabilization by the anomeric effect.  
 
Figure 1.21: X-ray crystallographic analysis of β-novioside. grey = carbon; red = oxygen; white = hydrogen. 
To sum up, we developed a new synthetic route to prepare D-novioside 1.103 in only six 
steps, which is the shortest synthesis reported so far for this enantiomer. Carbonylation and 
acylation of the carbohydrate gave then the desired precursor 1.102 for the total synthesis of 
fidaxomicin. The investigations of the β-selective noviosylation are described in 
Chapter 1.6.4. 
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1.5 Synthesis of the Resorcylate-Rhamnoside Fragment 
1.5.1 Previous Synthetic Contributions and Retrosynthetic Analysis 
Fidaxomicin is β-linked to a 2O-methyl-D-rhamnoside, which is substituted with a 
resorcylate unit – sometimes referred as homodichloro orsellinic acid. The previous synthetic 
studies of these fragments are limited to the separate units. Scharf and co-workers described 
the preparation of the dichloro resorcylate 1.122 in 1991, in order to verify the structural 
motif in fidaxomicin. (Scheme 1.26).84 The synthesis commenced with the intermolecular 
cyclization of ethyl acetoacetate 1.117 and ethyl pentenoate 1.118 under basic conditions. 
Then aromatization and bromination of 1.119 in anhydrous acetic acid was conducted to get 
to the homodibromo-orsellinate 1.120. To exchange the bromides with chlorides a two-step 
sequence was conducted. First, a reduction using Raney-Nickel in aqueous sodium hydroxide 
furnished the homo-orsellinate 1.121 and finally chlorination using sulfuryl chloride in ether 
gave the resorcylate 1.122. 
 
Scheme 1.26: The resorcylate synthesis by Scharf:84 a) Na, EtOH, 94%; b) Br2, AcOH, 40°C, 16 h, 65%; c) 
Raney Nickel, NaOH 1M aq., 0–5°C, 4 h, quant; d) SO2Cl2, Et2O, reflux, 10 min, 86%. 
Liptàk et al. reported so far the only synthesis of the 2O-methyl-D-rhamose 1.126 in 
1982.85 They commenced with the acetalization of methyl-D-mannoside 1.104 using α,α-
dimethoxy toluene and para-toluenesulfonic acid in DMF (Scheme 1.27). Then the 
regioselective opening of the five-membered acetal 1.123 with LAH and AlCl3 gave the O3-
benzylated intermediate, which was methylated at O2 using methyl iodide and Ag2O to give 
compound 1.124. After a regioselective opening of the six-membered acetal using 
LAH/AlCl3, the free primary alcohol was tosylated and reduced to give the dibenzylated 
rhamnoside 1.125. Hydrogenolysis of the benzyl ethers and subsequent acidic hydrolysis 
furnished the 2O-methyl-D-rhamose 1.126 in overall eight steps. 
                                                
84  M. Alexy, H.-D. Scharf, Liebigs Ann. Chem. 1991, 1363–1364. 
85  a) A. Lipták, Carbohydr. Res. 1982, 107, 300–302; b) A. Lipták, I. Czégény, J. Harangi, P. Nánási, 
Carbohydr. Res. 1979, 73, 327–331. 
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Scheme 1.27: Synthesis of the 2O-methyl-D-rhamnose by Liptàk et al.:85 a) PhCH(OCH3)2, pTSA, DMF, 95%; 
b) LAH, AlCl3, Et2O, CH2Cl2, 67%; c) MeI, Ag2O, DMF, 90%; d) LAH, AlCl3, Et2O, CH2Cl2, reflux, 67%; e) 
tosylation (not described); f) LAH, benzene, Et2O, reflux, 86%; g) Pd/C, AcOH, EtOH, 88%; h) aq. H2SO4, 
100°C, 6 h, 76%. 
Since thio-glycosides are common donors, which are generally stable under acidic 
conditions and still can be easily converted into other leaving groups, our synthetic target was 
the thio-rhamnoside 1.127. The flexibility was of special interest as β-selective 
rhamnosylations are a challenging task and not easy to predict (Chapter 1.6.2). TBS silyl ether 
protection of the C3 hydroxyl group in the rhamnoside should simplify the final global 
deprotection, as the core macrolide is silyl ether protected as well. These considerations led to 
the resorcylate-rhamnoside fragment 1.127, which could derive from the resorcylate unit 
1.128 and the appropriately protected rhamnoside 1.129 (Scheme 1.28). 
 
Scheme 1.28: Retrosynthetic analysis for the resorcylate-rhamnoside donor. 
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1.5.2 Biomimetic Synthesis of the Resorcylate Fragment 
To prepare the homodichloro-orsellinate, we imagined performing a biomimetic 
aromatization as elaborated by Barrett et al. (Scheme 1.29).86 In analogy to the existing 
procedures, the dioxinone 1.130 was acylated.86f Then the resulting product 1.131 was two-
fold deprotonated and acylated with propionyl imidazole. The intermediate diketodioxinone 
1.132 was then treated with Et3N to mediate aromatization to the homo orsellinate 1.133. 
 
Scheme 1.29: Biomimetic synthesis of the resorcylate fragment: a) LHMDS, THF, then AcCl, –78°C, 61%; b) 
LDA (2.1 equiv), propionyl imidazole (0.5 equiv), THF, −78°C then Et3N, 57%; c) SO2Cl2, CH2Cl2, reflux, 
98%; d) K2CO3, allyl bromide, DMF, 50°C, 95%. 
The aromatic compound was then efficiently chlorinated using sulfuryl chloride84 (98%) 
and the resulting homodichloro orsellinate 1.134 was protected as the allyl ether using K2CO3 
and allyl bromide (95%). In this way, the required resorcylate 1.128 was achieved in only four 
steps.  
1.5.3 The Synthesis of the 2O-Methyl-D-rhamnoside – 1st Approach 
As depicted in Scheme 1.28 we targeted the O2 methylated and O3-TBS protected 
rhamnoside 1.129 in the first attempt. Thus, we started from commercially available methyl-
D-mannoside 1.104 and protected the C6-C4 hydroxyl groups as the six-membered cyclic 
                                                
86  a) B. H. Patel, A. M. Mason, H. Patel, R. C. Coombes, S. Ali, A. G. M. Barrett, J. Org. Chem. 2011, 76, 
6209–6217; b) I. Navarro, C. Pöverlein, G. Schlingmann, A. G. M. Barrett, J. Org. Chem. 2009, 74, 8139–
8142; c) B. H. Patel, A. M. Mason, A. G. M. Barrett, Org. Lett. 2011, 13, 5156–5159; d) K. Anderson, F. 
Calo, T. Pfaffeneder, A. J. P. White, A. G. M. Barrett, Org. Lett. 2011, 13, 5748–5750; e) M. Fouché, L. 
Rooney, A. G. M. Barrett, J. Org. Chem. 2012, 77, 3060–3070; f) B. H. Patel, S. F. A. Heath, A. M. Mason, 
A. G. M. Barrett, Tetrahedron Lett. 2011, 52, 2258–2261. 
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benzylidene acetal. Various one step protocols using α,α-dimethoxy benzaldehyde in 
combination with e.g., ionic liquids,87 trichlorotriazine (TCT),88 HBF4,89 or pTSA at 200 
mbar,90 are described in literature. The reported yields range from 40 to 99%, in our hands the 
yields were always lower than described in the literature. The only protocol that gave reliable 
yields was the method by Leino and co-workers: Stirring of the mannoside 1.104 in DMF 
with an equivalent dimethoxy benzaldehyde and catalytic pTSA at 200 mbar and 60°C, to 
remove formed methanol, furnished the product 1.135 in 53% yield.  
 
Scheme 1.30: 1st Approach of the synthesis of the 2O-methyl-D-rhamnoside: a) PhCH(OCH3)2, pTSA, DMF, 
60°C, 200 mbar, 2 h, 53%; b) nBu2SnO, MeOH, reflux, 1 h, then TBSCl, TBAI, DMF, CH2Cl2, 16 h, 80%; c) 
NaH, MeI, THF, 0°C to RT, 82%; d) BH3·THF, TMSOTf, CH2Cl2, RT, 45 min, 91%; e) I2, PPh3, imid, toluene, 
100°C, 7 h, 85%; f) LAH, THF, 60°C, 6 h, 82%; or Pd/C, H2 (50 bar), Et3N, MeOH, 68%; g) TMSSPh, ZnI2, 
TBAI, DCE, 65°C, 79%; h) DDQ, CH2Cl2/H2O 10/1, RT, 82%. 
To distinguish between O2 and O3 the stannylidene acetal method was applied.91,92 Thus 
the tethered mannoside 1.135 was refluxed with dibutyltin oxide in methanol to give the 
dialkylstannylene acetal. Then the solvent was exchanged from methanol to DMF/CH2Cl2 and 
the stannane was reacted with TBSCl to give the selectively O3 TBS protected mannoside. 
Methylation of the O2 position was performed under standard conditions using sodium 
hydride and iodomethane to furnish the mannoside 1.136 (Scheme 1.30). 
                                                
87  J. Zhang, A. J. Ragauskas, Carbohydr. Res. 2005, 340, 2812–2815. 
88  M. Tatina, S. K. Yousuf, D. Mukherjee, Org. Biomol. Chem. 2012, 10, 5357–5360. 
89  H.-S. Cheon, Y. Lian, Y. Kishi, Org. Lett. 2007, 9, 3323–3326. 
90  a) M. Poláková, M. U. Roslund, F. S. Ekholm, T. Saloranta, R. Leino, Eur. J. Org. Chem. 2009, 870–888; b) 
F. Ekholm, M. Poláková, A. Pawłowicz, R. Leino, Synthesis 2009, 567–576. 
91  a) T. B. Grindley, Adv. Carbohydr. Chem. Biochem. 1998, 53, 17–142; b) T. B. Grindley, R. Thangarasa, 
Can. J. Chem. 1990, 68, 1007–1019; c) N.-C. Reichardt, M. Martín-Lomas, Angew. Chem. Int. Ed. 2003, 42, 
4674–4677. 
92  E. Bedini, A. Carabellese, G. Barone, M. Parrilli, J. Org. Chem. 2005, 70, 8064–8070. 
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The next sequence aimed for the reduction of the primary alcohol, the transformation of 
mannoside to rhamnoside. Selective, reductive opening of the benzylidene acetal 1.136 using 
borane THF complex and TMSOTf as Lewis acid furnished the O4 benzyl protected and O6 
deprotected compound 1.137.93 The primary alcohol was converted to the iodide using 
Garegg-Samuelsson conditions with iodine, triphenylphosphine and imidazole at reflux.94 The 
reduction of the iodide using lithium aluminiumhydride proofed to be superior over 
hydrogenation with Pd/C and triethylamine to furnish the rhamnoside 1.138. 
In order to have a flexible handle at the anomeric position we exchanged the anomeric 
acetal to the thioacetal using trimethylsilyl thiophenol, zinc iodide and tetrabutylammonium 
iodide in dichloroethane.95,96 This procedure gave the fully protected thio-rhamnoside 1.139 
in pleasant yield. At this stage the benzyl ether deprotection was the last task towards the 
selectively O4 deprotected carbohydrate 1.129. Confusingly, the deprotection using Pd/C in 
methanol or ethyl acetate even at 100 bar hydrogen pressure for two days did not show any 
conversion of the starting material 1.139. As we suspected the thioacetal to be interfering 
during the hydrogenation these conditions were also applied before thiophenol insertion on 
compound 1.138, but without success. Finally, we found DDQ in a CH2Cl2/water mixture to 
conduct the benzyl ether cleavage to give the desired thiorhamnoside 1.129.97 
1.5.4 Resorcylate-Rhamnoside Coupling – Take 1 
Having the appropriately protected rhamnoside 1.129 and the homodichloro orsellinate 
1.128 in hand we moved to the coupling of the two fragments (Scheme 1.31). Surprisingly, 
treating of the two fragments with sodium hydride in THF gave a mixture of the two 
constitutional isomers 1.127 and 1.140. Obviously, the silyl ether migrates faster from O3 to 
O4 than esterification with the resorcinol takes place. Wondering if migration of substituents 
at O3 occurs in general, we cleaved the silyl ether of 1.140 using TBAF and treated the O3 
                                                
93  a) K. Daragics, P. Fügedi, Tetrahedron Lett. 2009, 50, 2914–2916; b) R. Johnsson, D. Olsson, U. Ellervik, J. 
Org. Chem. 2008, 73, 5226–5232. 
94  P. J. Garegg, B. Samuelsson, J. Chem. Soc., Perkin Trans. 1 1980, 2866–2869. 
95  a) S. Hanessian, S. Hanessian, S. Hanessian, Y. Guindon, Y. Guindon, Y. Guindon, Carbohydr. Res. 1980, 
86, 3-6. b) D. A. Evans, B. Trotter, P. J. Coleman, B. Côté, L. C. Dias, Tetrahedron 1999, 55, 8671-8726. 
96  I. Paterson, T. Paquet, Org. Lett. 2010, 12, 2158–2161. 
97  D. Crich, O. Vinogradova, J. Org. Chem. 2007, 72, 3581–3584. 
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substituted rhamnoside 1.141 with sodium hydride again. Indeed, ester migration underwent 
smoothly to give the O4 substituted rhamnoside-resorcylate fragment 1.142. 
 
Scheme 1.31: Rhamnoside-resorcylate coupling, an unexpected migration. a) NaH, THF, RT, 4 h, 10% 1.127, 
59% 1.140; b) TBAF, THF, 2 h, 81%; c) NaH, THF, 18 h, 0°C to RT, clean conversion, % n.d. 
 
1.5.5 The Synthesis of the 2O-Methyl-D-rhamnoside – 2nd Approach 
As a logical consequence, of the observations above, a protecting group at O3 was 
obsolete. Esterification of the diol 1.145 with the resorcylate 1.128 should indeed give the O4 
substituted product 1.142, too. To proof our assumption, we synthesized the thioglycoside 
1.145 starting from the O2 methylated intermediate 1.136. Acidic hydrolysis of the 
benzylidene acetal and the silyl ether was conducted first to give the triol 1.143, followed by 
selective removal of the pimary alcohol using a mild Garegg Samuelsson iodination and a 
hydrogenolysis using Pd(OH)2 and triethylamine as HI-quencher under hydrogen atmosphere. 
The thiophenol 1.142 was then synthesized from the diol 1.144 using the same procedure as 
in the previous sequence. 
 
Scheme 1.32: Synthesis of the unprotected thiorhamnoside: a) aq. HCl 1M, MeOH, H2O, quant.; b) I2, PPh3, 
imid, THF, 65°C, 1.5 h, 58%; c) Pd(OH)2, H2 (atm.), Et3N, MeOH, RT, 6 h, 97%; d) TMSSPh, ZnI2, TBAI, 
DCE, 65°C, 70%. 
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1.5.6 Resorylate-Rhamnoside Coupling – Take 2 
Having the diol 1.145 in hand, we examined the regioselective esterification with the 
resorcylate 1.128 (Table 1.3). Pleasantly, under the same conditions previously used, a high 
regioselectivity (10:1) and good yield (83%) was achieved (Entry 1). Interestingly, initially 
within the first 30 minutes the O3 isomer 1.141 is formed, exclusively (Entry 8). A prolonged 
reaction time (18 h) is required until the equilibrium in favour of the O4 isomer 1.142 is 
reached. The same observation was made with the reactions in Entry 2, 4, 6-7. In DMF (Entry 
3) the reaction quickly reached its equilibrium (1:1 ratio) within 30 minutes. On the other 
hand, lithium hydride (Entry 5) mediated the reaction very slowly. Full conversion was 
reached after 14 h and heating of the reaction was required to initiate migration of the 
resorcylate unit.  
Table 1.3: Examination of the regioselective resorcylate ester couplings. 
 
Entry R Solvent Base (equiv) O3:O4 Yield  
1 SPh THF NaH (5.0) 1 : 10 83% 1.142 
2 SPh Et2O NaH (5.0) 1 : 10 66% 1.142 
3 SPh DMF NaH (5.0) 1 : 1 n.d. 
4 SPh toluene NaH (5.0) 1 : 17 50% 1.142 
5a SPh THF LiH (5.0) 1 : 1 n.d. 
6 OMe THF NaH (5.0) 1.4 : 1 22% 1.146, 16% 1.147 
7 OMe toluene NaH (5.0) 1 : 11 50% 1.147 
8b SPh Et2O NaH (5.0) 1 : 0 72% 1.141 
Conditions: 18 h, 0°C to RT. a Carried out at RT for 24 h then 50°C for 24 h. b Carried out at RT for 0.5 h. 
Clearly, using apolar solvents (Entry 4, 7) gives higher selectivity towards O4 substitution. 
Comparing Entry 1, 6 and Entry 4, 7 respectively, a remarkable difference of the O3:O4 ratios 
becomes apparent. Obviously, the methyl-rhamnoside 1.144 gives lower selectivity than the 
thioacetal 1.145.  
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1.5.7 The Synthesis of the 2O-Methyl-D-rhamnoside – 3rd and Final Approach 
Encouraged by the results for the resorcylate coupling, we targeted a new, shorter synthesis 
of the diol 1.145. The elaborate protecting group strategy as in the first strategy was not 
necessary anymore and thus the route could be reduced dramatically (Scheme 1.33). 
 
Scheme 1.33: Final version of the thio-rhamnoside synthesis: a) I2, PPh3, imid, THF, reflux, 95%; b) Pd(OH)2, 
H2 (atm.), Et3N, MeOH, RT, 3.5 h, quant.; c) HC(OMe)3, (CH3CO)2, CSA, MeOH, 90°C; d) NaH, MeI, THF, 
0°C to RT; e) CH2Cl2, TFA/H2O 9:1, RT, 72% (3 steps); f) TMSSPh,TBAI, ZnI2, DCE, 60°C, 73%. 
Again the starting point of our synthesis was methyl-D-mannoside 1.104 and the first step 
was, in analogy with the novioside synthesis (Chapter 1.4.2), the Garegg Samuelsson 
iodination. Next, the iodide was reduced using Pd(OH)2 and Hünig’s base to give methyl-D-
rhamnoside 1.148. Key to this approach was to introduce the trans-selective butane-2,3-
diacetal (BDA) protecting group.98 Thus the triol 1.148, 2,3-butadione, orthoformate and 
camphersulfonic acid was heated in a pressure tube at 90°C in methanol to give the O3/O4 
BDA-protected product 1.149. O2–Methylation was effected using sodium hydride and 
methyl iodide. Then BDA cleavage with TFA/water in CH2Cl2 gave the previously 
synthesized rhamnoside 1.144. The three steps (BDA protection, methylation, BDA 
deprotection) could be conveniently conducted without purification of the intermediates and 
afforded 1.144 in excellent overall yield (72%). 
To conclude, a straightforward synthesis of the 2O-methyl rhamnoside 1.145 was 
developed and a biomimetic aromatization approach furnished the homodichloro orsellinate 
1.128. The two fragments could be selectively coupled by an unexpected and simple 
esterification to give convenient access to the resorcylate-rhamnoside fragment 1.142. 
 
 
  
                                                
98  a) S. V. Ley, D. R. Owen, K. E. Wesson, J. Chem. Soc., Perkin Trans. 1 1997, 2805–2806; b) A. Hense, S. 
V. Ley, H. Osborn, D. R. Owen, J. Chem. Soc., Perkin Trans. 1 1997, 2023–2031. 
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1.6 Glycosylations 
1.6.1 Introduction 
In glycosylation reactions, a sugar molecule is attached to another molecule by a covalent 
linkage. Biosynthetically, this procedure by which saccharides are linked to lipids, proteins or 
other biomolecules is catalyzed by enzymes. In synthetic organic chemistry, problems arise 
due to the need to control the stereochemical outcome of the glycosylation reaction, which 
often cannot be reliably predicted by theoretical reasoning. The practical challenge lies in the 
combination of the many parameters that influence the attack at the anomeric position. These 
factors include the conformation of the glycosyl donor (dependent of the substitution pattern), 
its configuration, neighbouring-group effects of substituents, the leaving group on the 
anomeric center, the reactivity and steric demand of the acceptor, the promoter, the solvent 
and the reaction temperature. In natural product total synthesis, the choice of the 
carbohydrates’ substitution pattern is often limited, such that directing groups cannot be used 
and post-glycosylative modifications are not compatible with the structural motif. These 
circumstances make the total syntheses of complex glycosylated natural products highly 
challenging and the yields and selectivities are in many cases far from ideal.99 
 Figure 1.22 shows the general outline of O-glycosylation reactions by formation of an 
ether bond between the saccharide’s anomeric carbon atom and an alcohol (ROH). In the first 
step, a promoter (EX) reacts with the sugar to activate the leaving group on the glycosyl 
donor.100  Depending on the parameters mentioned above, activated and covalently bound 
donors or ion pairs with varying proximity are formed (CIP, SSIP or oxocarbenium ion) this 
either with the original leaving group, the solvent or anions present in the reaction mixture. 
Each of these states can be attacked by the acceptor (ROH) and thus the abundance and 
kinetic preference of a species determines the stereochemical outcome of the reaction. Tuning 
of the reaction conditions can direct to one or the other intermediates. Obviously, the polarity 
of the solvent has influences on the conformation and the stabilization of the oxocarbenium 
                                                
99 Y. Yang, X. Zhang, B. Yu, Nat. Prod. Rep. 2015, 32, 1331–1355. 
100 X. Zhu, R. R. Schmidt, Angew. Chem. Int. Ed. Engl. 2009, 48, 1900–1934. 
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ion and may even engage in weak covalent bonds (cf. the nitrile effect101). The lesser the 
solvents ability to separate/stabilize charges, the more favoured are intermediates featuring 
covalent bonds and contact ion pairs (CIP), which will then preferentially undergo an SN2 or 
SN2-like reaction with the acceptor. 
 
Figure 1.22: Intermediates that have an influence on the stereochemical outcome of the glycosylation reaction 
LG = leaving group; EX = Promoter (electrophile and leaving group), S = solvent; P = nonparticipating 
substituent. 
Clearly, the characteristics of the leaving group also determine the character of the 
nucleophilic substitution; the better the leaving group the more probable is an SN1-type 
reaction mechanism. The promoter (EX) plays a major role at this point, as it tunes the 
character of the leaving group. Furthermore, the nucleophilicity and streric bulk of the 
couneterion (X–) has a crucial effect on the reaction mechanism due to its plausible interaction 
with the oxocarbenium intermediate.  
                                                
101 a) J.-R. Pougny, P. Sinaÿ, Tetrahedron Lett. 1976, 17, 4073–4076; b) A. J. Ratcliffe, B. Fraser-Reid, J. Chem. 
Soc., Perkin Trans. 1 1990, 747–750; c) I. Braccini, C. Derouet, J. Esnault, C. H. E. de Penhoat, J. M. Mallet, 
V. Michon, P. Sinaÿ, Carbohydr. Res. 1993, 246, 23–41; d) R. R. Schmidt, M. Behrendt, A. Toepfer, Synlett 
1990, 694–696; e) D. Crich, M. Patel, Carbohydr. Res. 2006, 341, 1467–1475. 
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The reactivity of the oxocarbenium ion is also heavily influenced by the substituents of the 
carbohydrate. In 1988 Fraser-Reid et al. recognized that donors bearing benzyl protecting 
groups react substantially faster than the equivalent acetylated donors. To characterize their 
relative reactivity they termed them “armed” and “disarmed” donors.102 Electron-withdrawing 
groups reduce the reactivity of the glycosyl donor as they destabilize the transition state of 
bond dissociation between the anomeric carbon and the leaving group with its partial positive 
charge on the anomeric carbon. Later, the group of Fraser-Reid reported on the “arming” 
effect of cyclic groups like acetals.103 Glucosides, mannosides and galactosides, forced to 
adapt a twist conformation through the cyclic protecting group, reacted two to ten times faster 
than the non-tethered carbohydrates. Bols et al. went even further and developed so-called 
“superarmed” donors with bulky silyl groups that force the substituents in axial position. 
These conformationally armed donors did not only show much faster reaction rates but also 
higher diastereoselectivities.104 The use of this concept has become an important strategy in 
carbohydrate chemistry, and is especially useful in oligosaccharide one-pot-synthesis, as the 
reactivity of co-existing carbohydrate donors in can be controlled by protecting group 
decoration.105 
1.6.2 The 1,2-cis Problem 
The preparation of 1,2-cis configured rhamnosides and mannosides is generally difficult as 
they are sterically and electronically unfavourable. Thus, β-selective rhamnosylation is a 
challenging and widely recognized as an unsolved task in preparative carbohydrate 
chemistry.106 A breakthrough in β-mannosylation was Crich’s method to tether the O6-O4 by 
a benzylidene acetal (1.150) (Figure 1.23).107 The conformational restriction and the use of 
triflate-forming promoters leads to highly reactive intermediates bearing a triflate in α-
position (1.151), which readily react in an SN2-type with acceptors to give mannosides with 
high β-selectivity. 
                                                
102  D. R. Mootoo, P. Konradsson, U. Udodong, B. Fraser-Reid, J. Am. Chem. Soc. 1988, 110, 5583–5584. 
103  B. Fraser-Reid, Z. Wu, C. W. Andrews, J. Am. Chem. Soc. 1991, 113, 1434–1435. 
104  C. M. Pedersen, N. Lars Ulrik, M. Bols, J. Am. Chem. Soc. 2007, 129, 9222–9235. 
105 Review: C.-H. Hsu, S.-C. Hung, C.-Y. Wu, C.-H. Wong, Angew. Chem. Int. Ed. 2011, 50, 11872–11923. 
106  E. S. H. El Ashry, N. Rashed, E. S. I. Ibrahim, Tetrahedron 2008, 64, 10631–10648. 
107  a) D. Crich, S. Sun, J. Org. Chem. 1996, 61, 4506–4507; b) D. Crich, S. Sun, J. Org. Chem. 1997, 62, 1198–
1199; c) D. Crich, S. Sun, J. Am. Chem. Soc. 1997, 119, 11217–11223; d) D. Crich, M. Smith, Org. Lett. 
2000, 2, 4067–4069. 
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Figure 1.23: β-Selective mannosylation developed by the group of Crich. Tethering of the O6-O4 position and 
promoters of general formula EOTf give intermediate triflates, which are attacked by the acceptor from the β-
side in an SN2-like fashion.107 
This strategy is not directly applicable to the preparation of β-rhamnosides, as the C6-
position is not oxygenated. Thus, Crich and co-workers developed a benzylidene acetal bridge 
that can be reductively cleaved to give the C6 deoxygenated rhamnosides after mannosylation 
(Scheme 1.34).108 
  
Scheme 1.34: Crich`s approach for the highly selective preparation of β-rhamnosides.108 a) BSP, TTBP, Tf2O, 
CH2Cl2, –60°C, 10 min, then ROH, –60°C to RT, 3 h, 71–94%, β-only; b) Bu3SnH, AIBN, toluene, reflux, 74–
80%. 
Though this method furnished the β-mannosides in good yield and high 
diastereoselectivity, the method is not very practical for applications in total synthesis. The 
preparation of the acetal 1.152 is not straightforward and not many complex natural products 
would tolerate the chemoselective radical cleavage of the acetal using tributyltin hydride in 
boiling toluene. 
Most publications on rhamnosylations feature the more abundant and so-called natural L-
series. Unfortunately, the donors reported to give high β-selectivities and yields in literature 
are not compatible with the rhamnosyl donor suitable for the total synthesis of fidaxomicin 
(Figure 1.24). As post-glycosylative modifications should preferentially be avoided, the only 
modifiable sites in the rhamnosyl donor for the synthesis of fidaxomicin are the leaving 
group, the O3 substitution and the two phenolic groups at a considerable distance from the 
                                                
108  D. Crich, Q. Yao, J. Am. Chem. Soc. 2004, 126, 8232–8236. 
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pyranoside ring. Thus, the ulosyl bromide (A) strategy reported by Lichtenthaler109 and the 
approaches with a non-participating sulfonate at C2-position (B) by Schuerch110 (1981, LG = 
Cl) and Crich111 (2003, LG = SPh) cannot be used as precursors for the total synthesis. Also 
cyclic protecting groups (C–E) cannot be applied, so the precursor of general structure F is 
the only option left.  
 
Figure 1.24: Left: Rhamnosyl donor for the total synthesis of fidaxomicin; in blue: adaptable groups; right: 
Precursors giving the highest β-selective rhamnosylation in the L-series as reported in literature. P = protecting 
group; X = halogen; LG = leaving group. 
There are only few examples that give good 1,2-cis rhamnosylation results, using the 
general structure formula F. In general, Königs-Knorr glycosylations using heterogeneous 
catalysts gave good β-selectivities.112 Though this method is promising, the generation of the 
glycosyl halides often require harsh conditions. 
Interestingly, Inazu and co-workers found that rhamnosyl donors with an ester substituent 
at the C4-position (1.154, 1.155) showed increased β-selectivity compared to the benzyl ether 
1.153 (Scheme 1.35).113 They suggest that the oxocarbenium ion is intercepted by the ester in 
                                                
109  a) F. W. Lichtenthaler, T. Schneider-Adams, S. Immel, J. Org. Chem. 1994, 59, 6735–6738; b) F. W.  
Lichtenthaler, T. W. Metz, Tetrahedron Lett. 1997, 38, 5477–5480; c) F. W. Lichtenthaler, T. Metz, Eur. J. 
Org. Chem. 2003, 16, 3081–3093. 
110  V. K. Srivastava, C. Schuerch, J. Org. Chem. 1981, 46, 1121–1126. 
111  a) D. Crich, J. Picione, Org. Lett. 2003, 5, 781–784; b) D. Crich, T. K. Hutton, A. Banerjee, P. Jayalath, J. 
Picione, Tetrahedron: Asymm. 2005, 16, 105–119. 
112  a) H. Paulsen, W. Kutschker, O. Lockhoff, Chem. Ber. 1981, 114, 3233–3241; b) A. M. P. van Steijn, J. P. 
Kamerling, J. F. G. Vliegenthart, J. Carbohydr. Chem. 1992, 11, 665–689; c) E. Eichler, H. J. Jennings, D. 
M. Whitfield, J. Carbohydr. Chem. 1997, 16, 385–411. 
113  T. Yamanoi, K. Nakamura, H. Takeyama, K. Yanagihara, T. Inazu, Bull. Chem. Soc. Jpn. 1994, 67, 1359–
1366. 
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an intramolecular reaction, forming a 7-membered cyclic intermediate (Scheme 1.35). The 
incoming aglycon attacks this cyclic intermediate by an SN2-attack, thus forming the desired 
β-anomer. Although this reaction is carried out under rather harsh condition (iodine), the high 
yield and good diastereomeric ratio of α:β = 1:4 encouraged us to first look into the reactivity 
and selectivity of our thiophenyl-donor 1.142 in hand.  
 
Scheme 1.35: The influence of the C4-substituent on the stereoselectivity found by Inazu.113 a) iodine (1 eq), 
TrtClO4 (5mol%), 3β-cholestanol, benzene, m.s. 4Å, RT. 
It needs to be mentioned that the described neighbouring group effect (anchimeric 
assistance) with ester substituents on C4 is exceptional and has not been observed with other 
leaving groups or different substituents on C2 and C3. On the contrary, the reaction even 
proceeds with exclusive α-selectivity when structural parameters are changed.106,114 
In summary, there are only very few examples of rhamnosyl donors reported in literature 
that might be suitable for the total synthesis of fidaxomicin. The most reliable β-selective 
reactions known are the ones using glycosyl halides and heterogeneous promoters/scavengers. 
These glycosyl halides are unfortunately not easy to prepare due to their instability and the 
required conditions are typically harsh (vide supra). As changes regarding the choice of the 
substituents can have an unforeseen impact on the selectivity and no donors with the same 
rhamnoside substitution pattern as in fidaxomicin have been reported, we were not able to 
predict the stereochemical outcome of the glycosylation with our donor 1.142. As a 
consequence, we had to test its reactivity, and the stereochemistry of the glycosylation 
product. 
 
                                                
114  a) D. E. Long, P. Karmakar, K. A. Wall, S. J. Sucheck, Bioorg. Med. Chem. 2014, 22, 5279–5289; b) Y. Liu, 
N. Ding, H. Xiao, Y. Li, J. Carbohydr. Chem. 2006, 25, 471–489; c) J. Boutet, C. Guerreiro, L. A. Mulard, 
Tetrahedron 2008, 64, 10558–10572; d) D. Crich, M. Smith, J. Am. Chem. Soc. 2001, 123, 9015–9020. 
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1.6.3 β-Rhamnosylation – Screening 
For a start, we tested donor 1.142 in standard glycosylation reactions with different 
glycosyl acceptors, without installing additional protecting groups (Table 1.4). To our delight, 
the selectivity with the simple alcohol 1.159 was in favour of the desired β-anomer (Entry 1, 
2). The configuration of the products was determined by the  coupling constant 1JCH = 152 Hz 
for the β-anomer, which is close to the value in fidaxomicin (1JCH = 156 Hz)115 and is in the 
characteristic range of β-rhamnosides (β: 1JCH = 152.9–159.8 Hz; α: 1JCH = 167.2–
172.3 Hz).111a,116  
Table 1.4: Screening of reaction conditions for rhamnosylation using the unprotected glycosyldonor. 
 
Entry LG ROH Conditions Yield/Conv. α : β 
1 SPh 1.159 NIS, TfOH (cat.), CH2Cl2, –78°C to RT 63% conv. 1 : 2 
2 SPh 1.159 NBS, CH2Cl2, 40°C 40% conv. 1 : 2 
3 SPh 1.159 Tf2O, BSP, TTBP, CH2Cl2, –60 to –50°C 0% conv.  – 
4 SPh 1.160 NBS, CH2Cl2, RT 0% conv. – 
5 SPh 1.160 NIS, AgOTf (cat.), CH2Cl2, –78°C to RT 58% 1 : 2 
6 SPh 1.161 NIS, TfOH (cat.), CH2Cl2, –78°C to RT 0%a – 
7 S(O)Ph 1.161 Tf2O, DTBMP, CH2Cl2, –78°C to –35°C 0%b – 
The reactions were carried out under careful exclusion of water and in the presence of m.s. 3Å. Conversion 
was determined after quenching by 1H-NMR. a The acceptor was fully converted; b A complex mixture was 
obtained. 
                                                
115  A. Arnone, G. Nasini, B. Cavalleri, J. Chem. Soc., Perkin Trans. 1 1987, 1353–1359. 
116  K. Bock, C. Pedersen, J. Chem. Soc., Perkin Trans. 2 1974, 293–297. 
OHConditions
O
OMe
HO
O
Et OH
Cl
OAllyl
Cl
O
OR
O
OMe
HO
O
Et OH
Cl
OAllyl
Cl
LG
O
ROH:
ROH 1.159
1.142: LG = SPh
1.156: LG = S(O)Ph
EtO
O
OH
EtO
O
OH
1.160
1.161
1.157: R =
1.158: R = EtO
O
 Total Synthesis of the Antibiotic Fidaxomicin  63 
Unfortunately, the thioglycoside donor is unreactive and there was no sufficient conversion 
with the more sophisticated acceptors 1.160 and 1.161. Unlike with 1.159, the reaction with 
Nicolaou`s method117 did not proceed with substrate 1.160 and the donor was recovered 
(Entry 4). The more activating promoter system NIS/AgOTf118, on the other hand, furnished 
the glycosylated product in sufficient yield (58%) and with the same anomeric ratio as with 
acceptor 1.159 (Entry 5). However, this method failed with the more authentic acceptor 1.161 
(Entry 6). In this case, the donor was not converted, but the dienoate 1.161 was completely 
degraded. Not surprisingly, these conditions are not compatible with alkene functionalities. 
Thus, we also applied the method reported by Crich et al. using 1-benzenesulfonyl piperidine 
(BSP) and trifluoromethanesulfonic acid as activator. Surprisingly, even with this method, 
which is reported to promote even highly deactivated donors, thioglycoside 1.142 did not 
react with the acceptor (Entry 3). As the thioglycoside 1.142 seemed very unreactive, we 
oxidized the thioether to the sulfoxide 1.156 using mCPBA. Kahne’s glycosylation method 
using sulfoxide, is especially useful in cases of very unreactive donors.119 Indeed, this method 
efficiently converted the donor 1.156, but no desired glycosylated product could be isolated. 
We figured that in this case the free alcohol groups in the donor are competing with the 
acceptor and thus a complex mixture was obtained. 
As a consequence, we protected the resorcylate moiety as well as the C3-alcohol. From 
retrosynthetic perspective, protection as silyl ether made most sense, and thus we trapped the 
alkoxide from the resorcylate-rhamnoside esterification with TBSOTf to obtain thioglycoside 
1.162 (Scheme 1.36).  
 
Scheme 1.36: Synthesis of the TBS-protected donor: a) NaH, THF, 0°C to RT, 16 h, then TBSOTf, 3 h, RT, 
54%. 
                                                
117  K. C. Nicolaou, S. P. Seitz, D. P. Papahatjis, J. Am. Chem. Soc. 1983, 105, 2430–2434. 
118  P. Konradsson, U. E. Udodong, B. Fraser-Reid, Tetrahedron Lett. 1990, 31, 4313–4316. 
119  D. Kahne, S. Walker, Y. Cheng, D. Van Engen, J. Am. Chem. Soc. 1989, 111, 6881–6882. 
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Interestingly, the 1H-NMR coupling constants of 1.162 indicate a tendency towards a 1C4 
conformation of the pyranose ring (Table 1.5). The ring flip from the 4C1 conformation in the 
unprotected donor 1.142 to the 1C4 conformation of the protected donor 1.162 is the result of 
the clash of the bulky tert-butyldimethylsilyl ether at C3 with the resorcylate moiety, which 
forces them to adopt the transaxial conformation. Table 1.5 illustrates that the TBS group in 
the ring, but also the protecting group in the resorcylate is required to induce the ringflip. The 
1H-NMR of the mono-silylether protected sugar 1.141 does only show a slight decrease of the 
coupling constant 3JH3,4. The significant drop of the coupling constant can only be observed, 
when in addition, the phenolic hydroxyl group is protected as the allyl ether (1.165) or silyl 
ether (1.162). Though, the conformation of the TBS-protected donor 1.162 does not 
correspond to a perfect 1C4-chair – the coupling constants do not show according values – but 
rather a distorted ring, for representational reasons the donor will be drawn in this 
conformation. 
Table 1.5: Coupling constants of the pyranose ring with different protecting group decoration. 
 
3J [Hz] 1.142 1.162 1.163 1.165 1.141 1.165 
H1,2 0.7 0 0 1.2 1.8 2.5 
H2,3 3.6 – – 3.6 – 3.0 
H3,4 9.8 6.4 9.4 9.8 9.5 8.7 
H4,5 9.8 6.7 9.7 9.8 9.5 8.7 
This ring flip to a axial rich conformation was of special interest to us, since these 
pyranoses are known to be “superarmed” and the conformational change might also influence 
the anomeric selectivity in the subsequent glycosylation step.120 The common explanation for 
the higher reactivity is the decreased electron withdrawing effect of axial substituents, which 
                                                
120  a) H. Yamada, T. Ikeda, Chem. Lett. 2000, 432–433; b) T. Ikeda, H. Yamada, Carbohydr. Res. 2000, 329, 
889–893; c) C. M. Pedersen, N. Lars Ulrik, M. Bols, J. Am. Chem. Soc. 2007, 9222–9235; d) M. 
Heuckendorff, C. M. Pedersen, M. Bols, J. Org. Chem. 2012, 77, 5559–5568; e) M. Heuckendorff, H. D. 
Premathilake, Org. Lett. 2013, 15, 4904–4907; f) Review: H. Satoh, S. Manabe, Chem. Soc. Rev. 2013, 42, 
4297–4309. 
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reduces the destabilization of a partial positive charge in the ring. Confusingly, Bols et al. 
found the β-selectivity in glycosylations with rhamnosides featuring electron-withdrawing 
substituents in axial positions to be lower compared to their counterparts with the same 
electron-withdrawing substituents in equatorial positions,120c,d whereas Yamada and co-
workers120a,b describe the expected increase in β-selectivity. Thus we were conducting a set of 
reactions using the TBS-protected sugar 1.162 (Table 1.6). We first applied Nicolaou’s 
conditions, which had also been employed by Yamada120a for the glycosylation of 
thiorhamnosides with electron-withdrawing substituents in axial positions. On contrast to the 
reaction with the unreactive glycosyl donor 1.142, the desired glycoside 1.167 was furnished 
using the donor 1.162 and NBS as activating agent in dichloromethane (Table 1.6, Entry 1-5). 
Also, the diastereoselectivity was reversed in favour of the α-rhamnoside. Thus, we screened 
other solvents, but in hexane, toluene and ether only insufficient conversion or no reaction at 
all were observed (Entry 2-4). In acetonitrile, the reaction took place smoothly even at 0°C, 
though the solvent did not change the diastereoselectivity (Entry 5). The α-anomer was even 
more preferred at lower temperature using NIS/AgOTf in CH2Cl2 (α:β = 4:1, Entry 6). The 
Ph2SO/Tf2O promoter system developed by van der Marel and co-workers121 mainly resulted 
in cleavage of the allyl ether (Entry 7). Nevertheless, some glycosylated product was isolated 
in a ratio of α:β = 4:1. We then examined the sulfoxide leaving group and thus oxidized the 
thioglycoside 1.162 using a standard procedure to obtain 1.166.119 Kahne’s protocol, in which 
the sulfoxide is first activated with triflic anhydride to give the intermediate glycosyl triflate 
prior to addition of the glycosyl acceptor, furnished the product in good yield (quant., 
α:β = 4:1, Entry 8). Thus we used the protocol developed by Crich in which the acceptor and 
donor are premixed before adding triflic anhydride. In this procedure, the alcohol is supposed 
to intercept the formation of the glycosyl triflate and thus invert the selectivity.122 In our case, 
we did indeed observe a slight shift towards β-selectivity (α:β = 3:1), but the effect was much 
less pronounced than anticipated (Entry 9). Additionally, glycosylation under Königs-Knorr 
conditions were examined. Though it is expected that glycosyl chlorides would adopt an axial 
position at the anomeric centre, Bols reported a slight β-selectivity with their axially enriched 
rhamnosyl chloride.120d Unfortunately, under the same conditions our system only furnished 
the expected α anomer (Entry 10).  
                                                
121  J. D. C. Codée, R. E. J. N. Litjens, R. den Heeten, H. S. Overkleeft, J. H. van Boom, G. A. van der Marel, 
Org. Lett. 2003, 5, 1519–1522. 
122  a) D. Crich, S. Sun, J. Org. Chem. 1996, 61, 4506–4507; b) D. Crich, S. Sun, J. Org. Chem. 1997, 62, 1198–
1199. 
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Table 1.6: Screening of reaction conditions using rhamnosyl donors with axial rich conformation. 
 
Entry LG Conditionsa Yield/Conv.b α : βc 
1 SPh NBS, CH2Cl2, 0°C to RT full conv./bp. 1.7 : 1 
2 SPh NBS, hexane, 0°C to RT 0% conv. – 
3 SPh NBS, toluene, 0°C to RT 0% conv. – 
4 SPh NBS, Et2O, 0°C to RT low conv. – 
5 SPh NBS, MeCN, 0°C full conv. 2 : 1 
6 SPh NIS, AgOTf (cat.), CH2Cl2, –78 to –30°C 68% 4 : 1 
7 SPh Tf2O, SOPh2, TTBP, CH2Cl2, –60 to RT de-allylation 4 : 1 
8 S(O)Ph Tf2O, DTBMP, CH2Cl2, –78°C, then 1.160 quant. 4 : 1 
9 S(O)Ph 1.160, DTBMP, CH2Cl2, –78°C, then Tf2O full conv. 3 : 1 
10 SPh i) ICl, CDCl3 ii) 1.160, Ag2CO3, CH2Cl2, 60°C, 2 d 50% conv. 1 : 0 
a The reactions were carried out under careful exclusion of water and in presence of m.s. 3Å. b The screening was 
performed with small amounts, thus the yield was not always determined, but the conversion was monitored by 
1H-NMR analysis. c The anomers were inseparable, thus a silyl ether deprotection was performed to obtain 1.158 
in order to determine the identity of α and β. 
From the two screenings with the unprotected donor 1.142 and the conformationally armed 
donor 1.162 it follows that the 1C4 conformation of the D-rhamnoside is more reactive than 
the 4C1, but only at the expense of a lower β-selectivity. This is aggravated by the fact that the 
anomeric effect in the 1C4 conformation directs nucleophiles, such as triflate to the β-face, 
resulting in retention by the subsequent attack of the glycosyl acceptor. As a consequence, we 
decorated the donor with sterically less demanding protecting groups in order to retain the 4C1 
conformation. We reasoned that the trimethylsilylethoxymethyl acetal (SEM) protected donor 
1.163 might be suitable, as SEM is linear and can eventually be cleaved along with the other 
silyl ethers at the end of the total synthesis. Furthermore, we decided to protect the phenolic 
hydroxyl groups as the allyl ether, hoping that the C3 hydroxyl group of glycosyl donor 1.164 
would be too hindered to undergo self-condensation in presence of the primary acceptor 
alcohol (Scheme 1.37). Indeed, the two donors 1.163 and 1.164 showed coupling constants in 
the expected range for a 4C1 pyranose conformation (Table 1.5). 
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Scheme 1.37: Synthesis of protected thiophenyl-donors: a) allyl bromide, K2CO3, DMF, 50°C, 96%; b) NaH, 
SEMCl, DMF 0°C to RT, 48%. 
Table 1.7: Screening of protected, rhamnosyl donors. 
!
Entry Donor ROH Conditionsa Yield/Conv.b α : βc 
1 1.163 1.160 NBS, CH2Cl2, 0°C to RT 0% conv. – 
2 1.163 1.160 NBS, MeCN, 0°C to RT 0% conv. – 
3 1.163 1.160 NIS, AgOTf (cat.), CH2Cl2, –78 to –20°C deprotection 3 : 2 
4 1.163 1.160 NIS, AgOTf (1 eq.), DTBMP, CH2Cl2, RT full conv. 3 : 2 
5 1.167 1.160 Tf2O, DTBMP, CH2Cl2, –78°C, then ROH decomp. – 
6 1.164 1.160 NIS, AgOTf (cat.), CH2Cl2, RT 77% 5 : 6 
7 1.164 1.160 NIS, AgOTf (1 eq.), DTBMP, CH2Cl2, 0°C full conv. 2 : 3 
8 1.168 1.170 Tf2O, DTBMP, CH2Cl2, –78°C, then ROH full conv. 1 : 2 
9 1.169 1.170 TBSOTf, CH2Cl2, –78°C to –55°C full conv. 1 : 3 
a The reactions were carried out under careful exclusion of water and in presence of m.s. 3Å. b The screening 
was performed with small amounts, thus the yield was not always determined, but conversion was monitored 
by 1H-NMR analysis. c In the case of the SEM-protected rhamnosides, the anomeric ratio was determined by 
the characteristic shifts in the 1H-NMR spectrum (α: 5.0-4.8 ppm; β: 4.5-4.6 ppm). 
The SEM-protected donor 1.163 was inert under Nicolaou’s conditions117 with NBS in 
CH2Cl2, and even in acetonitrile the reaction did not take place (Table 1.7, Entry1-2). The 
phenolic SEM-group, proofed to be very labile under various reaction conditions. For 
instance, NIS/AgOTf at –20°C already effected deprotection and a complex mixture of 
starting materials and glycosylated products was obtained. Nevertheless, the anomeric ratio 
was determined after deprotection (Entry 3). The undesired deprotection during glycosylation 
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was avoided by addition of the bulky base di-tert-butyl-methylpyridine (DTBMP) and indeed 
the same diastereomeric ratio (α:β = 3:2) was obtained (Entry 4). Also Kahne’s sulfoxide 
method resulted in decomposition and the formation of a complex mixture (Entry 5). As the 
protected donor 1.163 showed preference for forming the α-anomer and as the SEM group 
turned out to be labile, we decided to cease further investigations.  
Next, we examined the double allyl-protected donor 1.164 using the Fraser-Reid activator 
(NIS, AgOTf)118, in order to compare the behaviour with the other donors (1.142, 1.162, 
1.163). Finally, we reached a higher preference for the β-anomer again (α:β = 5:6, Entry 6). 
With these results, we came to a conclusive analysis: Reactivity of the rhamnosyl donor 
increases with the steric bulk of the protecting groups employed. The TBS protected donor 
1.162 already reacts at a low –30°C (Table 1.6, Entry 6); the less hindered SEM protected 
rhamnoside 1.163 requires –20°C to proceed (Table 1.4, Entry 3) and the unprotected 1.142 
(Table 1.4, Entry 5) and allyl-protected donors 1.164 (Table 1.7, Entry 6) require 25°C for a 
prolonged time. Further, the more twisted the pyranoside, the lower the preference for β-
selective rhamnosylation.  
The selectivity with donor 1.164 was slightly improved by the use of stoichiometric 
amounts of silver triflate (Table 1.7, Entry 7). With Kahne’s glycosylation method, we 
reached full conversion and a diastereomeric ratio of α:β = 1:2 (Entry 8). We then applied a β-
rhamnosylation protocol123 using the N-phenyltrifluoroacetimidiate (PTFAI) as a leaving 
group, developed by the group of Yu.124 With this donor α:β ratios of 1:1 to 1:2.5 was 
reached. We thus hydrolysed thiophenol 1.164 using NBS in acetone/water to give pyranose 
1.173 as a α:β = 5:1 mixture of the two anomers (Scheme 1.38). Later, we synthesized the 
pyranose 1.173 from the donor 1.147, which was first allylated and then hydrolysed under 
acidic conditions. This sequence is shorter by one step, though, the overall yield is lower. The 
PTFAI was then installed using ClC(NPh)CF3 and potassium carbonate in wet acetone to 
furnish donor 1.169 (Scheme 1.38).  
                                                
123  A. E. Christina, D. van der Es, J. Dinkelaar, H. S. Overkleeft, G. A. van der Marel, J. D. C. Codée, Chem. 
Commun. 2012, 48, 2686–2688. 
124  a) B. Yu, H. Tao, Tetrahedron Lett. 2001, 42, 2405–2407; b) B. Yu, H. Tao, J. Org. Chem. 2002, 67, 9099–
9102; c) Review: B. Yu, J. Sun, Chem. Commun. 2010, 46, 4668–4679. 
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Scheme 1.38: Introduction of PTFAI as leaving group: a) allyl bromide, K2CO3, DMF, 92%; b) 1.164, NBS, 
acetone/H2O 10:1, 0°C to RT, 95%, α:β = 5:1; c) 1.172, AcOH, HCl aq. 1M, H2O, 120°C, 3.5 h, 55%, α:β = 5:1; 
d) ClC(NPh)CF3, K2CO3, acetone, 78%. 
Rhamnosylation of alcohol 1.170 with donor 1.169 using TBSOTf resulted in a good 
diastereomeric ratio of α:β = 1:3 and high conversion (Table 1.7, Entry 9). As this donor gave 
such promising results we moved on to test it on the fidaxomicin aglycon 1.53 (Scheme 1.39). 
As the macrolide 1.53 was only available in small amounts at that stage of the project, control 
of the equivalents was very difficult to achieve. Ideally, the macrolide 1.53 and the imidate 
1.169 should be used in equimolar amounts, since excess of imidate resulted in twofold 
glycosylation (confirmed by ESI-MS). On the other hand, if an excess of the macrolide was 
used the excess aglycon was difficult to separate from the glycosylated products. Thus, only 
low yields of β-rhamnosylated product 1.174 were obtained. 
 
Scheme 1.39: Rhamnosylation of the macrolide: a) TBSOTf (cat.), CH2Cl2, –78°C to –20°C, 16%, α:β = 1:3. 
At this time, we decided to introduce the rhamnoside moiety later, and after successful 
noviosylation, due to the results of our studies described in Chapter 1.6.4. The final 
rhamnosylation of the advanced noviosylated macrolide is described in the next chapter. 
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1.6.4  β-Noviosylation – a Novelty 
As described in Chapter 1.4, besides the fidaxomicin family, the noviobiocins are the only 
molecules that have been found to contain a novioside carbohydrate, however, α-linked to a 
phenol group. As a consequence, no β-selective noviosylation has been attempted so far, to 
the best of our knowledge. Nevertheless, the structural similarity of noviose and rhamnose 
allows conjectures about the reactivity of this rare carbohydrate. We thus based the design of 
the noviosyl donor on the knowledge gained from 1,2-cis rhamnosylations, as discussed in 
chapter 1.6.2. We opted for the introduction of the cyclic O-2,3 carbonate as the most 
promising protecting group strategy. Deprotection does not require acidic conditions that 
would most probably destroy the central macrolide. In addition, the cyclic carbonate is highly 
deactivating the noviose due to its strong electron-withdrawing effect, which is beneficial for 
high β-selectivity. Generally, Königs-Knorr glycosylations result in a high degree of SN2-like 
glycosylation under mild conditions. We thus prepared glycosyl bromide 1.175 from 
novioside 1.102 by reaction with hydrogen bromide in acetic acid. The labile glycosyl 
bromide 1.175 was then immediately used in the following Königs-Knorr glycosylation with 
cyclohexanol. We were pleased to find that the reaction with the heterogeneous silver oxide 
and silver carbonate catalysts gave exclusively the β-anomer 1.176. As expected, the use of 
soluble silver triflate resulted in the loss of SN2-type character of the reaction giving the 
glycosylated product in a diastereomeric ratio of α:β = 10:1 (Scheme 1.40). Though we could 
not obtain any spectroscopic evidence, the results obtained, strongly indicate that the 
intermediate noviosyl bromide is exclusively formed as the α-anomer 1.175. 
 
Scheme 1.40: β-Noviosylation using noviosyl bromide: a) HBr (33 wt% in AcOH), CH2Cl2, 0°C to RT; b) 
cylcohexanol, Ag2O, m.s. 4Å, CH2Cl2, RT, clean conversion, β only; c) cylcohexanol, Ag2CO3, m.s. 4Å, CH2Cl2, 
81%, β only; d) cylcohexanol, AgOTf, m.s. 4Å, CH2Cl2, clean conversion, α:β 10:1. 
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Encouraged by these preliminary results, we moved on to the noviosylation of the central 
macrolide. Unfortunately, under Königs-Knorr conditions with silver oxide and silver 
carbonate neither the aglycon acceptor 1.52 nor the rhamnosylated macrolide 1.174 were 
glycosylated. Even with silver oxide freshly prepared from silver nitrate and sodium 
hydroxide, no reaction was observed. Instead, the glycosyl bromide was mostly consumed 
through elimination of HBr to give the enolether 1.177 (Figure 1.25). This elimination 
competes with the glycosylation reaction, meaning that the acceptor is not reactive enough. 
 
Figure 1.25: Attempted Königs-Knorr noviosylation with macrolide acceptors using Ag2O and Ag2CO3 only 
resulted in elimination of HBr to give enolether 1.177. 
We then synthesized the fluoride- 1.179 and PTFAI-substituted donor 1.181 in order to 
increase the reactivity of the donor. Thus the methyl-novioside 1.102 was hydrolized in wet 
hydrogen bromide/acetic acid giving noviose 1.178 as an inseparable anomeric mixture of 
α:β = 2:1. Treating pyranose 1.178 with diethylaminosulfurtrifluoride (DAST) cleanly 
furnished noviosyl fluoride 1.179, which was used without purification in the glycosylation 
step (Scheme 1.41). The PTFAI donor was synthesized from noviose 1.178 using 
phenyltrifluoroacetimidate chloride and potassium chloride in wet acetone to obtain the 
chromatographically separable anomers 1.181 in good yield.  
The projected Mukaiyama glycosylation of the rhamnosylated macrolide 1.174 with 
fluoride donor 1.179 with an excess of tin dichloride did not give any conversion (Scheme 
1.41).125 The PTFAI-donor was first tested in the glycosylation of cyclohexanol. Interestingly, 
the α- and the β-imidate 1.181 both cleanly furnished the product 1.176 with the same 
diastereoselectivity of α:β = 3:2, using TBSOTf as the activator (Scheme 1.41). When the less 
bulky promoter TMSOTf was used the ratio shifted in favour of the α-product 1.176 (α:β = 
3:1). This finding is in accordance with the results obtained with Schmidt’s 
                                                
125  a) T. Mukaiyama, K. Takeuchi, H. Jona, H. Maeshima, T. Saitoh, Helv. Chim. Acta 2000, 83, 1901–1918; b) 
K. C. Nicolaou, H. J. Mitchell, R. M. Rodríguez, H. Suzuki, Chem. Eur. J. 2000, 6, 3116–3148; c) Review: 
K. Toshima, Carbohydr. Res. 2000, 327, 15–26. 
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trichloroacetimidate donor.126 It indicates that the electrophile (silyl) must be involved in the 
transition state of the selectivity determining nucleophilic attack. Thus, neither the glycosyl 
triflate CIP nor the covalent triflate intermediate is formed. As the leaving group can 
obviously migrate from one to the other face, a CIP between the donor and leaving group is 
likely.  
 
Scheme 1.41: Synthesis of the fluoride- and PTFAI-donor: a) HBr (in AcOH 33wt%), CH2Cl2, H2O RT then 
NaOH aq., 47%, α:β = 2:1; b) DAST, CH2Cl2, 0°C, quant.; c) ClC(NPh)CF3, acetone, K2CO3, 88%, α:β = 4:3; d) 
1.174, SnCl2, CH2Cl2, m.s. 4Å, 0°C to RT, 0% conv.; e) α-1.181, cyclohexanol, TBSOTf, CH2Cl2, m.s. 4Å, –
78°C, full conversion, α:β = 3:2; or β-1.181, cyclohexanol, TBSOTf, CH2Cl2, m.s. 4Å, –78°C, full conversion, 
α:β = 3:2; or α-1.181, cyclohexanol, TMSOTf, CH2Cl2, m.s. 4Å, –78°C, full conversion, α:β = 3:1. 
Though the anomeric selectivity was not in favour of the desired diastereomer, we 
intended to test the imidate donor 1.181 on the aglycon 1.52, since the imidate donor has a 
high reactivity. On contrast to cyclohexanol, the aglycon was not consumed at –78°C. Thus, 
the reaction was allowed to slowly warm to room temperature, whereupon a complex mixture 
was obtained. After elaborative preperative TLC purification, we were able to isolate small 
amounts of the α-1.182 novioside product; the β-1.182 epimer could not be identified in the 
product mixture. 
                                                
126  T. Ikeda, H. Yamada, Carbohydr. Res. 2000, 329, 889–893. 
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Scheme 1.42: α-Noviosylation of the fidacomicin aglycon: a) TBSOTf, CH2Cl2, m.s. 4Å, –78°C to RT, yield not 
determined, α-only. 
Since, none of the noviosylations with the macrolide were successful and as only the α-
anomer was isolated, we concluded that the macrolide acceptor was too unreactive to undergo 
efficient β-noviosylation. We thus approached a new strategy towards the total synthesis of 
fidaxomicin, in which the novioside is introduced at an earlier stage (chapter 1.6.5). 
1.6.5 Step Back to Step Further – The Final Glycosylations 
As a consequence of the low reactivity of the macrolide towards noviosylation (chapter 
1.6.4), we decided to introduce the novioside on a linear, more flexible fragment at an early 
stage of the total synthesis. We chose the iodide fragment 1.184 as a suitable acceptor for this 
task. Thus intermediate 1.183 was deprotected using DIBAL-H in quantitative yield (Scheme 
1.43).127, 128 The secondary alcohol 1.184 was submitted to Königs-Knorr glycosylation 
conditions with noviosyl bromide 1.175 to give the desired β-anomer 1.185 exclusively, but 
in low yield (20%). Encouraged by this result, we aimed to optimize the yield. We thus, 
lowered and increased the temperature, slowly added the donor to the acceptor and inverse, 
and added an excess of the glycosyl bromide. Unfortunately, all these variations did not lead 
to improved yields. Thus, we changed the promoter to silver carbonate, which worked as 
good as the reaction with silver oxide (Scheme 1.43). Employing conditions reported by 
Helferich129 with mercury oxide and catalytic amounts of mercury bromide to mediate the 
reaction gave 63% yield of noviosylated fragment 1.185, but not exclusively as the β-anomer, 
though still in good anomeric ratio (α:β = 1:3). 
                                                
127  The previous method using K2CO3/MeOH was troublesome for purification reasons as the PNB-acid was not 
separable from alcohol 1.184.  
128  The reaction was performed by M.Sc. Hiromu Hattori, PhD-Student at the University of Basel/Zurich. 
129  a) B. Helferich, K. F. Wedemeyer, Liebigs Ann. Chem. 1949, 563, 139-145; b) L. R. Schroeder, J. W. Green, 
J. Chem. Soc. C 1966, 530. c) Y. Chen, M. J. Heeg, P. G. Braunschweiger, W. Xie, P. G. Wang, Angew. 
Chem. Int. Ed. 1999, 38, 1768-1769. 
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Scheme 1.43: β-Noviosylation of the linear iodide fragment: a) DIBAL-H, CH2Cl2, −78 to 0°C, quant.; b) HgO 
(6 equiv.), HgBr2 (0.1 equiv.), m.s. 4Å, CH2Cl2, 63%, α:β = 1:3; c) Ag2O, m.s. 4Å, CH2Cl2, RT, 20%, β-only; d) 
Ag2CO3, m.s. 4Å, CH2Cl2, 20%, β-only. 
With the novioside installed, we moved on to the assembly of the remaining parts. 
Fragment 1.186 was prepared from the known precursor 1.41130 by Yamaguchi esterification 
(61%) with dienoic acid 1.55 (Scheme 1.44).128 The following Suzuki cross coupling of the 
boronate 1.186 and noviosylated iodide 1.185 was highly effective and furnished product 
1.187 in good yield.128 Fortunately, the basic conditions ([Pd(PPh3)4], TlOEt in THF/H2O), 
also used by Altmann and Glaus in their aglycon synthesis,130 did affect neither the base labile 
carbonate nor the ester moiety, which can be attributed to the very short reaction time (less 
than 30 min).131 As in the synthesis of the aglycon (chapter 1.3), treatment of linear fragment 
1.187 with the second generation Grubbs catalyst (20 mol%) for one hour at 100°C gave the 
macrolide with an (E/Z) ratio of 2:1 in 75% yield (54% of E-1.188).128 Chromatographic 
separation of the E/Z isomers, allowed for a subsequent recycling of the (Z)-isomer. As a 
result, the overall yield of (E)-1.188 in this transformation was increased to 63%. Selective 
deprotection of the primary TBS-ether was achieved with trihydrogenfluoride triethylamine in 
moderate yield (Scheme 1.44). The last step in fragment assembly was the rhamnosylation, 
which we had examined earlier on the aglycon 1.189 (chapter 1.6.3). Under the conditions 
that were found to work best in our screening with the PTFAI-rhamnosyl donor and TBSOTf 
as catalytic promoter, we reached the desired fidaxomicin precursor 1.189 in good yield 
(62%) and excellent anomeric ratio (α:β = 1:4). Finally, as all the fragments were successfully 
assembled, the last task was the global deprotection to furnish fully synthetic fidaxomicin for 
the first time (chapter 1.7.2). 
                                                
130  F. Glaus, K.-H. Altmann, Angew. Chem. Int. Ed. 2015, 54, 1937–1940. 
131  S. A. Frank, H. Chen, R. K. Kunz, A. M. J. Schnaderbeck, W. R. Roush, Org. Lett. 2000, 2, 2691–2694. 
b/c or d
TBSO
O
TBSO
OPNB
II
β-1.185
a
TBSO
OH
I
1.1841.183
O
O
OO
OO
Br1.175
O
O
O
O
O
O
H
 Total Synthesis of the Antibiotic Fidaxomicin  75 
 
Scheme 1.44: Final assembly of the fragments and rhamnosylation: a) 1.55, 2,4,6-Cl3H2C6COCl, Et3N, DMAP, 
toluene, RT, 61%; b) 1.185, [Pd(PPh3)4] (20 mol%), TlOEt, THF/H2O 3:1, RT, 77%; c) Grubbs II (20 mol%), 
toluene, 100°C, 1 h, 75%, E:Z = 2:1; d) Grubbs II (20 mol%), toluene, 100°C, 11 h, 44% of (E)-1.188; e) 
3HF·Et3N, THF/CH3CN 1:1, RT, 8 h, 49%; f) 1.169, TBSOTf (20 mol%), CH2Cl2, –78 to –30°C, 62%, α:β = 
1:4. !
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1.7 Global Deprotection and Relay Synthesis  
In order to test our protecting group strategy as well as to get insights into the behaviour 
and stability of the advanced intermediates, we aimed to synthesize the appropriately 
protected compound 1.189 from commercially available fidaxomicin. In this chapter the 
relay-synthesis to the fully protected fidaxomicin and the global deprotection of semisynthetic 
and fully synthetic material is discussed. 
1.7.1 Fidaxomicin Protection – Relay Synthesis 
To selectively decorate the natural product, we first approached the allyl-protection of the 
phenols on the resorcylate unit using allyl bromide and potassium carbonate in DMF to 
furnish the desired diallyl-protected fidaxomicin 1.191 in good yield (89%, Scheme 1.45). We 
also tried to mono-protect the resorcylate by simply reducing the amount of allyl bromide to 
1.0–1.5 equivalents. Thereby, we found that the phenolic OH group para to the ester reacts 
first, which was unambigiously identified by the characteristic signal at around 10 ppm 
corresponding to the phenol-group in ortho-position. The following carbonate-protection of 
the cis-diol proved to be sluggish. Repetitive addition of carbonyl diimidazole was required 
throughout the reaction, while carefully monitoring conversion by TLC. An excess of the 
reagent resulted in reaction with the free hydroxyl groups. The use of triphosgene/pyridine for 
the carbonylation was low-yielding and decomposition of the starting material was observed. 
We then protected the hydroxyl groups on the core macrolide as the TBS-ether, without 
affecting the free alcohol at the rhamnoside moiety (C3’-OH). Conveniently, the three 
hydroxyl groups reacted with very different rates (C18-OH > C7-OH >> C3’-OH). Thus, the 
protection using TBS-triflate could be controlled by the choice of the reaction time, the 
concentration and equivalents of the reactants. In this way, we achieved the desired late stage 
intermediate 1.189 of our total synthesis in 50% overall yield.  
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Scheme 1.45: Relay synthesis of the advanced protected intermediate of the total synthesis: a) allyl bromide, 
K2CO3, DMF, 45°C, 3 h, 89%; b) (imid)2CO, Et3N, CH2Cl2, RT, 24 h, 90%; c) TBSOTf, 2,6-lutidine, CH2Cl2, 
0°C to RT, 5 h, 63%. 
1.7.2 The Global Deprotection Towards Fidaxomicin 
With the intermediate 1.189 in hand, we examined the conditions for the projected 
deprotection reactions of our protecting group strategy. We planned to perform the global 
deprotection in the reverse order as the protection. Thus, we exposed the silyl ether 1.189 to 
trihydrogenfluoride triethylamine in THF (Scheme 1.46). As already recognized in the TBS-
protection, the reaction rate of the two silyl ethers differs substantially. While the 1st silyl 
ether at position C18 was already cleaved at room temperature after few hours, the silyl ether 
at C7 required much harsher conditions (50°C, 24 h). In this way, the carbonate/allyl-
protected fidaxomicin 1.190 was isolated in good yield (88%). It should be mentioned, that 
the yield using fully synthetic starting material – probably due to its lower purity – was lower 
(60%). 
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Scheme 1.46: a) 3HF·Et3N, THF, 50°C, 24 h, 88%; b) NaH (0.04 mol%), ethylene glycol, THF, 0°C, 15 min, 
46% (53%brsm); c) morpholine, [Pd(PPh3)4] cat., THF, 0°C, 30 min, 86%. 
The carbonate cleavage was highly challenging, mainly due to competing hydrolysis and 
isobutyrate ester-migration to adjacent positions. To find the optimal conditions with the best 
selectivity and conversion, we screened different bases and nucleophiles (Table 1.8). The 
quality of the deprotection was determined by NMR spectroscopy since the desired product 
1.191 was inseparable by column chromatography from the products bearing the ester at C2” 
and C3”. No conversion was observed using DBU in dry CH2Cl2 (Entry 1), but in wet 
solvents (Entry 2,3), a rather complex mixture of hydrolized and migrated products with some 
desired products were formed. DMAP in CH2Cl2/CH3OH showed only little conversion and 
seemed to stop, even addition of more base did not push the reaction to completion (Entry 5). 
Triethylamine in methanol, on the other hand, was very unselective and induced migration of 
the ester to a large extent (Entry 6,7). Even less selective was the secondary amine 2-
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(methylamino)-ethanol, giving a 1 : 1 mixture of fully hydrolysed to mono esterified products, 
while starting material was still present (Entry 8). Astonishingly, the rather harsh conditions 
reported in Entry 9 to 11 did not lead to any conversion of the starting material. We were very 
pleased to find Barton’s base to be sufficiently selective, if the reaction was stopped as soon 
as the formation of fully hydrolysed byproduct was monitored (Entry 12). Purification of this 
reaction by column chromatography gave 16% of recovered starting material and 54% of the 
desired product 1.191 along with inseparable byproducts. This material was directly subjected 
to the next deprotection step using tetrakis(triphenylphosphine) palladium (0) and morpholine 
at 0°C. This furnished fidaxomicin smoothly within 30 minutes. Purification first by column 
chromatography and then RP-HPLC gave only 10% yield over the two steps (conducted with 
semisynthetic and fully synthetic material).  
Table 1.8: Screening of conditions for the carbonate deprotection. 
 Reagent ([v/v]) Solvent/Temp. [°C] time Observation 
1 DBU (0.02) dry CH2Cl2; RT 18 h no conv. 
2 DBU (0.02) wet CH2Cl2; RT 16 h 13% p./bp 
3 DBU (0.02) wet THF; RT 0.5 h p. + many bp. 
4 DABCO cat. wet CH2Cl2; RT 2 h no conv. 
5 DMAP cat. CH2Cl2/CH3OH; RT 18 h low conversion 
6 Et3N (0.1) MeOH; RT 12 h p. + many bp. + s.m. 
7 Et3N (0.1) MeOH; 40°C 4 h p. + many bp. + s.m. 
8 
 (0.02) 
Hex/CH2Cl2; RT 18 h p:bp 1:1 + s.m. 
9 K2CO3 (0.07 g/mL) H2O/THF; 50°C 1.5 h no conv. 
10a – H2O/THF; 150°C 0.5 h no conv. 
11a DIBAL-H CH2Cl2; –40°C  no conv. 
12a Barton’s base (0.02) wet CH2Cl2; RT 5 h 54% p./minor bp.+16% s.m. 
13 NaH (cat.) THF/MEG; 0°C 15 min 55% p./minor bp.+13% s.m. 
p. = product; bp. = byproduct (mainly fully hydrolized and migrated ester); s.m.= starting material; 
a experiments conducted by Dr. Hideki Miyatake Ondozabal, post doctoral researcher at Univ. of Basel. 
Though, we could not conclusively figure out the reason for the low yield of the last two 
steps in the deprotection sequence, we further investigated on the carbonate deprotection step. 
We found that catalytic amount of sodium hydride in THF/ethylene glycol (10/1) efficiently 
furnished the desired product with only a minimum amount of byproducts (Entry 13). 
Purification by column chromatography and subsequent RP-HPLC gave 46% yield of  
HO
H
N
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allylated fidaxomicin 1.191. This material was further deprotected to obtain fidaxomicin in 
86% yield without the need for another elaborate RP-HPLC purification (Scheme 1.46). To 
illustrate the differences of Entry 3, 12 and 13 (Table 1.8), the 1H-NMR spectra of the 
reactions after column chromatography are shown in Figure 1.26. The reaction using 
NaH/ethylene glycol gives a ratio of product to inseparable byproducts of around 5:1. The 
deprotections using DBU and Barton’s base, on the other hand, led to formation of  
inseparable byproducts in substantial amounts. Further, the overall yield of the two last steps 
using Barton’s base was only 10% and the one using NaH/ethylene glycol 40%. Thus the 
global deprotection sequence using the latter carbonate deprotection is the route of choice.  
 
 
 
Figure 1.26: 1H-NMR spectra of the carbonate deprotection after column chromatography. Green: product peak; 
orange: byproduct peaks; blue: superimposed product and byproduct peaks. Top: NaH (cat.), ethylene glycol, 
THF, 0°C, 15 min; middle: Barton’s base, wet CH2Cl2, RT, 5 h; bottom: DBU, wet CH2Cl2, RT, 18 h. 
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Confusingly, after global deprotection and RP-HPLC purification of fully synthetic 
fidaxomicin, the 1H-NMR-spectra did not fully match with the spectra of natural fidaxomicin 
(Figure 1.27). The signals of the resorcylate-rhamnosyl part were shifted, whereas the signals 
from the macrolide and the novioside were identical with the corresponding signals of the 
authentic fidaxomicin sample.  
 
Figure 1.27: Proof of co-identity of the natural and fully synthetic (containing formate) fidaxomicin in CD3OD. 
We figured that the acidic phenol groups of the resorcylate might be shifted due to the 
formate salt present in the fully synthetic sample. This assumption was confirmed by 
equimolar mixing of the authentic with the fully synthetic sample. The spectra of this mixed 
sample showed only one set of signals, which proofs the co-identity of the fully synthetic and 
natural fidaxomicin. Further proof was gained by addition of ammonium formate to an 
authentic sample and comparison with the spectra under neutral conditions. Also in this case 
the signals of the resorcylate-rhamnosyl part were shifted (Figure 1.28).  
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Figure 1.28: Comparison of the chemical shifts of pure fidaxomicin and a sample treated with ammonium 
formate. Depicted regions are highlighted: red, δ 5.10 ppm: CH4’ triplett of rhamnosyl part; green, δ 2.92 ppm 
methlyene substituent at resorcylate; blue, δ 1.35 ppm CH6’ methyl group of rhamnosyl part. 
Further proof of the co-identity was obtained by co-injection of fully synthetic and natural 
fidaxomicin on an RP-HPLC instrument (Figure 1.29).  
 
Figure 1.29: RP-HPLC co-injection of the authentic and synthetic compound. Black = authentic sample; blue = 
fully synthetic sample; pink = mixture of authentic and fully synthetic sample. 
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1.8 Conclusion and Outlook 
In this project, we accomplished the first total synthesis of the antibiotic fidaxomicin. The 
natural product is a novel therapeutic for the treatment of Clostridium difficile infections 
(CDI) in the gastrointestinal tract. Besides the advantageous activity against CDI, the natural 
product is active against various other pathogens, most strikingly against multidrug-resistant 
strains of Mycobacterium tuberculosis. Unfortunately, the pharmacological properties of the 
natural product are not suitable for the treatment of systemic diseases. Thus, structural 
modifications of the antibiotic are highly desirable in order to improve its pharmacokinetic 
characteristics. 
Fidaxomicin consists of a central macrolide attached to a D-noviose and a D-rhamnose-
resorcylate fragment. The unusual D-novioside 1.103 was prepared by a novel and short 
synthetic approach (six steps). The resorcylate unit 1.128 was synthesized using a biomimetic 
aromatization approach (four steps), and a regioselective esterification with the rhamnoside 
1.144 (five steps) furnished the resorcylate-rhamnoside fragment in a very straightforward 
way. The synthesis of the central macrolide was based on three main fragments, assembled by 
a Stille cross-coupling, a vinylogous Mukaiyama aldol reaction and a ring-closing metathesis 
(14 steps). Attempts to introduce the novioside at the central macrolactone failed due to the 
low reactivity of the macrolide acceptor. Thus, noviosylation was performed on a linear 
fragment 1.184 before assembly of the macrolide, constituting the first β-selective 
noviosylation reported. The connection of the remaining fragments feature a Suzuki cross-
coupling of sterically demanding substrates and a ring-closing metathesis. The challenging β-
rhamnosylation has been elaborated by systematic variation of the donor-conformation and 
screening of leaving groups, to finally reach high diastereomeric ratio with the PTFAI-donor 
1.169 in the 4C1 conformation. Subsequent global deprotection furnished fully synthetic 
fidaxomicin for the first time. NMR and HPLC measurements unambiguously established the 
co-identity of the synthetic material and an authentic sample of the natural product. The 
reported  total synthesis is highly convergent (six fragments) and the longest linear sequence 
is only 16 steps.  
The total synthesis as well as the results of the semisynthetic studies pave the way for the 
generation of structurally diverse analogues. In our laboratories, investigations using fully 
synthetic and semisynthetic strategies are on-going, to address the shortcomings of the 
pharmaceutical. 
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2 Methionine-Derived Iminium Lactones 
2.1 Introduction 
The inception of this project was the idea of a distinct chemical transformation. The 
application of the transformation or its product was only vague at that time. Thus, the aim of 
the project was very flexible and the project purely curiosity-driven. Along the study of this 
venture, a sudden observation shifted our attention to a different objective. This introducing 
chapter, thus, starts with the general idea, followed by some background information, which 
also applies for the second objective.  
The initial idea of this project was a simple and unusual chemical transformation. In this 
reaction a peptidic methionine building block should be transformed to a 5,6-dihydro-4H-1,3-
oxazine (Figure 2.1). To initiate the reaction, an electrophile should convert the thioether into 
a leaving group and a subsequent 6-exo-tet cyclisation by the attack of the amide portion 
should take place. 
 
Figure 2.1 The general concept: Transformation of methionine to a 1,3-oxazine by electrophilic activation and 
subsequent attack of the amide portion. 
This transformation is interesting since it yields functionalized 1,3-oxazines from relatively 
cheap, chiral starting materials in a straightforward way. Furthermore, 5,6-dihydro-4H-1,3-
oxazines are valuable synthetic intermediates and present in molecules with interesting 
bioactivities (Chapter 2.1.2). Also, the oxazines could be an interesting motif in 
peptidomimetic research (Chapter 2.3.3). In the following sections, background to related 
synthetic contributions in literature, 5,6-dihydro-4H-1,3-oxazines and peptide drugs are given.  
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2.1.1 Related Synthetic Contributions 
The transformation of thioethers to leaving groups through electrophilic activation is a 
common concept. Mostly, methyl iodide or 2-iodo acetates are used as alkylating agent to 
obtain the corresponding sulfonium ions. So far only five-membered rings and no six-
membered rings have been synthesized in this way. In the following section, several examples 
of intramolecular cyclisations using the thioether as triggerable leaving group are mentioned.  
Methionine is a frequently used precursor for homoserine lactones, such as 2.2. It can be 
easily prepared by the treatment of 2.1 with an alkylating agent in acidic aqueous media 
(equation 1, Scheme 2.1).132 Similarly, boiling hydroxylamide 2.3 with methyl iodide and 
subsequent addition of base gave the cyclized hydroxylimino ether 2.4 (equation 2).133 
Alkylation and subsequent base treatment of methionine linked by a secondary amide at the 
C-terminus, such as 2.5 gave γ-lactam 2.6 (equation 3).134 The concept was also recognized as 
a useful too for peptide sequencing and identification by peptide bond cleavage C-terminal to 
methionine, using cyanogen bromide (equation 4).135 In addition, 1,3-oxazolidines 2.12 
(equation 5) have been prepared from thioether 2.11 and dimethyl(methylthio)sulfonium 
fluoroborate (DMTSF).136 
 
                                                
132  a) G. A. Rosenthal, D. L. Dahlman, P. A. Crooks, S. N. Phuket, L. S. Trifonov, J. Agric. Food Chem. 1995, 
43, 2728–2734; b) A. G. Jamieson, N. Boutard, K. Beauregard, M. S. Bodas, H. Ong, C. Quiniou, S. 
Chemtob, W. D. Lubell, J. Am. Chem. Soc. 2009, 131, 7917–7927; c) S. Natelson, E. A. Natelson, 
Microchem. J. 1989, 40, 226–232. 
133  a) K. Barlos, D. Papaioannou, Liebigs Ann. Chem. 1988, 1127–1133; b) P. Dionissios, B. Kleomenis, F. 
George W, B. Trond, A. Dagfinn W, M.-M. Knut, Acta Chem. Scan. 1990, 44, 189–194. 
134  a) C. Chan, A. D. Borthwick, D. Brown, C. L. Burns-Kurtis, M. Campbell, L. Chaudry, C.-W. Chung, M. A. 
Convery, J. N. Hamblin, L. Johnstone, et al., J. Med. Chem. 2007, 50, 1546–1557; b) D. Damour, F. Herman, 
R. Labaudinière, G. Pantel, M. Vuilhorgne, S. Mignani, Tetrahedron 1999, 55, 10135–10154. 
135  a) E. Gross, B. Witkop, J. Am. Chem. Soc. 1961, 83, 1510–1511; b) W. B. Lawson, E. Gross, C. M. Foltz, B. 
Witkop, J. Am. Chem. Soc. 1962, 84, 1715–1718; c) R. Kaiser, L. Metzka, Anal. Biochem. 1999, 266, 1–8. 
136  a) B. M. Trost, T. Shibata, J. Am. Chem. Soc. 1982, 104, 3225–3228. 
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Scheme 2.1: Selected methionine activation/cyclization reactions. 
In contrast, the 6-exo-tet cyclisations to prepare 5,6-dihydro-4H-1,3-oxazines with other 
leaving groups than trialkylsulfonium ions has been widely applied, and some are depicted in 
Scheme 2.2. Probably the most common among them feature a halogen as leaving group. The 
reaction can be enhanced with silver salts, but also takes place spontaneously as shown by 
Prabhakaran et al. (equation 1).137 Various conditions for the activation of hydroxy groups, 
                                                
137  a) D. N. Reddy, E. N. Prabhakaran, J. Org. Chem. 2011, 76, 680–683; b) P. Deslongchamps, P. Soucy, 
Tetrahedron 1981, 37, 4385–4390; d) T. Nishikawa, D. Urabe, K. Yoshida, T. Iwabuchi, M. Asai, M. Isobe, 
Org. Lett. 2002, 4, 2679–2682. 
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followed by cyclisations have been reported.138 In equation 2, a functionalized homoserine 
2.15 was treated with (diethylamino)sulfur trifluoride (DAST) to give the 1,3-oxazine 2.16 in 
high yield. Also, silyl ether protected alcohols have been activated using DAST (equation 
3).139 In a recent example, 1,3-oxazine 2.20 was furnished by cyclopropane ring-opening of 
2.19, induced by bromination with 1,3-dibromo-5,5-dimethyl-hydantoin (DBH) and catalytic 
amounts of Ph3PS as activator.140 
 
Scheme 2.2: Selected 6-exo-tet cyclisations with internal amide bond to form 1,3-oxazines. 
                                                
138  a) T.-S. Kim, Y.-J. Lee, K. Lee, B.-S. Jeong, H.-G. Park, S.-S. Jew, Synlett 2009, 2009, 671–674; b) M.-F. 
Pouliot, L. Angers, J.-D. Hamel, J.-F. Paquin, Tetrahedron Letters 2012, 53, 4121–4123; c) T. Sauvaître, M. 
Barlier, D. Herlem, N. Gresh, A. Chiaroni, A. D. Guenard, C. Guillou, J. Med. Chem. 2007, 50, 5311–5323; 
d) J. Huber, J. Wölfling, G. Schneider, I. Ocsovszki, M. Varga, I. Zupkó, E. Mernyák, Steroids 2015, 102, 
76–84. 
139  a) B. B. Metaferia, B. J. Fetterolf, S. Shazad-Ul-Hussan, M. Moravec, J. A. Smith, S. Ray, M.-T. Gutierrez-
Lugo, C. A. Bewley, J. Med. Chem. 2007, 50, 6326–6336; b) T. Kline, N. H. Andersen, E. A. Harwood, J. 
Bowman, A. Malanda, S. Endsley, A. L. Erwin, M. Doyle, S. Fong, A. L. Harris, et al., J. Med. Chem. 2002, 
45, 3112–3129. 
140  Y.-C. Wong, Z. Ke, Y.-Y. Yeung, Org. Lett. 2015, 17, 4944–4947. 
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2.1.2 5,6-Dihydro-4H-1,3-oxazines 
5,6-Dihydro-4H-1,3-oxazines are abundant structural motifs in bioactive compounds, such 
as choline acetyl transfer inhibitors,141 acetylcholine-esterase inhibitors,138c cytostatics138d and 
β-secretase inhibitors for clinical evaluation against Alzheimer’s disease.142  
 
 
Figure 2.2 5,6-Dihydro-4H-1,3-oxazines as versatile synthetic precursor. a) i. NaBH4, THF/EtOH/H2O, ii. aq. 
oxalic acid, 60-70%;143 b) i. MeI, RT ii. RMgX, ether, iii. aq. oxalic acid, 22-85%;144 c) R1=CH2CO2Et, NaH, 
ICH2CH(OEt)2, DMSO, RT then TFA, toluene, reflux;145 d) R2CO, H2 (50 atm.), Pd/C, RT, 30-91%;148 e) HCl or 
HBr, H2O, % n.d.;147a f) R1=Ph; R2=Ph; R4=OR, Amberlyst, acetone, H2O, RT, quant;146a g) R1=Ar, 
R2CH2CO2Tos, Et3N, CH2Cl2, RT, 48h;149a h) ethylene oxide, 120-200°C, 27–61%.149b 
The heterocycle also gained attention as valuable synthetic intermediate for aldehydes,143  
ketones, 144  pyrroles, 145  β-amido aldehydes, 146  β-amino esters, 147  aminoalcohols 148  and 
                                                
141  N. B. Mehta, D. L. Musso, H. L. White, Eur. J. Med. Chem. 1985, 20, 443-446.   
142  H. Hilpert, W. Guba, T. J. Woltering, W. Wostl, E. Pinard, H. Mauser, A. V. Mayweg, M. Rogers-Evans, R. 
Humm, D. Krummenacher, T. Muser, C. Schnider, H. Jacobsen, L. Ozmen, A. Bergadano, D. W. Banner, R. 
Hochstrasser, A. Kuglstatter, P. David-Pierson, H. Fischer, A. Polara, R. Narquizian, J. Med. Chem. 2013, 
56, 3980–3995. 
143  a) A. I. Meyers, A. Nabeya, H. W. Adickes, J. Am. Chem. Soc. 1969, 91, 763–764; b) A. I. Meyers, A. 
Nabeya, H. W. Adickes, J. M. Fitzpatrick, G. R. Malone, I. R. Politzer, J. Am. Chem. Soc. 1969, 91, 764–
765.  
144 A. I. Meyers, E. M. Smith, J. Org. Chem. 1972, 37, 4289–4293. 
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bicycles149 (Figure 2.2). The cyclic imidate is stable in water and cold basic media, but 
hydrolyses under acidic aqueous conditions. 
Further, it was found those terminal 1,3-oxazine in peptides are able to force a peptide 
bond into a natively disallowed conformation (cf. the Ramachandran map) (Figure 2.3).137a,150 
This behaviour might be useful to stabilize secondary structures in peptides and is thus of 
special interest for the design of peptidomimetics. 
 
Figure 2.3 The amide to imidate modification gives access to an otherwise disallowed conformation.137a a) NaH, 
THF, 0°C to RT, 97% to quant. 
 
 
 
 
 
                                                                                                                                                   
145 T. A. Narwid, A. I. Meyers, J. Org. Chem. 1974, 39, 2572–2574. 
146 a) P. Gizecki, R. Dhal, L. Toupet, G. Dujardin, Org. Lett. 2000, 2, 585–588; b) S. H. Kang, C. M. Kim, J. H. 
Youn, Tetrahedron Lett. 1999, 40, 3581–3582. 
147 a) S. Gabriel, Liebigs Ann. Chem. 1915, 409, 305–327; b) P. Wipf, G. B. Hayes, Tetrahedron 1998, 54, 6987–
6998. 
148 A. Balazs, Z. Szakonyi, J. Heterocycl. Chem. 2007, 44, 403–406. 
149 a) M. Miykae, N. Tokutake, M. Kirisawa, Synthesis 1983, 833–835; b) W Seeliger, E. Aufderhaar, W. 
Diepers, R. Feinauer, R. Nehring, W. Thier, H. Hellmann, Angew. Chem. Int. Ed. 2015, 5, 875–888. 
150  a) D. N. Reddy, R. Thirupathi, S. Tumminakatti, Tetrahedron 2012, 53, 4413–4417; b) D. N. Reddy, R. 
Thirupathi, E. N. Prabhakaran, Chem. Commun. 2011, 47, 9417–9419. 
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2.1.3 The Peptide and Protein Architecture 
Proteins and peptides are essential for all the living species on our planet.151 They are 
fulfilling a range of diverse functions in living organisms in the form of enzymes, signalling 
molecules, toxins, antibodies or structural proteins. Nature has twenty proteogenic amino 
acids on hand to build these peptides by linear covalent amide bond connections (primary 
structure) during translation. Various post-translational modifications increase the range of 
diversity of proteins even further.152  
 
Figure 2.4: The proteogenic amino acids encoded by RNA codons. 
The peptide chains arrange in a distinct, yet flexible and three-dimensional shape (e.g. α-
helices, β-sheets) with high complexity (secondary and tertiary structure). Thereby, the side 
                                                
151  J. Reece, L. A. Urry, N. Meyers, M. L. Cain, Campbell Biology, Pearson Benjamin Cummings, 2011. 
152   D. Voet, J. G. Voet, C. W. Pratt, Fundamentals of Biochemistry, John Wiley & Sons Incorporated, 2006. 
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chains of the amino acids, which interact with each other by covalent (disulfide bridges) or 
noncovalent bonds, such as ionic interactions, hydrogen bonds or Van der Waals interactions, 
determine the folding of the protein (Figure 2.5). 153  Also, hydrophobic/hydrophilic 
interactions play an important role for the arrangement of the proteins in the physiological, 
aqueous media. The three dimensional structure of enzymes usually bear an active pocket 
where a certain substrate binds. This pocket is formed by folding of the linear chain, and is 
highly important for the biological function of proteins. Denaturation or unfolding of the 
peptide results in loss of the catalytic activity and is a major challenge for peptide-drug 
development.  
 
Figure 2.5: Important amino acid interactions for the peptide folding. 
 
 
 
                                                
153  B. Alberts, A. Johnson. J. Lewis, D. Morgan, M. Raff, K. Roberts, P. Walter, Molecular Biology of the Cell, 
Garland Science, 2015, 6th Ed.  
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2.1.4 Peptidomimetics – Chemically Modified Peptides 
Proteins, peptides or so-called peptidomimetics made up one third of the top 100 
prescription drugs in the US in 2013.154 In the development of new drugs, scientists in 
medical research are faced with some shortcomings of natural peptides, such as rapid 
metabolization by proteases, fast hydrolysis and denaturation in the stomach or low 
membrane permeability.155 A further disadvantage is the high conformational flexibility of 
peptides, which may result in nonspecific bindings to different targets, and thus undesired 
side effects of a drug can occur. Since peptides are only rarely suitable drug candidates, 
especially considering the low oral bioavailability, scientists aim to develop small molecules 
– so called peptidomimetics – that retain the biological activity but overcome the 
shortcomings of the parent compounds. These peptidomimetics are compounds that should 
imitate the structure of a peptide in its receptor-bound conformation.155 To reach this 
challenging and time-consuming goal, manifold strategies have been developed. Mainly, 
increasing rigidity of the active conformer and, thus, optimizing the selectivity has been tried, 
while avoiding recognition by proteolytic enzymes (cf. amide bond isosteres e.g azapeptides, 
oligoureas, phoshphonopeptides) to reach higher bioavailability. 156  Generally the lead-
structure is found through structure-activity studies of the protein-ligand interaction, X-ray 
analysis, and also computational chemistry.157 In this way, the important pharmacophoric 
groups and the three-dimensional conformation can be elicited. While the computational 
models are highly advanced, they are still not sufficient and laborious experimental work is 
required (trial and error). Chemists have developed various chemical modules to avoid 
recognition by proteolytic enzymes, to increase rigidity, to make a peptide more lipophilic, or 
to induce a distinct secondary structure such as helices, sheets or β-turns (Figure 2.6).  
A simple idea was the incorporation of D-enantiomeric amino acids into peptides, which 
became useful to prevent proteolytic recognition, but also for the modulation of secondary 
structures (e.g. D-Pro-L-Pro induces a β-turn).158 The α,α-dialkylamino acids have been 
                                                
154  N. A. McGrath, M. Brichacek, J. T. Njardarson, J. Chem. Educ. 2010, 87, 1348–1349. 
155  N. Sewald, H.-D. Jakubke, Peptides: Chemistry and Biology, Wiley-VCH, 2009. 
156  V. J. Hruby, Drug Discovery Today 1997, 2, 165–167. 
157  J. Gante, Angew. Chem. 1994, 106, 1780–1802. 
158  a) J. A. Robinson, J. Pept. Sci. 2013, 19, 127–140; b) C. M. Nair, M. Vijayan, Y. V. Venkatachalapathi, P. 
Balaram, J. Chem. Soc., Chem. Commun. 1979, 1183–1184. 
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successfully applied to induce and stabilize helixes in small peptides.159 Especially, 2-
aminoisobutyric acid (Aib) exhibits a strong helix induction in peptides.159c-f  
 
Figure 2.6: Selected examples of chemical modules to influence the structural properties of a peptide. 
AA = amino acids. 
Also, the β-amino acids contributed a powerful tool for the definition of secondary 
structures such as β-turns and 314 helices160 and they have been applied to increase proteolytic 
stability of peptides.161 Oligoglycins with the sidechain attached to the amide nitrogen instead 
of the α-carbon, the so-called peptoids, have been designed to inhibit the formation of α-
helices and β-sheets.162 These peptoids are achiral along the backbone and the hydrogen 
bonding interactions are suppressed. Also, N-methylation of the peptide backbone reduces the 
hydrogen donor capacity, as well as the proteolytic recognition, and is a common method to 
increase lipohilicity or alter the conformation of peptides.163 N-methylated amino acids 
                                                
159  a) K.-H. Altmann, E. Altmann, M. Mutter, Helv. Chim. Acta 1992, 75, 1198–1210; b) E. Altmann, K.-H. 
Altmann, K. Nebel, M. Mutter, Int. J. Pept. Protein Res. 1988, 32, 344–351; c) M. Mutter, K.-H. Altmann, 
A. Flörsheimer, J. R. Herbert, Helv. Chim. Acta 1986, 69, 786–792; d) F. R. Carbone, B. S. Fox, R. H. 
Schwartz, Y. Paterson, J. Immun. 1987, 138, 1838–1844; e) I. L. Karle, J. L. Flippen-Anderson, K. Uma, P. 
Balaram, Int. J. Pept. Prot. Res. 1988, 32, 536–543; f) D. Seebach, B. Jaun, R. Sebesta, R. I. Mathad, O. 
Flögel, M. Limbach, H. Sellner, S. Cottens, Helv. Chim. Acta 2006, 89, 1801–1825; g) C. Toniolo, E. 
Benedetti, Macromolecules 1991, 24, 4004–4009. 
160  a) K. Gademann, T. Kimmerlin, D. Hoyer, D. Seebach, J. Med. Chem. 2001, 44, 2460–2468; b) D. Seebach, 
P. E. Ciceri, M. Overhand, B. Jaun, D. Rigo, L. Oberer, U. Hommel, R. Amstutz, H. Widmer, Helv. Chim. 
Acta 1996, 79, 2043–2066. 
161  M. Rodriguez, A. Aumelas, J. Martinez, Tetrahedron Lett. 1990, 31, 5153–5156. 
162  R. N. Zuckermann, T. Kodadek, Curr. Opin. Mol. Ther. 2009, 11, 299–307. 
163  a) L. Aurelio, R. T. C. Brownlee, A. B. Hughes, Chem. Rev. 2004, 104, 5823–5846; c) D. P. Fairlie, G. 
Abbenante, D. R. March, Curr. Med. Chem. 1995, 2, 654–686. 
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(NMA’s) are also abundant structural motifs in bioactive natural products like vancomycin 
and cyclosporine.  
Another tool used is depsipeptides bearing at least one ester in the backbone in place of an 
amide (Figure 2.6). This is a common feature in natural products, but also caught the attention 
as a feature in peptidomimetics, especially in the so-called switch-peptides.164 The secondary 
structures of switch-peptides are convertible from one distinct shape to another by exterior 
influences. The depsipeptides can be triggered to induce an O-to-N acyl-migration, thereby 
transforming the ester with a random coil chain into a regular peptide, forming α-helices or β-
sheets.164a,165 These transformations have become of particular interest in neurodegenerative 
disease research. 
 
Figure 2.7: Switch peptide concept: A depsipeptide having a random coil shape is triggered by deprotection of 
the N-protecting group (Y). The free amine then undergoes an O-to-N acyl migration to give a regular peptide 
backbone. The new peptide then folds into a new shape (e.g β-sheet) and coagulates. 
A disadvantage with the above mentioned unnatural amino acids (Figure 2.6) is that they 
still have rotational freedom around their bonds and thus the secondary structure is not easy to 
predict. To address this challenge, amino acid mimetics and dipeptide mimetics with fixed 
conformations have been developed (Figure 2.8) – so-called secondary structure mimetica. 
The most abundant shapes successfully mimicked are the β- and γ-turns.166 In the following 
section some selected examples are given. 
                                                
164  a) M. Mutter, A. Chandravarkar, C. Boyat, J. Lopez, S. Dos Santos, B. Mandal, R. Mimna, K. Murat, L. 
Patiny, L. Saucède, G. Tuchscherer, Angew. Chem. Int. Ed. 2004, 43, 4172–4178; b) M. Mutter, Chimia 
2013, 67, 868–873. 
165  N. Nepomniaschiy, V. Grimminger, A. Cohen, S. DiGiovanni, H. A. Lashuel, A. Brik, Org. Lett. 2008, 10, 
5243–5246. 
166  Review: A. Giannis, T. Kolter, Angew. Chem. 1993, 105, 1303–1326. 
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Tetrahydroisochinolinecarboxylic acid (Tic) is a bridged unnatural amino acid, which has 
been used to mimic phenylalanine in opioid antagonists (Figure 2.8).167 Tic has limited 
conformational freedom in the side chain and the N-bridged peptide bond is forced into a Z 
configuration. The Freidinger lactam is a dipeptide turn-mimetic that was successfully used in 
biologically active compounds.168 Also E-locked motifs, such as the aza-lactam have been 
developed.169 The bicyclic dipeptide β-turn mimetic found application as an analogue of a 
dopamine receptor modulating-peptide.170  
 
Figure 2.8: Selected building blocks that give fixed secondary structures. 
Another bicyclic motif is the Gly-Leu-turn mimetic, which gave rise to a potent neurokinin 
antagonist.171 Also, more complex building blocks like the [7.6]-bicycle were developed as 
shape mimetic and found application in a protease inhibitor.172  
                                                
167  W. Kazmierski, V. J. Hruby, Tetrahedron 1988, 44, 697–710. 
168  a) R. M. Freidinger, D. F. Veber, D. S. Perlow, J. R. Brooks, R. Saperstein, Science 1980, 210, 656–658; b) 
R. M. Freidinger, D. S. Perlow, D. F. Veber, J. Org. Chem. 1982, 47, 104–109; c) J. D. Aebi, D. Guillaume, 
B. E. Dunlap, D. H. Rich, J. Med. Chem. 1988, 31, 1805–1815. 
169  P. A. Ottersbach, J. Schmitz, G. Schnakenburg, M. Gütschow, Org. Lett. 2013, 15, 448–451. 
170 a) U. Nagai, K. Sato, Tetrahedron Lett. 1985, 26, 647–650; b) N. L. Subasinghe, R. J. Bontems, E. McIntee, 
R. K. Mishra, R. L. Johnson, J. Med. Chem. 1993, 36, 2356–2361. 
171  a) M. G. Hinds, N. G. J. Richards, J. A. Robinson, J. Chem. Soc., Chem. Commun. 1988, 1447–1449; b) P. 
Ward, G. B. Ewan, C. C. Jordan, S. J. Ireland, R. M. Hagan, J. R. Brown, J. Med. Chem. 1990, 33, 1848–
1851; c) M. G. Hinds, J. H. Welsh, D. M. Brennand, J. Fisher, M. J. Glennie, N. G. J. Richards, D. L. Turner, 
J. A. Robinson, J. Med. Chem. 1991, 34, 1777–1789. 
172 H. Nakanishi, R. A. Chrusciel, R. Shen, S. Bertenshaw, M. E. Johnson, T. J. Rydel, A. Tulinsky, M. Kahn, 
Proc. Nat. Ac. Sc. USA 1992, 89, 1705–1709. 
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2.2 Towards Methionine-Derived 1,3-Oxazines 
We decided to start with a C- and N-terminus amide bond linked methionine model 
system. Since C-terminal secondary amides undergo 5-exo-tet cyclisations to give γ-lactams 
(Scheme 2.1), we blocked the nitrogen with an alkyl group. Thus, we synthesized the 
benzoylated tertiary amides 2.23-2.27 from the known, racemic benzoylated precursors 
2.21173 and 2.22,174 using standard peptide coupling reactions (Table 2.1).  
Table 2.1: Preparation of methionine tertiary amide precursors. 
 
Ar Amine Conditions Product Yield  
Ph Et2NH BOP, Et3N, THF, 0°C to RT 2.23: R = NEt2 56% 
Ph piperidine EDC·HCl, DMAP, CH2Cl2, RT 2.24: R = piperidine quant. 
Ph pyrrolidine EDC·HCl, DMAP, CH2Cl2, RT 2.25: R = pyrrolidine 96% 
Ph morpholine EDC·HCl, DMAP, CH2Cl2, RT 2.26: R = morpholine 92% 
PMP piperidine EDC·HCl, DMAP, CH2Cl2, RT 2.27: R = piperidine 56% 
The peptide coupling with the sterically demanding diisopropylamine using the procedure 
above, did not furnish the desired amide 2.30. Most likely the issue was a competing 
intramolecular attack of the benzoyl moiety. Thus, peptide coupling of the Boc-protected 
methionine 2.28 and hydrolysis of the Boc group was performed to get the amine 2.29. The 
desired amide 2.30 was synthesized using benzoyl chloride (Scheme 2.3). 
 
Scheme 2.3: Synthesis of the sterically demanding amide 2.30: a) i. BOP, Et3N, THF, diisopropylamine, 0°C to 
RT; ii. HCl aq. conc., MeOH, RT, 26%; b) PhCOCl, EtNiPr2, CH2Cl2, RT, 79%. 
                                                
173  H. L. Holland, P. R. Andreana, R. Salehzadeh-Asl, A. van Vliet, N. J. Ihasz, F. M. Brown, Chem. Month. 
2000, 131, 667–672. 
174  S. Benvenuti, F. Severi, L. Costantino, G. Vampa, M. Melegari, Farmaco 1998, 53, 439–442. 
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To begin with, the alkylations were performed using iodo-ethylacetate (Table 2.2). The 
reactions were monitored by UPLC-MS and the isolated compounds were purified by 
triturations or short column chromatography using aprotic solvents. Indeed we found cyclized 
and eliminated products under these reaction conditions. Unexpectedly, the morpholine amide 
2.26 did not show any product formation. Alarmed by that fact, we realized that instead of 6-
exo-tet cyclisations, forming 1,3-oxazines A, 5-exo-tet cyclisations took place, to give 
iminium lactones B. This was unambiguously confirmed by X-ray crystal structure analysis of 
the diisopropyl compound 2.35. 
Table 2.2: Methionine activation with iodo-acetate furnishing iminium lactones. 
 
Amide Ar R Yield of B 
2.23 Ph NEt2 29%, 2.31 
2.24 Ph piperidine 29%, 2.32 
2.25 Ph pyrrolidine n.d.a, 2.33 
2.26 Ph morpholine   0%b 2.34 
2.30 Ph NiPr2 63%, 2.35 
2.27 PMP piperidine n.d.c, 2.36 
Conditions: a) ICH2CO2Et, MeCN, 50°C, 1 d. a Decomposed during HPLC purification, 
UPLC-MS showed a single product. b Elimination did not occur, alkylation occurred. 
c UPLC-MS showed m/z of the product along with starting material and alkylated 
product. 
 
Figure 2.9: X-ray crystal structure of iminium ether 2.35. grey = carbon; white = hydrogen; red = oxygen; 
blue = nitrogen; magenta = iodine. 
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The conversion of the reactions were generally very low. During the reaction, initially 
product B is exclusively formed and with prolonged reaction time, the alkylated compounds 
C were observed. A reasonable explanation for this observation is shown by the equilibrium 
in Figure 2.10. In the first, step alkylation takes place to give the sulfonium species A, then 
the cyclisation to the iminium lactone B takes place by releasing of ethyl 2-(methylthio) 
acetate. The cyclisation is reversible as the thioether can attack the iminium lactone to reform 
A. The sulfonium species might also react with the iodide to form methyl iodide and the 
corresponding thioether C. Since the methyl iodide is volatile, slow accumulation of product 
C occured. 
 
Figure 2.10: Proposed equilibrium of the methionine alkylation reaction. 
As a consequence of the competing iminium ether formation, we wanted to eliminate the 
amide moiety at the C-terminus. Thus, the carboxylic acid 2.21 was treated with thionyl 
chloride in methanol (Scheme 2.4) and the resulting methyl ester 2.37 was then treated with 
iodo-ethylacetate. The reaction was stirred for 2 days, without observing any 1,3-oxazine 2.38 
formation. Instead, the corresponding alkylated product C (Figure 2.10) was detected by 
UPLC-MS. 
 
Scheme 2.4: a) SOCl2, MeOH, 0°C to RT, 55%; b) ICH2CO2Et, MeCN, 60°C, 2 d, 0%. 
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As an ultimate test, we synthesized the unfuctionalized thioether 2.42 (Scheme 2.5). 
Nucleophilic exchange of the chloride in the Boc protected amine 2.39 by methanethiolate 
and subsequent aqueous acidic deprotection furnished the ammonium salt 2.41. Next, 
amidation with benzoic anhydride gave the desired decarboxy-methionine substrate 2.42. 
Again, treatment with iodo-ethylacetate and stirring at 60°C for 2 days did not furnish the 
desired 1,3-oxazine 2.43, but the alkylated byproduct 2.44 was found. 
 
Scheme 2.5: Synthesis of the unfunctionalized thioether 2.42: a) NaSMe, EtOH, 50°C, 18 h, 85%; b) HCl aq. 
conc., THF, 50°C, 45 min., 96%; c) benzoic anhydride, MeCN, toluene, 60°C, 5 h, 66%; d) ICH2CO2Et, MeCN, 
60°C, 2 d, 0% 2.43. 
Though the desired transformation could be more elaborated (e.g. addition of base, other 
alkylating agents, solvent), with this experiment we ended our investigations on the 
methionine-derived 1,3-oxazines. The observed iminium ether formation (Table 2.2) caught 
our attention, and is the topic of the next Chapter 2.3. 
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2.3 Methionine-Derived Iminium Lactones 
2.3.1 Introduction 
Iminium ethers I have been found to be useful electrophiles in medicinal chemistry175 and 
also as ambident intermediates176 (Figure 2.11). 
 
Figure 2.11: Iminium lactones are valuable electrophlic intermediates. B = base; Nu = nucleophile. 
Generally, iminium lactones are prone to hydrolysis and in aqueous media homoserine 
lactones II and homoserine-amides III are equally formed. 177  The lactone II can be 
selectively synthesised by hydrolysis on wet silica178 or in aqueous, slightly basic media.179,180 
Interestingly, in strongly basic media the hydroxy amide III is favourably formed.180 
Interestingly, iminium ethers show an ambident behaviour with nucleophiles. Soft 
nucleophiles (e.g. secondary amines, PPh3, N3–, RS–) react at the sp3 carbon to form amides 
IV, whereas hard and small nucleophiles (e.g. H–) rather react at the sp2 carbon, followed by 
ring-opening to give alcohols V.179 Furthermore, iminium ethers can be deprotonated in α-
position to obtain enamines VI, which are very useful as nucleophiles to prepare α-
functionalized iminium ethers. 179,181  
                                                
175  a) M. Wang, M. Gao, Q.-H. Zheng, Bioorg. Med. Chem. Lett. 2013, 23, 5259–5263; b) R. A. Stokbroekx, J. 
Vandenberk, A. H. M. T. Van Heertum, G. M. L. W. Van Laar, M. J. M. C. Van der Aa, W. F. M. Van 
Bever, P. A. J. Janssen, J. Med. Chem. 1973, 16, 782–786. 
176  Review: S. Hünig, Angew. Chem. 1964, 76, 400–412. 
177  P. Deslongchamps, S. Dubé, C. Lebreux, Can. J. Chem. 1975, 53, 2791–2807. 
178  . Felix, U. M. Kempe, A. Eschenmoser, Helv. Chim. Acta 1972, 55, 2198–2205. 
179  B. Peng, D. H. O'Donovan, I. D. Jurberg, N. Maulide, Chem. Eur. J. 2012, 18, 16292–16296. 
180  M. V. Zlokazov, V. V. Veselovsky, Russ. Chem. Bull., Int. Ed. 2009, 58, 322–326. 
181  a) R. J. Sundberg, B. C. Pearce, J. Org. Chem. 1985, 50, 425–432; b) T. M. Ugurchieva, A. V. Lozanova, M. 
V. Zlokazov, V. V. Veselosky, Russ. Chem. Bull., Int. Ed. 2007, 56, 1544–1549. 
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As in our case, the vast majority of iminium lactone I syntheses follow an exo-tet 
cyclication mechanism (Figure 2.12). γ-Halo-amides VII have been found to be in 
equilibrium with iminium lactones I in solution. The higher the positive inductive effect (+I) 
of R1 and R2, better the leaving halogenide (Cl<Br<I), and more polar the solvent, the more is 
the equilibrium shifted to I.182 Other common precursors are the γ,δ-unsaturated amides VIII, 
which can be activated by bromine183 or by sulfonyl azides to furnish intermediate aziridines 
X184 . Also, cylopropane ring-opening by mesyl activation of the adjacent alcohol IX 
furnished functionalized iminium ethers I at RT.180  
 
Figure 2.12: Preparation of iminium lactones. 
Another approach was developed by Maulide and co-workers (Scheme 2.6). In their 
synthesis, the γ-allylether amide 2.45 was activated using triflic anhydride, which gave the 
ketene iminium salt 2.46. Attack by the ether furnished the oxonium species 2.47 that 
underwent a [3,3]-sigmatropic rearrangement to give the isolable α-allyl iminium ether 2.48. 
 
Scheme 2.6: Maulides approach towards iminium ether 2.48: a) Tf2O, 2,4,6-collidine, 120°C, CH2Cl2, µw, 
5 min, 61%. 
 
                                                
182  M. V. Zlokazov, A. V. Lozanova, V. V. Veselovsky, Russ. Chem. Bull., Int. Ed. 2004, 53, 547–550. 
183  a) P. N. Craig, J. Am. Chem. Soc. 1952, 74, 129–131; b) A. V. Lozanova, T. M. Ugurchieva, M. V. Zlokazov, 
A. V. Stepanov, V. V. Veselovsky, Mend. Comm. 2006, 16, 15–16; c) T. M. Ugurchieva, A. V. Lozanova, 
M. V. Zlokazov, Russ. Chem. Bull., Int. Ed. 2008, 57, 657–659 
184  I. V. Tkachenko, I. N. Tarabara, S. V. Shishkina, O. V. Shishkin, L. I. Kas’yan, Russ. J. Org. Chem. 2009, 
45, 1143–1148. 
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2.3.2 Substrate Scope 
As a first task, we aimed to push the equilibrium towards the desired product (Figure 2.10, 
Chapter 2.2). One way to do so, was to remove the leaving group from the reaction mixture 
and thus prevent the possibility of the back reaction. As a logical consequence, we changed 
our alkylating agent from iodo-ethylacetate to the trimethyloxonium tetrafluoroborate 
(Meerwein’s salt), which led to the volatile dimethylsulfide as leaving group. Indeed, this 
change was successful, the sulfonium ion was formed immediately after addition of 
Meerwein’s salt and the conversion went to completion. We then evaluated the scope of the 
reaction by changing the substituents at the C and N-terminus of methionine (Table 2.3). The 
syntheses of the substrates 2.49–2.54 have been performed using standard peptide coupling 
conditions, and are described in detail in the experimental part of this thesis (BOP or EDC; 
52–99%). 
Table 2.3: Substrate scope of the iminium ether formation. 
 
Substrate R1 R2 Yield Conditions 
2.23-rac. BzNH NEt2 47%a, 2.55 130°C, µw, 0.5 h 
2.24-rac. BzNH piperidine quant., 2.56 80°C, 18 h 
2.30 BzNH NiPr2 51%b, 2.35 130°C, 0.5 h, µw, then NaI 
2.49-rac. BzNH N(Me)Ph full conv.c, 2.57 130°C, µw, 0.5 h 
2.50-rac. BzNH N(Me)OMe 0%, 2.58 80°C, 18 h 
2.51-rac. BzNH N(Me)AlaBoc 0%, 2.59 130°C, µw, 0.5 h 
2.52 BocNH NEt2 70%a, 2.60 80°C, 18 h 
2.53 Boc(Me)N NEt2 50%a, 2.61 80°C, 18 h 
2.54 CbzNH NEt2 91%, 2.62 130°C, µw, 0.5 h 
a After purification by column chromatography b The yield corresponds to the iodide salt. c The conversion 
was determined by UPLC-MS. 
Concerning the yield, the major issue of the reaction is purification. The best yields were 
obtained when the iminium lactone was purified by trituration (2.56, 2.62). Unfortunately the 
yield dramatically dropped if a column chromatography of the product had to be performed 
(2.55, 2.60, 2.61). Clearly, the amide substituents have great influence on the reactivity of the 
amide, which becomes apparent by the nonreactive electron-poor amides 2.50 and 2.51. It 
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should be mentioned here that the high temperatures of 130°C effected Boc-deprotection of 
2.52 and 2.53. 
Unfortunate but not unexpected, racemisation is occurring during the reaction. This was 
proved by chiral HPLC analysis of the homoserinelactone 2.63, synthesized from L- and rac-
methionine (Scheme 2.7). 
 
Scheme 2.7: The racemisation of the α-carbon was determined by chiral HPLC of 2.63. a) Me3OBF4, MeCN, 
130°C, µw, 0.5 h, 91%; b) SiO2, H2O, MeOH, 50°C, 18 h, 47%. 
 
 
2.3.3 The Synthetic Utility of Methionine-Derived Iminium Lactones 
In this chapter, our investigations of the synthetic value of the methionine-derived iminium 
lactones as intermediates are described. As mentioned in Chapter 2.3.2, the iminium ether is 
prone to racemise, meaning that its α-proton is acidic. We thus envisioned deprotonation in α-
position of I and then oxidation of the formed enamine II to get access to 2,3-amino furan III 
(Figure 2.13). Commonly the deprotonation of iminium ethers can be easily achieved using 
various bases (Chapter 2.3.1), while the oxidation of enamines similar to II instead has been 
reported only once.185 
 
Figure 2.13: Envisioned transformation of the iminium lactone I to the 2,3-aminofuran III. 
 
 
                                                
185 C. Funke, A. M. Es-Sayed, A. Meijere, Org. Lett. 2000, 2, 4249–4251. 
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Unfortunately, we were not able to prepare the desired enamine with various bases (Table 
2.4). In most cases the starting material was re-isolated and in other cases the hydrolysed 
homoserine product was found. Even the N-methylated derivative 2.61, which doesn`t bear 
any other removable proton, did not furnish the enamine. Most likely, the deprotonation of 
our starting material bearing the α-nitrogen substituent led to unstable enamines that cannot 
be isolated.  
Table 2.4: Iminium lactone deprotonation experiments. 
 
We then moved on to investigate the reactivity of the iminium ether towards various 
nucleophiles (Table 2.5). We first examined some nucleophiles that have already been 
reported to react with iminium lactones (NaBH4, NaN3, KCN).179 The reduction to the tertiary 
amine 2.64 using NaBH4 in methanol was the highest yielding reaction in our screening 
(81%). The reaction with sodium azide gave only low yield of the amide 2.65 (35%) and 
potassium cyanide did not convert the starting material, even at elevated temperatures. In 
contrast to sodium azide, hydroxylamine reacted at the sp2-center to give the hydroxylactam 
2.66 along with the homoserinelactone 2.63 – a consequence of the aqueous media. On the 
other hand, the benzyloxyamine reacted at the sp2-carbon and sp3-carbon to form the lactam 
2.67 and the benzyloxyamine 2.68 to equal extents. The reaction with potassium phthalate 
gave only poor yield of the amide 2.69 and the primary alanine amine did not react with the 
iminium lactone at all. 
 
Entry Starting material Conditions 
1 
2 
3 
2.35 
 
DMAP, MeCN 
NaH, MeCN 
nBuLi, THF, –78°C 
4 
5 
6 
7 
8 
2.60 
 
DBU, MeCN 
CaH2, THF, 45°C 
Cs2CO3, MeCN 
NaHMDS, Et2O 
KOtBu, THF 
9 2.61 
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Table 2.5: Reactivity of the methionine-derived iminium lactone towards nucleophiles. 
 
Nucleophile Conditions Product Yield 
NaBH4 MeOH, RT, 16 h 
 
81%, 2.64 
NaN3 MeCN, RT, 24 h 
 
35%, 2.65 
KCN MeCN, 130°C, µw, 1.5 h — 0% 
NH2OH (aq.) MeCN, RT, 24 h  
 
22%, 2.66 
 
17%, 2.63 
NH2OBn MeCN, RT, 48 h  
 
36%, 2.67 
 
 
35%, 2.68 
K-Phtalimide MeCN, RT, 2 h 
 
19%, 2.69 
H3N+-Ala-OMe Et3N, MeCN, 130°C, µw, 5 h — 0% 
 
The last experiment approached, arose from the idea to increase the nucleophilicity of the 
amide moiety, which eventually would prohibit the racemisation of the iminium lactone. We 
wanted to make use of the β-silyl effect, which is stabilizing positive charges in β-position of 
the silicon. This silyl iminium lactone might then be used as an azomethine ylide-precursor 
for a 3+2 dipolar cycloaddition, as decribed by Fishwick et al. (Scheme 2.8).186 
                                                
186  a) A. Alanine, C. Fishwick, C. Szantay Jr., Tetrahedron Lett. 1989, 30, 6573–6576; b) A. Alanine, C. 
Fishwick, C. Szantay Jr., Tetrahedron Lett. 1989, 30, 6777–6780; c) C. Fishwick, R. J. Foster, R. E. Carr, 
Tetrahedron Lett. 1996, 37, 5163–5166. 
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Scheme 2.8: Iminium lactone derived azomethine ylide for 3+2 dipolar cycloadditions (Fishwick et al.186a): a) 
CsF, DME, –70°C to RT, 65%. 
Thus, we first synthesized the silyl amine 2.75 using a known protocol187 followed by a 
standard peptide coupling using BOP to get the methionine substrate 2.76 (Scheme 2.9). As 
we expected, the cyclization of the silyl amide 2.76 using Me3OBF4 was much faster (90°C, 
0.5 h) than with the previously used tertiary amides (130°C, 0.5 h; 80°C 18 h). Unfortunately, 
also in this case racemisation occurred, as chiral HPLC analysis of the hydrolysed iminium 
lactone 2.77 showed, and we did not pursue this reaction further. 
 
Scheme 2.9: Synthesis of the silyl-iminium lactone 2.77: a) MeNH2 aq. (40%), 80°C, 5 h, µw, 59%; b) 
CbzMetOH, BOP, Et3N, THF, diethylamine, 0°C to RT, 75%; c) Me3OBF4, MeCN, 90°C, µw, 0.5 h 84%, d) 
CsF (wet), MeCN, RT, 24 h, 36%. 
 
 
 
 
                                                
187  B. P. Roberts, A. R. Vazquez-Persaud, J. Chem. Soc., Perkin Trans. 2 1995, 1087–1095. 
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2.4 Conclusion and Outlook 
In this project, we examined intramolecular cyclisations of methionine substrates using the 
thioether moiety as a triggerable leaving group. Thereby, we developed a new straightforward 
methodology that gives access to iminium γ-lactones. In our experiments, we found 6-exo-tet 
cyclisations to be unfavourable, and the initially expected 1,3-oxazines were not formed. 
Instead, 5-exo-tet cyclisations of the prepared methionine substrates bearing C-terminal 
tertiary amides was observed, and readily gave access to isolable iminium lactones upon 
alkylation of the thioether with Meerwein’s salt. Unfortunately, under the reaction conditions 
applied, racemisation of the enantiopure starting material occurred. We then investigated on 
the utility of these novel iminium lactones and tested their reactivity towards various 
nucleophiles. In our tests we found an ambident behaviour of the electrophile, depending on 
the nature of the nucleophile. Though we found racemisation, α-deprotonation of the iminium 
ethers to obtain the corresponding enamines could not be affected using various bases. This is 
likely due to instability of the formed enamines with the particular nitrogen substituent. 
Future work will include an elaborate screening of reactivity of the iminium ether towards 
nucleophiles, deprotonation in presence of electrophiles for α-functionalization, and solvent 
screening in the cyclisation step. But the biggest challenge to make synthetic use out of the 
methionine-derived iminium lactones, would be to overcome racemisation; an 
enantioselective version of this process is highly desirable. One possibility to overcome that 
issue would be the introduction of chiral amide substituents at the C-terminus, which induces 
a preferential configuration at the α-carbon (Figure 2.14). 
 
Figure 2.14: Inducement of enantioselectivity by a chiral amide substituent. 
Even if the racemisation problem can not be circumvented by this measure, our approach 
could be a useful tool for the design of α,α-dialkyl amino acids. In combination with 
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Bannwarth’s188 cleavable bispicolylamide, additional practicability would be gained in respect 
to further peptide couplings and incorporation in peptidomimetics (Figure 2.15). 
 
Figure 2.15: Application of our elaborated method for the synthesis of α,α-dialkyl amino acids, equipped with 
the readily, cleavable bispicolylamide. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                
188  M. C. Bröhmer, S. Mundinger, S. Bräse, W. Bannwarth, Angew. Chem. Int. Ed. 2011, 50, 6175–6177. 
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3 Conclusion 
This thesis, entitled Total Synthesis of the Glycosylated Antibiotic Fidaxomicin and 
Methionine-Derived Iminium Lactones, describes two distinct organic chemical research 
projects.  
Chapter 1 was dedicated to the achievement of the first total synthesis of fidaxomicin, an 
FDA- and EMA- approved antibiotic against Clostridium difficile infection (CDI). The 
natural product exhibited potent biological activity against multi-drug resistant pathogens e.g., 
Mycobacterium tuberculosis. Unfortunately, poor pharmacokinetics prohibit its use as a 
treatment for this type of infections. The understanding of the macrolides chemical behaviour 
is crucial in respect to its bioactivity and thus total synthesis was essential. Fidaxomicin 
consists of a central 18-membered macrolide attached to a noviose and a rhamnose-
resorcylate fragment. Key features of the described synthetic route include a rapid access to 
the rhamnosyl side-chain, the first ever β-selective noviosylation, followed by Suzuki cross-
coupling, a ring-closing metathesis of complex noviosylated precursors, and a β-selective 
rhamnosylation. In particular, the stereo-selective 1,2-cis instalments of both β-linked 
carbohydrate units constitutes a notable feature of the approach. This total synthesis 
contributes to a detailed understanding of the chemistry of fidaxomicin and paves the way for 
the generation of analogues addressing some of the shortcoming of the natural product.  
In Chapter 2, we explored methionine derivatives as synthetic precursors of 5,6-dihydro-
4H-1,3-oxazines. The 6-exo-tet cyclisation was approached by alkylation of the thioether 
moiety to generate a leaving group. Though this desired reaction could not be enforced, a new 
5-exo-tet cyclisation leading to isolable iminium lactones was explored and elaborated 
instead. A screening revealed the ambident behaviour of the electrophilic methionine-derived 
iminium lactones, depending on the nature of the nucleophile. The interesting synthetic utility 
of the discovered transformation is hampered through racemisation, occurring during the 
cyclisation. All over, we established a good base of fundamental research for the synthesis of 
iminium lactones from methionine. Further experimental investigations are required to 
overcome the stereochemical challenge, and to potentially provide a new and useful tool in 
peptidomimetic research.  
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4 Experimental Part 
General Methods and Materials 
All reactions were performed in oven-dried round-bottomed flasks using anhydrous solvents 
and under an argon atmosphere unless otherwise stated. The following anhydrous reaction 
solvents were obtained by filtration and passing through activated anhydrous alumina 
columns (Innovative Technology solvent purification system); THF, CH2Cl2, Et2O, toluene. 
All other solvents (DMF, MeOH, MeCN, CHCl3) and reagents were obtained from 
commercial suppliers and used without further purification. Syringes or stainless steel cannula 
were used to transfer air and moisture sensitive liquids and solutions. Analytical thin layer 
chromatography (Merck silica gel 60 F254 plates) was utilized for monitoring reactions and the 
spots were visualized by UV light (254 nm and 350nm) or by staining using p-anisalhdehyde 
or ceric ammonium molybdate (CAM) followed by gentle heating with a heat gun. Flash 
Chromatography was performed using SiliCycle silica gel 60 (230-400 Mesh) and the Rf 
values of compounds are indicated. Preparative thin layer chromatography (preparative TLC) 
was performed using Merck TLC silica gel 60 F254 or Merck PLC silica gel 60 F254, 0.5 mm 
plates. Reversed-phase high-performance liquid chromatography (RP-HPLC) for analytical 
and separation purposes was performed on a Dionex HPLC equipped with a P680 HPLC 
Pump, an ASI-100 automated sample injector, a PDA-100 photodiode array detector, a MSQ-
ESI mass spectrometric detector and a Gemini NX 3 µm 150x4.6 mm (Phenomenex) column 
and the respective retention times (tR) are indicated. ESI-MS were measured on a ultra high 
performance liquid chromatography with Mass Spectrometry (UHPLC-MS) Agilent 1290 
Infinity instrument equipped with an Eclipse Plus C18 column and an Agilent 6130 ESI-MS 
detector using a formic acid buffered MeCN/H2O gradient. Chiral high performance liquid 
chromatography (Chiral HPLC) analysis was performed on a Dionex HPLC equipped with a 
UV-detecor and a Chiralpak IA or ODH column, using isocratic nhexane/iPrOH eluents. 
NMR spectra were recorded on Varian Gemini Bruker DPX 400 MHz (1H) & 101 MHz (13C) 
& 128 MHz (11B), Bruker DRX 500 MHz (1H) & 126 MHz (13C) or a Bruker Bruker Avance 
III 600 MHz proton frequency equipped with a cryogenic 1.7 mm TCI cryoprobe at 298K in 
the indicated deuterated solvent, unless otherwise stated. Chemical shifts (δ) are quoted in 
parts per million (ppm) and the multiplicity is reported as follows: s = singlet; d = duplet; dd 
= duplet of duplet (etc.); t = triplet; q = quartet; quin = quintet; hept = heptet; m = multiplet or 
unresolved signal; the prefix ap = apparent is stated wherever further multiplicity could not be 
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determined; the prefix br = broad is statet where the signal is not sharp. The 1H-NMR spectra 
were referenced to the residual solvent peak (δ 7.26 ppm for CHCl3; δ 2.05 ppm for acetone; δ 
3.31 ppm for methanol), 13C-NMR spectra were recorded with 1H-decoupling and referenced 
to the residual solvent peak (δ 77.16 ppm for CHCl3; δ 29.84 ppm for acetone; δ 49.00 ppm 
for methanol). Melting points (M.p.) were determined using a Büchi B-545 apparatus in open 
capillaries and are uncorrected. IR spectra were recorded on a Varian 800 FT-IR ATR 
spectrometer and data are reported in terms of frequency of absorption (v, cm-1). Optical 
rotations [α]D were recorded at 24.5°C on a Jasco P-2000 digital polarimeter with a path 
length of 1 dm, using the 589.3 nm D-line of sodium. Concentrations (c) are quoted in g/100 
mL. All mass spectra (HRMS-ESI) were recorded by Dr. Heinz Nadig at University of Basel 
on a Bruker maXis 4G QTOF ESI mass spectrometer. Intermediates that are not labelled in 
the theoretical part but in the experimental part are labelled with Xb (afterwards in synthetic 
order).  
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4.1 Total Synthesis of Fidaxomicin 
4.1.1 Novioside Substrates 
(3aS,4S,7S,7aS)-4-methoxy-6,6-dimethyl-2-oxotetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-
7-yl isobutyrate (1.102) 
To a solution of novioside 1.103 (106 mg, 0.55 mmol) in 1,2-dichloroethane (5.0 mL), 1,1'-
carbonyldiimidazole (98 mg, 0.61 mmol) was added and the reaction mixture was stirred at 
reflux for 3 h. Then, 1,1'-carbonyldiimidazole was added in portions until TLC indicated full 
consumption of the starting material. The reaction was quenched with aq. HCl (1 M, 10 mL), 
and extracted with CH2Cl2 (3x10 mL). The combined org. layers were dried (MgSO4), filtered 
and evaporated under reduced pressure. This residue was dissolved in CH2Cl2 (4.0 mL), and 
Et3N (0.39 mL) and subsequently isobutyryl chloride (0.17 mL, 1.65 mmol) were added 
dropwise. After stirring for 1 h at RT the mixture was quenched with H2O (10 mL) and HCl 
(1 M, 10 mL). The aq. layer was extracted with CH2Cl2 (3x10 mL) and the org. layers washed 
with aq. NaHCO3 (20 mL), combined, dried (MgSO4), filtered and evaporated under reduced 
pressure. Purification by column chromatography (Et2O/pentane 1/2 to Et2O) afforded the two 
anomers (α-1.102: 66 mg, 42%; β-1.102: 40 mg, 25%) as white solids. 
α-1.102: Rƒ = 0.63 (Et2O/pentane 1/1); M.p. = 89.0–90.0°C; [α]D = +18.5° 
(c = 0.3, CHCl3); 1H-NMR (400 MHz, CDCl3) δ 5.06 (d, J = 7.6 Hz, 1H), 
4.85 (d, J = 2.9 Hz, 1H), 4.72 (pt, J = 7.7 Hz, 1H), 4.62 (dd, J = 7.8, 
2.9 Hz, 1H), 3.40 (s, 3H), 2.56 (qq, J = 7.0 Hz, 1H), 1.22 (s, 6H), 1.14 (d, J 
= 7.0 Hz, 3H), 1.14 (d, J = 7.0 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 175.6, 153.2, 97.3, 
76.6, 75.4, 74.7, 72.0 56.1, 34.1, 26.9, 23.2, 19.0, 18.8; HRMS ESI calcd. for [C13H21O7]+ 
[M+H]+: 289.1282; found: 289.1281; IR ν = 2988, 1793, 1737, 1464, 1392, 1340, 1127, 
1087, 1026, 969, 818 cm-1. 
β-1.102: Rƒ = 0.3 (Et2O/pentane 1/1); M.p. = 134.0–137.0°C; [α]D = –
101.9° (c = 0.2, CHCl3); 1H-NMR (400 MHz, CDCl3) δ 5.73–5.66 (m, 
1H), 4.79–4.75 (m, 1H), 4.73–4.70 (m, 2H), 3.45 (s, 3H), 2.61–2.49 (qq, J 
= 7.0 Hz, 1H), 1.21 (s, 3H), 1.14 (d, J = 7.0 Hz, 3H), 1.14 (d, J = 7.0 Hz, 
3H), 1.14 (s, 3H); 13C-NMR (101 MHz, CDCl3) δ 175.2, 153.9, 95.8, 75.7, 75.0, 72.3, 71.9, 
56.2, 34.1, 28.7, 24.3, 19.1, 18.8; HRMS ESI calcd. for [C13H21O7]+ [M+H]+: 289.1282; 
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found: 289.1281; IR ν = 2984, 1790, 1740, 1472, 1394, 1355, 1148, 1048, 962, 807, 
774 cm-1. 
 
 (3S,4S,5S)-6-methoxy-2,2-dimethyltetrahydro-2H-pyran-3,4,5-triol (1.103) 
To a solution of furanoside 1.112 (210 mg, 0.90 mmol) in MeOH (2.0 mL), 
TFA (1.0 mL) was added. The colourless solution was heated in the 
microwave to 100°C for 3 h. The reaction mixture was diluted with toluene 
(10 mL), evaporated under reduced pressure and the residue was submitted to column 
chromatography (CH2Cl2/MeOH 20/1 to 10/1) to afford the desired pyranoside 1.103 and a 
mixture of deprotected furanoside 1.113 with starting material 1.112. The same protocol was 
used twice to convert this mixture to the pyranoside 1.103. In this way the desired compound 
1.103 (141 mg, 81%) was obtained as a mixture of two inseparable anomers. 
Rƒ = 0.28 (CH2Cl2/MeOH 10/1); 1H-NMR (400 MHz, CD3OD, α:β 2:1) δ 4.57 (d, J = 1.5 Hz, 
1H), 4.54 (d, J = 1.0 Hz, 0.5H), 3.85 (dd, J = 3.0, 1.0 Hz, 0.5H), 3.83–3.78 (m, 1H) 3.81 (s, 
1H), 3.63 (d, J = 9.1 Hz, 1H), 3.57 (dd, J = 10.0, 3.1 Hz, 0.5H), 3.52 (d, J = 10.0 Hz, 0.5H), 
3.45 (s, 1.5H), 3.37 (s, 3H), 1.29 (s, 1.5H), 1.28 (s, 6H), 1.18 (s, 1.5H); 13C-NMR (101 MHz, 
CD3OD, α:β 2:1) δ 104.1, 98.4 (0.5C), 79.0, 76.2 (0.5C), 74.8 (0.5C), 74.7, 72.8, 72.5 (0.5C), 
71.9 (0.5C), 69.3, 56.9 (0.5C), 55.8, 29.2, 28.7 (0.5C), 22.7, 18.5 (0.5C); HRMS ESI calcd. 
for [C8H16NaO5]+ [M+Na]+: 215.0890; found: 215.0890; IR ν = 3377, 2981, 2925, 2361, 
1673, 1445, 1369, 1193, 1135, 1065, 1037, 979, 803, 736 cm-1. 
 
 (2S,3S,4S, 5S, 6S)-2-(iodomethyl)-6-methoxytetrahydro-2H-pyran-3,4,5-triol (1.105) 
To a solution of methyl α-D-mannopyranoside (1.104, 5.00 g, 25.7 mmol) in 
THF (45 mL), triphenylphosphine (9.46 g, 36.0 mmol) and imidazole (3.51 g, 
51.5 mmol) were added and the mixture was heated to reflux. A solution of 
iodine (9.15 g, 36.0 mmol) in THF (15 mL) was added slowly via dropping 
funnel (the dark orange color of iodine fades immediately). The light yellow suspension was 
kept at reflux until complete consumption of the starting material (2.5 h). Then the solution 
was cooled to RT, eventually formed solids were filtered off and the THF was evaporated 
under reduced pressure. The residue was dissolved in EtOAc and washed with aq. sat. 
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Na2S2O3 solution and brine. The water layers were reextracted each with EtOAc (6x). The 
organic layers were combined, dried (Na2SO4), filtered and evaporated under reduced 
pressure. The crude product was purified by column chromatography (CH2Cl2/MeOH, 15:1) 
and the desired product 1.105 was obtained as white crystals (5.60 g, 72%). 
The analytical data matched those reported in the literature: P. R. Skaanderup, C. S. Poulsen, 
L. Hyldtoft, M. R. Jørgensen, R. Madsen, Synthesis 2002, 1721–1727. 
Rƒ = 0.1 (CH2Cl2/MeOH 10/1); M.p.: 122–123°C; [α]D = +60.7° (c = 0.4, H2O); 1H-NMR 
(400 MHz, D2O) δ 4.74 (d, J = 1.7 Hz, 1H), 3.94 (dd, J = 3.5, 1.7 Hz, 1H), 3.77 (dd, J = 9.5, 
3.4 Hz, 1H), 3.65 (dd, J = 11.0, 2.2 Hz, 1H), 3.58 (pt, J = 9.4 Hz, 1H), 3.49–3.45 (m, 1H), 
3.45 (s, 3H), 3.38 (dd, J = 10.9, 7.0 Hz, 1H); 13C-NMR (101 MHz, D2O) δ 101.1, 71.5, 70.6, 
70.1, 69.9, 55.0, 6.2.  
 
(3aS,4S,6S,73aS,7aS)-6-(iodomethyl)-4-methoxy-2,2-dimethyltetrahydro-4H-
[1,3]dioxolo[4,5-c]pyran-7-ol (1.106) 
To a suspension of iodinated mannopyranoside 1.105 (1.00 g, 3.3 mmol) in 
2,2-dimethoxypropane (5 mL), ca. 100 mg Amberlite IR120 hydrogen form 
(washed with methanol and diethyl ether before use) was added (suspension 
turns slowly into a solution). The reaction mixture was stirred for 3 h at RT, 
then it was filtrated and evaporated under reduced pressure. The crude product was treated 
with Et2O/pentane 1/3 then more pentane was added, such that a white precipitate was 
formed. The suspension was filtrated and the filter washed with pentane. The yellow filtrate 
was evaporated under reduced pressure, the residue suspended in pentane and filtrated again, 
yielding white crystals. The combined solid parts were dried under reduced pressure affording 
the desired acetonide-protected product 1.106 (1.10 g, 94%) as a white powder. 
Rƒ = 0.2 (Et2O/pentane 1/3); M.p. = 110–111°C; [α]D = +44.9° (c = 1.2, CHCl3); 1H-NMR 
(400 MHz, CDCl3) δ 4.93 (s, 1H), 4.15–4.10 (m, 2H), 3.59 (dd, J = 10.6, 2.6 Hz, 1H), 3.57–
3.46 (m, 5H), 3.31 (dd, J = 10.5, 7.1 Hz, 1H), 2.38 (d, J = 4.3 Hz, 1H), 1.52 (s, 3H), 1.35 (s, 
3H); 13C-NMR (101 MHz, CDCl3) δ 109.8, 98.5, 78.2, 75.7, 73.2, 69.3, 55.6, 28.0, 26.1, 6.6. 
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(3aS, 4S, 6R,6aS)-2,2-dimethyl-6-vinyltetrahydrofuro[3,4-d][1,3]dioxol-4-ol (1.107) 
This procedure is a modified version of a Vitamine B12-catalyzed Vasella-
Bernet fragmentation: M. Kleban, U. Kautz, J. Greul, P. Hilgers, R. Kugler, H.-
Q. Dong, V. Jäger, Synthesis 2000, 7, 1027–1033. To a solution of iodo-
mannopyranoside 1.106 (4.42 g, 12.8 mmol) in MeOH (40 mL), zinc powder 
(8.40 g, 128 mmol) was added and the grey suspension was heated to 60°C. Solid NH4Cl 
(0.150 g, 2.80 mmol) was added and it was stirred for 30 minutes. Then another portion of 
solid NH4Cl (0.150 g, 2.80 mmol) was added. After stirring for 90 minutes the mixture was 
allowed to cool to RT. The grey suspension was filtered through Celite, the filtercake washed 
with CH2Cl2 (3x20 mL) and the solvent was evaporated under reduced pressure. Purification 
by column chromatography (Et2O/pentane 1/3) afforded the desired furanose 1.107 (2.20 g, 
91%) as a colourless oil which crystallized at –20°C. 
The analytical data matched those reported in the literature: M. Kleban, U. Kautz, J. Greul, P. 
Hilgers, R. Kugler, H.-Q. Dong, V. Jäger, Synthesis 2000, 7, 1027–1033.  
Rƒ = 0.6 (Et2O/pentane 1/1); M.p. = 58.0–59.0°C; [α]D = –28.7° (c = 0.54, CHCl3); 1H-NMR 
(400 MHz, CDCl3) δ 5.99 (ddd, J = 17.6, 10.4, 7.4 Hz, 1H), 5.42 (ddd, J = 17.4, 1.6, 1.1 Hz, 
1H), 5.41 (d, J = 2.3 Hz, 1H), 5.34 (ddd, J = 10.4, 1.6, 0.8 Hz, 1H), 4.73 (dd, J = 5.8, 3.7 Hz, 
1H), 4.64 (d, J = 5.8 Hz, 1H), 4.62–4.59 (m, 1H), 2.69 (d, J = 2.3 Hz, 1H), 1.49–1.46 (m, 3H), 
1.32 (d, J = 0.4 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 132.2, 119.3, 112.7, 101.1, 85.8, 
81.6, 26.1, 24.9. 
 
 (3aS,4S,6R,6aS)-4-methoxy-2,2-dimethyl-6-vinyltetrahydrofuro[3,4-d][1,3]dioxole 
(1.108) 
To a solution of furanose 1.107 (1.00 g, 5.45 mmol) in MeOH (10 mL) and 
2,2-dimethoxypropane (5 mL), 10-camphorsulfonic acid (250 mg, 1.10 mmol) 
was added. The solution was heated to 55°C for 18 h. Then, the dark solution 
was neutralized with Et3N turning into a bright yellow solution and the solvents were 
carefully evaporated under reduced pressure. The residue was treated with H2O (100 mL) and 
the aq. layer extracted with Et2O (3x50 mL). The combined org. layers were dried (MgSO4), 
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filtered and evaporated under reduced pressure. Purification by Kugelrohr distillation afforded 
product 1.108 (1.08 g, 99%) as a colourless liquid. 
The analytical data matched those reported in the literature: K. Bock, C. Pedersen, Acta 
Chem. Scand. 1977, B31, 248–250. 
Rƒ = 0.6 (Et2O/pentane 1/3); B.p. = 130°C (5.6 mbar); [α]D = +24.3° (c = 0.5, CHCl3); 1H-
NMR (400 MHz, CDCl3) δ 5.99 (ddd, J = 17.3, 10.1, 7.4 Hz, 1H), 5.42 (ddd, J = 17.4, 1.7, 
1.1 Hz, 1H), 5.34 (ddd, J = 10.4, 1.5, 0.8 Hz, 1H), 4.91 (s, 1H), 4.68 (dd, J = 5.8, 3.7 Hz, 1H), 
4.58 (d, J = 5.8 Hz, 1H), 4.39 (dd, J = 7.4, 3.7 Hz, 1H), 3.35 (s, 3H), 1.47 (s, 3H), 1.31 (s, 
3H); 13C-NMR (101 MHz, CDCl3) δ 132.3, 119.1, 112.6, 107.2, 85.3, 81.5, 81.1, 54.7, 26.1, 
24.9. 
 
methyl (3aR,4S, 6S, 6aS)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-
carboxylate (1.109) 
A solution of furanoside 1.108 (1.03 g, 5.14 mmol) in CH2Cl2 (20 mL) and 
methanolic NaOH (5.0 mL, 2.5 M) was cooled to –78°C. Then ozone was 
bubbled through the solution. The solution turned orange and faded to 
yellow after a while, after 1 h it turned deep blue. After 8 h, again methanolic NaOH (5.0 mL, 
2.5 M) was added (solution turns yellow and turbid again which faded again after 45 minutes). 
Additional methanolic NaOH (2.5 M) was added until full conversion to the ester (monitored 
by TLC). Then, oxygen was bubbled through the solution for 15 minutes before it was diluted 
with CH2Cl2 (50 mL) and H2O (20 mL). The reaction mixture was allowed to warm to RT 
then aq. sat. NH4Cl (30 mL) was added. The layers were separated and the aq. layer was 
extracted with CH2Cl2 (4x50 mL). The org. layers were dried (MgSO4), filtered and 
evaporated under reduced pressure. Purification by column chromatography 
(Et2O/pentane 1/3 to 1/2) afforded the desired ester 1.109 (0.740 g, 62%) as a colourless fluid. 
Or  
To a solution of aldehyde 1.110 (795 mg, 3.9 mmol) in MeOH (24 mL) and water (4 mL) at 
RT, NaHCO3 (5.30 g, 63 mmol) was added. Under vigorous stirring bromine (0.65 mL, 
13 mmol) was added and the mixture was heated to 40°C. After stirring for 3 h again bromine 
(50 µL, 1.0 mmol) was added and it was stirred for another 1 h. The reaction mixture was 
O
O O
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quenched with aq. sat. Na2S2O3 (50 mL) and the reaction mixture was diluted with water (50 
mL), and extracted with EtOAc (3x70 mL). The org. layers were washed with water (50 mL) 
and brine (50 mL), dried (MgSO4), filtered and evaporated under reduce pressure. This 
afforded the ester 1.109 (0.840 g, 92%) as a colourless fluid. 
Rƒ = 0.17 (Et2O/pentane 1/3); [α]D = +23.5° (c = 0.65, CHCl3); 1H-NMR (400 MHz, CDCl3) 
δ 5.07 (s, 1H), 4.98 (dd, J = 5.8, 4.3 Hz, 1H), 4.60–4.55 (m, 2H), 3.81 (s, 3H), 3.35 (s, 3H), 
1.42 (s, 3H), 1.31–1.27 (m, 3H); 13C-NMR (101 MHz, CDCl3) δ 167.9, 113.4, 107.5, 84.0, 
80.6, 79.5, 55.1, 52.2, 25.9, 25.1; HRMS ESI calcd. for [C10H16NaO6]+ [M+Na]+: 255.0839; 
found: 255.0840; IR ν = 2990, 2942, 2839, 1769, 1739, 1439, 1374, 1208, 1095, 1061, 967, 
860, 775, 613 cm-1. 
 
(3aS,4S,6S,6aS)-6-methoxy-2-oxotetrahydrofuro[3,4-d][1,3]dioxole-4-carbaldehyde 
(1.110) 
A solution of olefin 1.108 (1.10 g, 5.5 mmol) in CH2Cl2 (20 mL) and MeOH 
(5 mL) was cooled to –78°C. Then ozone was bubbled through the solution 
until it turned blue. The solution was purged with O2, and then DMS (2 mL) 
was added. The colourless solution was allowed to warm to RT and the 
solvent was evaporated under reduced pressure. Purification by column chromatography 
(EtOAc/cHex 1/4 to 1/1) yielded the desired aldehyde 1.110 (798 mg, 72%) as colourless oil. 
The analytical data matched those reported in the literature: J. M. J. Tronchet, B. Gentile, A. 
P. Bonenfant, O. R. Martin, Helv. Chim. Acta 1979, 62, 696–699. 
Rƒ = 0.1 (Et2O/pentane 1/3); [α]D = +44.5° (c = 1.2, CHCl3); 1H-NMR (400 MHz, CDCl3) δ 
9.66 (d, J = 1.2 Hz, 1H), 5.09 (s, 1H), 5.07 (dd, J = 5.9, 4.3 Hz, 1H), 4.61 (d, J = 5.8 Hz, 1H), 
4.37 (d, J = 4.3 Hz, 1H), 3.36 (s, 3H), 1.43 (s, 3H), 1.29 (d, J = 0.7 Hz, 3H); 13C-NMR 
(101 MHz, CDCl3) δ 197.9, 113.7, 108.0, 84.7, 84.1, 81.0, 55.2, 26.0, 24.7. 
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2-((3aS,4S,6S,6aS)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-
propan-2-ol (1.112) 
To a solution of ester 1.109 (735 mg, 3.2 mmol) in Et2O (28 mL), MeMgBr 
(3 M solution in Et2O, 3.2 mL, 9.5 mmol) was added dropwise at RT and the 
mixture heated to 35°C for 30 minutes. The reaction was cooled to RT and 
carefully quenched with aq. sat. NH4Cl (10 mL) Then H2O (30 mL) was 
added and the mixture was extracted with Et2O (3x20 mL). The org. layers were dried 
(MgSO4), filtered and evaporated under reduced pressure, giving the pure title compound 
1.112 (721 mg, 99%) as colourless oil.  
The analytical data matched those reported for its enantiomer in the literature: A. Klemer, M. 
Waldmann, Liebigs Ann. Chem. 1986, 2, 221–406. 
Rƒ = 0.4 (Et2O/pentane 1/1); [α]D = +84.0° (c = 1.15, MeOH); 1H-NMR (400 MHz, CDCl3) δ 
5.01 (s, 1H), 4.86 (dd, J = 5.9, 3.4, Hz, 1H), 4.58 (d, J = 5.9 Hz, 1H), 3.71 (d, J = 3.3 Hz, 1H), 
3.56 (s, 1H), 3.35 (s, 3H), 1.52 (s, 3H), 1.40 (s, 3H), 1.36 (s, 3H), 1.33 (s, 3H); 13C-NMR 
(101 MHz, CDCl3) δ 112.8, 106.6, 85.2, 82.9, 80.7, 70.9, 54.5, 27.3, 27.3, 25.8, 24.2; IR ν = 
3525, 2979, 2937, 1465, 1374, 1209, 1153, 1092, 1031, 964, 881, 854 cm-1. 
 
(3aS,7S,7aS)-4-methoxy-6,6-dimethyl-2-oxotetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-7-yl 
acetate (1.116) 
To a solution of novioside 1.103 (47 mg, 0.25 mmol) in THF (2.5 mL) at 50°C, 1,1'-
carbonyldiimidazole (140 mg, 0.86 mmol) was added over a period of 3 h. Then the mixture 
was cooled to RT and quenched with aq. HCl (6 M, 0.6 mL), and the mixture was stirred for 
1 h. EtOAc was added and the THF was evaporated under reduced pressure. The residual 
solution was then washed with brine, reextracted with EtOAc and the org. layers were dried 
(MgSO4), filtered and evaporated under reduced pressure. The residue was dissolved in 
pyridine (0.7 mL) and acetic anhydride (0.7 mL). The colourless solution was stirred for 1 h 
at RT. The solvents were evaporated under reduced pressure and azeotropized with toluene. 
Purification by column chromatography (EtOAc/toluene 1/8) afforded the two anomers (α-
1.116: 24 mg, 38%; β-1.116: 9 mg, 14% and a mix-fraction of α-/β-1.116: 10 mg, 16%) as 
white solids. 
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α-1.116: Rƒ = 0.61 (EtOAc/toluene 1/3); [α]D = +21.6° (c = 0.82, CHCl3); 
1H-NMR (400 MHz, CDCl3) δ 5.11 (d, J = 7.7 Hz, 1H), 4.91 (d, J = 
3.0 Hz, 1H), 4.78 (pt, J = 7.7 Hz, 1H), 4.68 (dd, J = 7.8, 3.0 Hz, 1H), 3.46 
(s, 3H), 2.13 (s, 3H), 1.28 (s, 3H), 1.27 (s, 3H); 13C-NMR (63 MHz, 
CDCl3) δ 169.6, 153.2, 97.3, 76.7 75.4, 74.7, 72.4, 56.1, 26.7, 23.1, 20.9; HRMS ESI calcd. 
for [C11H16NaO7]+ [M+Na]+: 283.0788; found: 283.0790; IR ν = 2987, 2945, 2848, 1827, 
1809, 1748, 1374, 1223, 1174, 1130, 1082, 1035, 883, 768 cm-1. 
β-1.116: Rƒ = 0.44 (EtOAc/toluene 1/3); [α]D = –91.6° (c = 1.10, CHCl3); 
1H-NMR (400 MHz, CDCl3) δ 5.80–5.72 (m, 1H), 4.86–4.82 (m, 1H), 
4.81–4.74 (m, 2H), 3.52 (s, 3H), 2.14 (s, 3H), 1.28 (s, 3H), 1.20 (s, 3H); 
13C-NMR (101 MHz, CDCl3) δ 169.2, 153.9, 95.8, 75.7, 75.0, 72.6, 71.9, 
56.2, 28.7, 24.2, 21.0; HRMS ESI calcd. for [C11H16NaO7]+ [M+Na]+: 283.0788; found: 
283.0793; IR ν = 2983, 2940, 2849, 1806, 1745, 1371, 1223, 1171, 1075, 1042, 770 cm-1. 
 
 (3aS,4R,7S,7aS)-4-(cyclohexyloxy)-6,6-dimethyl-2-oxotetrahydro-4H-[1,3]dioxolo[4,5-
c]pyran-7-yl isobutyrate (β-1.176) 
To a solution of novioside 1.102 (2.5 mg, 9 µmol) in CH2Cl2 (0.2 mL) 
at 0°C and protected from light, HBr (33% in AcOH, 0.2 mL) was 
added and the solution was stirred for 2 h at RT. The solution was 
cooled to 5°C and diluted with CH2Cl2 (3 mL). The reaction was 
quenched with ice and H2O. The layers were separated and the org. layer was washed with aq. 
sat. NaHCO3 (8 mL) The aq. solutions were extracted with CH2Cl2 (2x3 mL) and the 
combined org. layers were dried (Na2SO4), filtered and evaporated under reduced pressure at 
RT. The residual glycosyl bromide 1.175 was dissolved in CH2Cl2 (0.1 mL) and added 
dropwise to a suspension of cyclohexanol (1.1 µL, 10 µmol), Ag2CO3 (120 mg, excess), and 
powdered molecular sieves (3Å, 100 mg) in CH2Cl2 (0.1 mL). The suspension was stirred for 
1.5 h. Then it was diluted with CH2Cl2 (2 mL), quenched with Et3N (0.05 mL), filtered 
through Celite, the filter was washed with CH2Cl2 (2 mL) and the filtrate evaporated under 
reduced pressure. The residue was purified by column chromatography (EtOAc/cHex 1/4) to 
give the product β-1.176 (2.5 mg, 81%). 
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Rƒ = 0.27 (EtOAc/cHex 1/4); 1H-NMR (400 MHz, CDCl3) δ 5.96 (d, J = 6.6 Hz, 1H), 5.05 
(d, J = 3.1 Hz, 1H), 4.82–4.72 (m, 2H), 3.73 (tt, J = 8.4, 3.5 Hz, 2H), 2.62 (dt, J = 14.0, 
7.0 Hz, 1H), 1.94–1.83 (m, 1H), 1.83–1.65 (m, 3H), 1.60–1.20 (m, 6H), 1.24 (s, 3H), 1.21 (d, 
J = 7.0 Hz, 6H), 1.18 (s, 3H); HRMS ESI calcd. for [C18H28NaO7]+ [M+Na]+: 379.1727; 
found: 379.1725. 
 
(3aS,4S,7S,7aS)-4-(cyclohexyloxy)-6,6-dimethyl-2-oxotetrahydro-4H-[1,3]dioxolo[4,5-
c]pyran-7-yl isobutyrate (α-1.176) 
To a solution of novioside 1.102 (2.5 mg, 9 µmol) in CH2Cl2 (0.2 mL) 
at 0°C and protected from light, HBr (33% in AcOH, 0.2 mL) was 
added. and the solution was stirred for 2 h at RT. Then solution was 
cooled to 5°C and diluted with CH2Cl2 (3 mL). The reaction was quenched with ice and H2O. 
The layers were separated and the org. layer was washed with aq. sat. NaHCO3 (8 mL) The 
aq. solutions were extracted with CH2Cl2 (2x3 mL) and the combined org. layers were dried 
(Na2SO4), filtered and evaporated under reduced pressure at RT. The residual glycosyl 
bromide 1.175 was dissolved in CH2Cl2 (0.1 mL) and added dropwise to a suspension of 
cyclohexanol (1.1 µL, 0.01 mmol), AgOTf (22.3 mg, 0.086 mmol), and powdered molecular 
sieves (3Å, 100 mg) in CH2Cl2 (0.1 mL). The suspension was stirred for 1 h then it was 
diluted with CH2Cl2 (2 mL), quenched with Et3N (0.05 mL), filtered through Celite, the filter 
was washed with CH2Cl2 (2 mL) and the solvents were evaporated under reduced pressure. 
The residue was purified by column chromatography (EtOAc/cHex 1/8) to give the product α-
1.176 (n.d., quant. conv.). 
Rƒ = 0.5 (EtOAc/cHex 1/4); [α]D = +19.2° (c = 0.19, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 
5.14 (s, 1H), 5.13 (d, J = 4.1 Hz, 1H), 4.79 (t, J = 7.9 Hz, 1H), 4.67 (dd, J = 7.9, 3.7 Hz, 1H), 
3.68 (td, J = 9.1, 4.5 Hz, 1H), 2.62 (hept, J = 7.0 Hz, 1H), 1.95–1.84 (m, 2H), 1.78–1.70 (m, 
2H), 1.56–1.50 (m, 2H), 1.45–1.35 (m, 1H), 1.35–1.27 (m, 1H), 1.28 (s, 6H), 1.25–1.20 (m, 
2H), 1.21 (d, J = 1.6 Hz, 3H), 1.20 (d, J = 1.6 Hz, 3H); 13C-NMR (126 MHz, CDCl3) δ 175.5, 
153.3, 93.3, 77.0, 76.0, 75.5, 74.5, 71.9, 34.0, 33.1, 31.0, 26.6, 25.5 (2C), 24.0, 23.7, 18.9, 
18.7; HRMS ESI calcd. for [C18H28NaO7]+ [M+Na]+: 379.1727; found: 379.1725; IR ν = 
2937, 2859, 1791, 1736, 1467, 1375, 1348, 1184, 1129, 1063, 1029, 984, 956, 899, 793, 
770 cm-1. 
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(3aS,7S,7aS)-4-hydroxy-6,6-dimethyl-2-oxotetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-7-yl 
isobutyrate (1.178) 
To a solution of novioside 1.102 (19 mg, 0.07 mmol) in CH2Cl2 (0.5 mL, 
wet) at RT, HBr (33% in AcOH (wet), 0.4 mL) was added. The slightly 
orange solution was then stirred at RT for 0.5 h. Then it was diluted with 
CH2Cl2 (2 mL) and quenched with NaOH (1 M, 2 mL). The layers were 
separated and the aq. layer extracted with CH2Cl2 (2x3 mL). The combined org. layers were 
dried (MgSO4), filtered and evaporated under reduced pressure. Purification by column 
chromatography (EtOAc/CyHex 1/4 to 1/1) gave the desired noviose 1.178 (8.5 mg, 47%) as 
an inseparable anomeric mixture (α:β = 2:1). 
1H-NMR (400 MHz, CDCl3, major/minor anomer 2/1) δ 5.50 (d, J = 5.3 Hz, 1H), 5.39 (d, J = 
3.6 Hz, 0.5H), 5.22 (d, J = 2.0 Hz, 1H), 5.16 (d, J = 7.2 Hz, 0.5H), 4.85–4.80 (m, 1.5H), 4.76 
(dd, J = 8.5, 2.3 Hz, 1H), 4.70 (dd, J = 8.0, 3.6 Hz, 0.5H), 3.62 (br s, 1H), 3.49 (br s, 0.5H), 
2.70–2.56 (m, J = 7.0 Hz, 2H), 1.36 (s, 3H), 1.30 (s, 1.5H), 1.30 (s, 1.5H), 1.25–1.16 (m, 
12H); 13C-NMR (126 MHz, CDCl3) δ 175.6 (minor), 175.2, 153.6, 153.4 (minor), 90.8 
(minor), 88.2, 76.8 (minor), 76.1, 75.3 (minor), 75.0, 75.0 (minor), 73.5, 71.4 (minor), 70.3, 
34.12, 34.10 (minor), 28.6, 26.8 (minor), 24.5 (minor), 23.1, 19.1, 19.0 (minor), 18.9, 18.8 
(minor). 
 
(3aS,7S,7aS)-4-fluoro-6,6-dimethyl-2-oxotetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-7-yl 
isobutyrate (1.179) 
To a solution of noviose 1.178 (3 mg, 0.01 mmol) CH2Cl2 (0.5 mL) at 0°C, 
diethylaminosulfur trifluoride (a drop) was added. The reaction was stirred 
for 30 minutes at this temperature then it was quenched with aq. sat. 
NaHCO3 (2 mL). The aq. layer was extracted with Et2O (3x2 mL), the 
combined org. layers dried (MgSO4), filtered and evaporated under reduced pressure. This 
furnished the title compound 1.179 (3 mg, quant.) in high purity. 
1H-NMR (400 MHz, CDCl3) δ 5.75 (d, J = 50.7 Hz, 1H), 5.11–5.07 (m, 1H), 4.82–4.79 (m, 
2H), 2.56 (dq, J = 14.0, 7.0 Hz, 1H), 1.25 (s, 3H), 1.18 (s, 3H), 1.16 (d, J = 1.6 Hz, 3H), 1.14 
(d, J = 1.5 Hz, 3H). 
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(3aS,4S,7S,7aS)-6,6-dimethyl-2-oxo-4-((E)-2,2,2-trifluoro-1-(phenylimino)ethoxy)-
tetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-7-yl isobutyrate (α-1.181);  
(3aS,4R,7S,7aS)-6,6-dimethyl-2-oxo-4-((E)-2,2,2-trifluoro-1-(phenylimino)ethoxy)-
tetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-7-yl isobutyrate (β-1.181) 
To a solution of noviose 1.178 (7.1 mg, 26 µmol) in acetone (0.6 mL) at RT, K2CO3 (14 mg, 
0.10 mmol) and 2,2,2-trifluoro-N-phenylacetimidoyl chloride (9 µL, 50 µmol) were added 
and the mixture was stirred at RT for 1 h. Then it was filtered and the solvents were 
evaporated under reduced pressure. Purification by column chromatography (Et2O/pentane 
1/4 to 1/2 to 1/0) gave the two anomers 1.181 (α-1.181 5.8 mg, 50%; β-1.181 4.4 mg, 38%) as 
colourless resins. 
α-1.181: Rƒ = 0.5 (EtOAc/cHex 1/4); 1H-NMR (400 MHz, CDCl3) δ 
7.35–7.29 (m, 2H), 7.17–7.10 (m, 1H), 6.86–6.81 (m, 2H), 6.50 (br s, 
1H), 5.23 (d, J = 5.8 Hz, 1H), 4.97–4.89 (m, 2H), 2.64 (hept, J = 
7.0 Hz, 1H), 1.36 (s, 3H), 1.35 (s, 3H), 1.22 (d, J = 7.0 Hz, 6H); IR ν 
= 2986, 1794, 1725, 1720, 1598, 1469, 1325, 1155, 1115, 1074, 1040, 940, 774, 695 cm-1. 
β-1.181: Rƒ = 0.25 (EtOAc/cHex 1/4); 1H-NMR (400 MHz, Acetone-
d6) δ 7.42–7.33 (m, 2H), 7.18–7.12 (m, 1H), 6.90 (d, J = 7.5 Hz, 2H), 
6.60 (br s, 1H), 5.74 (d, J = 7.3 Hz, 1H), 5.45 (dd, J = 9.0, 3.2 Hz, 
1H), 5.26 (dd, J = 8.9, 7.3 Hz, 1H), 2.72 (hept, J = 7.0 Hz, 1H), 1.33 
(s, 3H), 1.31 (s, 3H), 1.21 (d, J = 3.2 Hz, 3H), 1.20 (d, J = 3.2 Hz, 3H); IR ν = 2983, 1794, 
1738, 1549, 1452, 1376, 1241, 1146, 1115, 1078, 1025, 756 cm-1.  
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4.1.2 Rhamnoside-Resorcylate Substrates 
7-(allyloxy)-6,8-dichloro-5-ethyl-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (1.128)  
To a suspension of resorcylate 1.134 (492 mg, 1.7 mmol) and K2CO3 
(701 mg, 5.1 mmol) in DMF (5.0 mL), allyl bromide (0.44 mL, 5.1 mmol) 
was added and the reaction mixture was stirred at RT for 4 h. The reaction 
mixture was then quenched with H2O (50 mL) and aq. sat. NaHCO3 (50 mL) 
The aq. layer was extracted with Et2O (3x50 mL), the org. layers washed with H2O (50 mL) 
and brine (50 mL). The combined org. layers were dried (MgSO4), filtered and evaporated 
under reduced pressure to afford the allyl-protected resorcylate 1.128 (534 mg, 95%) as a 
beige, crystalline compound. 
Rƒ = 0.74 (pentane/Et2O 3/1); M.p. = 93.5-94.5°C; 1H-NMR (400 MHz, CDCl3) δ 6.15 (ddt, 
J = 17.1, 10.3, 6.0 Hz, 1H), 5.45 (ddd, J = 17.1, 1.4, 2.9 Hz, 1H), 5.32 (ddd, J = 10.3, 2.4, 
1.1 Hz, 1H), 4.63 (dt, J = 6.0, 1.3 Hz, 2H), 3.30 (q, J = 7.4 Hz, 2H), 1.74 (s, 6H), 1.21 (t, J = 
7.4 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 158.5, 156.9, 152.7, 146.2, 132.5, 124.9, 119.3, 
115.9, 109.9, 105.9, 74.6, 25.6 (2C), 24.5, 13.4; HRMS ESI calcd. for [C15H16Cl2NaO4]+ 
[M+Na]+: 353.0318; found: 353.0312; IR ν = 2990, 2943, 1733, 1573, 1380, 1277, 1231, 
1204, 1112, 1047, 911, 787 cm-1. 
 
2R,3R,4S,5S,6R)-4-((tert-butyldimethylsilyl)oxy)-5-methoxy-2-methyl-6-
(phenylthio)tetrahydro-2H-pyran-3-ol (1.129) 
To a solution of thioglycoside 1.139 (18 mg, 38 µmol) in CH2Cl2 (1.0 mL) 
and H2O (0.1 mL) under vigorous stirring, DDQ (86 mg, 0.38 mmol) was 
added. The resulting brown mixture was stirred at RT for 5 h, then 
additional DDQ (34 mg, 0.15 mmol) was added, and stirred for another 2.5 h. Then it was 
quenched with aq. sat. NaHCO3 (20 mL) and the reaction mixture was extracted with CH2Cl2 
(4x10 mL). The combined org. layers were dried (MgSO4), filtrated and evaporated under 
reduced pressure. Purification by column chromatography (Et2O/pentane 1/3) gave the 
desired alcohol 1.129 (12 mg, 82%) as colourless oil. 
 
Rƒ = 0.32 (Et2O/pentane 1/3); 1H-NMR (400 MHz, CDCl3) δ 7.52–7.45 (m, 2H), 7.35–7.20 
(m, 3H), 5.54 (d, J = 1.0 Hz, 1H), 4.11 (dq, J = 9.3, 6.2 Hz, 1H), 3.85 (dd, J = 9.3, 3.1 Hz, 
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1H), 3.64 (dt, J = 3.2, 1.5 Hz, 1H), 3.61 (dd, J = 9.3, 2.6 Hz, 1H), 3.47 (s, 3H), 2.10 (d, J = 
2.7 Hz, 1H), 1.34 (d, J = 6.2 Hz, 3H), 0.95 (s, 9H), 0.18 (s, 3H), 0.18 (s, 2H); 13C-NMR 
(101 MHz, CDCl3) δ 134.9, 130.9 (2C), 129.1 (2C), 127.2, 85.4, 82.7, 73.9, 73.1, 69.5, 58.8, 
25.9 (3C), 18.9, 17.7, –4.29, –4.61.  
 
5-ethyl-7-hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (1.133) 
To a solution of diisopropylamine (0.35 mL, 2.5 mmol) in THF (25 mL) at –
78°C, nBuLi (1.6 M in hexane; 1.57 mL, 2.5 mmol) was added slowly. The 
solution was stirred for 40 minutes before keto-dioxinone 1.131 (221 mg, 
1.2 mmol) in THF (1.5 mL) was added. The resulting orange reaction mixture was stirred for 
100 minutes at –78°C. Then propionyl imidazole (74 mg, 0.60 mmol) dissolved in THF 
(1.1 mL) was added. After stirring the reaction mixture for 2.5 h at –78°C, the reaction was 
quenched with aq. sat. NH4Cl (20 mL) The medium was adjusted to pH 3 using aq. HCl 
(1 M), extracted with EtOAc (3x50 mL) and the combined org. layers were dried (MgSO4), 
filtered and evaporated under reduced pressure. The yellow residue was dissolved in CH2Cl2 
(15 mL) and Et3N (2 mL, excess). After stirring for 16 h, the mixture was acidified to pH 1 
using aq. HCl (1 M) and the aq. layer was extracted with CH2Cl2 (3x50 mL), the combined 
org. layers were dried (MgSO4), filtered and evaporated under reduced pressure. Purification 
by column chromatography (Et2O/pentane 1/2 to 2/1) afforded the isopropylidene-protected 
resorcylate 1.133 (76 mg, 57%) as a yellow crystalline solid.  
Rƒ = 0.45 (Et2O/pentane 1/2); M.p. = 138.0–140.0°C; 1H-NMR (400 MHz, CDCl3) δ 8.03 (s, 
1H), 6.54 (d, J = 2.4 Hz, 1H), 6.36 (d, J = 2.4 Hz, 1H), 3.05 (q, J = 7.4 Hz, 2H), 1.68 (s, 6H), 
1.22 (t, J = 7.4 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 163.2, 161.8, 159.3, 152.1, 112.6, 
105.1, 103.8, 101.7, 27.8, 25.5 (2C), 14.9; HRMS ESI calcd. for [C12H15O4]+ [M+H]+: 
223.0965; found: 223.0967; IR ν = 3224, 3000, 2955, 2870, 1688, 1608, 1499, 1442, 1294, 
1213, 1154, 1048, 915, 840, 704 cm-1. 
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6,8-dichloro-5-ethyl-7-hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (1.134) 
To a solution of resorcylate 1.133 (500 mg, 2.3 mmol) in CH2Cl2 (25 mL) at 
RT, sulfuryl chloride (0.43 mL, 5.3 mmol) was added dropwise. The resulting 
yellow solution was heated to reflux for 1.5 h and subsequently the solvent 
was evaporated under reduced pressure. The yellow residue was triturated 
with pentane (3x7 mL). The remaining solid was dried under HV to afford the title compound 
1.134 (639 mg, 98%) as beige solid. 
Rƒ = 0.25 (pentane/Et2O 3/1); M.p. = 172.5-173.5°C; 1H-NMR (400 MHz, CDCl3) δ 6.47 (s, 
1H), 3.30 (q, J = 7.4 Hz, 2H), 1.75 (s, 6H), 1.21 (t, J = 7.4 Hz, 3H); 13C-NMR (101 MHz, 
CDCl3) δ 158.6, 153.3, 152.9, 145.9, 116.5, 107.2, 106.3, 105.9, 25.6 (2C), 24.5, 13.3; 
HRMS ESI calcd. for [C12H11Cl2O4]+ [M+H] +: 289.0040; found: 289.0037; IR ν = 3287, 
3001, 2974, 2950, 2881, 1716, 1584, 1561, 1437, 1280, 1192, 1044, 786, 621 cm-1. 
 
(2R,4aR,6S,7S,8R,8aS)-6-methoxy-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-7,8-diol 
(1.135) 
This procedure was adopted from F. Ekholm, M. Poláková, A. Pawłowicz, 
R. Leino, Synthesis 2009, 567–576. Methyl α-D-mannopyranoside 1.104 
(100 mg, 0.50 mmol), benzaldehyde dimethyl acetal (80 µL, 0.50 mmol) 
and para-toluenesulfonic acid monohydrate (10.0 mg, 0.50 mmol) were 
dissolved in DMF (2.5 mL). The reaction mixture was rotated in a rotary evaporater at 
200 mbar at 60°C for 2 h. The reaction mixture was then quenched with H2O (50 mL), 
extracted with EtOAc (3x50 mL), the combined org. layers were dried (MgSO4), filtered and 
the solvent was evaporated under reduced pressure. Purification by column chromatography 
(EtOAc/pentane 1/2 to pure EtOAc) yielded the title compound 1.135 (78.0 mg, 53%) as a 
white solid. 
The analytical data are in good agreement with the literature: P. S. Kumar, G. D. K. Kumar, 
S. Baskaran, Eur. J. Org. Chem. 2008, 63, 6063–6067. 
[α]D = +65.3° (c = 1.0, CHCl3); M.p. = 144.4–144.3°C; 1H-NMR (400 MHz, CDCl3) δ 7.52–
7.45 (m, 1H), 7.41–7.35 (m, 2H), 5.55 (s, 1H), 4.71 (d, J = 1.2 Hz, 1H), 4.33 – 4.21 (m, 1H), 
4.03 (dd, J = 9.5, 3.5 Hz, 1H), 3.97 (d, J = 3.5 Hz, 1H), 3.89 (t, J = 9.2 Hz, 1H), 3.86–3.78 
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(m, 2H), 3.38 (s, 2H), 2.94 (br s, 1H), 2.90 (br s, 1H); 13C-NMR (101 MHz, CDCl3) δ 137.2, 
129.3, 128.4, 126.3, 102.3, 101.3, 78.9, 70.9, 68.8, 68.6, 62.9, 55.1; IR ν = 3562, 3000, 2928, 
2856, 1463, 1381, 1253, 1120, 1075, 1099, 1048, 860, 836, 781, 697 cm-1. 
 
(2R,4aR,6S,7S,8R,8aR)-8-((tert-butyldimethylsilyl)oxy)-6-methoxy-2-
phenylhexahydropyrano[3,2-d][1,3]dioxin-7-ol (1.135b) 
4,6-Benzylidene acetal-protected compound 1.135 (2.00 g, 7.1 mmol) and 
dibutyltin oxide (2.12 g, 8.5 mmol) were suspended in MeOH (50 mL) and 
heated to reflux. After stirring for 1 h, the suspension turned into a slightly 
turbid solution. The volatiles were evaporated under reduced pressure and 
the residue was dried under high vacuum for 2 h. The resulting oily residue was dissolved in 
DMF (40 mL) and evacuated to 0.2 mbar until bubbling ceased. Then a solution of TBSCl 
(2.45 mL, 14.0 mmol) and TBAI (52.3 mg, 0.14 mmol) in CH2Cl2 (3 mL) was added and the 
reaction was stirred for 16 h. The reaction mixture was quenched with MeOH (2.5 mL), 
diluted with water (200 mL), and extracted with Et2O (3x100 mL), the org. layers were 
washed with brine (200 mL). The combined org. layers were dried (MgSO4), filtered and 
evaporated under reduced pressure. Purification by column chromatography (Et2O/pentane 
1/3) afforded the TBS-protected product 1.135b (2.24 g, 80%) as a colourless oil. 
Rƒ = 0.57 (pentane/Et2O 1/1); [α]D = +24.8° (c = 0.59, CHCl3); 1H-NMR (400 MHz, CDCl3) 
δ 7.50–7.45 (m, 2H), 7.39–7.32 (m, 3H) 5.55 (s, 1H), 4.79 (d, J = 1.2 Hz, 1H), 4.29–4.23 (m, 
1H), 4.07 (dd, J = 9.1, 3.8 Hz, 1H), 3.87 (dd, J = 5.6, 3.9 Hz, 1H), 3.86–3.75 (m, 3H), 3.39 (s, 
3H), 2.82 (br s, 1H), 0.88 (s, 9H), 0.10 (s, 3H), 0.05 (s, 3H); 13C-NMR (101 MHz, CDCl3) δ 
137.5, 128.9, 128.1 (2C), 126.1 (2C), 101.9, 100.9, 79.1, 72.0, 69.8, 68.9, 63.0, 55.0, 25.7 
(3C), 18.1, –4.4, –5.0; HRMS ESI calcd. for [C20H33O6Si]+ [M+H]+: 397.2041; found: 
397.2040; IR ν = 3562, 3000, 2928, 2856, 1463, 1381, 1253, 1120, 1075, 1099, 1048, 860, 
836, 781, 697 cm-1. 
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tert-butyl(((2R,4aR,6S,7S,8S,8aR)-6,7-dimethoxy-2-phenylhexahydropyrano[3,2-
d][1,3]dioxin-8-yl)oxy)dimethylsilane (1.136) 
To a solution of TBS protected mannose 1.135b (105.0 mg, 0.27 mmol) in 
THF (1 mL) at 0°C, sodium hydride (31.5 mg, 0.80 mmol, 60 % dispersion 
in oil) was added and the mixture was stirred for 40 minutes at 0 °C. MeI 
(0.04 mL, 0.66 mmol) was then added and the mixture was stirred for 30 
minutes at 0 °C. The reaction mixture was warmed to RT, stirred 8 h and the reaction mixture 
was diluted with EtOAc (2 mL) and quenched with water (2 mL). The layers were separated, 
the aqueous layer reextracted with EtOAc (3x5 mL), the combined org. layers washed with 
aq. sat. NH4Cl (5 mL), dried (MgSO4), filtered and evaporated under reduced pressure. 
Purification by column chromatography (Et2O/pentane 1/5) yielded the 2O-methylated 
mannose 1.136 (89.0 mg, 82%) as colourless oil. 
Rƒ = 0.27 (pentane/Et2O 5/1, CAM, UV); [α]D = +32.0° (c = 1.14, CHCl3); 1H-NMR 
(400 MHz, CDCl3) δ 7.50–7.45 (m, 2H), 7.38–7.32 (m, 3H), 5.56 (s, 1H), 4.72 (d, J = 1.5 Hz, 
1H), 4.23 (dd, J = 10.0, 4.6 Hz, 1H), 4.13 (dd, J = 9.7, 3.3 Hz, 1H), 3.91 (t, J = 9.5 Hz, 1H), 
3.83 (t, J = 10.2 Hz, 1H), 3.74 (dd, J = 9.5, 4.6 Hz, 1H), 3.59 (s, 3H), 3.45 (dd, J = 3.3, 1.6 
Hz, 1H), 3.38 (s, 3H), 0.89 (s, 9H), 0.09 (s, 3H), 0.04 (s, 3H); 13C-NMR (101 MHz, CDCl3) δ 
137.7, 128.8, 128.1 (2C), 126.2 (2C), 101.9, 100.5, 81.9, 79.2, 70.5, 68.9, 64.1, 60.8, 54.9, 
25.8 (3C), 18.3, –4.4, –4.9; HRMS ESI calcd. for [C21H34NaO6Si]+ [M+Na]+: 433.2017; 
found: 433.2013; IR ν = 2928, 2967, 2856, 1463, 1386, 1251, 1126, 1100, 1055, 1024, 975, 
864, 836, 779, 697 cm-1. 
 
((2R,3R,4S,5S,6S)-3-(benzyloxy)-4-((tert-butyldimethylsilyl)oxy)-5,6-
dimethoxytetrahydro-2H-pyran-2-yl)methanol (1.137) 
To a solution of acetal 1.136 (88 mg, 0.21 mmol) in CH2Cl2 (2.5 mL), 
borane THF complex (1M, 1.18 mL, 1.2 mmol) and TMSOTf (0.7 µL, 40 
µmol) were added and the colourless solution was stirred at RT for 45 
minutes. The reaction mixture was quenched with Et3N (0.3 mL) followed 
by slow addition of MeOH (1 mL). The reaction mixture was then evaporated under reduced 
pressure, the residue dissolved in MeOH (3 mL) and evaporated again. Purification by 
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column chromatography (Et2O/pentane 1/2 to Et2O) gave the primary alcohol 1.137 (80 mg, 
91%) as colourless oil. 
Rƒ = 0.3 (Et2O/pentane 1/1); [α]D = +74.0° (c = 0.94, CHCl3); 1H-NMR (400 MHz, CDCl3) δ 
7.24–7.19 (m, 4H), 7.16 (dq, J = 6.8, 4.0 Hz, 1H), 4.77 (d, J = 11.3 Hz, 1H), 4.59 (d, J = 
1.7 Hz, 1H), 4.47 (d, J = 11.3 Hz, 1H), 3.95 (dd, J = 9.2, 3.2 Hz, 1H), 3.67 (ddd, J = 11.6, 5.4, 
2.8 Hz, 1H), 3.61 (t, J = 9.5 Hz, 1H), 3.60–3.54 (m, 1H), 3.45 (ddd, J = 8.6, 4.2, 2.3 Hz 1H), 
3.42 (s, 3H), 3.26 (dd, J = 3.1, 1.9 Hz, 1H), 3.23 (s, 3H), 2.01 (t, J = 6.5 Hz, 1H), 0.84 (s, 9H), 
0.01 (d, J = 8.2 Hz, 6H); 13C-NMR (101 MHz, CDCl3) δ 138.6, 128.4 (2C), 127.8 (2C), 
127.7, 99.0, 81.5, 75.9, 75.2, 73.2, 72.3, 62. 4, 60.0, 54.9, 26.1 (3C), 18.2, –4.3, –4.5; HRMS 
ESI calcd. for [C21H37O6Si]+ [M+H]+: 413.2354; found: 413.2352; IR ν = 3482, 2929, 2857, 
1383, 1252, 1191, 1125, 1097, 1057, 866, 836, 776, 734, 697 cm-1.  
 
(((2S,3R,4S,5S,6S)-3-(benzyloxy)-2-(iodomethyl)-5,6-dimethoxytetrahydro-2H-pyran-4-
yl)oxy)(tert-butyl)dimethylsilane (1.137b) 
To a solution of the primary alcohol 1.137 (100 mg, 0.24 mmol) toluene 
(2 mL), iodine (92 mg, 0.36 mmol), imidazole (97 mg, 1.4 mmol) and 
triphenylphosphine (184 mg, 0.70 mmol) were added. The orange solution 
was heated to 100°C, becoming a colourless solution, and stirred for 7 h at 
this temperature. Then the solvent was evaporated under reduced pressure. Purification by 
column chromatography (pentane to Et2O/pentane 1/7, dry loading) yielded the iodide 1.137b 
(107 mg, 85%) as a colourless oil. 
Rƒ = 0.75 (Et2O/pentane 1/2); [α]D = +55.7° (c = 0.48, CHCl3); 1H-NMR (400 MHz, CDCl3) 
δ 7.37–7.27 (m, 5H), 4.94 (d, J = 11.4 Hz, 1H), 4.73 (d, J = 1.7 Hz, 1H), 4.62 (d, J = 11.4 Hz, 
1H), 4.05 (dd, J = 8.7, 3.2 Hz, 1H), 3.56–3.45 (m, 3H), 3.53 (s, 3H), 3.41 (s, 3H), 3.37 (dd, 
J = 3.2, 1.8 Hz, 1H), 3.25–3.18 (m, 1H), 0.95 (s, 9H), 0.13 (s, 3H), 0.11 (s, 3H); 13C-NMR 
(101 MHz, CDCl3) δ 138.2, 128.4 (2C), 127.7, 127.7 (2C), 98.6, 81.4, 79.6, 75.4, 72.9, 71.6, 
59.7, 55.1, 26.0 (3C), 18.1, 6.96, –4.43, –4.60; IR ν = 2954, 2929, 2856, 1462, 1408, 1253, 
1194, 1124, 1061, 967, 865, 836, 776, 733, 697 cm-1.  
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(((2R,3R,4S,5S,6S)-3-(benzyloxy)-5,6-dimethoxy-2-methyltetrahydro-2H-pyran-4-
yl)oxy)(tert-butyl)dimethylsilane (1.138) 
To a solution of iodide 1.137b (16 mg, 30 µmol) in THF (1 mL) at RT, 
LAH (1 M in THF, 90 µL, 90 µmol) was added. The reaction mixture was 
then heated to 60°C and stirred for 6 h. MeOH (1 mL) and silica gel (ca. 
200 mg) were added and the suspension was evaporated under reduced pressure. The residue 
was filtrated over silica using Et2O and the solvent was evaporated under reduced pressure 
yielding the rhamnoside 1.138 (10 mg, 82%) as colourless oil. 
Or 
To a solution of iodide 1.137b (107 mg, 0.21 mmol) in MeOH (1.0 mL), Et3N (0.06 mL, 
0.41 mmol) and Pd/C (10%, 25 mg) were added. The black suspension was then stirred in an 
autoclave for 2 h at RT and 50 bar hydrogen atmosphere. The reaction mixture was filtrated 
over Celite washed with Et2O (10 mL) and evaporated under reduced pressure. The residue 
was purified by column chromatography (Et2O/pentane 1/3) to yield the rhamnoside 1.138 
(55 mg, 68%) as colourless oil. 
Rƒ = 0.45 (Et2O/pentane 1/3); 1H-NMR (400 MHz, CDCl3) δ 7.25–7.14 (m, 5H), 4.80 (d, J = 
11.2 Hz, 1H), 4.55 (d, J = 1.8 Hz, 1H), 4.48 (d, J = 11.3 Hz, 1H), 3.91 (dd, J = 9.2, 3.2 Hz, 
1H), 3.52 (dq, J = 9.5, 6.3 Hz, 1H), 3.44 (s, 3H), 3.31 (d, J = 9.4 Hz, 1H), 3.26 (dd, J = 3.3, 
1.9 Hz, 1H), 3.23 (s, 3H), 1.17 (d, J = 6.3 Hz, 3H), 0.85 (s, 9H), 0.03 (s, 3H), –0.00 (s, 3H); 
13C-NMR (101 MHz, CDCl3) δ 138.7, 128.3 (2C), 127.7 (2C), 127.5, 98.6, 81.6, 81.4, 75.3, 
73.0, 67.9, 59.7, 54.7, 26.0 (3C), 18.1, 18.0, –4.42, –4.57; HRMS ESI calcd. for 
[C21H36NaO5Si]+ [M+Na]+: 419.2224; found: 419.2222. 
 
(((2R,3R,4S,5S,6R)-3-(benzyloxy)-5-methoxy-2-methyl-6-(phenylthio)tetrahydro-2H-
pyran-4-yl)oxy)(tert-butyl)dimethylsilane (1.139) 
To a solution of pyranoside 1.138 (55 mg, 0.14 mmol) in DCE (1.0 ml) at 
RT, TMSSPh (0.13 mL, 0.69 mmol), ZnI2 (133 mg, 0.42 mmol) and 
tetrabutlyammonium iodide (77 mg, 0.21 mmol) were added and the 
mixture was stirred at 65°C for 2 h. The reaction mixture was quenched with aq. sat. Ba(OH)2 
(10 mL), diluted with CH2Cl2 (10 mL), the layers were separated and the aq. layer extracted 
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with CH2Cl2 (3x10 mL). The combined org. layers were dried (MgSO4), filtrated and 
evaporated under reduced pressure. Purification by column chromatography (adsorbed on 
silica, Et2O/pentane 1/10) yielded the thioglycoside 1.139 (52 mg, 79%) as a colourless solid. 
Rƒ = 0.35 (Et2O/pentane 1/10); 1H-NMR (400 MHz, CDCl3) δ 7.40–7.36 (m, 2H), 7.26–7.12 
(m, 9H), 5.44 (d, J = 1.4 Hz, 2H), 4.83 (d, J = 11.2 Hz, 1H), 4.52 (d, J = 11.2 Hz, 1H), 4.04 
(dq, J = 9.4, 6.2 Hz, 1H), 3.93 (dd, J = 9.2, 3.1 Hz, 1H), 3.56 (dd, J = 3.1, 1.8 Hz, 1H), 3.42 
(s, 3H), 3.40 (t, J = 9.3 Hz, 1H), 1.21 (d, J = 6.3 Hz, 3H), 0.88 (s, 9H), 0.08 (s, 3H), 0.06 (s, 
3H); 13C-NMR (101 MHz, CDCl3) δ 138.6, 135.1, 130.9 (2C), 129.0 (2C), 128.3 (2C), 127.8 
(2C), 127.6, 127.2, 85.2, 83.3, 81.5, 75.5, 73.5, 69.4, 58.9, 26.0 (3C), 18.2, 17.9, –4.47 (2C); 
ESI-MS m/z = 497.3 [M+Na]+; IR ν = 3059, 2952, 2930, 2884, 2858, 1471, 1386, 1255, 
1127, 1099, 1075, 1032, 867, 833, 764, 736, 694, 670 cm-1.  
 
(2R,3R,4R,5S,6R)-3-((tert-butyldimethylsilyl)oxy)-5-methoxy-2-methyl-6-(phenylthio)-
tetrahydro-2H-pyran-4-yl 4-(allyloxy)-3,5-dichloro-2-ethyl-6-hydroxybenzoate (1.140) 
To a solution of TBS-protected thioglycoside 1.129 (12 mg, 30 µmol) and resorcylate 1.128 
(16.5 mg, 50 µmol) in THF (1.0 mL), NaH (60% dispersion in mineral oil, 6.2 mg, 
0.16 mmol) was added and the reaction mixture was stirred at RT for 4 h. Then the mixture 
was diluted with Et2O (3 mL) and quenched with aq. sat. NH4Cl (2 mL), the layers were 
seperated, and the aq. layer was extracted with Et2O (3x3 mL). The combined org layers were 
dried (MgSO4), filtrated and evaporated under reduced pressure. Purification by column 
chromatography (Et2O/pentane 1/20) afforded the title compound 1.140 (O3, 12 mg, 59%) 
and its regioisomer 1.127 (O4, 2 mg, 10%).  
1.140 (O3): 1H-NMR (400 MHz, CDCl3) δ 11.44 (s, 1H), 7.43–7.39 
(m, 2H), 7.28–7.18 (m, 3H), 6.07 (ddt, J = 17.2, 10.3, 6.0 Hz, 1H), 
5.53 (d, J = 1.7 Hz, 1H), 5.40 (t, J = 9.5 Hz, 1H), 5.36 (dq, J = 17.5, 
1.5 Hz, 1H), 5.22 (dq, J = 10.3, 1.2, Hz, 1H), 4.54 (ddd, J = 6.0, 1.3, 
1.3, Hz, 2H), 4.30 (dq, J = 9.8, 6.2 Hz, 1H), 4.03 (dd, J = 9.4, 
3.1 Hz, 1H), 3.63 (dd, J = 3.0, 1.9 Hz, 1H), 3.42 (s, 3H), 3.08 (dq, J = 12.8, 7.3 Hz, 1H), 2.91 
(dq, J = 12.9, 7.3 Hz, 1H), 1.25 (d, J = 6.2 Hz, 3H), 1.19 (t, J = 7.3 Hz, 3H), 0.70 (s, 9H), 0.00 
(s, 3H), –0.17 (s, 3H). 
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1.127 (O4): 1H-NMR (400 MHz, CDCl3) δ 9.59 (s, 1H), 7.54–7.49 
(m, 2H), 7.37–7.27 (m, 3H), 6.16 (ddt, J = 17.2, 10.3, 5.9 Hz, 1H), 
5.64 (d, J = 1.4 Hz, 1H), 5.44 (dq, J = 17.2, 1.5 Hz, 1H), 5.36–5.26 
(m, 3H), 4.62 (ddd, J = 5.9, 1.3, 1.3 Hz, 2H), 4.22 (dq, J = 9.0, 
6.2 Hz, 1H), 4.05 (dd, J = 3.5, 1.7 Hz, 1H), 3.85 (t, J = 9.1 Hz, 1H), 
3.44 (s, 3H), 3.12 (dq, J = 12.9, 7.4 Hz, 1H), 2.87 (dq, J = 12.9, 7.3 Hz, 1H), 1.32 (d, J = 
6.2 Hz, 3H), 1.25 (t, J = 7.3 Hz, 3H), 0.80 (s, 9H), 0.04 (s, 3H), –0.18 (s, 3H); ESI-MS m/z = 
679.2 (681.2, 680.2) [M+Na]+. 
 
(2R,3R,4S,5S,6R)-3-hydroxy-5-methoxy-2-methyl-6-(phenylthio)tetrahydro-2H-pyran-4-
yl 4-(allyloxy)-3,5-dichloro-2-ethyl-6-hydroxybenzoate (1.141) 
To a solution of the rhamnose 1.145 (163 mg, 0.60 mmol) and the 
resorcylate 1.128 (200 mg, 0.60 mmol) in THF (6 mL) at 0°C, NaH 
(60% dispersion in mineral oil, 121 mg, 3.0 mmol) was added in 
portions. The grey turbid mixture was stirred at RT for 0.5 h. The 
reaction was quenched with aq. sat. NH4Cl (10 mL) and the aq. 
layer was extracted with tBME (3x10 mL), the combined org. layers were dried (MgSO4), 
filtered and evaporated under reduced pressure. Purification by column chromatography 
(tBME/pentane 1/5) afforded the desired title compound 1.141 (272 mg, 83%) as colourless 
oil. 
Or 
To a solution of silyl ether 1.140 (12 mg, 18 µmol) in THF (1.0 mL) at RT, TBAF (1M in 
THF, 18 µL, 18 µmol) was added. The solution was stirred for 2 h, then quenched with aq. 
sat. NH4Cl, and the THF was evaporated under reduced pressure. The residue was extracted 
with Et2O (3x), the combined org. layer were dried (MgSO4) filtered and evaporated under 
reduced pressure, giving the title compound 1.141 (8 mg, 81%). 
Rƒ = 0.24 (tBME/pentane 1/5); [α]D = +58.0° (c = 0.78, CHCl3); 1H-NMR (400 MHz, CDCl3) 
δ 10.25 (s, 1H), 7.49–7.39 (m, 2H), 7.32–7.20 (m, 3H), 6.09 (ddt, J = 17.2, 10.3, 5.9 Hz, 1H), 
5.56 (d, J = 1.5 Hz, 1H), 5.38 (ddd, J = 17.1, 1.5, 1.5 Hz, 1H), 5.26 (dd, J = 9.9, 3.4 Hz, 1H), 
5.23 (ddd, J = 10.3, 1.2, 1.2 Hz, 1H), 4.53 (dt, J = 5.9, 1.3 Hz, 2H), 4.20 (dq, J = 9.4, 6.2 Hz, 
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1H), 4.00 (dd, J = 3.4, 1.6 Hz, 1H), 3.83 (t, J = 9.6 Hz, 1H), 3.34 (s, 3H), 3.02 (qd, J = 7.4, 
2.0 Hz, 2H), 2.03 (br s, 1H), 1.32 (d, J = 6.2 Hz, 3H), 1.18 (t, J = 7.4 Hz, 3H); 13C-NMR 
(101 MHz, CDCl3) δ 168.7, 155.9, 155.8, 143.4, 134.1, 132.8, 131.5, 129.3, 127.8, 122.0, 
119.2, 115.9, 112.1, 84.0, 79.7, 76.2, 74.5, 71.1, 69.7, 58.1, 25.9, 17.6, 14.2; HRMS ESI 
calcd. for [C25H28Cl2NaO7S]+ [M+Na]+: 565.0825; found: 565.0827; IR ν = 3387, 2978, 
2936, 1735, 1659, 1582, 1547, 1453, 1393, 1301, 1220, 1104, 1071, 988, 966, 812, 748, 
691 cm-1. 
 
(2R,3S,4S,5S,6R)-4-hydroxy-5-methoxy-2-methyl-6-(phenylthio)tetrahydro-2H-pyran-3-
yl 4-(allyloxy)-3,5-dichloro-2-ethyl-6-hydroxybenzoate (1.142) 
To a solution of the rhamnose 1.145 (163 mg, 0.60 mmol) and the 
resorcylate 1.128 (200 mg, 0.60 mmol) in THF (6 mL) at 0°C 
NaH (60% dispersion in mineral oil, 114 mg, 2.84 mmol) was 
added in portions. The grey turbid mixture was stirred at RT for 
16 h. The reaction was quenched with aq. sat. NH4Cl (10 mL) and the aq. layer was extracted 
with Et2O (3x10 mL), the combined org. layers were dried (MgSO4), filtered and evaporated 
under reduced pressure. Purification by column chromatography (tBME/cHex 1/3) afforded 
the desired title compound 1.142 (272 mg, 83%) as pale yellow oil. 
Rƒ = 0.1 (Et2O/pentane 1/3); [α]D = +138.4° (c = 1.25, CHCl3); 1H-NMR (400 MHz, CDCl3) 
δ 10.29 (s, 1H), 7.44–7.40 (m, 2H), 7.30–7.22 (m, 3H), 6.09 (ddt, J = 16.3, 10.3, 5.9 Hz, 2H), 
5.60 (d, J = 0.7 Hz, 1H), 5.39 (ddd, J = 17.2, 3.0, 1.5 Hz, 1H), 5.24 (ddd, J = 10.3, 2.5, 
1.1 Hz, 1H), 5.19 (dd, J = 9.8, 9.8 Hz 1H), 4.54 (ddd, J = 5.9, 1.2, 1.2 Hz, 2H), 4.31 (dq, J = 
9.8, 6.1 Hz, 1H), 3.96–3.87 (m, 1H), 3.78 (dd, J = 3.6, 1.3 Hz, 1H), 3.44 (s, 3H), 3.02–2.94 
(m, 2H), 2.47 (d, J = 10.9 Hz, 1H), 1.23 (d, J = 6.3 Hz, 3H), 1.20 (t, J = 7.5 Hz, 3H); 13C-
NMR (101 MHz, CDCl3) δ 169.2, 155.5, 155.4, 142.5, 133.9, 132.7, 131.2 (2C), 129.2 (2C), 
127.7, 121.7, 119.1, 115.6, 112.4, 83.8, 81.6, 76.8, 74.3, 69.9, 66.9, 58.0, 26.0, 17.5, 14.0; 
HRMS ESI calcd. for [C25H28Cl2NaO7S]+ [M+Na]+: 565.0825; found: 565.0825; IR ν = 
2980, 2936, 2878, 1737, 1664, 1583, 1549, 1392, 1311, 1222, 1099, 998, 840, 764, 742, 
691 cm-1. 
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(2R,3S,4S,5S,6S)-2-(hydroxymethyl)-5,6-dimethoxytetrahydro-2H-pyran-3,4-diol (1.143) 
To a turbid mixture of acetal-protected compound 1.136 (967 mg, 2.4 mmol) 
in MeOH (20 mL) and H2O (1 mL), 1 M HCl (2 mL) was added and the 
solution was heated to 55°C for 1.5 h. Then it was quenched with aq. sat. 
NaHCO3 until pH 7 then the solvent was evaporated under reduced pressure 
and the residue was azeotropized three times using acetonitrile. The residual crude product 
was filtrated through a short plug of silica and the cake was washed with CH2Cl2/MeOH 
(10/1). After evaporation under reduced pressure product 1.143 (491 mg, quant.) was obtained 
as colourless oil. 
Rƒ = 0.24 (CH2Cl2/MeOH 10/1); [α]D = +50.6° (c = 0.35, CHCl3); 1H-NMR (400 MHz, 
CDCl3) δ 4.80 (d, J = 1.2 Hz, 1H), 3.87–3.83 (m, 2H), 3.81–3.68 (m, 2H), 3.57–3.51 (m, 1H), 
3.48 (s, 3H), 3.49–3.46 (m, 1H) 3.38 (s, 3H), 3.31 (d, J = 2.9 Hz, 1H), 2.90 (d, J = 9.2 Hz, 
1H), 2.57 (t, J = 6.3 Hz, 1H); 13C-NMR (101 MHz, CDCl3) δ 97.7, 80.1, 71.6, 71.5, 68.8, 
62.4, 59.0, 55.0; HRMS ESI calcd. for [C8H16NaO6]+ [M+Na]+: 231.0839; found: 231.0840; 
IR ν = 3371, 2935, 2837, 1647, 1135, 1104, 1041, 963 cm-1. 
 
(2S,3S,4S,5S,6S)-2-(iodomethyl)-5,6-dimethoxytetrahydro-2H-pyran-3,4-diol (1.143b) 
To a solution of methyl mannopyranoside 1.143 (254 mg, 1.2 mmol), 
triphenylphosphine (480 mg, 1.8 mmol,) and imidazole (168 mg, 2.4 mmol) 
in THF (10 mL), iodine (403 mg, 1.5 mmol) was added. The orange solution 
was heated to reflux for 1.5 h turning into a white suspension. Then the 
solvent was evaporated under reduced pressure and the residue was dissolved in Et2O (25 
mL), extracted with aq. sat. NH4Cl (25 mL) and the org. layer was dried (MgSO4), filtrated 
and evaporated under reduced pressure. Purification by column chromatography 
(Et2O/pentane 1/3 to Et2O) afforded the desired compound 1.143b (226 mg, 58%).  
Rƒ = 0.28 (Et2O); [α]D = +45.1° (c = 0.95, CHCl3); 1H-NMR (400 MHz, CDCl3) δ 4.88 (d, J = 
1.0 Hz, 1H), 3.74 (ddd, J = 10.9, 8.8, 3.8 Hz, 1H), 3.54–3.44 (m, 3H), 3.50 (s, 3H), 3.49 (s, 
3H), 3.29 (dd, J = 10.6, 8.1 Hz, 1H), 2.45 (d, J = 2.1 Hz, 1H), 2.37 (d, J = 10.8 Hz, 1H); 13C-
NMR (101 MHz, CDCl3) δ 97.3, 79.9, 72.5, 71.4, 71.3, 58.8, 55.3, 6.5; HRMS ESI calcd. for 
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[C8H15INaO5]+ [M+Na]+: 340.9856; found: 340.9856; IR ν = 3398, 2930, 2910, 2832, 1439, 
1414, 1379, 1190, 1132, 1102, 1050, 962, 874, 808 cm-1. 
 
 (2R,3S,4S,5S,6S)-5,6-dimethoxy-2-methyltetrahydro-2H-pyran-3,4-diol (1.144) 
To a solution of D-rhamnoside 1.148 (494 mg, 2.8 mmol) in MeOH (28 mL), 
2,3-butadione (0.29 mL, 3.3 mmol), trimethyl orthoformate (1.17 mL, 
10.6 mmol) and 10-camphorsulfonic acid (41.1 mg, 0.16 mmol) were added. 
The mixture was heated in a sealed tube to 90°C for 24 h. Then the reaction mixture was 
neutralized with Et3N and the solvent was removed under reduced pressure, yielding the 
protected intermediate which was used in the next step without further purification.  
To the protected intermediate in THF (17 mL) at 0°C, NaH (223 mg, 5.6 mmol, 60 % 
dispersion in mineral oil) was added in portions. The mixture was allowed to warm to RT and 
was stirred for an additional 1 h. Then MeI (0.19 mL, 3.1 mmol) was added dropwise and the 
mixture was stirred for 3.5 h at RT. The reaction was quenched with aq. sat. NH4Cl (20 mL), 
the volatiles was removed under reduced pressure and the remaining aq. suspension was 
diluted with H2O (40 mL). The mixture was extracted with CH2Cl2 (3x50 mL) and the org. 
layers were washed with brine (30 mL), combined, dried (Na2SO4), filtered and evaporated 
under reduced pressure. The methylated intermediate was used in the next step without further 
purification.  
To a solution of methylated intermediate in CH2Cl2 (30 mL), a mixture of TFA/H2O (9/1, 
2.4 mL) was added. The reaction was stirred for 1 h while the mixture turned slightly yellow. 
The reaction was quenched with Et3N (2.5 mL), diluted with toluene (10 mL), and the 
solvents were removed under reduced pressure. Azeotropic removal of Et3N was carried out 
twice with toluene (5 mL). Purification by column chromatography (Et2O) afforded the 
desired product 1.144 (356 mg, 72% over three steps) as a colourless oil.  
Or 
To a solution of iodomannopyranoside 1.143b (174 mg, 0.55 mmol) in Et3N/MeOH (1/10 
1.1 mL), Pd(OH)2 (20wt% on activated carbon, 115 mg, 0.16 mmol) were added. The dark 
turbid mixture was degassed with argon during 10 minutes, then hydrogen was bubbled 
through the suspension for 0.5 h, and the reaction mixture was subsequently stirred under a 
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hydrogen atmosphere for 6 h. The hydrogen atmosphere was exchanged by argon and the 
solution was filtered through Hyflo. The filtrate was evaporated under reduced pressure and 
the residue purified by column chromatography (Et2O) to yield the rhamnoside 1.144 (102 
mg, 97%) as a colourless oil.  
Rƒ = 0.18 (Et2O); [α]D = +40.2° (c = 0.48, CHCl3); 1H-NMR (400 MHz, CDCl3) δ 4.75 (d, J = 
1.1 Hz, 1H), 3.72–3.65 (m, 1H), 3.59 (dq, J = 9.3, 6.2 Hz, 1H), 3.47 (s, 3H), 3.45 (dd, J = 3.9, 
1.5 Hz, 1H), 3.37 (s, 3H), 3.38–3.32 (m, 1H) 2.50 (d, J = 2.7 Hz, 1H), 2.43 (d, J = 10.4 Hz, 
1H), 1.31 (d, J = 6.2 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 97.2, 80.2, 74.0, 71.5, 67.5, 
58.8, 54.8, 17.5; HRMS ESI calcd. for [C8H16NaO5]+ [M+Na]+: 215.0890; found: 215.0889; 
IR ν = 3426, 2976, 2935, 2905, 2832, 1540, 1378, 1190, 1136, 1104,1046, 966, 836, 
807 cm-1. 
 
(2R,3S,4S,5S,6R)-5-methoxy-2-methyl-6-(phenylthio)tetrahydro-2H-pyran-3,4-diol 
(1.145) 
To a solution of pyrannoside 1.144 (240 mg, 1.3 mmol) in DCE (10 mL), 
tetrabutylammonium iodide (692 mg, 1.9 mmol), zinc iodide (1.19 g, 
3.8 mmol) and trimethyl(phenylthio)silane (1.14 g, 6.2 mmol) were added. 
The white turbid mixture was heated to 65°C for 2.5 h. Then it was cooled to RT and a 
solution of TFA/H2O (9/1, 3 mL) was added. After stirring for 30 min, toluene (5 mL) was 
added and evaporated under reduced pressure. The residue was treated with Et2O (10 mL) and 
the biphasic mixture was stirred for 5 minutes. The ethereal extract was decanted and the 
remaining oil was reextracted twice in the same manner. The combined etheral extracts were 
evaporated under reduced pressure and purified by column chromatography (Et2O) to afford 
the title compound 1.145 (247 mg, 73%) as yellowish oil. 
Rƒ = 0.3 (Et2O); [α]D = +184.4° (c = 0.47, CHCl3); 1H-NMR (400 MHz, CDCl3) δ 7.50–7.46 
(m, 2H), 7.35–7.30 (m, 2H), 7.30–7.27 (m, 1H), 5.62 (ap s, 1H), 4.13 (dqd, J = 9.4, 6.2, 
0.6 Hz 1H), 3.77–3.70 (m, 2H), 3.48–3.43 (m, 1H), 3.46 (s, 3H), 2.41 (d, J = 10.0 Hz, 1H), 
2.39 (d, J = 2.6 Hz, 1H), 1.32 (d, J = 6.2 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 134.4, 
131.3 (2C), 129.1 (2C), 127.4, 84.0, 81.7, 74.3, 72.1, 68.9, 58.1, 17.4; HRMS ESI calcd. for 
[C13H18NaO4S]+ [M+Na]+: 293.0818; found: 293.0817; IR ν = 3523, 3296, 2976, 2932, 2898, 
2831, 1581, 1478, 1438, 1355, 1141, 1099, 1055, 1021, 839, 740, 690 cm-1. 
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(2R,3R,4S,5S,6S)-3-hydroxy-5,6-dimethoxy-2-methyltetrahydro-2H-pyran-4-yl 
4-(allyloxy)-3,5-dichloro-2-ethyl-6-hydroxybenzoate (1.146) 
(2R,3S,4S,5S,6S)-4-hydroxy-5,6-dimethoxy-2-methyltetrahydro-2H-pyran-3-yl 
4-(allyloxy)-3,5-dichloro-2-ethyl-6-hydroxybenzoate (1.147) 
To a solution of rhamnoside 1.144 (40 mg, 0.21 mmol) and resorcylate 1.128 (69 mg, 
0.21 mmol) in THF (2 mL) at 0°C, NaH (60 % dispersion in mineral oil, 42 mg, 1.0 mmol) 
was added in portions. The white turbid mixture was then slowly warmed to RT and stirred 
for 24 h. The reaction was diluted with tBME (8 mL), quenched with aq. sat. NH4Cl (20 mL). 
Then the layers were separated, the aq. layer extracted with tBME (20 mL) and the combined 
org. layers were dried (MgSO4), filtered and evaporated under reduced pressure. Purification 
by column chromatography (EtOAc/cHex 1/3) gave the two inseperable regioisomers 1.146 
and 1.147 (36 mg, 47%) in a 1.4:1 ratio. 
Or 
To a solution of rhamnoside 1.147 (32 mg, 68 µmol) in toluene (3 mL) at 0°C, NaH (60 % 
dispersion in mineral oil, 11 mg, 0.28 mmol) was added. The white turbid mixture was 
warmed to RT and then heated to 40°C for 48 h. The reaction was diluted with tBME (4 mL), 
quenched with aq. sat. NH4Cl (4 mL), the layers were separated and the aq. layer was 
extracted with tBME (2x3 mL). The combined org. layers were dried (MgSO4), filtered and 
evaporated under reduced pressure. Purification by column chromatography (EtOAc/cHex 
1/3) gave the O4 isomer 1.147 (24 mg, 75%) as a colourless oil. 
Or 
To a solution of rhamnoside 1.144 (233 mg, 1.2 mmol) and resorcylate 1.128 (401 mg, 
1.2 mmol) in toluene (5 mL) at 0°C, NaH (60 % dispersion in mineral oil, 242 mg, 6.1 mmol) 
was added in portions. The white turbid mixture was then slowly warmed to RT and then 
heated to 40°C for 48 h. The reaction was diluted with tBME (20 mL), quenched with aq. sat. 
NH4Cl (30 mL) and the layers were separated. The aq. layer was extracted with tBME (20 
mL) and the combined org. layers were dried (MgSO4), filtered and evaporated under reduced 
pressure. Purification by column chromatography (EtOAc/cHex 1/3) gave the desired 
regioisomer 1.147 (282 mg, 50%). 
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1.146 (O3): Rƒ = 0.29 (EtOAc/cHex 1/3); [α]D = +11.0° (c = 0.8, 
CHCl3); 1H-NMR (250 MHz, CDCl3) δ 10.42 (s, 1H), 6.15 (ddt, 
J = 17.2, 10.3, 5.9 Hz, 1H), 5.45 (ddd, J = 17.1, 1.5, 1.5 Hz, 1H), 
5.33 (dd, J = 9.2, 3.6 Hz, 1H), 5.30 (ddd, J = 10.0, 1.2, 1.2 Hz, 1H), 
4.80 (d, J = 1.7 Hz, 1H), 4.60 (dt, J = 5.9, 1.3 Hz, 2H), 3.86–3.68 
(m, 3H), 3.43 (s, 3H), 3.42 (s, 3H), 3.09 (qd, J = 7.3, 2.0 Hz, 2H), 1.91 (br s, 1H), 1.38 (d, J = 
5.8 Hz, 3H), 1.24 (t, J = 7.4 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 168.9, 155.9, 155.7, 
143.4, 132.9, 121.9, 119.2, 115.8, 112.2, 97.5, 78.2, 76.3, 74.5, 71.0, 68.4, 58. 9, 55.2, 25.9, 
17.7, 14.1; HRMS ESI calcd. for [C20H26Cl2NaO8]+ [M+Na]+: 487.0897; found: 487.0892; 
IR ν = 3376, 2979, 2937, 2834, 2363, 2340, 1736, 1660, 1582, 1548, 1452, 1393, 1302, 1247, 
1224, 1131, 1107, 1059, 968, 812, 766 cm-1. 
1.147 (O4): Rƒ = 0.19 (EtOAc/cHex 1/3); [α]D = +27.5° (c = 0.48, 
CHCl3); 1H-NMR (250 MHz, CDCl3) δ 10.45 (s, 1H), 6.16 (ddt, 
J = 17.1, 10.3, 6.0 Hz, 1H), 5.45 (ddd, J = 17.1, 1.5, 1.5 Hz, 1H), 
5.30 (ddd, J = 10.3, 1.2, 1.2 Hz, 1H), 5.17 (t, J = 9.9 Hz, 1H), 
4.82 (d, J = 1.4 Hz, 1H), 4.59 (dt, J = 5.9, 1.3 Hz, 2H), 3.95 (dd, J = 9.9, 3.7 Hz, 1H), 3.83 
(dq, J = 9.9, 6.2 Hz, 1H), 3.55 (dd, J = 3.7, 1.5 Hz, 1H), 3.52 (s, 3H), 3.41 (s, 3H), 3.03 (qd, 
J = 7.4, 2.0 Hz, 2H), 1.28 (d, J = 6.3 Hz, 3H), 1.24 (d, J = 7.4 Hz, 3H); 13C-NMR (101 MHz, 
CDCl3) δ 169.4, 155.7, 155.5, 142.6, 132.9, 121.7, 119.2, 115.8, 112.6, 97.2, 80.3, 77.4, 74.4, 
69.5, 65.7, 58.9, 55.4, 26.1, 17.7, 14.1; HRMS ESI calcd. for [C20H26Cl2NaO8]+ [M+Na]+: 
487.0897; found: 487.0898; IR ν = 3419, 2982, 2937, 2835, 2361, 1737, 1665, 1583, 1453, 
1413, 1392, 1376, 1313, 1293, 1244, 1224, 1131, 1107, 1068, 1003, 970, 802, 766 cm-1. 
 
(2S,3S,4S,5S,6R)-2-methoxy-6-methyltetrahydro-2H-pyran-3,4,5-triol (1.148)  
To a solution of iodomannopyranoside 1.105 (3.59 g, 12 mmol) in MeOH 
(42 mL), N,N-diisopropylethylamine (6.19 mL, 35 mmol) and Pd(OH)2 
(20wt% on activated carbon, 0.83 g, 1.2 mmol) were added. The dark turbid 
mixture was degassed with argon during 10 minutes, then hydrogen was bubbled through the 
suspension for 0.5 h, and the reaction mixture was subsequently stirred under a hydrogen 
atmosphere for 3 h. The hydrogen atmosphere was exchanged by argon and the solution was 
filtered through Hyflo. The filtrate was evaporated under reduced pressure and purified by 
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column chromatography (MeOH/CH2Cl2 1/10) to yield the rhamnoside 1.148 (2.19 g, quant.) 
as a colourless oil.  
The analytical data matched those reported in the literature: P. Wang, G. J. Shen, Y. F. Wang, Y. 
Ichikawa, C.-H. Wong, J. Org. Chem. 1993, 58, 3985–3990. 
1H-NMR (400 MHz, CD3OD) δ 4.56 (d, J = 1.7 Hz, 1H), 3.78 (dd, J = 3.5, 1.7 Hz, 1H), 3.61 
(dd, J = 9.4, 3.5 Hz, 1H), 3.57–3.48 (m, 1H), 3.38 (pt, J = 9.5 Hz, 1H), 3.35 (s, 3H), 1.27 (d, 
J = 6.2 Hz, 3H); 13C-NMR (101 MHz, CD3OD) δ 102.8, 74.0, 72.4, 72.2, 69.6, 55.1, 18.0.  
 
(2R,3S,4S,5S,6R)-4-hydroxy-5-methoxy-2-methyl-6-((S)-phenylsulfinyl)tetrahydro-2H-
pyran-3-yl 4-(allyloxy)-3,5-dichloro-2-ethyl-6-hydroxybenzoate (1.156) 
The sulfoxide was prepared following the representative 
procedure for 1.168. Purification by column chromatography 
(MeOH/CH2Cl2 1/10) afforded the sulfoxide 1.156 (5 mg, 
81%). 
1H-NMR (400 MHz, CDCl3) δ 10.20 (br s, 1H), 7.69–7.64 (m, 2H), 7.63–7.56 (m, 3H), 6.16 
(ddt, J = 17.2, 10.3, 5.9 Hz, 1H), 5.48 (q, J = 1.5 Hz, 1H), 5.44 (q, J = 1.5 Hz, 1H), 5.33 (q, J 
= 1.2 Hz, 1H), 5.30 (q, J = 1.2 Hz, 1H), 5.28 (t, J = 9.9 Hz, 1H), 4.61 (dt, J = 6.0, 1.3 Hz, 
2H), 4.58 (br s, 1H), 4.35 (dd, J = 10.0, 4.0 Hz, 1H), 4.28 (dq, J = 9.6, 6.1 Hz, 1H), 4.06 (dd, 
J = 4.0, 1.3 Hz, 1H), 3.26 (s, 3H), 3.04 (qd, J = 7.4, 4.8 Hz, 2H), 1.31 (d, J = 6.1 Hz, 3H), 
1.26 (t, J = 7.4 Hz, 3H). 
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(2R,3R,4S,5S,6R)-4-((tert-butyldimethylsilyl)oxy)-5-methoxy-2-methyl-6-(phenylthio)-
tetrahydro-2H-pyran-3-yl 4-(allyloxy)-2-((tert-butyldimethylsilyl)oxy)-3,5-dichloro-6-
ethylbenzoate (1.162) 
To a solution of the rhamnoside 1.145 (102 mg, 0.38 mmol) and 
resorcylate 1.128 (125 mg, 0.38 mmol) in THF (2.5 mL) at 0°C, 
NaH (60% dispersion in mineral oil, 76 mg, 1.9 mmol) was added 
and the mixture was slowly warmed to RT in 30 minutes and 
stirred for 16 h. TBSOTf (63 µL, 1.5 mmol) was then added dropwise. The resulting beige 
suspension was stirred for 3 h then it was quenched with aq. sat. NH4Cl, and extracted with 
Et2O (5x). The combined org. layers were dried (MgSO4), filtered and evaporated. 
Purification by column chromatography (Et2O/pentane 1/10) gave the desired product 1.162 
(157 mg, 54%) as a colourless oil. 
Rƒ = 0.71 (Et2O/pentane 1/8); [α]D = +63.7° (c = 0.5, CHCl3); 1H-NMR (400 MHz, CDCl3) δ 
7.53–7.47 (m, 2H), 7.31–7.23 (m, 3H), 6.15 (ddt, J = 17.1, 10.3, 6.0 Hz, 1H), 5.44 (dq, J = 
17.2, 1.5, 1.5 Hz, 1H), 5.39 (br s, 1H), 5.30 (ddd, J = 10.4, 1.2, 1.2 Hz, 1H), 4.90 (t, J = 
6.4 Hz, 1H), 4.55 (dt, J = 6.0, 1.3 Hz, 2H), 4.25–4.15 (m, 2H), 3.44 (s, 3H), 2.76 (dq, J = 
14.1, 7.2 Hz, 1H), 2.64 (dq, J = 14.5, 7.5 Hz, 1H), 1.46 (d, J = 6.7 Hz, 3H), 1.21 (t, J = 
7.0 Hz, 3H), 1.20 (t, J = 7.4 Hz, 3H), 0.99 (s, 9H), 0.89 (s, 9H), 0.24 (s, 3H), 0.23 (s, 3H), 
0.08 (s, 3H), 0.03 (s, 3H); 13C-NMR (101 MHz, C6D6, HMBC) δ 165.9, 153.8, 149.4, 139.2, 
135.5, 133.4, 131.6 (2C), 129.3 (2C), 127.4, 125.0, 123.0, 120.2, 118.3, 84.4, 81.4, 77.8, 74.2, 
71.2, 69.8, 58.2, 26.7 (3C), 26.2 (3+1C), 19.4, 19.2, 18.6, 14.5, –2.28, –2.60, –4.49, –4.57; 
HRMS ESI calcd. for [C37H56Cl2NaO7SSi2]+ [M+Na]+: 793.2555; found: 793.2564; IR ν = 
2954, 2932, 2887, 2858, 1741, 1560, 1469, 1409, 1239, 1112, 1086, 1006, 969, 835, 779, 741, 
690 cm-1. 
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(2R,3R,4S,5S,6R)-5-methoxy-2-methyl-6-(phenylthio)-4-((2-(trimethylsilyl)ethoxy)-
methoxy)tetrahydro-2H-pyran-3-yl 4-(allyloxy)-3,5-dichloro-2-ethyl-6-((2-(trimethyl-
silyl)ethoxy)methoxy)benzoate (1.163) 
To a solution of the diol 1.142 (73 mg, 0.13 mmol) in DMF 
(1.0 mL) at 0°C, NaH (60% dispersion in mineral oil, 12 mg, 
0.30 mmol,) was added and the mixture was stirred for 30 minutes 
at RT. To the resulting orange solution SEM-Cl (71 µL, 
0.40 mmol) was added dropwise and the beige suspension was stirred for 1.5 h. Then it was 
diluted with tBME (5 mL) and quenched with water (20 mL). The layers were separated and 
the organic layer was washed with water (20 mL) and brine (20 mL). The aq. layers were 
reextracted with tBME (20 mL) and the combined org. layers were dried (MgSO4), filtered 
and evaporated under reduced pressure. Purification by column chromatography (tBME/cHex 
1/10) gave the desired product 1.163 (52 mg, 48%) as a colourless oil. 
Rƒ = 0.24 (Et2O/pentane 1/8); [α]D = +116.6° (c = 0.5, CHCl3); 1H-NMR (400 MHz, CDCl3) 
δ 7.53–7.44 (m, 2H), 7.35–7.24 (m, 3H), 6.16 (ddt, J = 16.3, 10.4, 5.9 Hz, 1H), 5.63 (s, 1H), 
5.45 (dq, J = 17.2, 1.4 Hz, 1H), 5.37 (t, J = 9.4 Hz, 1H), 5.31 (ap dd, J = 10.3, 1.3 Hz, 1H), 
5.17 (s, 2H), 4.85 (d, J = 7.1 Hz, 1H), 4.75 (d, J = 7.1 Hz, 1H), 4.55 (dt, J = 5.9, 1.1 Hz, 2H), 
4.32 (dq, J = 9.7, 6.1 Hz, 1H), 3.95 (s, 1H), 3.96–3.77 (m, 4H), 3.57–3.50 (m, 1H), 3.49 (s, 
3H), 2.75 (ddq, J = 28.2, 13.4, 7.4 Hz, 2H), 1.41 (d, J = 6.2 Hz, 3H), 1.39 (m, 3H), 1.19 (t, J = 
7.4 Hz, 3H), 1.05–0.86 (m, 4H), 0.01 (s, 9H), 0.01 (s, 9H); 13C-NMR (126 MHz, CDCl3) δ 
165.6, 153.2, 149.1, 139.0, 134.7, 133.0, 131.2 (2C), 129.2 (2C), 127.6, 127.5, 125.7, 121.9, 
119.0, 98.8, 95.8, 84.2, 81.0, 76.3, 74.5, 74.4, 68.5, 68.0, 65.9, 58.0, 25.3, 18.5, 18.3, 18.0, 
14.3, –1.25 (3C), –1.27 (3C); HRMS ESI calcd. for [C37H56Cl2NaO9SSi2]+ [M+Na]+: 
825.2453; found: 825.2451; IR ν = 2952, 2892, 1739, 1568, 1389, 1245, 1095, 1031, 935, 
901, 861, 834, 765, 745, 692 cm-1. 
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(2R,3S,4S,5S,6R)-4-hydroxy-5-methoxy-2-methyl-6-(phenylthio)tetrahydro-2H-pyran-3-
yl 2,4-bis(allyloxy)-3,5-dichloro-6-ethylbenzoate (1.164) 
To a suspension of the rhamnose 1.142 (90 mg, 0.17 mmol) and 
K2CO3 (69 mg, 0.50 mmol) in DMF (2.0 mL), allyl bromide 
(22 µL, 0.25 mmol) was added and the suspension was heated to 
50°C for 3 h. It was subsequently diluted with Et2O (5 mL), 
quenched with aq. sat. NH4Cl (50 mL) and extracted with Et2O (3x20 mL). The org. layers 
were washed with brine (40 mL), combined, dried (MgSO4), filtered and evaporated under 
reduced pressure to afford the double allyl-protected product 1.164 (93 mg, 96%) as a 
colourless oil. 
Rƒ = 0.3 (Et2O/pentane 1/3); [α]D = +111.1° (c = 0.54, CHCl3); 1H-NMR (400 MHz, CDCl3) 
δ 7.40–7.36 (m, 2H), 7.26–7.17 (m, 3H), 6.07 (ddt, J = 17.3, 10.4, 5.9 Hz, 2H), 5.97 (ddt, J = 
17.2, 10.3, 5.9, 1H) 5.57 (d, J = 1.2 Hz, 1H), 5.36 (ddd, J = 17.1, 1.5, 1.5 Hz, 1H), 5.30 (ddd, 
J = 17.1, 1.5, 1.5 Hz, 1H), 5.22 (ddd, J = 10.3, 2.6, 1.1 Hz, 1H), 5.17 (ddd, J = 10.3, 2.6, 1.1 
Hz, 1H), 5.10 (dd, J = 9.7, 9.7 Hz, 1H), 4.52 (dddd, J = 11.6, 5.9, 1.4, 1.4 Hz, 1H) 4.48 (ddd, 
J = 5.9, 1.3, 1.3 Hz, 2H) 4.42 (dddd, J = 11.5, 6.0, 1.3, 1.3 Hz, 1H), 4.22 (dq, J = 9.8, 6.2 Hz, 
1H), 3.85 (dd, J = 9.8, 3.6 Hz, 1H), 3.73 (dd, J =3.6, 1.4 Hz, 1H), 3.42 (s, 3H), 3.39 (q, J = 
7.0 Hz, 2H) 2.83–2.66 (m, 2H), 1.25 (d, J = 6.2 Hz, 3H), 1.14 (t, J = 7.4 Hz, 3H); 13C-NMR 
(101 MHz, CDCl3) δ 166.5, 153.3, 151.1, 139.2, 134.1, 132.9, 132.9, 131.4 (2C), 129.3 (2C), 
127.7, 127.3, 125.7, 121.7, 119.1, 113.0, 84.2, 81.9, 76.6, 75.9, 74.4, 70.2, 67.2, 58.3, 25.3, 
17.6, 14.1; HRMS ESI calcd. for [C28H34Cl2NaO7S]+ [M+Na]+: 605.1138; found: 605.1130; 
IR ν = 3548, 2978, 2936, 2883, 1736, 1570, 1402, 1314, 1246, 1099, 998, 929, 841, 742, 692 
cm-1. 
 
(2R,3R,4S,5S,6R)-4-((tert-butyldimethylsilyl)oxy)-5-methoxy-2-methyl-6-(phenylthio)-
tetrahydro-2H-pyran-3-yl 2,4-bis(allyloxy)-3,5-dichloro-6-ethylbenzoate (1.165) 
To a solution of thiorhamnoside 1.141 (6.0 mg, 91 µmol) and 
K2CO3 (1.3 mg, 91 µmol) in DMF (0.5 mL) at RT, allyl bromide 
(one drop) was added. The reaction mixture was stirred for 30 
minutes then it was diluted with Et2O (3 mL) and brine (6 mL), 
and the layers were separated. The aqueous layer was reextraced with Et2O (4x3 mL) and the 
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combined org. layers were dried (MgSO4), filtered and evaporated under reduced pressure 
yielding the title compound 1.165 (7.0 mg, quant.). 
1H-NMR (400 MHz, CDCl3) δ 7.44–7.36 (m, 2H), 7.29–7.20 (m, 3H), 6.04 (dddt, J = 33.3, 
17.2, 10.4, 5.8 Hz, 2H), 5.46 (d, J = 2.5 Hz, 1H), 5.37 (dq, J = 8.7, 1.5 Hz, 1H), 5.33 (dq, J = 
8.8, 1.5 Hz, 1H), 5.23 (dq, J = 10.3, 1.2 Hz, 1H), 5.18 (dq, J = 10.4, 1.3 Hz, 1H), 5.16 (t, J = 
8.7 Hz, 1H), 4.58–4.45 (m, 4H), 4.16 (dq, J = 8.7, 6.3 Hz, 1H), 4.03 (dd, J = 8.6, 3.0 Hz, 1H), 
3.57 (br s, 1H), 3.42 (s, 3H), 2.75 (dq, J = 13.2, 7.4 Hz, 1H), 2.51 (dq, J = 13.1, 7.3 Hz, 1H), 
1.31 (d, J = 6.4 Hz, 3H), 1.14 (t, J = 7.4 Hz, 3H), 0.82 (s, 9H), 0.00 (s, 2H), 0.00 (s, 1H), -
0.07 (s, 1H), -0.10 (s, 2H). 
 
(2R,3R,4S,5S,6R)-4-((tert-butyldimethylsilyl)oxy)-5-methoxy-2-methyl-6-((S)-
phenylsulfinyl)tetrahydro-2H-pyran-3-yl 4-(allyloxy)-2-((tert-butyldimethylsilyl)oxy)-
3,5-dichloro-6-ethylbenzoate (1.166) 
The sulfoxide was prepared following the representative 
procedure for 1.168. Purification by column chromatography 
(MeOH/CH2Cl2 1/20) afforded the sulfoxide 1.166 (15 mg, 
80%) as a mix of epimers (1:4, calcd. from 1H-NMR). 
Rƒ = 0.33 (Et2O/pentane 1/3); 1H-NMR (400 MHz, CDCl3, major epimer) δ 7.64–7.58 (m, 
2H), 7.53–7.43 (m, 3H), 6.15 (ddt, J = 17.3, 10.3, 5.9 Hz, 1H), 5.44 (dq, J = 17.1, 1.5 Hz, 
1H), 5.30 (dq, J = 10.4, 1.2 Hz, 1H), 4.87 (t, J = 4.6 Hz, 1H), 4.73 (d, J = 7.1 Hz, 1H), 4.55 
(dt, J = 6.0, 1.3 Hz, 2H), 4.29 (dd, J = 4.4, 2.8 Hz, 1H), 4.22–4.15 (m, 1H), 3.71 (dd, J = 7.1, 
2.8 Hz, 1H), 3.22 (s, 3H), 2.69–2.55 (m, 2H), 1.47 (d, J = 6.8 Hz, 3H), 1.15 (t, J = 7.5 Hz, 
3H), 0.98 (s, 9H), 0.87 (s, 9H), 0.21 (s, 3H), 0.21 (s, 3H), 0.05 (s, 3H), 0.02 (s, 3H); IR ν = 
2931, 2885, 2858, 1737, 1561, 1472, 1408, 1239, 1119, 1090, 1043, 970, 836, 779, 748, 690 
cm-1. 
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(2R,3R,4S,5S,6R)-5-methoxy-2-methyl-6-((R)-phenylsulfinyl)-4-((2-
(trimethylsilyl)ethoxy)methoxy)tetrahydro-2H-pyran-3-yl 4-(allyloxy)-3,5-dichloro-2-
ethyl-6-((2-(trimethylsilyl)ethoxy)methoxy)benzoate (1.167) 
The sulfoxide was prepared following the representative 
procedure for 1.168. Purification by preperative TLC 
(Et2O/pentane 1/1) afforded the sulfoxide 1.167 (5 mg, 82%) as 
a single of epimer. 
Rƒ = 0.57 (Et2O/pentane 1/1); 1H-NMR (400 MHz, CDCl3) δ 7.68–7.61 (m, 2H), 7.59–7.51 
(m, 3H), 6.16 (ddt, J = 16.5, 10.3, 5.9 Hz, 1H), 5.46 (dq, J = 17.1, 1.6 Hz, 1H), 5.37 (dd, J = 
9.4, 9.4 Hz, 1H), 5.31 (dq, J = 10.4, 1.4 Hz, 1H), 5.16 (s, 2H), 4.84 (d, J = 7.0 Hz, 1H), 4.80 
(d, J = 6.9 Hz, 1H), 4.56 (dt, J = 5.9, 1.3 Hz, 2H), 4.53 (d, J = 1.9 Hz, 1H), 4.33 (dd, J = 9.3, 
3.4 Hz, 1H), 4.24–4.15 (m, 2H), 3.94–3.71 (m, 3H), 3.58–3.46 (m, 1H), 3.28 (s, 3H), 2.83–
2.64 (m, 2H), 1.39 (d, J = 6.2 Hz, 3H), 1.19 (t, J = 7.5 Hz, 3H), 1.02–0.82 (m, 4H), 0.02 (s, 
9H), –0.01 (s, 9H). 
 
 (2R,3S,4S,5S,6R)-4-hydroxy-5-methoxy-2-methyl-6-((S)-phenylsulfinyl)tetrahydro-2H-
pyran-3-yl 2,4-bis(allyloxy)-3,5-dichloro-6-ethylbenzoate (1.168) 
To a solution of thioglycoside 1.164 (105 mg, 0.18 mmol) in 
CH2Cl2 (5 mL) at –78°C, mCPBA (34.0 mg, 0.20 mmol) was 
added. The solution was stirred at this temperature for 1.5 h and 
then slowly warmed to –50°C and stirred for 3 h. At this 
temperature the reaction mixture was quenched with aq. sat. NaHCO3 (20 mL) and extracted 
with CH2Cl2 (3x20 mL), dried (MgSO4), filtered and evaporated under reduced pressure. The 
residue was purified by column chromatography (EtOAc/cHex 1/2) to yield the epimers 
(1:20, calcd. from 1H-NMR) of sulfoxide 1.168 (96.0 mg, 89%) as colourless oil. 
Rƒ = 0.21 (EtOAc/cHex 1/2); 1H-NMR (400 MHz, CDCl3, major epimer) δ 7.67–7.60 (m, 
2H), 7.61–7.22 (m, 3H), 6.16 (ddt, J = 17.0, 10.3, 5.9 Hz, 1H), 6.04 (ddt, J = 16.3, 10.4, 
6.0 Hz, 1H), 5.45 (ddd, J = 17.2, 3.0, 1.5 Hz, 1H), 5.38 (ddd, J = 17.2, 2.8, 1.4 Hz, 1H), 5.31 
(ddd, J = 10.3, 2.2, 1.1 Hz, 1H), 5.25 (ddd, J = 10.4, 2.8, 1.4 Hz, 1H), 5.19 (dd, J = 9.8, 
9.8 Hz, 1H), 4.61 (dddd, J = 11.6, 5.9, 1.2, 1.2 Hz 1H), 4.56 (ddd, J = 6.0, 1.1, 1.1 Hz, 2H), 
O
O
O
OAllyl
Cl
AllylO
Cl
HO S(O)Ph
Et
OMe
O
O
O
OSEM
Cl
AllylO
Cl
SEMO S(O)Ph
Et
OMe
 Experimental Part 147  
4.54 (s, 1H), 4.48 (dddd, J = 11.5, 6.1, 1.2, 1.2 Hz, 2H), 4.25 (dd, J = 9.9, 3.1 Hz, 1H), 4.19–
4.06 (m, 2H), 3.33 (s, 3H), 2.91–2.74 (m, 2H), 1.31 (d, J = 6.1 Hz, 3H), 1.21 (t, J = 7.4 Hz, 
3H); 13C-NMR (101 MHz, CDCl3, HMBC) δ 166.4, 153.4, 151.1, 139.3, 132.9, 132.9, 131.8, 
129.6 (2C), 127.1, 125.8, 124.5 (2C), 121.7, 119.1, 119.0, 100.1, 95.0 (HMQC), 77.4, 75.9, 
75.3, 74.5, 72.8, 70.1, 58.3, 25.3, 18.0, 14.2; HRMS ESI calcd. for [C28H32Cl2NaO8S]+ 
[M+Na]+: 621.1087; found: 621.1085; IR ν = 3359, 3084, 2977, 2938, 2879, 1736, 1569, 
1444, 1402, 1314, 1247, 1124, 1103, 1039, 998, 932, 747, 691 cm-1. 
 
(2R,3S,4S,5S,6R)-4-hydroxy-5-methoxy-2-methyl-6-((E)-2,2,2-trifluoro-1-(phenylimino)-
ethoxy)tetrahydro-2H-pyran-3-yl 2,4-bis(allyloxy)-3,5-dichloro-6-ethylbenzoate (1.169) 
To a solution of rhamnose 1.173 (4.5 mg, 9.2 µmol) in 
acetone (0.3 mL, techn.), K2CO3 (5.0 mg, 0.40 mmol) was 
added. The white suspension was cooled to 0°C and 
ClC(NPh)CF3 (1.7 µL, 10 µmol) in acetone (0.1 mL) was 
added dropwise. Then the reaction mixture was stirred at RT for 3 h. The suspension was 
diluted with toluene (1 mL), filtered and evaporated under reduced pressure. Purification by 
preparative TLC (EtOAc/cHex 1/4) afforded the imidate 1.169 (6.0 mg, 98%) as a colourless 
oil. 
Rƒ = 0.5 (EtOAc/cHex 1/4); [α]D = +20.2° (c = 0.07, CHCl3); 1H-NMR (400 MHz, Acetone-
d6) δ 7.42–7.32 (m, 2H), 7.18–7.12 (m, 1H), 6.99–6.89 (m, 2H), 6.24 (br, 1H), 6.23–6.02 (m, 
2H), 5.46 (ddd, J = 17.2, 1.6, 1.6 Hz, 1H), 5.40 (ddd, J = 17.2, 1.6, 1.6 Hz, 1H), 5.31–5.23 
(m, 2H), 5.19 (dd J = 10.0, 10.0 Hz, 1H), 4.68–4.58 (m, 3H), 4.54 (dddd, J = 11.8, 5.7, 1.4, 
1.4 Hz, 2H), 4.20 (d, J = 9.4, 1H), 4.04–3.88 (m, 2H), 3.83 (br, 1H), 3.50 (br, 3H), 2.92–2.75 
(m, 2H), 1.35–1.26 (m, 3H), 1.17 (t, J = 7.4 Hz, 3H); HRMS ESI calcd. for 
[C30H32Cl2F3NaO8]+ [M+Na]+: 684.1349; found: 684.1348; IR ν = 3546, 2981, 2937, 1737, 
1569, 1454, 1404, 1330, 1316, 1249, 1211, 1164, 1118, 1024, 2012, 975, 929, 777, 752, 695 
cm-1. 
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(2R,3S,4S,5S,6R)-4-hydroxy-5-methoxy-2-methyl-6-(phenylthio)tetrahydro-2H-pyran-3-
yl 2,4-bis(allyloxy)-3,5-dichloro-6-ethylbenzoate (1.172) 
To a suspension of the rhamnose 1.147 (32.0 mg, 68 µmol) and 
K2CO3 (14.3 mg, 0.10 mmol) in DMF (0.4 mL), allyl bromide 
(9 µL, 0.10 mmol) was added and the suspension was heated to 
50°C for 1 h. Then it was diluted with tBME (2 mL), quenched 
with aq. sat. NH4Cl (5 mL) and extracted with tBME (3x5 mL). The org. layers were washed 
with brine (2x10 mL), combined, dried (MgSO4), filtered and evaporated under reduced 
pressure to afford the double allyl-protected product 1.172 (32.0 mg, 92%) as a colourless oil. 
Rƒ = 0.53 (EtOAc/cHex 1/2). [α]D = +9.9° (c = 1.07, CHCl3); 1H-NMR (400 MHz, CDCl3) δ 
6.14 (ddt, J = 17.1, 10.4, 5.9 Hz, 1H), 6.04 (ddt, J = 17.3, 10.3, 6.0 Hz, 1H), 5.43 (ddd, J = 
17.2, 1.5, 1.5 Hz, 1H), 5.37 (ddd, J = 17.2, 1.5, 1.5 Hz, 1H), 5.29 (ddd, J = 10.3, 1.2, 1.2 Hz, 
1H), 5.24 (ddd, J = 10.3, 1.2, 1.2 Hz, 1H), 5.07 (t, J = 9.8 Hz, 1H), 4.79 (d, J = 1.5 Hz, 1H), 
4.58 (ddt, J = 11.5, 5.9, 1.5 Hz, 1H), 4.54 (dt, J = 5.9, 1.4 Hz, 2H), 4.48 (ddt, J = 11.5, 6.0, 
1.3 Hz, 1H), 3.88 (dd, J = 9.8, 3.7 Hz, 1H), 3.75 (dq, J = 9.8, 6.3 Hz, 1H), 3.53–3.50 (m, 1H), 
3.51 (s, 3H), 3.36 (s, 3H), 2.91–2.72 (m, 2H), 2.33 (br s, 1H), 1.31 (d, J = 6.3 Hz, 3H), 1.19 (t, 
J = 7.4 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 166.5, 153.2, 151.1, 139.2, 132.9, 132.9, 
127.4, 125.6, 121.6, 119.0, 118.9, 97.4, 80.5, 76.6, 75.9, 74.4, 69.7, 65.8, 59.1, 55.1, 25.3, 
17.7, 14.1; HRMS ESI calcd. for [C23H30Cl2KO8]+ [M+K]+: 543.0949; found: 543.0948. IR 
ν = 3508, 2979, 2937, 2835, 1735, 1569, 1460, 1403, 1316, 1249, 1134, 1107, 1067, 1005, 
973, 931, 803, 748 cm-1. 
 
 (2R,3S,4S,5S)-4,6-dihydroxy-5-methoxy-2-methyltetrahydro-2H-pyran-3-yl 
2,4-bis(allyloxy)-3,5-dichloro-6-ethylbenzoate (1.173) 
To a solution of thioglycoside 1.164 (17.5 mg, 30 µmol) in 
acetone (1.0 mL) and H2O (0.1 mL) at 0°C, NBS (5.9 mg, 
30 µmol) was added. The orange reaction mixture was stirred at 
0°C for 15 minutes then it was warmed to RT. The colourless 
solution was treated with NBS in the same manner until full consumption of the starting 
material was observed by TLC. The reaction mixture was quenched with aq. sat. NaHCO3 
(10 mL) extracted with CH2Cl2 (3x10 mL), and the combined org. layers were dried 
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(MgSO4), filtered and evaporated under reduced pressure. Purification by column 
chromatography (EtOAc/cHex 1/4 to 1/2) gave the desired pyranose 1.173 (14.0 mg, 95%, 
α:β = 5:1) as a colourless oil of inseparable anomers.  
Or 
A solution of the rhamnoside 1.172 (277 mg, 0.55 mmol) in acetic acid (12.0 mL), HCl (1M, 
5 mL) and water (2.5 mL) was heated to 120°C in a µw-oven for 3 h. Then it was diluted with 
water (40 mL), and extracted with tBME (2x40 mL), washed with aq. sat. NaHCO3 (40 mL), 
and the combined org. layers were dried (MgSO4), filtered and evaporated under reduced 
pressure. Purification by column chromatography (tBME/cHex 1/1) gave the title compound 
1.173 (140 mg, 52%, 57% brsm) as colourless oil. 
Rƒ = 0.18 (EtOAc/cHex 1/2); 1H-NMR (400 MHz, CDCl3, major anomer) δ 6.15 (ddt, J = 
16.4, 10.4, 5.9 Hz, 1H), 6.05 (ddt, J = 16.4, 10.4, 6.0 Hz, 1H), 5.44 (ddd, J = 17.1, 1.4, 
1.4 Hz, 1H), 5.39 (ddd, J = 17.1, 1.4, 1.4 Hz, 1H), 5.35 (s, 1H), 5.32 (ddd, J = 10.3. 1.2, 
1.2 Hz, 1H), 5.27 (ddd, J = 10.4, 1.3, 1.3 Hz, 1H), 5.09 (dd J = 9.8, 9.8 Hz, 1H), 4.60 (dddd, 
J = 11.5, 5.9, 1.3, 1.3 Hz, 1H), 4.57 (ddd, J = 6.0, 1.3, 1.3 Hz, 2H), 4.51 (dddd, J = 11.5, 6.1, 
1.3, 1.3 Hz, 1H), 4.03 (dq, J = 9.8, 6.2 Hz, 1H) 3.99 (dd, J = 9.8, 3.7 Hz, 1H), 3.58 (dd, J = 
3.6, 1.5 Hz, 1H), 3.53 (s, 3H), 2.89–2.73 (m, 2H), 1.30 (d, J = 6.2 Hz, 3H), 1.20 (t, J = 7.4 Hz, 
3H); 13C-NMR (101 MHz, CDCl3, major anomer) δ 166.6, 153.2, 151.1, 139.2, 132.9, 132.9, 
127.4, 125.7, 121.7, 119.1, 119.0, 91.1, 80.7, 75.6, 75.9, 74.5, 69.3, 66.1, 59.2, 25.3, 17.8, 
14.1; HRMS ESI calcd. for [C22H28Cl2NaO8]+ [M+Na]+: 513.1053; found: 513.1052; IR ν = 
3442, 2936, 1734, 1567, 1460, 1403, 1315, 1248, 1100, 1065, 1041, 995, 930, 798, 748 cm-1. 
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4.1.3 Glycosylations and End-Game 
General procedure for the rhamnosylation using NIS:  
To a solution of the thioglycoside (1.0 eq) and ethyl 2-(hydroxymethyl)acrylate (1.0 eq) in 
CH2Cl2 (0.05 M), powdered m.s. 3Å (50 mg/mL) was added. The white suspension was 
stirred for 0.5 h and then cooled to –78°C. N-Iodosuccinimide (1.2 eq) and AgOTf (0.1 eq) 
was added and the mixture was stirred for 1 h at that temperature. The white suspension was 
slowly warmed to 0°C (or –30°C) and was kept at that temperature until TLC indicated full 
conversion (reaction mixtures turn orange to red). The reaction mixture was then diluted with 
CH2Cl2, quenched with aq. sat. NH4Cl and aq. sat. Na2S2O3 and the layers were separated, the 
aq. layer was reextracted with CH2Cl2, the org. layer was dried (MgSO4), filtered and 
evaporated. The crude products were purified as described in the specific procedures. 
 
(2R,3S,4S,5S,6S)-6-((2-(ethoxycarbonyl)allyl)oxy)-4-hydroxy-5-methoxy-2-methyl-
tetrahydro-2H-pyran-3-yl 4-(allyloxy)-3,5-dichloro-2-ethyl-6-hydroxybenzoate (α-1.158) 
(2R,3S,4S,5S,6R)-6-((2-(ethoxycarbonyl)allyl)oxy)-4-hydroxy-5-methoxy-2-methyl-
tetrahydro-2H-pyran-3-yl 4-(allyloxy)-3,5-dichloro-2-ethyl-6-hydroxybenzoate (β-1.158) 
The glycosylation with the donor 1.142 was performed following the general procedure (see 
above). Purification by column chromatography (EtOAc/cHex 1/4) gave an anomeric mixture 
of 1.158 (3.9 mg, 94%, α:β = 1:2) as a colourless oil. 
For further characterization the anomeric mixture was separated by preparative TLC 
(tBME/cHex 1/1). 
α-1.158: Rƒ = 0.37 (tBME/cHex 1/1); [α]D = +12.2° (c = 
0.35, CHCl3); 1H-NMR (400 MHz, CDCl3) δ 10.35 (s, 
1H), 6.33 (d, J = 1.3 Hz, 1H), 6.16 (ddt, J = 17.2, 10.4, 
6.0 Hz, 1H), 5.84 (d, J = 1.5 Hz, 1H), 5.45 (dq, J = 17.1, 
1.5 Hz, 1H), 5.30 (dq, J = 10.4, 1.1 Hz, 1H), 5.18 (t, J = 
9.8 Hz, 1H), 5.02 (d, J = 1.2 Hz, 1H), 4.59 (dt, J = 5.9, 1.2 Hz, 2H), 4.46 (dt, J = 13.5, 1.3 Hz, 
1H), 4.29–4.17 (m, 3H), 4.05–3.94 (m, 1H), 3.90 (dq, J = 9.7, 6.2 Hz, 1H), 3.59 (dd, J = 3.7, 
1.5 Hz, 1H), 3.52 (s, 3H), 3.09–2.94 (m, 2H), 2.45 (br d, J = 11.2 Hz, 1H), 1.32 (t, J = 7.1 Hz, 
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3H), 1.28 (d, J = 6.2 Hz, 3H), 1.22 (t, J = 7.4 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 169.3, 
165.6, 155.6, 155.5, 142.5, 136.9, 132.9, 126.5, 121.7, 119.2, 115.8, 112.7, 95.8, 80.3, 76.8, 
74.4, 69.5, 66.1, 66.1, 61.1, 59.0, 26.1, 17.7, 14.4, 14.1; HRMS ESI calcd. for 
[C25H32Cl2NaO10]+ [M+Na]+: 585.1265; found: 585.1265; IR ν = 3416, 2981, 2931, 2361, 
2342, 1715, 1665, 1582, 1550, 1459, 1412, 1392, 1372, 1310, 1269, 1213, 1189, 1129, 1106, 
1068, 1053, 1001, 965, 802, 766, 745, 718 cm-1. 
β-1.158: Rƒ = 0.45 (tBME/cHex 1/1); [α]D = –39.4° (c = 
0.31, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 10.33 (s, 
1H), 6.34 (q, J = 1.4 Hz, 1H), 6.15 (ddt, J = 16.6, 10.3, 
5.9 Hz, 1H), 5.89 (q, J = 1.7 Hz, 1H), 5.45 (dq, J = 17.1, 
1.5 Hz, 1H), 5.30 (dq, J = 10.2, 1.2 Hz, 1H), 5.15 (t, J = 9.4 Hz, 1H), 4.65 (dt, J = 13.9, 
1.5 Hz, 1H), 4.62 (s, 1H), 4.59 (dt, J = 5.9, 1.3 Hz, 2H), 4.31 (dt, J = 14.0, 1.5 Hz, 1H), 4.24 
(q, J = 7.1 Hz, 2H), 3.71 (s, 3H), 3.74–3.68 (m, 2H), 3.51 (dq, J = 9.4, 6.1 Hz, 1H), 3.01 (p, 
J = 7.5 Hz, 2H), 2.60 (br d, J = 11.1 Hz, 1H), 1.34 (d, J = 6.2 Hz, 3H), 1.32 (t, J = 7.4 Hz, 
3H), 1.22 (t, J = 7.4 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 169.3, 165.7, 155.7, 155.5, 
142.4, 136.8, 132.9, 126.2, 121.7, 119.2, 115.8, 112.6, 101.5, 80.4, 76.7, 74.5, 71.9, 70.1, 
68.3, 62.3, 61.0, 26.1, 17.7, 14.4, 14.1; HRMS ESI calcd. for [C25H32Cl2NaO10]+ [M+Na]+: 
585.1265; found: 585.1264; IR ν = 3421, 2981, 2917, 2849, 2360, 2341, 1713, 1665, 1582, 
1550, 1455, 1392, 1371, 1307, 1266, 1213, 1198, 1178, 1108, 1071, 1020, 965, 855, 802, 768, 
745 cm-1. 
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(2R,3S,4S,5S,6S)-6-((2-(ethoxycarbonyl)allyl)oxy)-4-hydroxy-5-methoxy-2-methyl-
tetrahydro-2H-pyran-3-yl 2,4-bis(allyloxy)-3,5-dichloro-6-ethylbenzoate (α-1.164b) 
(2R,3S,4S,5S,6R)-6-((2-(ethoxycarbonyl)allyl)oxy)-4-hydroxy-5-methoxy-2-methyl-
tetrahydro-2H-pyran-3-yl 2,4-bis(allyloxy)-3,5-dichloro-6-ethylbenzoate (β-1.164b) 
The glycosylation with the donor 1.164 was performed following the general procedure (see 
above). Purification by column chromatography (tBME/cHex 1/3) gave the partially separated 
anomers (16 mg, 77%, α:β = 5:6) as a colourless oil. 
α-1.164b: Rƒ = 0.33 (tBME/cHex 1/1); [α]D = +6.0° (c = 
0.23, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 6.32 (d, 
J = 1.2 Hz, 1H), 6.17 (ddt, J = 17.1, 10.3, 5.9 Hz, 1H), 
6.06 (ddt, J = 17.0, 10.4, 6.0 Hz, 1H), 5.82 (q, J = 
1.5 Hz, 1H), 5.46 (dq, J = 17.2, 1.4 Hz, 1H), 5.39 (dq, J = 17.2, 1.4 Hz, 1H), 5.32 (dq, J = 
10.4, 1.2 Hz, 1H), 5.27 (dd, J = 10.3, 1.4 Hz, 1H), 5.11 (t, J = 9.8 Hz, 1H), 5.01 (d, J = 
1.3 Hz, 1H), 4.60 (ddt, J = 11.5, 6.0, 1.2 Hz, 1H), 4.57 (dt, J = 5.9, 1.2 Hz, 2H), 4.50 (ddt, J = 
11.5, 6.1, 1.2 Hz, 1H), 4.42 (dt, J = 13.7, 1.3 Hz, 2H), 4.27–4.18 (m, 3H), 3.95 (br s, 1H), 
3.83 (dq, J = 9.9, 6.3 Hz, 1H), 3.58 (dd, J = 3.7, 1.5 Hz, 1H), 3.54 (s, 3H), 2.90–2.75 (m, 2H), 
1.36–1.28 (m, 6H), 1.22 (q, J = 7.5, 7.0 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 166.5, 
165.7, 153.2, 151.1, 139.2, 136.9, 133.0, 132.9, 127.4, 126.3, 125.67, 121.7, 119.1, 119.0, 
96.1, 80.5, 76.5, 75.9, 74.5, 69.8, 66.3, 66.0, 61.0, 59.2, 25.3, 17.7, 14.3, 14.1; HRMS ESI 
calcd. for [C28H36Cl2NaO10]+ [M+Na]+: 625.1578; found: 625.1578; IR ν = 3493, 2979, 2934, 
1718, 1636, 1568, 1462, 1402, 1370, 1353, 1313, 1276, 1248, 1178, 1130, 1106, 1066, 995, 
973, 931, 802, 748, 721 cm-1. 
β-1.164b: Rƒ = 0.40 (tBME/cHex 1/1); [α]D = –37.3° 
(c = 0.45, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 6.33 
(q, J = 1.2 Hz, 1H), 6.15 (ddt, J = 17.1, 10.4, 5.9 Hz, 
1H), 6.04 (ddt, J = 17.0, 10.4, 6.0 Hz, 1H), 5.89 (q, J = 
1.6 Hz, 1H), 5.44 (dq, J = 17.2, 1.4 Hz, 1H), 5.37 (dq, J = 17.2, 1.4 Hz, 1H), 5.30 (dq, J = 
10.4, 1.1 Hz, 1H), 5.25 (dq, J = 10.4, 1.4 Hz, 1H), 5.06 (t, J = 9.5 Hz, 1H), 4.65 (dt, J = 14.1, 
1.6 Hz, 1H), 4.58 (ddt, J = 11.4, 5.6, 1.3 Hz, 1H), 4.56 (s, 1H), 4.55 (dt, J = 5.9, 1.2 Hz, 2H), 
4.47 (ddt, J = 11.5, 6.1, 1.2 Hz, 1H), 4.29 (dt, J = 14.1, 1.4 Hz, 1H), 4.24 (q, J = 7.1 Hz, 2H), 
3.70 (s, 3H), 3.66 (d, J = 3.6 Hz, 1H), 3.63 (br s, 1H), 3.42 (dq, J = 9.6, 6.2 Hz, 1H), 2.87–
2.74 (m, 2H), 2.60 (br s, 1H), 1.37 (d, J = 6.2 Hz, 3H), 1.37 (t, J = 7.1 Hz, 3H), 1.19 (t, J = 
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7.5 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 166.4, 165.8, 153.3, 151.1, 139.2, 136.9, 133.0, 
132.9, 127.3, 126.0, 125.7, 121.7, 119.1, 101.4, 80.6, 76.4, 75.9, 74.5, 72.2, 70.3, 68.2, 62.3, 
61.0, 29.9, 25.3, 17.6, 14.4, 14.1; HRMS ESI calcd. for [C28H36Cl2NaO10]+ [M+Na]+: 
625.1578; found: 625.1576; IR ν = 3497, 2971, 2932, 1733, 1707, 1648, 1572, 1457, 1403, 
1372, 1310, 1251, 1201, 1166, 1141, 1110, 1082, 1038, 1022, 992, 932, 856, 776, 751 cm-1.  
 
(2R,3R,4S,5S,6S)-4-((tert-butyldimethylsilyl)oxy)-6-((2-(ethoxycarbonyl)allyl)oxy)-5-
methoxy-2-methyltetrahydro-2H-pyran-3-yl 4-(allyloxy)-2-((tert-butyldimethylsilyl)oxy)-
3,5-dichloro-6-ethylbenzoate (α-1.167) 
(2R,3R,4S,5S,6R)-4-((tert-butyldimethylsilyl)oxy)-6-((2-(ethoxycarbonyl)allyl)oxy)-5-
methoxy-2-methyltetrahydro-2H-pyran-3-yl 4-(allyloxy)-2-((tert-butyldimethylsilyl)oxy)-
3,5-dichloro-6-ethylbenzoate (β-1.167) 
The glycosylation with the donor 1.162 was performed 
following the general procedure, the reaction was 
warmed to –30°C and was kept for 30 minutes at this 
temperature before workup. Purification by column 
chromatography (tBME/cHex 1/10) gave the anomers 
1.167 as an inseparable mixture (14 mg, 68%, α:β = 
5:1). 
 
For further structural confirmation the anomeric mixture was deprotected and compared with 
α-1.158 and β-1.158: 
To a solution of the TBS-protected anomeric mixture of 1.167 (14 mg, 18 µmol) in THF 
(0.4 mL), Et3N·3HF (60 µL, excess) was added. The colourless solution was heated to 50°C 
for 6 h. Then the yellow solution was poured on aq. sat. NaHCO3 (5 mL) and extracted with 
tBME (2x2 mL). The org. layers were dried (MgSO4), filtered and evaporated under reduced 
pressure giving an anomeric mixture of α-1.158 and β-1.158 (7 mg, 70%, α:β = 4.5:1). 
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(3aS,4R,7S,7aS)-4-(((1E,3R,4S,5E,7S)-7-((tert-butyldimethylsilyl)oxy)-4-ethyl-1-iodo-2,6-
dimethyldeca-1,5,9-trien-3-yl)oxy)-6,6-dimethyl-2-oxotetrahydro-4H-[1,3]dioxolo[4,5-
c]pyran-7-yl isobutyrate (1.185) 
To a solution of novioside 1.102 (50.0 mg, 0.17 mmol) in CH2Cl2 (1.0 mL) at 0°C and 
protected from light, HBr (33% in AcOH, 1.0 mL) was added. The solution was stirred for 2 h 
at RT before it was cooled to 5°C and diluted with CH2Cl2 (3 mL). The reaction was 
quenched with ice and H2O. The layers were separated and the org. layer was washed with aq. 
sat. NaHCO3 (8 mL) The aq. solutions were extracted with CH2Cl2 (2x3 mL) and the 
combined org. layers were dried (Na2SO4), filtered and evaporated under reduced pressure at 
RT. The residual glycosyl bromide 16 was dissolved in CH2Cl2 (0.5 mL) and added dropwise 
to a suspension of alcohol 1.184 (50.0 mg, 0.11 mmol), HgO (152 mg, 0.70 mmol), HgBr2 
(5.8 mg, 20 µmol) and powdered molecular sieves 3Å (100 mg) in CH2Cl2 (0.6 mL) over 
20 minutes. The orange suspension was stirred for 50 minutes before it was diluted with 
CHCl3 (2 mL), filtered through silica gel and washed with CHCl3 (2 mL). The filtrate was 
evaporated under reduced pressure and the residue was suspended in CHCl3 (0.4 mL) and 
filtered through cotton. The filtrate was diluted with CHCl3 (5 mL), washed with aq. sat. 
NaHCO3 (5 mL), dried (Na2SO4), filtrated and evaporated under reduced pressure. 
Purification by column chromatography (EtOAc/cHex 1/10) afforded the anomer β-1.185 (37 
mg, 48%) and further purification by column chromatography (Et2O/pentane 1/10) yielded 
the other anomer α-1.185 (12 mg, 15%). 
β-1.185: Rƒ = 0.38 (EtOAc/cHex 1/4); [α]D = –23.1° (c = 0.22, 
CHCl3); 1H-NMR (400 MHz, CDCl3) δ 6.22 (d, J = 0.9 Hz, 
1H), 5.79 (ap dd, 4.0, 2.9 Hz, 1H) 5.75–5.62 (m, 1H), 5.03–
4.97 (m, 3H), 4.86 (d, J = 10.5 Hz, 1H), 4.79–4.76 (m, 2H), 
3.94 (dd, J = 6.1, 6.1 Hz, 1H), 3.82 (d, J = 9.3 Hz, 1H), 2.62 
(hept, J = 7.0 Hz, 1H), 2.58–2.48 (m, 1H), 2.27–2.14 (m, 2H), 1.92–1.78 (m, 1H), 1.78 (d, J = 
0.9, 3H), 1.57 (d, J = 1.2, 3H), 1.21 (d, J = 6.9, 6H), 1.16 (s, 3H), 1.14 (s, 3H), 0.87 (s, 9H) 
0.81 (t, J = 7.4, 3H), 0.01 (s, 3H), –0.03 (s, 3H); 13C-NMR (101 MHz, CDCl3) δ 175.2, 
153.8, 147.6, 140.0, 135.6, 123.6, 116.5, 95.3, 89.8, 81.6, 75.7, 75.1, 72.1, 71.8, 42.6, 42.0, 
34.1, 28.0, 26.0 (3C), 25.6, 28.8, 24.3, 19.8, 19.1, 18.8, 18.3, 12.8, 11.2, –4.2, –4.7; HRMS 
ESI calcd. for [C32H53INaO8Si]+ [M+Na]+: 743.2447; found: 743.2445; IR ν = 2954, 2929, 
2856, 1818, 1749, 1468, 1389, 1253, 1145, 1091, 1074, 1034, 915, 837, 775 cm-1. 
OOTBS
I
O
O
O
O
O iPr
O
 Experimental Part 155  
α-1.185: Rƒ = 0.56 (EtOAc/cHex 1/4); [α]D = +31.6° (c = 0.8, 
CHCl3); 1H-NMR (400 MHz, CDCl3) δ 6.23 (d, J = 1.0 Hz, 
1H), 5.70 (dddd, J = 17.2, 10.2, 7.1, 7.1 Hz, 1H), 5.13 (d, J = 
8.3 Hz, 1H), 5.04–4.98 (m, 2H), 4.90 (ap d, J = 10.5 Hz, 1H), 
4.78 (dd, J = 8.3, 8.3 Hz, 1H), 4.78 (d, J = 5.2 Hz, 1H), 4.66 
(dd, J = 8.4, 5.2 Hz, 1H), 4.06 (d, J = 9.2 Hz, 1H), 3.95 (dd, J = 6.1, 6.1 Hz, 1H), 2.63 (hept, J 
= 7.0 Hz, 1H), 2.53–2.45 (m, 1H), 2.27–2.15 (m, 2H), 1.85–1.76 (m, 1H), 1.67 (d, J = 1.1 Hz, 
3H), 1.57 (d, J = 1.3 Hz, 3H), 1.25 (s, 3H), 1.24 (s, 3H), 1.21 (d, J = 1.3 Hz, 3H), 1.20 (d, J = 
1.3 Hz, 3H), 1.18–1.10 (m, 1H), 0.88 (s, 9H), 0.80 (t, J = 7.4 Hz, 3H), 0.01 (s, 3H), –0.02 (s, 
3H); 13C-NMR (101 MHz, CDCl3) δ 175.5, 153.2, 145.4, 139.8, 135.5, 123.7, 116.4, 91.8, 
83.9, 82.3, 77.5, 76.6, 75.6, 74.8, 72.0, 41.9, 41.5, 33.9, 25.9 (3C), 25.8, 25.0, 23.8, 18.9, 
18.7, 18.7, 18.2, 12.5, 10.9, –4.28, –4.85; HRMS ESI calcd. for [C32H53INaO8Si]+ [M+Na]+: 
743.2447; found: 743.2451; IR ν = 2954, 2931, 2858, 1831, 1748, 1468, 1389, 1253, 1138, 
1080, 1037, 914, 837, 777 cm-1. 
 
(2R,3S,Z)-2-((tert-butyldimethylsilyl)oxy)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)hept-5-en-3-ol (1.41)  
This compound was synthesized and characterized by Hiromu Hattori. 
CuCl (15.6 mg, 0.15 mmol, 5 mol%), PPh3 (46.0 mg, 0.18 mmol, 
6 mol%) and KOtBu (67 mg, 0.59 mmol, 20 mol%) were dissolved in 
THF (8.0 mL) and stirred at RT for 30 min, forming a brown solution. 
(Bpin)2 (824 mg, 3.25 mmol) in THF (10.0 mL) was added and the reaction mixture was 
stirred for additional 10 minutes before it was cooled to 0°C and a solution of alkyne 1.65 
(714 mg, 2.95 mmol) and MeOH (240 µL, 5.90 mmol) in THF (6.0 mL) were added dropwise 
in 5 minutes. The reaction mixture was warmed to RT and stirred for 26 h. Then it was 
filtered through Celite, washed with Et2O (30 mL) and the solvent was removed under 
reduced pressure. The crude material was purified by column chromatography (Et2O/pentane 
1/8 to 1/6 to 1/4) yielding the boronic ester 1.41 (867 mg, 79%) as a colourless oil. The 
product should be purified immediately by silica gel chromatography to avoid slow 
decomposition of boronate under air. 
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Rf = 0.35 (Et2O/pentane 1/4); [α]D = –13.2° (c = 0.62, CHCl3). 1H-NMR (500 MHz, CDCl3) δ 
6.37 (tq, J = 6.7, 1.5 Hz, 1H), 3.77 (qd, J = 6.2, 3.8 Hz, 1H), 3.64–3.59 (m, 1H), 2.26 (ap d, 
J = 10.0 Hz, 1H), 2.24 (ap d, J = 10.0 Hz, 1H), 2.12 (d, J = 3.5 Hz, 1H), 1.69 (s, 3H), 1.24 (s, 
12H), 1.09 (d, J = 6.3 Hz, 3H), 0.87 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H); 13C-NMR (126 MHz, 
CDCl3) δ 142.1, 128.3, 83.3 (2C), 74.9, 71.2, 31.7, 25.9 (3C), 24.9 (4C), 18.2, 17.5, 14.3, –
4.3, –4.7; HMBC (δH: 1.69 ppm, δC: 128.3 ppm); 11B-NMR (128 MHz, CDCl3) δ 29.85; 
HRMS ESI calcd. for [C19H39BNaO4Si]+ [M+Na]+: 393.2603; Found: 393.2604; IR ν = 
3479, 2977, 2956, 2931, 2888, 2858, 1633, 1463, 1369, 1310, 1254, 1214, 1143, 1083, 975, 
833, 775, 667 cm-1.  
 
(2R,3S,Z)-2-((tert-butyldimethylsilyl)oxy)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)hept-5-en-3-yl (E)-2-(((tert-butyldimethylsilyl)oxy)methyl)penta-2,4-dienoate (1.186) 
This compound was synthesized and characterized by Hiromu Hattori. 
To a stirred solution of carboxylic acid 1.55 (40 mg, 0.17 mmol) in 
benzene (1.5 mL) at RT, Et3N (49 µL, 0.35 mmol) and 2,4,6-
trichlorobenzoyl chloride (29 µL, 0.18 mmol) were added and stirred 
for 1.5 h. To this mixture, alcohol 1.41 (51 mg, 0.14 mmol) and 
DMAP (17 mg, 0.14 mmol) in PhH (1.5 mL) were added and stirred for 7 h at RT. The 
reaction was quenched with aq. sat. NH4Cl (10 mL) and the aq. layer was extracted with Et2O 
(3x10 mL). The org. layers were washed with aq. sat. NaHCO3 (15 mL) and brine (15 mL), 
dried (Na2SO4), filtered and concentrated under reduced pressure. Purification by silica gel 
chromatography (Et2O/pentane 1/40 to 1/30 to 1/20) gave the desired ester 1.186 (50 mg, 
61%) as a colourless oil. 
Rf = 0.40 (Et2O/pentane 1/12); [α]D = –43.5° (c = 1.08, CHCl3); 1H-NMR (500 MHz, CDCl3) 
δ 7.20 (d, J = 11.4 Hz, 1H), 6.92 (ddd, J = 16.9, 11.5, 10.0 Hz, 1H), 6.33 (ddt, J = 7.1, 5.3, 1.8 
Hz, 1H), 5.56 (ddd, J = 16.9, 1.8, 0.8 Hz, 1H), 5.48 (dd, J = 10.0, 1.8 Hz, 1H), 4.88 (dt, J = 
7.9, 4.6 Hz, 1H), 4.49 (d, J = 1.5 Hz, 2H), 3.97 (qd, J = 6.3, 4.0 Hz, 1H), 2.58–2.44 (m, 2H), 
1.69 (s, 3H), 1.22 (s, 12H), 1.15 (d, J = 6.4 Hz, 3H), 0.87 (s, 9H), 0.87 (s, 9H), 0.06 (s, 6H), 
0.02 (s, 3H), 0.01 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 166.9, 141.6, 141.4, 132.6, 131.3, 
129.3, 125.6, 83.2 (2C), 77.8, 69.4, 57.9, 28.6, 26.0 (3C), 25.9 (3C), 24.92 (2C), 24.89 (2C), 
20.1, 18.5, 18.1, 14.2, –4.30, –4.7, –5.1 (2C); HMBC (δ H: 1.69 ppm, δ C: 129.3 ppm); 11B-
NMR (128 MHz, CDCl3) δ 29.60; HRMS ESI calcd. for [C31H59BNaO6Si2]+ [M+Na]+ : 
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617.3835; Found: 617.3839; IR ν = 2930, 2887, 2858, 1706, 1634, 1370, 1305, 1370, 1145, 
1072, 834, 775, 668 cm-1.  
 
(5R,6S,8E,10E,12R,13S,14E,16S)-16-allyl-13-ethyl-12-(((3aS,4R,7S,7aS)-7-(isobutyryl-
oxy)-6,6-dimethyl-2-oxotetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-4-yl)oxy)-2,2,3,3,5,9, 
11,15,18,18,19,19-dodecamethyl-4,17-dioxa-3,18-disilaicosa-8,10,14-trien-6-yl (E)-2-
(((tert-butyldimethylsilyl)oxy)methyl)penta-2,4-dienoate (1.187) 
This compound was synthesized and characterized by 
Hiromu Hattori. A water stock solution of TlOEt was 
prepared as follows: To a vial under Ar, TlOEt (12.0 mg) 
and degassed H2O (120 µL) were added and stirred until the 
residue was completely dissolved. To a solution of iodide 
1.185 (16.5 mg, 23 µmol) and boronate 1.186 (22.5 mg, 34 
µmol) in degassed THF (600 µL) and degassed H2O (150 
µL), Pd(PPh3)4 (5.4 mg, 20 mol%) was added and stirred for 5 minutes at RT. Then the stock 
solution of TlOEt (45 µL, ca. 4.5 mg, 18 µmol) was added dropwise for 2 minutes. After 
stirring for 30 minutes at the same temperature, the reaction mixture was diluted with Et2O (5 
mL) and quenched with brine (5 mL) and aq. sat. NH4Cl (5 mL). The aq. layer was extracted 
with Et2O (3x10 mL). The combined org. layers were washed with brine (20 mL), dried 
(Na2SO4), filtered and concentrated under reduced pressure. Purification by column 
chromatography (Et2O/pentane 1/6 to 1/4) gave alkene 1.187 (20 mg, 82%) as a colourless 
oil. 
Rf = 0.43 (EtOAc/cHex 1/4); [α]D = –48.5° (c = 0.57, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 
7.20 (d, J = 11.4 Hz, 1H), 6.92 (ddd, J = 16.9, 11.4, 9.9 Hz, 1H), 5.85–5.79 (m, 1H), 5.74 (s, 
1H), 5.69 (ddt, J = 17.2, 10.1, 7.2 Hz, 1H), 5.56 (dd, J = 16.8, 1.0 Hz, 1H), 5.50 (dd, J = 10.1, 
1.7 Hz, 1H), 5.32 (t, J = 7.3 Hz, 1H), 5.03 (d, J = 1.7 Hz, 1H), 4.97 (dd, J = 17.2, 2.2 Hz, 1H), 
4.93–4.92 (m, 1H), 4.92 (dd, J = 19.2, 2.2 Hz, 1H), 4.89–4.81 (m, 1H), 4.76 (d, J = 1.2 Hz, 
1H), 4.75 (d, J = 1.9 Hz, 1H), 4.51 (d, J = 12.2 Hz, 1H), 4.47 (d, J = 12.2 Hz, 1H), 3.98–3.90 
(m, 2H), 3.66 (d, J = 8.9 Hz, 1H), 2.65-2.56 (m, 1H), 2.56–2.37 (m, 3H), 2.18 (t, J = 6.9 Hz, 
2H), 1.86–1.77 (m, 1H), 1.74 (d, J = 1.3 Hz, 3H), 1.71 (d, J = 1.2 Hz, 3H), 1.62–1.56 (m, 1H), 
1.56 (d, J = 1.3 Hz, 3H), 1.21 (s, 3H), 1.20 (s, 3H), 1.16 (s, 3H), 1.15 (d, J = 5.0 Hz, 3H), 1.12 
(s, 3H), 0.88 (s, 9H), 0.88 (s, 9H), 0.85 (s, 9H), 0.80 (t, J = 7.4 Hz, 3H), 0.07 (s, 3H), 0.07 (s, 
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3H), 0.03 (s, 3H), 0.02 (s, 3H), –0.03 (s, 3H), –0.09 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 
175.2, 166.8, 153.9, 141.5, 138.8, 135.8, 134.3, 133.8, 133.6, 132.5, 131.3, 126.5, 125.7, 
124.8, 116.3, 94.1, 92.1, 78.1, 77.7, 75.8, 74.9, 72.3, 72.0, 69.5, 57.9, 42.3, 42.0, 34.1, 28.4, 
28.2, 26.1 (3C), 26.0 (3C), 25.9 (3C), 24.7, 24.3, 20.0, 19.1, 18.8, 18.5, 18.3, 18.1, 17.2, 13.8, 
12.7, 11.3, –4.3, –4.5, –4.7, –4.9, –5.10, –5.12; HRMS ESI calcd. for [C57H100NaO12Si3]+ 
[M+Na]+: 1083.6415; Found: 1083.6417; IR ν = 2954, 2929, 2856, 1818, 1747, 1468, 1254, 
1146, 1091, 1035, 837, 777, 668 cm-1. 
 
(3aS,4R,7S,7aS)-4-(((2S,4E,6E,8R,9S,10E,12S,14E,16E)-12-((tert-butyldimethylsilyl)oxy)-
2-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-17-(((tert-butyldimethylsilyl)oxy)methyl)-9-
ethyl-5,7,11-trimethyl-18-oxooxacyclooctadeca-4,6,10,14,16-pentaen-8-yl)oxy)-6,6-
dimethyl-2-oxotetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-7-yl isobutyrate (1.188) 
This compound was synthesized and characterized by Hiromu 
Hattori. To a degassed solution of alkene 1.187 (5.5 mg, 52 
µmol) in benzene (1.0 mL), Grubbs-II catalyst (0.9 mg, 10 
µmol, 20 mol%) was added using Schlenk technique and the 
resulting mixture was heated to 100°C in a pre-heated oil bath 
for 75 minutes. After cooling to RT, the reaction mixture was 
diluted with Et2O (3 mL) and H2O (3 mL). The layers were separated and the aq. layer was 
extracted with Et2O (3x8 mL). The combined org. layers were dried (Na2SO4), filtered and 
concentrated. 1H-NMR analysis of the crude mixture revealed the desired product formation 
as a 2:1 (E/Z) mixture at C4-C5 olefin. Purification by prep. TLC (Et2O/pentane 1/4) gave the 
desired (E)-1.188 (2.9 mg, 54%) as a colourless oil. In addition, (Z)-1.188 (1.1 mg, 21%) was 
also obtained as an impure mixture. 
Isomerization of (Z)-1.188 to (E)-1.188: 
To a degassed solution of (Z)-1.188 (7.9 mg, 7.5 µmol) in PhMe (1.5 mL), Grubbs-II catalyst 
(1.3 mg, 1.5 µmol, 20 mol%) was added using Schlenk technique and the resulting mixture 
was heated to 100°C in a pre-heated oil bath for 11 h. After cooling to RT, the reaction 
mixture was diluted with Et2O (3.0 mL) and H2O (3.0 mL). The org. layer was separated and 
the resulting aq. layer was extracted by Et2O (2x10 mL). The combined org. layers were dried 
(Na2SO4), filtered and concentrated under reduced pressure. 1H-NMR analysis revealed the 
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desired product formation as a 2:1 (E/Z) mixture at C4-C5 olefin. Purification by prep. TLC 
(Et2O/pentane 1/4, 3 times) gave the desired (E)-1.188 (3.5 mg, 44%) as a colourless oil.  
Rf = 0.20 (Et2O/pentane 1/4); [α]D = –42.5° (c = 0.41, CHCl3); 1H-NMR (500 MHz, CDCl3) 
δ 6.97 (d, J = 11.5 Hz, 1H), 6.48 (ddd, J = 14.8, 11.4, 1.4 Hz, 1H), 5.85–5.80 (m, 2H), 5.71 
(ddd, J = 14.8, 10.0, 4.5 Hz, 1H), 5.44 (t, J = 8.3 Hz, 1H), 5.11–5.03 (m, 2H), 4.80–4.74 (m, 
2H), 4.68–4.62 (m, 1H), 4.45 (d, J = 12.0 Hz, 1H), 4.35 (d, J = 12.0 Hz, 1H), 4.16 (br, 1H), 
4.10 (p, J = 6.1 Hz, 1H), 3.67 (d, J = 9.8 Hz, 1H), 2.82–2.72 (m, 1H), 2.69–2.62 (m, 1H), 
2.66–2.58 (m, 1H), 2.55 (dt, J = 15.0, 2.4 Hz, 1H), 2.32–2.22 (m, 2H), 1.89 (dt, J = 7.4, 
4.5 Hz, 1H), 1.83 (s, 3H), 1.76 (s, 3H), 1.60 (m, 1H), 1.59 (s, 3H), 1.22–1.20 (m, 9H), 1.14 (d, 
J = 6.2 Hz, 3H), 1.13 (s, 3H), 0.88 (s, 18H), 0.85 (s, 9H), 0.82 (t, J = 7.4 Hz, 3H), 0.07 (s, 
3H), 0.06 (s, 3H), 0.04 (s, 3H), 0.02 (s, 3H), 0.02 (s, 3H), –0.02 (s, 3H); 13C-NMR (126 MHz, 
CDCl3) δ 175.3, 167.9, 154.0, 142.6, 140.4, 135.8, 135.4, 133.1, 128.2, 127.8, 126.9, 125.7, 
124.0, 93.6, 93.1, 77.1, 75.7, 75.0, 73.2, 72.4, 72.1, 68.4, 57.6, 42.0, 37.5, 34.1, 28.4, 26.9, 
26.1 (3C), 26.0 (3C), 25.9 (3C), 25.4, 24.2, 20.8, 19.1, 18.8, 18.5, 18.3, 18.1, 17.0, 15.1, 13.4, 
10.9, –4.1, –4.5, –4.9, –5.0, –5.1, –5.2; HRMS ESI calcd. for [C55H96NaO12Si3]+ [M+Na]+: 
1055.6102; Found: 1055.6104; IR ν = 2930, 2857, 1820, 1751, 1703, 1645, 1465, 1252, 
1145, 1072, 1004, 838, 776 cm-1. 
(3aS,4R,7S,7aS)-4-(((2S,4E,6E,8R,9S,10E,12S,14E,16E)-12-((tert-butyldimethylsilyl)oxy)-
2-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-9-ethyl-17-(hydroxymethyl)-5,7,11-
trimethyl-18-oxooxacyclooctadeca-4,6,10,14,16-pentaen-8-yl)oxy)-6,6-dimethyl-2-
oxotetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-7-yl isobutyrate (1.188b) 
To a solution of macrolide 1.188 (8.0 mg, 7.7 µmol) in 
THF/MeCN 1/1 (1.0 mL) at 0°C, trihydrogenfluoride 
triethylamine (50 µL, 0.31 mmol) was added dropwise. The 
reaction mixture was stirred at RT for 8 h, then it was 
quenched with aq. sat. NaHCO3 (5 mL), extracted with 
CH2Cl2 (3x2 mL), dried (MgSO4), filtered and evaporated 
under reduced pressure. Purification by preparative TLC (EtOAc/cHex 1/4) afforded the 
alcohol 1.188b (3.5 mg, 49%) as a colourless oil which was used without further purification 
in the next step. 
Rƒ = 0.24 (EtOAc/cHex 1/4).  
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 (2R,4S,5R)-6-(((3E,5E,8S,9E,11S,12R,13E,15E,18S)-8-((tert-butyldimethylsilyl)oxy)-18-
((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-11-ethyl-12-(((4R,7S,7aR)-7-(isobutyryloxy)-
6,6-dimethyl-2-oxotetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-4-yl)oxy)-9,13,15-trimethyl-
2-oxooxacyclooctadeca-3,5,9,13,15-pentaen-3-yl)methoxy)-4-hydroxy-5-methoxy-2-
methyltetrahydro-2H-pyran-3-yl 2,4-bis(allyloxy)-3,5-dichloro-6-ethylbenzoate (1.189). 
 
To a solution of alcohol 1.188b (2.8 mg, 3.1 µmol) and acetimidate 1.169 (3.0 mg, 3.1 µmol) 
in CH2Cl2 (0.3 mL) molecular sieves  (4Å, 30 mg) was added and the white suspension was 
stirred for 30 minutes at RT. Then, it was cooled to –78°C and TBSOTf (0.15 mL, 20 mol%) 
in CH2Cl2 (50 µL) was added dropwise. The reaction mixture was warmed to –50°C and 
subsequently warmed to –30°C over 1 h. The reaction mixture was diluted with CH2Cl2 
(1 mL), quenched with a drop of Et3N, filtered, washed with toluene and evaporated under 
reduced pressure. Purification by preparative TLC (EtOAc/cHex 1/4) afforded the desired 
anomer 1.189 (β-1.189: 3.3 mg, 62%; α:β 1:4, calculated by 1H-NMR of the crude reaction 
mixture) containing a minor inseparable impurity. 
Or: 
To a solution of carbonate protected fidaxomicin 1.190 (23 mg, 18 µmol) in CH2Cl2 (0.5 mL) 
at 0°C, 2,6-lutidine (20 µL, 0.18 mmol) and TBSOTf (24 µL, 90 µmol) were added. The 
solution was stirred at RT for 5 h. Then it was quenched with aq. sat. NH4Cl (5 mL) and 
extracted with EtOAc (3x3 mL). The combined org. layers were dried (MgSO4), filtered and 
evaporated under reduced pressure. Purification by column chromatography (Et2O/pentane 
1/1) gave the protected fidaxomicin 1.1.189 (13 mg, 52%). 
Rƒ = 0.32 (EtOAc/cHex 1/4), 0.45 (Et2O/pentane); [α]D = –45.3° (c = 0.6, MeOH); 1H-NMR 
(400 MHz, acetone-d6) δ 7.19 (d, J = 11.5 Hz, 1H), 6.64–6.56 (m, 1H), 6.23–6.05 (m, 2H), 
5.95 (s, 1H), 5.92 (ddd, J = 14.8, 10.3, 4.5 Hz 1H), 5.77 (d, J = 7.0 Hz, 1H), 5.55 (dd, J = 8.3, 
8.3 Hz, 1H), 5.49–5.37 (m, 2H), 5.31–5.23 (m, 2H), 5.19 (d, J = 3.2 Hz, 1H), 5.17 (ap d, J = 
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11.0 Hz 1H), 5.12–5.05 (m, 2H), 5.03 (dd, J = 9.6, 9.6 Hz, 1H), 4.67–4.56 (m, 4H), 4.64 (s, 
1H), 4.52 (dddd, J = 11.7, 5.9, 1.4, 1.4 Hz, 1H), 4.35 (d, J = 10.8 Hz, 1H), 4.36–4.34 (m, 1H), 
4.27–4.20 (m, 1H), 3.90 (d, J = 10.1 Hz, 1H), 3.76 (d, J = 9.8 Hz, 1H), 3.69 (ddd, J = 9.7, 9.7, 
3.3, Hz, 1H), 3.55 (d, J = 3.5 Hz, 1H), 3.54–3.47 (m, 1H) 3.52 (s, 3H), 2.92–2.76 (m, 3H), 
2.75–2.63 (m, 3H), 2.40 (ddd, J = 14.8, 10.3, 4.5 Hz, 1H), 2.32 (ddd, J = 13.8, 7.6, 4.1 Hz, 
1H), 2.02–1.94 (m, 1H), 1.91 (ap s, 3H), 1.87 (ap s, 3H), 1.71 (ap s, 3H), 1.34 (d, J = 6.2 Hz, 
3H), 1.22–1.14 (m, 19H), 0.91 (s, 9H), 0.88 (s, 9H), 0.85 (t, J = 7.4 Hz, 3H), 0.09 (s, 3H), 
0.09 (s, 3H), 0.08 (s, 3H), 0.04 (s, 3H); 13C-NMR (101 MHz, acetone-d6) δ 175.8, 167.9, 
166.5, 154.7, 153.9, 152.0, 145.2, 142.9, 140.0, 136.7, 136.5, 136.0, 134.5, 134.2, 134.1, 
128.7, 128.6, 127.8, 126.0, 125.4, 124.8, 122.3, 118.8, 118.7, 102.2, 95.1, 93.4, 81.8, 77.9, 
77.5, 76.4, 76.4, 75.4, 75.0, 74.0, 73.2, 73.0, 72.4, 70.8, 69.2, 63.2, 61.7, 42.9, 38.1, 34.6, 
28.8, 27.1, 26.3, 26.2, 26.0, 25.6, 24.1, 20.9, 19.2, 19.0, 18.8, 18.6, 18.4, 17.3, 15.2, 14.4, 
13.9, 11.3, –4.1, –4.2, –4.8, –4.9; HRMS ESI calcd. for [C71H108Cl2NaO19Si2]+ [M+Na]+: 
1408.6739; found: 1408.6725; IR ν = 2928, 2856, 2361, 1819, 1741, 1643, 1566, 1462, 1371, 
1324, 1249, 1094, 1069, 1018, 1003, 938, 836, 774 cm-1. 
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(2R,3R,6S)-6-(((3E,5E,8S,9E,11S,12R,13E,15E,18S)-11-ethyl-8-hydroxy-18-((R)-1-
hydroxyethyl)-12-(((3aS,4R,7S,7aS)-7-(isobutyryloxy)-6,6-dimethyl-2-oxotetrahydro-4H-
[1,3]dioxolo[4,5-c]pyran-4-yl)oxy)-9,13,15-trimethyl-2-oxooxacyclooctadeca-3,5,9,13,15-
pentaen-3-yl)methoxy)-4-hydroxy-5-methoxy-2-methyltetrahydro-2H-pyran-3-yl 2,4-
bis(allyloxy)-3,5-dichloro-6-ethylbenzoate (1.190). 
 
To a solution of the macrolide 1.189 (4 mg, 2 µmol) in THF (0.5 mL), trihydrogenfluoride 
triethylamine (120 µL, excess) was added dropwise. The solution was stirred for 24 h at 50°C 
before it was quenched by the addition of aq. sat. NaHCO3 (3 mL) The aq. layer was extracted 
with EtOAc (4x2 mL) and the combined org. layers were dried (MgSO4), filtered and 
evaporated under reduced pressure. Purification by preparative TLC (acetone/pentane 2/3) 
yielded the triol 1.190 (2.8 mg, 88%). 
Or  
To a solution of allyl protected fidaxomicin 1.191 (130 mg, 0.11 mmol) in CH2Cl2 (5.0 mL) 
at RT, Et3N (0.32 mL, 2.3 mmol) and 1,1’-carbonyldiimidazole (28 mg, 0.17 mmol) were 
added and the mixture was stirred for 24 h. Then it was quenched with aq. sat. NH4Cl 
(10 mL) and extracted with CH2Cl2 (1x10 mL). The combiner org. layers were dried 
(MgSO4), filtered and evaporated under reduced pressure. Purification by column 
chromatography (Et2O) gave the desired carbonate protected fidaxomicin 1.190 (120 mg, 
90%). 
Rƒ = 0.85 (acetone/pentane 2/3); [α]D = –55.3° (c = 0.02, MeOH); 1H-NMR (400 MHz, 
acetone-d6) δ 7.19 (d, J = 11.4 Hz, 1H), 6.63 (dd, 14.4, 12.0 1H), 6.17 (ddt, J = 17.2, 10.4, 
5.8 Hz, 1H), 6.09 (ddt, J = 17.1, 10.4, 5.8 Hz, 1H), 6.00–5.90 (m, 1H) 5.93 (s, 1H), 5.74 (d, 
J = 6.9 Hz, 1H), 5.61 (dd, J = 8.1, 8.1 Hz, 1H), 5.43 (ap ddq, J = 20.4, 17.2, 1.6 Hz, 1H), 
5.31–5.23 (m, 2H), 5.21–5.16 (m, 2H), 5.18 (d, J = 3.2 Hz, 1H), 5.12–4.99 (m, 3H), 4.72–
4.67 (m, 1H), 4.64 (s, 1H), 4.64–4.57 (m, 4H), 4.53 (dddd, J = 11.7, 5.8, 1.4, 1.4 Hz, 1H), 
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4.39 (d, J = 11.5 Hz, 1H), 4.29–4.24 (m, 1H), 4.07–4.00 (m, 2H), 3.86 (d, J = 10.1 Hz, 1H), 
3.80 (d, J = 9.8 Hz, 1H), 3.75 (d, J = 4.2 Hz, 1H), 3.73–3.66 (m, 1H), 3.55 (d, J = 3.3 Hz, 
1H), 3.55–3.50 (m, 1H), 3.52 (s, 3H), 2.92–2.62 (m, 6H), 2.50 (ddd, J = 14.7, 9.6, 4.4 Hz, 
1H), 2.40 (ddd, J = 13.7, 8.3, 4.4 Hz, 1H), 1.96–1.90 (m, 1H), 1.89 (ap s, 3H), 1.79 (ap s, 3H), 
1.68 (ap s, 3H), 1.33 (d, J = 6.2 Hz, 3H), 1.25–1.12 (m, 19H), 0.82 (t, J = 7.4 Hz, 3H); 13C-
NMR (101 MHz, acetone-d6) δ 176.0, 168.1, 166.5, 154.7, 153.9, 152.0, 145.1, 143.1, 140.0, 
137.3, 136.0, 135.5, 134.7, 134.1, 134.1, 128.7, 128.4, 127.5, 126.0, 125.6, 123.8, 122.3, 
118.8, 118.7, 101.9, 95.3, 93.0, 81.9, 78.5, 77.5, 76.4, 76.4, 75.4, 75.0, 73.3, 73.1, 72.9, 72.4, 
70.7, 66.1, 63.5, 61.8, 42.8, 37.4, 34.6, 28.5, 28.4, 26.0, 25.6, 23.9, 20.4, 19.2, 19.0, 18.3, 
17.4, 15.3, 14.4, 13.8, 11.2; HRMS ESI calcd. for [C59H80Cl2NaO19]+ [M+Na]+: 1185.4563; 
found: 1185.4570; IR ν = 3461, 2976, 2935, 2878, 2360, 2324, 2231, 2167, 2049, 1814, 1737, 
1701, 1642, 1565, 1459, 1400, 1370, 1319, 1246, 1066, 1041, 1024, 933, 902, 769 cm-1. 
 
(2R,3R,6S)-6-(((3E,5E,8S,9E,11S,12R,13E,15E,18S)-12-(((2R,3S,4R,5S)-3,4-dihydroxy-5-
(isobutyryloxy)-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-11-ethyl-8-hydroxy-18-((R)-
1-hydroxyethyl)-9,13,15-trimethyl-2-oxooxacyclooctadeca-3,5,9,13,15-pentaen-3-yl)-
methoxy)-4-hydroxy-5-methoxy-2-methyltetrahydro-2H-pyran-3-yl 2,4-bis(allyloxy)-3,5-
dichloro-6-ethylbenzoate (1.191) 
 
To a solution of the protected macrolide 1.190 (8 mg, 7 mmol) in THF (0.2 mL) at 0°C, a 
solution of sodium hydride in ethylene glycol (20 µL, 0.5 mg/mL) was added. The mixture 
was stirred vigorously for 15 minutes and quenched with aq. sat. NH4Cl (2 mL) and EtOAc 
(3 mL) was added. The layers were separated and the aq. layer was extracted with EtOAc 
(2x3 mL). The combined org. layers were dried (MgSO4), filtered and evaporated under 
reduced pressure. Purification by column chromatography (EtOAc/toluene 2/3 to 1/1 to 3/2) 
gave the carbonate-deprotected intermediate along with minor a minor byproduct and starting 
material (1.0 mg, 13%). The compound was further purified by RP-HPLC (A: H2O+0.1% 
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HCOOH; Solvent B: CH3CN+0.1% HCOOH; 1 mL/min; T = 20°C; B[%] (tR [min])= 65 (0 to 
3); 90 (15); 100 (16)). The impure allylated fidaxomicin was dissolved in CH3CN (0.15 mL) 
and separated in portions (100 µL). The product 1.191 eluted at tR = 14.0 minutes and the 
solvents were evaporated under reduced pressure to give pure 1.190 (3.6 mg, 46%, 53% brsm) 
as an amorphous solid. 
or  
To a solution of fidaxomicin (400 mg, 0.38 mmol) in DMF (10 mL), K2CO3 (209 mg, 
1.51 mmol) was added. To the suspension allyl bromide (82 µL, 0.95 mmol) was added and 
the colourless reaction mixture was stirred at 45°C for 3 h. The orange-red reaction mixture 
was quenched with aq. sat. NH4Cl and the mixture was extracted with EtOAc (3x). The 
organic layers were washed with brine, dried (MgSO4), filtered and evaporated under reduced 
pressure. Purification by column chromatography (acetone/pentane 2/3) gave the allylated 
fidaxomicin 1.190 (384 mg, 89%) as a colourless resin. 
1H-NMR (400 MHz, acetone-d6) δ 7.22 (d, J = 11.4 Hz, 1H), 6.62 (dd, J = 15.2, 11.5 Hz, 
1H), 6.13 (dddt, J = 32.0, 17.2, 10.4, 5.8 Hz, 2H), 5.96 (ddd, J = 14.7, 9.6, 4.7 Hz, 1H), 5.83 
(s, 1H), 5.62 (t, J = 8.2 Hz, 1H), 5.43 (ddq, J = 20.4, 17.2, 1.6 Hz, 2H), 5.33–5.23 (m, 2H), 
5.21 (dt, J = 10.5, 1.6 Hz, 1H), 5.02 (t, J = 9.7 Hz, 1H), 4.99 (d, J = 10.1 Hz, 1H), 4.77 (d, J = 
1.3 Hz, 1H), 4.76–4.69 (m, 1H), 4.64 (d, J = 0.8 Hz, 1H), 4.63–4.58 (m, 4H), 4.53 (ddt, J = 
11.8, 5.8, 1.4 Hz, 1H), 4.40 (d, J = 11.5 Hz, 1H), 4.26 (br s, 1H), 4.02 (p, J = 6.4 Hz, 1H), 
3.95 (dd, J = 3.4, 1.2 Hz, 1H), 3.75–3.66 (m, 3H), 3.59 (ddd, J = 3.1, 2.3, 1.3 Hz, 1H), 3.55 
(dd, J = 3.6, 0.8 Hz, 1H), 3.52 (s, 3H), 2.94–2.59 (m, 6H), 2.56 (p, J = 7.0 Hz, 1H), 2.52–2.38 
(m, 1H), 1.99–1.87 (m, 1H), 1.81 (d, J = 1.4 Hz, 3H), 1.73 (d, J = 1.4 Hz, 3H), 1.66 (dd, J = 
1.4, 0.7 Hz, 3H), 1.33 (d, J = 6.1 Hz, 3H), 1.30–1.21 (m, 1H), 1.19–1.12 (m, 15H), 1.09 (d, J 
= 0.6 Hz, 3H), 0.82 (t, J = 7.5 Hz, 3H). 
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Fidaxomicin (Tiacumicin B, Lipiarmycin A3) 
 
To a solution of the protected macrolide 1.190 (0.9 mg, 0.8 µmol) in CH2Cl2 (0.2 mL), a drop 
of Barton’s base and a drop of H2O were added. The mixture was stirred vigorously for 1.5 h 
before it was diluted with EtOAc (2 mL) and quenched with aq. sat. NH4Cl (2 mL) The layers 
were separated and the aq. layer was extracted with EtOAc (3x2 mL). The combined org. 
layers were dried (MgSO4), filtered and evaporated under reduced pressure. Purification by 
preparative TLC (MeOH/toluene 1/5) gave the carbonate deprotected intermediate 1.190 (0.4 
mg) with minor impurities.  
To a solution of the crude allyl-protected intermediate 1.191 in THF (0.2 mL) at 0°C 
morpholine (0.3 mL, 3.6 mmol) in CH2Cl2 (10 mL) and Pd(PPh3)4 (0.14 mg, 10 mol%) were 
added and the reaction mixture was stirred at this temperature for 20 minutes. The reaction 
mixture was quenched with aq. sat. NH4Cl (2 mL), extracted with EtOAc (4x2 mL). The 
combined org. layers were dried (MgSO4), filtered and evaporated under reduced pressure. 
Purification by preparative TLC (MeOH/CH2Cl2 1/10) yielded fidaxomicin (0.4 mg) as a 
colourless oil with minor impurities.  
The compound was further purified by RP-HPLC (A: H2O+0.1% HCOOH; Solvent B: 
MeCN+0.1% HCOOH; 1 mL/min; T = 20°C; B[%] (tR [min])= 50 (0 to 3); 65 (15); 100 (16)). 
The impure fidaxomicin was dissolved in MeCN (0.15 mL) and separated in portions 
(3x50 µL). Fidaxomicin (1) eluted at tR = 12.3 minutes and the solvents were evaporated 
under a constant stream of nitrogen yielding fidaxomicin contaminated with formate (ca. 
0.1 mg 10% over 2 steps, calculated from a UV-standard curve of an authentic sample of 
fidaxomicin by linear regression analysis). 
Or 
To a solution of the pure allyl-protected intermediate 1.191 (3.0 mg, 2.6 µmol) in THF 
(0.5 mL) at 0°C morpholine (0.5 mL in 10 mL THF) and Pd(PPh3)4 (0.3 mg, in 0.1 mL THF) 
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were added and the reaction mixture was stirred at this temperature for 30 minutes. The 
reaction mixture was diluted with EtOAc (2 mL) and quenched with aq. sat. NH4Cl (2 mL). 
The Layers were separated and the aq. layer was extracted with EtOAc (3x2 mL), the 
combined org. layers were dried (MgSO4), filtered and evaporated under reduced pressure. 
Purification by column chromatography (acetone/pentane 2/3 to 1/1) yielded pure 
fidaxomicin (2.4 mg, 86%).  
Rƒ = 0.44 (MeOH/CH2Cl2 1/10); [α]D = –7.6° (c = 0.96, MeOH) 1H-NMR (600 MHz, 
CD3OD, containing HCOO–) δ 7.23 (d, J = 11.5 Hz, 1H), 6.60 (dd, J = 14.9, 11.8 Hz, 1H), 
5.95 (ddd, J = 14.7, 9.5, 4.8 Hz, 1H), 5.83 (s, 1H), 5.57 (ap t, J = 8.2 Hz, 1H), 5.14 (ap d, J = 
10.7, 1H), 5.13 (dd, J = 9.7 Hz, 1H), 5.02 (d, J = 10.2 Hz, 1H), 4.74–4.70 (m, 1H), 4.71 (s, 
1H), 4.64 (s, 1H), 4.61 (d, J = 11.6 Hz, 1H), 4.44 (d, J = 11.6 Hz, 1H), 4.22 (ap s, 1H), 4.02 
(p, J = 6.3 Hz, 1H), 3.92 (dd, J = 3.2, 1.2 Hz, 1H), 3.75 (ddd, J = 13.9, 10.2, 3.3 Hz, 1H) 3.71 
(d, J = 9.7 Hz 1H), 3.58–3.52 (m, 2H) 3.54 (s, 3H), 3.15–3.06 (m, 1H), 3.04–2.95 (m, 1H), 
2.76–2.66 (m, 3H), 2.60 (hept, J = 7.0 Hz, 1H), 2.49 (ddd, J = 14.9, 9.5, 4.4 Hz, 1H), 2.43 
(ddd, J = 13.8, 8.8, 4.5 Hz, 1H), 2.05–1.98 (m, 1H), 1.82 (d, J = 1.3 Hz, 3H), 1.76 (ap s, 3H), 
1.66 (ap s, 3H), 1.32–1.27 (m, 4H), 1.22–1.15 (m, 12H), 1.15 (s, 3H), 1.13 (s, 3H), 0.88 (t, J = 
7.4 Hz, 3H); 13C-NMR (101 MHz, CD3OD) δ 178.4, 169.7, 169.1, 154.6, 153.9, 146.2, 143.7, 
141.9, 137.0, 137.0, 136.4, 134.6, 128.5, 126.9, 125.6, 124.6, 114.8, 112.7, 108.8, 102.2, 97.2, 
94.3, 82.5, 78.6, 76.9, 75.9, 74.5, 73.5, 73.2, 72.8, 71.6, 70.6, 68.3, 63.9, 62.2, 42.5, 37.3, 
35.4, 28.7, 28.4, 26.9, 26.4, 20.3, 19.5, 19.1, 18.7, 18.1, 17.5, 15.4, 14.5, 13.9, 11.3; 1H-NMR 
(400 MHz, acetone-d6) δ 7.24 (dd, J = 11.5, 0.8 Hz, 1H), 6.63 (dddd, J = 14.8, 11.6, 2.0, 
1.0 Hz, 1H), 5.96 (ddd, J = 14.6, 9.3, 4.6 Hz, 1H), 5.83 (s, 1H), 5.71–5.54 (m, 1H), 5.22 (dt, 
J = 10.6, 1.5 Hz, 1H), 5.10 (t, J = 9.8 Hz, 1H), 5.00 (d, J = 10.1 Hz, 1H), 4.77 (d, J = 1.3 Hz, 
1H), 4.75–4.71 (m, 1H), 4.68 (d, J = 0.8 Hz, 1H), 4.60 (d, J = 11.5 Hz, 1H), 4.42 (d, J = 
11.5 Hz, 1H), 4.26 (s, 1), 4.05–3.99 (m, 1H), 3.95 (dd, J = 3.4, 1.2 Hz, 1H), 3.80 (dd, J = 9.9, 
3.4 Hz, 1H), 3.75–3.73 (m, 1H), 3.73–3.70 (m, 1H), 3.65–3.60 (m, 1H,), 3.59 (d, J = 2.5 Hz, 
1H), 3.52 (s, 3H), 3.01 (qd, J = 7.4, 2.0 Hz, 2H), 2.76 (dd, J = 14.4, 7.2 Hz, 1H), 2.72–2.67 
(m, 1H), 2.67–2.60 (m, 1H), 2.56 (sept, J = 7.0 Hz, 1H), 2.53–2.46 (m, 1H), 2.46–2.38 (m, 
1H), 1.93 (qdd, J = 10.5, 6.3, 1.9 Hz, 1H), 1.81 (d, J = 1.3 Hz, 3H), 1.73 (d, J = 1.5 Hz, 3H), 
1.65 (dd, J = 1.4, 0.7 Hz, 3H), 1.31 (d, J = 6.2 Hz, 3H), 1.29–1.24 (m, 1H), 1.22 (t, J = 
7.4 Hz, 3H), 1.18 (d, J = 6.3 Hz, 3H), 1.16–1.12 (m, 9H), 1.09 (s, 3H), 0.83 (t, J = 7.5 Hz, 
3H); HRMS ESI calcd. for [C52H74Cl2NaO18]+ [M+Na]+: 1079.4144; found: 1079.4151; IR 
ν = 3452, 2974, 2933, 2363, 2327, 2189, 1703, 1643, 1584, 1370, 1312, 1242, 1199, 1146, 
1068, 1024, 900, 797, 762 cm-1.  
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4.2 Methionine-Derived Iminium Lactones 
General procedure for the amide coupling using EDC·HCl  
 
To a solution of the carboxylic acid (1.0 eq), DMAP (0.50 eq) and EDC·HCl (1.5 eq) in 
CH2Cl2 (c = 0.2 mol/L) at RT, the amine (1.0 eq) was added. The solution was stirred at RT 
until full conversion was indicated by TLC. The reaction was quenched with aq. sat. 
NaHCO3, and the layers were separated. The org. layer was washed with aq. HCl (1M), the aq. 
layers were reextracted with CH2Cl2 (2x) and the combined org. layers were dried (MgSO4 or 
Na2SO4), filtered and evaporated under reduced pressure. The products were further purified 
by column chromatography. 
 
General procedure for the amide coupling using BOP. 
 
 
To a solution of the carboxylic acid (1.0 eq) and the amine (1.0 eq) in THF (c = 0.15-0.4 
mol/L) at RT, Et3N (2.0 eq) was added. The solution was cooled to 0°C and BOP (1.3 eq) was 
added portion-wise. The mixture was stirred at 0°C for further 2 h before it was warmed to 
RT and stirred until TLC indicated full conversion. The reaction was quenched with water 
and THF removed by evaporation under reduced pressure. The aq. residue was extracted with 
CH2Cl2 (3x), and org. layers were washed with aq. sat. NaHCO3, combined, dried (MgSO4 or 
Na2SO4), filtered and evaporated under reduced pressure. The products were further purified 
by column chromatography. 
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N-(1-(diethylamino)-4-(methylthio)-1-oxobutan-2-yl)benzamide (2.23) 
The reaction was performed according to the general procedure using BOP. 
Purification by column chromatography (EtOAc/pentane 1/2 to 1/1) yielded 
the title compound 2.23 (78 mg, 56%) as a white solid. 
Rƒ = 0.36 (EtOAc/pentane 1/1); M.p. = 126.0°C; 1H-NMR (400 MHz, CDCl3) δ 7.86–7.80 
(m, 2H), 7.53–7.47 (m, 1H), 7.46–7.40 (m, 2H), 7.22 (br d, J = 8.1 Hz, 1H), 5.25 (td, J = 8.1, 
4.4 Hz, 1H), 3.62–3.48 (m, 2H), 3.42 (dq, J = 14.4, 7.1 Hz, 1H), 3.27 (dq, J = 14.1, 7.1 Hz, 
1H), 2.68–2.51 (m, 2H), 2.15–2.05 (m, 1H), 2.11 (s, 3H), 2.05–1.93 (m, 1H), 1.28 (t, J = 
7.2 Hz, 3H), 1.14 (t, J = 7.1 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 170.9, 167.0, 134.0, 
131.9, 128.7, 127.3, 48.8, 42.2, 40.7, 33.7, 30.4, 15.9, 14.7, 13.0; HRMS ESI calcd. for 
[C16H25N2NaO2S]+ [M+Na]+: 331.1451; found: 331.1451; IR ν = 3327, 2968, 2919, 1662, 
1616, 1531, 1490, 1462, 1431, 1365, 1306, 1263, 1218, 1138, 1083, 955, 807, 715, 632 cm-1. 
 
N-(4-(methylthio)-1-oxo-1-(piperidin-1-yl)butan-2-yl)benzamide (2.24) 
The reaction was performed according to the general procedure using 
EDC·HCl. Purification by recrystallization from tBME yielded the desired 
title compound 2.24 (410 mg, quant.). 
Rƒ = 0.18 (EtOAc/pentane 1/1); M.p. = 123.0°C; 1H-NMR (400 MHz, CDCl3) δ 7.86–7.80 
(m, 2H), 7.55–7.47 (m, 1H), 7.46–7.40 (m, 2H), 7.35 (br d, J = 7.2 Hz, 1H), 5.30 (ddd, J = 
7.8, 4.2, 4.2 Hz, 1H), 3.67–3.50 (m, 4H), 2.69–2.48 (m, 2H), 2.19–2.09 (m, 1H), 2.10 (s, 3H), 
1.99–1.86 (m, 1H), 1.73–1.52 (m, 6H); 13C-NMR (101 MHz, CDCl3) δ 169.6, 167.0, 134.1, 
131.8, 128.7, 127.2, 48.7, 46.8, 43.6, 33.4, 30.3, 26.7, 25.7, 24.6, 15.8; HRMS ESI calcd. for 
[C17H24N2NaO2S]+ [M+Na]+: 343.1451; found: 343.1447; IR ν = 3302, 2941, 2858, 1631, 
1536, 1467, 1442, 1307, 1246, 1138, 1086, 1011, 695, 652 cm-1. 
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N-(4-(methylthio)-1-oxo-1-(pyrrolidin-1-yl)butan-2-yl)benzamide (2.25) 
The reaction was performed according to the general procedure using 
EDC·HCl. No column chromatography was necessary. In this way the title 
compound 2.25 (116 mg, 96%) was isolated as a white solid.  
The analytical data matched those reported in the literature: J. Gardiner, A. D. Abell, Org. 
Biomol. Chem. 2004, 2, 2365–2370. 
1H-NMR (400 MHz, CDCl3) δ 7.84 (d, J = 8.1 Hz, 2H), 7.54–7.48 (m, 1H), 7.47–7.41 (m, 
2H), 7.27 (br d, J = 7.7 Hz, 1H), 5.13 (ddd, J = 7.9, 5.1, 5.1 Hz, 1H), 3.78 (ddd, J = 10.2, 6.6, 
6.6 Hz, 1H), 3.64–3.43 (m, 3H), 2.70–2.53 (m, 2H), 2.23–2.11 (m, 1H), 2.12 (s, 3H), 2.10–
1.96 (m, 3H), 1.97–1.86 (m, 2H). 
 
N-(4-(methylthio)-1-morpholino-1-oxobutan-2-yl)benzamide (2.26) 
The reaction was performed according to the general procedure using 
EDC·HCl. No column chromatography was necessary. In this way the 
title compound 2.26 (110 mg, 92%) was isolated as a white solid. 
Rƒ = 0.15 (EtOAc/cHex 1/1); M.p. = 128.0°C; 1H-NMR (400 MHz, CDCl3) δ 7.85–7.80 (m, 
2H), 7.55–7.49 (m, 1H), 7.48–7.41 (m, 2H), 7.19 (br d, J = 7.7 Hz, 1H), 5.30 (ddd, J = 7.9, 
4.6, 4.6 Hz, 1H), 3.80–3.57 (m, 8H), 2.70–2.51 (m, 2H), 2.17–2.06 (m, 1H), 2.11 (s, 3H), 
2.03–1.91 (m, 2H); 13C-NMR (101 MHz, CDCl3) δ 170.2, 167.1, 133.9, 132.0, 128.7, 127.2, 
66.9, 66.8, 48.3, 46.3, 42.8, 33.2, 30.4, 15.9; HRMS ESI calcd. for [C16H22N2NaO3S]+ 
[M+Na]+: 345.1243; found: 345.1240; IR ν = 3271, 3058, 2973, 2920, 2857, 1655, 1619, 
1533, 1435, 1351, 1302, 1241, 1115, 1070, 1033, 865, 697, 669 cm-1. 
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4-methoxy-N-(4-(methylthio)-1-oxo-1-(piperidin-1-yl)butan-2-yl)benzamide (2.27) 
The reaction was performed according to the general procedure using 
EDC·HCl. Purification by column chromatography (EtOAc/pentane 1/2) 
yielded the title compound 2.27 (78 mg, 56%) as a white solid. 
Rƒ = 0.24 (EtOAc/pentane 1/1); M.p. = 143.8°C; 1H-NMR (400 MHz, 
CDCl3) δ 7.84–7.75 (m, 2H), 7.20 (br d, J = 7.6 Hz, 1H), 6.97–6.88 (m, 
2H), 5.27 (td, J = 7.8, 4.2 Hz, 1H), 3.85 (s, 3H), 3.68–3.50 (m, 4H), 2.68–2.49 (m, 2H), 2.16–
2.06 (m, 1H), 2.10 (s, 3H), 1.96–1.85 (m, 1H), 1.63 (m, 6H); 13C-NMR (101 MHz, CDCl3) δ 
169.7 166.48, 162.4, 129.1, 126.4, 113.8, 55.5, 48.6, 46.7, 43.5, 33.4, 30.3, 26.6, 25.7, 24.5, 
15.8; HRMS ESI calcd. for [C18H26N2NaO3S]+ [M+Na]+: 373.1556; found: 373.1556; IR ν = 
3286, 2942, 2855, 1610, 1543, 1504, 1463, 1440, 1298, 1249, 1180, 1139, 1107, 1015, 954, 
845, 771, 658 cm-1. 
 
(S)-2-amino-N,N-diisopropyl-4-(methylthio)butanamide (2.29) 
The reaction was performed according to the general procedure using BOP 
and Boc-L-Met-OH. Purification by column chromatography 
(EtOAc/pentane 1/3) yielded the Boc protected amide, which was 
dissolved in MeOH (1 mL). To the solution aq. HCl conc. (few drops) was added and the 
reaction was stirred at RT for 3 h. The reaction mixture was neutralized with NaOH 1M and 
extracted with CH2Cl2 (3x5 mL). The combined org. layers were dried (MgSO4), filtered and 
evaporated under reduced pressure to give the title compound 2.29 (52 mg, 26%). 
Rƒ = 0.18 (CH2Cl2/MeOH 20/1); 1H-NMR (400 MHz, CDCl3) δ 4.01 (p, J = 6.6 Hz, 1H), 
3.71 (dd, J = 8.7, 3.4 Hz, 1H), 3.44 (br s, 1H), 2.70–2.50 (m, 2H), 2.05 (s, 3H), 1.86 (br s, 
2H), 1.74 (dddd, J = 14.0, 8.2, 7.2, 3.7 Hz, 1H), 1.61 (dddd, J = 14.1, 8.8, 7.1, 5.2 Hz, 1H), 
1.34 (d, J = 6.8 Hz, 3H), 1.31 (d, J = 6.8 Hz, 3H), 1.18 (d, J = 7.0 Hz, 3H) 1.16 (d, J = 7.6 Hz, 
7H); IR ν = 3368, 292966, 2929, 1630, 1441, 1369, 1327, 1210, 1135, 1040, 958, 920, 873, 
847 cm-1. 
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(S)-N-(1-(diisopropylamino)-4-(methylthio)-1-oxobutan-2-yl)benzamide (2.30) 
To a solution of amine 2.29 (200 mg, 0.86 mmol) in CH2Cl2 (3 mL) N,N-
diisopropylethylamine (0.18 mL, 1.1 mmol) was added. To the colourless 
solution benzoyl chloride (0.12 mL, 1.0 mmol) was added dropwise. The 
mixture was stirred at RT for 18 h. Aq. citric acid (1M) was added and the mixture was 
extracted with CH2Cl2 (3x). The org. layers were washed with water, aq. sat. NaHCO3 and the 
combined org. layers were dried (MgSO4), filtrated and evaporated under reduced pressure. 
Purification by recrystallization from EtOAc/pentane 1/4 and Et2O/pentane gave the desired 
product 2.30 (230 mg, 79%) as a white powder. 
Rƒ = 0.24 (EtOAc/pentane 1/4); M.p. = 141.4°C; 1H-NMR (400 MHz, CDCl3) δ 7.87–7.82 
(m, 2H), 7.54–7.47 (m, 1H), 7.46–7.40 (m, 3H), 5.19 (td, J = 7.5, 3.8 Hz, 1H), 4.16 (p, J = 
6.6 Hz, 1H), 3.56–3.44 (m, 1H), 2.63 (ddd, J = 13.1, 9.6, 6.6 Hz, 1H), 2.53 (ddd, J = 13.1, 
9.7, 5.1 Hz, 1H), 2.18–2.08 (m, 1H), 2.10 (s, 3H), 1.91 (dddd, J = 14.3, 9.6, 7.6, 5.1 Hz, 1H), 
1.41 (d, J = 3.1 Hz, 3H), 1.40 (d, J = 3.1 Hz, 3H), 1.29 (d, J = 6.6 Hz, 3H), 1.25 (d, J = 6.6 
Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 169.9, 166.8, 134.2, 131.8, 128.7, 127.3, 49.8, 48.7, 
46.5, 33.7, 31.8, 30.1, 21.4, 20.8, 20.3, 15.9, 11.3; IR ν = 3256, 3068, 2973, 2935, 1652, 
1616, 1546, 1473, 1438, 1368, 1337, 1325, 1295, 1210, 1157, 1136, 1088, 1044, 801, 737, 
690, 658, 610 cm-1. 
 
tert-butyl (3-(methylthio)propyl)carbamate (2.40) 
To a solution of tert-butyl (3-chloropropyl)carbamate (2.39, 165 mg, 
0.85 mmol) in EtOH (2 mL) sodium methanethiolate (153 mg, 2.0 mmol) was added and the 
white suspension was heated to 50°C and stirred for 18 h. Then it was filtrated over silica, 
washed with Et2O and evaporated under reduced pressure to yield the desired thioether 2.40 
(148 mg, 85%). 
The analytical data matched those reported in the literature: Y. Yoshimi, T. Itou, M. 
Hatanaka, Chem. Commun. 2007, 5244–5246. 
1H-NMR (400 MHz, CDCl3) δ 4.62 (s br, 1H), 3.22 (t, J = 6.8 Hz, 2H), 2.52 (t, J = 7.2 Hz, 
2H), 2.10 (s, 3H), 1.78 (p, J = 7.0 Hz, 2H), 1.44 (s, 9H). 
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3-(methylthio)propan-1-aminium chloride (2.41) 
To a solution of thioether 2.40 (140 mg, 0.68 mmol) in THF (3 ml) aq. 
conc. HCl (1 mL) was added and the mixture was heated to 50°C for 
45 minutes. The clear solution was evaporated under reduced pressure to yield the ammonium 
salt 2.41 (93 mg, 96%), which was used without further purification in the next step. 
 
N-(3-(methylthio)propyl)benzamide (2.42) 
To a suspension of the ammonium salt 2.41 (93 mg, 0.66 mmol) in 
toluene (2 mL), MeCN (1 mL) and Et3N (0.4 mL) at 50°C, benzoic 
anhydride (312 mg, 1.31 mmol) was added and the reaction was stirred for 5 h at 60°C. The 
MeCN was evaporated under reduced pressure and the residue was treated with water and 
basified with aq. conc. NaOH, extracted with Et2O (3x). The org. layers were washed with aq. 
HCl (1M), and the combined org. layers were dried (MgSO4), filtered and evaporated under 
reduced pressure. Purification by column chromatrography (Et2O/pentane 1/3 to pure Et2O) 
gave the desired amide 2.42 (90 mg, 66%). 
The analytical data matched those reported in the literature: J. Barluenga, F. Foubelo, F. J. 
Fañanás, M. Yus, Tetrahedron 1989, 45, 2183–2192. 
1H-NMR (400 MHz, CDCl3) δ 7.80–7.74 (m, 2H), 7.51–7.38 (m, 3H), 6.53 (br s, 1H), 3.58 
(q, J = 6.4 Hz, 2H), 2.61 (t, J = 7.4 Hz, 2H), 2.12 (s, 3H), 1.94 (ap, J = 6.8 Hz, 2H). 
 
N-(1-(benzyl(methyl)amino)-4-(methylthio)-1-oxobutan-2-yl)benzamide (2.49) 
The reaction was performed according to the general procedure using 
EDC·HCl. Purification by column chromatography (EtOAc/pentane 1/3) 
yielded the desired title compound 2.49 (75 mg, 53%). 
1H-NMR (400 MHz, CDCl3, major/minor rotamer 2/1) δ 7.89-7.79 (m, 3H), 7.56-7.49 (m, 
1.5H), 7.48-7.41 (m, 3H), 7.40-7.27 (m, 4.5H), 7.25-7.21 (m, 3H), 7.19 (br d, 1H) 5.41 (ddd, 
J = 8.1, 4.0, 4.0 Hz, 0.5H), 5.35 (ddd, J = 7.9, 4.4, 4.4 Hz, 1H), 4.77 (d, J = 16.4 Hz, 1H), 
4.74 (d, J = 14.6 Hz, 2H), 4.70 (d, J = 16.4 Hz, 1H), 4.50 (d, J = 14.6 Hz, 1H), 3.10 (s, 3H), 
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2.97 (s, 1.5H), 2.70-2.47 (m, 3H), 2.22-2.11 (m, 1H), 2.10 (s, 3H), 2.04 (s, 0.5H), 2.05-1.93 
(m, 1H). 
 
N-(1-(methoxy(methyl)amino)-4-(methylthio)-1-oxobutan-2-yl)benzamide (2.50) 
The reaction was performed according to the general procedure using 
EDC·HCl. No column chromatography was necessary. In this way the title 
compound 2.50 (50 mg, 52%) was isolated as a white solid. 
Rƒ = 0.39 (EtOAc/cHex 1/1); M.p. = 91.7°C; 1H-NMR (400 MHz, CDCl3, major/minor 
rotamer 5/1) δ 7.86–7.79 (m, 2.4H), 7.53–7.46 (m, 1.2H), 7.46–7.40 (m, 2.4H), 7.16 (br d, J = 
8.3 Hz, 1H), 7.07 (br d, J = 7.4 Hz, 0.2H), 5.38–5.27 (ddd, J = 8.1, 4.8, 4.8 Hz, 1H), 4.88 
(ddd, J = 7.1, 5.2, 5.2 Hz, 0.2H), 3.84 (s, 3.6H), 3.24 (s, 3.6H), 2.60 (pt, J = 7.5 Hz, 2.4H), 
2.23–2.12 (m, 1.2H), 2.10 (s, 3H), 2.09 (s, 0.6H), 2.07–1.93 (m, 1.2H); 13C-NMR (101 MHz, 
CDCl3) δ 174.0, 172.2, 167.4, 134.0, 131.9, 128.8, 128.7, 127.3, 62.0, 52.4, 49.3, 32.3, 30.4, 
15.7; HRMS ESI calcd. for [C14H20N2NaO3S]+ [M+Na]+: 319.1087; found: 319.1086; IR ν = 
3292, 3061, 2911, 1731, 1632, 1538, 1488, 1315, 1188, 1076, 974, 713, 691 cm-1. 
 
tert-butyl N-(benzoylmethionyl)-N-methylglycinate (2.51) 
The reaction was performed according to the general procedure 
using BOP. Purification by column chromatography 
(EtOAc/pentane 1/2) yielded the title compound 2.51 (310 mg, 
69%) as a white solid. 
Rƒ = 0.35 (EtOAc/pentane 1/2); M.p. = 112.7°C; 1H-NMR (400 MHz, CDCl3, major/minor 
rotamer 3/1) δ 7.86–7.77 (m, 2.6 H), 7.54–7.47 (m, 1.3H), 7.47–7.40 (m, 2.6H), 7.18 (br d, 
J = 7.8 Hz, 1H), 7.12 (br d, J = 7.5 Hz, 0.3H), 5.36 (td, J = 7.8, 4.5 Hz, 1H), 5.17 (td, J = 7.8, 
4.6 Hz, 0.3H), 4.39 (d, J = 18.2 Hz, 0.3H), 4.33 (d, J = 17.1 Hz, 1H), 4.03 (d, J = 18.2 Hz, 
0.3H), 3.74 (d, J = 17.1 Hz, 1H), 3.22 (s, 3H), 3.00 (s, 0.9H), 2.70–2.52 (m, 2.6H), 2.27–2.14 
(m, 1.3H), 2.12 (s, 3H), 2.09 (s, 0.9H), 2.00 (dq, J = 14.1, 7.9 Hz, 1.3H), 1.46 (s, 11.7H); 13C-
NMR (101 MHz, CDCl3) δ 172.3 (0.3C), 172.1, 167.9 (0.3C), 167.7, 167.0, 166.9 (0.3C), 
133.9, 133.8 (0.3C), 131.8 (0.3C), 131.8, 128.6 (2.6C), 127.2 (0.6C), 127.2 (2C), 83.0 (0.3C), 
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82.2, 52.2 (0.3C), 50.6, 48.7, 48.5 (0.3C), 36.6, 35.2 (0.3C), 32.7 (0.3C), 32.6, 30.2 (0.3C), 
30.1, 28.1 (3C), 28.1 (0.9C), 15.7, 15.7 (0.3C); HRMS ESI calcd. for [C19H28N2NaO4S]+ 
[M+Na]+: 403.1662; found: 403.1666; IR ν = 3292, 3047, 2979, 1733, 1651, 1623, 1528, 
1489, 1447, 1403, 1366, 1318, 1291, 1227, 1151, 1116, 1029, 846, 800, 725, 691 cm-1. 
 
tert-butyl (S)-(1-(diethylamino)-4-(methylthio)-1-oxobutan-2-yl)carbamate (2.52) 
The reaction was performed according to the general procedure using 
BOP. Purification by column chromatography (EtOAc/pentane 1/1) 
yielded the title compound 2.52 (665 mg, quant.) as colourless oil. 
The analytical data matched those reported in the literature: M. L. Richmond, C. M. Sprout, 
C. T. Seto, J. Org. Chem. 2005, 70, 8835–8840. 
Rƒ = 0.37 (EtOAc/pentane 1/3); 1H-NMR (400 MHz, CDCl3) δ 5.36 (br s, 1H), 4.70 (m, 1H), 
3.60–3.41 (m, 2H), 3.35 (dq, J = 14.3, 7.0 Hz, 1H), 3.23 (dq, J = 14.1, 7.1 Hz, 1H), 2.54 (t, J 
= 7.1, 2H), 2.10 (s, 3H), 1.97–1.78 (m, 2H), 1.43 (s, 9H), 1.24 (t, J = 7.1 Hz, 3H), 1.12 (t, J = 
7.1 Hz, 3H). 
 
tert-butyl (S)-(1-(diethylamino)-4-(methylthio)-1-oxobutan-2-yl)(methyl)carbamate 
(2.53) 
The reaction was performed according to the general procedure using BOP. 
The corresponding carboxylic acid was obtained from methylation of 
BocMetOH following the literature procedure: S. J. deSolms, S. L. Graham, 
(Bristol-Myers Squibb Company), US 5439918, 1995. Purification by column 
chromatography (EtOAc/pentane 1/2) yielded the title compound 2.53 (80 mg, 86%) as 
yellow oil. 
Rƒ = 0.68 (EtOAc/pentane 1/1); 1H-NMR (400 MHz, CDCl3, two rotamer 1/1) δ 5.06 (dd, J = 
8.0, 6.6 Hz, 1H), 4.95 (dd, J = 7.8, 6.4 Hz, 1H), 3.49–3.12 (m, 8H), 2.66 (s, 3H), 2.66 (s, 3H), 
2.52–2.28 (m, 4H), 2.10–2.0 (m, 2H), 2.03 (s, 3H), 2.02 (s, 3H), 1.89–1.76 (m, 2H), 1.43 (s, 
9H), 1.39 (s, 9H), 1.13–1.01 (m, 12H). 
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benzyl (S)-(1-(diethylamino)-4-(methylthio)-1-oxobutan-2-yl)carbamate (2.54) 
The reaction was performed according to the general procedure using 
BOP. Purification by column chromatography (EtOAc/pentane 1/2) 
yielded the title compound 2.54 (580 mg, 99%) as a colourless oil. 
Rƒ = 0.35 (EtOAc/pentane 1/2); [α]D = -4.8° (c = 0.5, CHCl3); 1H-NMR (400 MHz, CDCl3) δ 
7.31–7.21 (m, 5H), 5.61 (br d, J = 8.5 Hz, 1H), 5.05 (d, J = 12.3 Hz, 1H), 5.00 (d, J = 12.3 
Hz, 1H), 4.70 (td, J = 8.4, 4.5 Hz, 1H), 3.52–3.33 (m, 2H), 3.28 (dq, J = 14.4, 7.1 Hz, 1H), 
3.15 (dq, J = 14.0, 7.1 Hz, 1H), 2.54–2.40 (m, 2H), 2.03 (s, 3H), 1.92–1.73 (m, 2H), 1.18 (t, J 
= 7.1 Hz, 3H), 1.05 (t, J = 7.1 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 170.8, 156.2, 136.5, 
128.6, 128.3, 128.2, 67.0, 50.0, 42.0, 40.6, 33.7, 30.3, 15.8, 14.7, 13.1; HRMS ESI calcd. for 
[C17H26N2NaO3S]+ [M+Na]+: 361.1556; found: 361.1553; IR ν = 3233, 3053, 2984, 2930, 
1711, 1630, 1541, 1356, 1285, 1255, 1142, 1073, 1041, 975, 790, 734, 690 cm-1. 
rac-2.54: M.p. = 69.7°C (only racemate is crystalline); 
 
benzyl (S)-(1-(methyl((trimethylsilyl)methyl)amino)-4-(methylthio)-1-oxobutan-2-yl)-
carbamate (2.76) 
The reaction was performed according to the general procedure 
using BOP. Purification by column chromatography (tBME/cHex 
1/1) yielded the title compound 2.76 (193 mg, 75%) as colourless 
oil. 
Rƒ = 0.29 (tBME/cHex 1/1); [α]D = +2.0° (c = 0.5, CHCl3); 1H-NMR (400 MHz, CDCl3, 
major rotamer) δ 7.38–7.27 (m, 5H), 5.65 (d, J = 8.5 Hz, 1H), 5.10 (s, 2H), 4.84 (td, J = 8.3, 
4.6 Hz, 1H), 3.11 (s, 3H), 3.07 (d, J = 14.9 Hz, 1H), 2.81 (d, J = 14.9 Hz, 1H), 2.62–2.48 (m, 
2H), 2.10 (s, 3H), 2.00–1.90 (m, 1H), 1.88–1.77 (m, 1H), 0.07 (s, 9H); 13C-NMR (101 MHz, 
CDCl3, major rotamer) δ 171.4, 157.6, 137.9, 130.0, 129.6, 129.4, 68.3, 51.2, 42.2, 39.2, 34.6, 
31.6, 17.2, 0.0; HRMS ESI calcd. for [C19H30N2O3SSi]+ [M+H]+: 383.1818; found: 
383.1817; IR ν = 3273, 2953, 1714, 1627, 1497, 1455, 1419, 1247, 1043, 844, 738, 696 cm-1. 
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methyl benzoylmethioninate (2.37) 
To a solution of carboxylate 2.21 (69 mg, 0.27 mmol) in MeOH (1 mL) at 
0°C, thionyl chloride (30 µL, 0.41 mmol) was added slowly and the clear 
solution was alowed to warm to RT. After stirring for 30 minutes the 
reaction mixture was evaporated under reduced pressure yielding the ester 2.37 (40 mg, 55%). 
1H-NMR (400 MHz, CDCl3) δ 7.86–7.79 (m, 2H), 7.57–7.49 (m, 1H), 7.49–7.41 (m, 2H), 
6.93 (d, J = 7.7 Hz, 1H), 4.94 (td, J = 7.2, 5.1 Hz, 1H), 3.80 (s, 3H), 2.59 (tt, J = 9.8, 5.2 Hz, 
2H), 2.30 (dtd, J = 14.7, 7.4, 5.1 Hz, 1H), 2.19–2.07 (m, 1H). 
 
Methionine to Iminium Lactone Reaction 
 
General procedure for the iminium lactone formation using ethyl iodoacetate 
To a solution of the methionine derivative (1.0 eq), in MeCN (c = 0.1 mol/L) at RT, ethyl 
iodoacetate (1.1 eq) was added. The colourless solution was heated to 50°C for 1 d and the 
reaction solvent was evaporated under reduced pressure. The respective purification is 
specified for each product. 
General procedure for the iminium lactone formation using Me3OBF4 at 80°C 
To a solution of the methionine derivative (1.0 eq), in MeCN (c = 0.1– 0.28 mol/L) at RT, 
Me3OBF4 (1.1 eq) was added. The colourless solution was heated to 80°C for 18 h and the 
reaction solvent was evaporated under reduced pressure. The respective purification is 
specified for each product. 
General procedure for the iminium lactone formation using Me3OBF4 at 130°C in the 
microwave 
To a solution of the methionine derivative (1.0 eq), in MeCN (c = 0.15 mol/L) at RT, 
Me3OBF4 (1.1 eq) was added. The colourless solution was heated to 130°C for 0.5 h in a µw 
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oven and the reaction solvent was evaporated under reduced pressure. The respective 
purification is specified for each product. 
 
N-(3-benzamidodihydrofuran-2(3H)-ylidene)-N-ethylethanaminium iodide (2.31) 
The reaction was performed according to the general procedure using ethyl 
iodoacetate. The crude product was purified by a quick column 
chromatography (MeCN) yielding the title compound 2.31 (22 mg, 29%) as 
colourless oil. 
1H-NMR (400 MHz, CD3CN) δ 9.08 (br d, J = 6.9 Hz, 1H), 7.96–7.87 (m, 2H), 7.50–7.40 
(m, 1H), 7.40–7.31 (m, 2H), 5.37 (ddd, J = 11.3, 7.4, 4.5 Hz, 1H), 5.02 (ap td, J = 8.7, 7.7 Hz, 
1H), 4.76 (ap td, J = 9.0, 5.1 Hz, 1H), 3.70 (dq, J = 14.3, 7.2 Hz, 1H), 3.57–3.40 (m, 3H), 
2.78–2.62 (m, 1H), 2.30 (ap ddt, J = 13.4, 9.0, 4.8 Hz, 1H), 1.12 (t, J = 7.2 Hz, 3H), 0.97 (t, 
J = 7.2 Hz, 3H); ESI-MS  m/z = 261.2 [M-I]+. 
 
1-(3-benzamidodihydrofuran-2(3H)-ylidene)piperidin-1-ium iodide (2.32) 
The reaction was performed according to the general procedure using ethyl 
iodoacetate. The crude product was purified by successive trituration of the 
residue with MeCN, tBME and MeCN yielding the title compound 2.32 
(18 mg, 29%) as a brown oil purity.  
1H-NMR (400 MHz, CD3CN) δ 8.89 (br d, J = 4.4 Hz, 1H), 8.05–7.93 (m, 2H), 7.65–7.54 
(m, 1H), 7.53–7.40 (m, 2H), 5.39 (ddd, J = 10.9, 7.2, 4.4 Hz, 1H), 5.11 (p q, J = 8.5 Hz, 1H), 
4.87 (p td, J = 8.9, 5.0 Hz, 1H), 3.95–3.80 (m, 2H), 3.72–3.55 (m, 2H), 2.92–2.75 (m, 1H), 
2.49–2.36 (m, 1H), 1.83–1.57 (m, 4H), 1.53–1.38 (m, 2H); 13C-NMR (63 MHz, CD3CN) δ 
177.1, 167.9, 133.5, 133.0, 129.7 (2C), 128.7 (2C), 78.9, 52.4, 51.5, 50.3, 31.2, 30.9, 25.8, 
23.3; ESI-MS  m/z = 273.2 [M-I]+. 
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N-(3-benzamidodihydrofuran-2(3H)-ylidene)-N-isopropylpropan-2-aminium 
iodide (2.35) 
The reaction was performed according to the general procedure using ethyl 
iodoacetate. The crude product was purified by a quick column 
chromatography (MeCN) giving title compound 2.35 (46 mg, 63%) as a 
colourless resin which eventually crystallized. 
Or 
The reaction was performed according to the general procedure using Me3OBF4 at 130°C in 
the µw oven. Then NaI was added to the reaction mixture and it was stirred for 15 minutes. 
The colourless mixture was filtered over silica, and the resulting yellow filtrate was 
evaporated under reduced pressure leaving a yellow solid. The residue triturated with CH2Cl2 
(4x) to leave a beige solid. The decanted layer was evaporated under reduced pressure and 
triturated with EtOAc (3x). The combined residues were dried under vacuum to leave the 
desired iminolactone 2.35 (33 mg, 51%) as beige solid. 
1H-NMR (400 MHz, CD3CN) δ 9.15 (br d, J = 6.6 Hz, 1H), 8.08–7.99 (m, 2H), 7.64–7.55 
(m, 1H), 7.54–7.45 (m, 2H), 5.47 (ddd, J = 10.9, 7.1, 3.9 Hz, 1H), 5.17 (ap q, J = 8.6 Hz, 1H), 
4.94 (ap td, J = 9.2, 4.5 Hz, 1H), 4.65 (hept, J = 6.6 Hz, 1H), 3.96 (hept, J = 6.8 Hz, 1H), 
2.89–2.74 (m, 1H), 2.42–2.30 (m, 1H), 1.42 (d, J = 6.8 Hz, 3H), 1.41 (d, J = 6.8 Hz, 3H), 1.33 
(d, J = 6.6 Hz, 3H), 1.02 (d, J = 6.6 Hz, 3H); 13C-NMR (101 MHz, CD3CN) δ 177.4, 166.8, 
132.2, 131.7, 128.4, 127.3, 78.1, 55.4, 52.7, 51.0, 29.1, 18.5, 18.27, 18.25, 17.49; HRMS ESI 
calcd. for [C17H25N2O2]+ [M-I]+: 289.1911; found: 289.1914; IR ν = 3450, 3217, 2978, 2361, 
2336, 1659, 1523, 1485, 1284, 1047, 905, 719 cm-1; X-ray: in the appendix. 
 
N-(3-benzamidodihydrofuran-2(3H)-ylidene)-N-ethylethanaminium tetrafluoroborate 
(2.55) 
The reaction was performed according to the general procedure using 
Me3OBF4 at 130°C in the µw oven. The crude product was purified by two 
quick column chromatographies (MeCN and MeCN/tBME 1/2) yielding 
title compound 2.55 (105 mg, 47%) as colourless oil. 
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1H-NMR (400 MHz, CD3CN) δ 8.16 (d, J = 7.2 Hz, 1H), 7.88–7.82 (m, 2H), 7.65–7.58 (m, 
1H), 7.56–7.48 (m, 2H), 5.27 (ddd, J = 10.7, 7.2, 4.5 Hz, 1H), 5.10 (td, J = 8.7, 7.5 Hz, 1H), 
4.90 (td, J = 9.0, 5.1 Hz, 1H), 3.74–3.56 (dq, J = 19.6, 7.1 Hz, 4H), 2.86 (dddd, J = 13.5, 10.5, 
9.1, 7.4 Hz, 1H), 2.41 (ddt, J = 13.5, 8.7, 5.1 Hz, 1H), 1.27 (t, J = 7.3 Hz, 3H), 1.13 (t, J = 
7.2 Hz, 3H); 13C-NMR (101 MHz, CD3CN) δ 178.8, 168.2, 133.7, 133.1, 129.9 (2C), 128.4 
(2C), 79.1, 53.1, 47.6, 46.6, 31.3, 12.4, 12.0; 19F-NMR (376 MHz, CD3CN) δ –151.67; 11B-
NMR (128 MHz, CD3CN) δ –1.12; ESI-MS  m/z = 261.2 [M-BF4]+. 
 
1-(3-benzamidodihydrofuran-2(3H)-ylidene)piperidin-1-ium tetrafluoroborate (2.56) 
The reaction was performed according to the general procedure using 
Me3OBF4 at 80°C. The crude product was not further purified yielding the 
title compound 2.56 (59 mg, quant) was isolated as colourless oil.  
1H-NMR (400 MHz, CD3CN) δ 8.15 (d, J = 7.1 Hz, 1H), 7.91–7.81 (m, 2H), 7.66–7.59 (m, 
1H), 7.55–7.48 (m, 2H), 5.22 (ddd, J = 10.9, 7.1, 4.3 Hz, 1H), 5.08 (td, J = 8.7, 7.6 Hz, 1H), 
4.89 (td, J = 9.0, 5.0 Hz, 1H), 3.97–3.86 (m, 1H), 3.83–3.74 (m, 1H), 3.68–3.56 (m, 2H), 
2.90–2.77 (m, 1H), 2.47–2.37 (m, 1H), 1.83–1.59 (m, 5H), 1.50–1.37 (m, 1H); 13C-NMR (63 
MHz, CD3CN) δ 177.0, 168.3, 133.7, 133.1, 129.9, 128.4, 78.9, 52.8, 51.3, 50.24, 31.2, 26.0, 
23.4; 19F-NMR (376 MHz, CD3CN) δ –151.33; ESI-MS  m/z = 273.2 [M-BF4]+. 
 
N-(3-((tert-butoxycarbonyl)amino)dihydrofuran-2(3H)-ylidene)-N-ethylethanaminium 
tetrafluoroborate (2.60) 
The reaction was performed according to the general procedure using 
Me3OBF4 at 80°C. The crude product was purified by a quick column 
chromatography (MeCN/tBME 4/1) yielding the title compound 2.60 
(273 mg, 70%) as colourless oil. 
1H-NMR (400 MHz, CD3CN) δ 6.41 (br d, J = 7.7 Hz, 1H), 5.09–4.95 (m, 2H), 4.82 (ap td, J 
= 8.9, 5.8 Hz, 1H), 3.83–3.55 (m, 4H), 2.91–2.71 (m, 1H), 2.43–2.25 (m, 1H), 1.46 (s, 9H), 
1.30 (t, J = 7.2 Hz, 3H), 1.26 (t, J = 7.2 Hz, 3H); 13C-NMR (101 MHz, CD3CN) δ 179.0, 
O
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156.0, 82.0, 78.5, 53.6, 47.4, 46.6, 31.1, 28.3 (3C), 12.5, 11.8; 19F-NMR (376 MHz, CD3CN) 
δ –152.23; 11B-NMR (128 MHz, CD3CN) δ –1.19; ESI-MS  m/z = 258.2 [M-BF4]+. 
 
N-(3-((tert-butoxycarbonyl)(methyl)amino)dihydrofuran-2(3H)-ylidene)-N-
ethylethanaminium tetrafluoroborate (2.61) 
The reaction was performed according to the general procedure using 
Me3OBF4 at 80°C. The crude product was purified by a quick column 
chromatography (MeCN/tBME 2/3) yielding the title compound 2.61 (44 mg, 
50%) as colourless oil. 
1H-NMR (400 MHz, CD3CN) δ 4.96 (td, J = 8.8, 7.4 Hz, 1H), 4.88–4.75 (m, 2H), 3.70–3.46 
(m, 4H), 2.97 (s, 3H), 2.86–2.71 (m, 1H), 2.31 (ddt, J = 13.6, 9.3, 4.8 Hz, 1H), 1.44 (s, 9H), 
1.24 (t, J = 7.2, 6H); ESI-MS  m/z = 271.2 [M-BF4]+. 
 
N-(3-(((benzyloxy)carbonyl)amino)dihydrofuran-2(3H)-ylidene)-N-ethylethanaminium 
tetrafluoroborate (2.62) 
The reaction was performed according to the general procedure using 
Me3OBF4 at 130°C in the μw oven. The crude product was purified by 
trituration and decanting with toluene. In this way the title compound 2.62 
was isolated as colourless oil (50 mg, 91%). 
1H-NMR (400 MHz, CDCl3) δ 7.27 (br s, 5H), 6.59 (d, J = 7.8 Hz, 1H), 5.06–4.92 (m, 3H), 
4.89 (q, J = 8.2 Hz, 1H), 4.77–4.65 (m, 1H), 3.57–3.43 (m, 4H), 2.78–2.62 (m, 1H), 2.30–
2.17 (m, 1H), 1.12 (t, J = 7.3 Hz, 3H), 1.04 (t, J = 7.2 Hz, 3H); 13C-NMR (101 MHz, CDCl3) 
δ 177.7, 155.7, 136.3, 128.6, 128.3, 128.2, 77.7, 67.4, 53.0, 46.6, 45.8, 30.1, 11.5, 10.9; 19F-
NMR (376 MHz, CDCl3) δ –152.0; 11B-NMR (128 MHz, CDCl3) δ –1.14; ESI-MS m/z = 
291.2 [M-BF4]+. 
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(E,Z)-N-(3-(((benzyloxy)carbonyl)amino)dihydrofuran-2(3H)-ylidene)-N-methyl-1-
(trimethylsilyl)methanaminium tetrafluoroborate (2.77) 
The reaction was performed according to the general procedure using 
Me3OBF4 at 90°C in the μw oven. The reaction mixture was evaporated 
under reduced pressure yielding the title compound 2.77 (25 mg, 84%) 
as colourless oil. 
1H-NMR (400 MHz, CD3CN, major isomer) δ 7.57–7.42 (m, 5H), 6.79 (br d, J = 7.6 Hz, 1H), 
5.25 (d, J = 12.4 Hz, 1H), 5.21 (d, J = 12.3 Hz, 1H), 5.15–5.01 (m, 2H), 4.86 (td, J = 8.8, 
5.9 Hz, 1H), 3.49 (d, J = 14.7 Hz, 1H), 3.37 (s, 3H), 3.22 (d, J = 14.7, Hz, 1H), 2.97–2.84 (m, 
1H), 2.54–2.43 (m, 1H), 0.24 (s, 9H); 13C-NMR (101 MHz, CD3CN, major isomer) δ 176.1, 
156.6, 137.3, 129.5, 129.2, 129.0, 128.8, 78.1, 68.2, 53.7, 47.3, 42.0, 31.3, –2.1; 19F-NMR 
(376 MHz, CD3CN) δ –151.7; HRMS ESI calcd. for [C17H27N2O3Si]+ [M-BF4]+: 335.1786; 
found: 335.1780; IR ν = 3372, 2956, 1695, 1523, 1455, 1419, 1252, 1045, 847, 741, 
698 cm-1. 
 
benzyl (2-oxotetrahydrofuran-3-yl)carbamate (2.63) 
To a solution of imidate 2.62 (58 mg, 0.16 mmol) in MeOH (1 mL) silica gel 
was added and the suspension was stirred for 2 h at RT. A drop of H2O was 
added and the reaction was heated to 50°C and stirred for another 18 h. The solvent was 
evaporated under reduced pressure and the residue was purified by column chromatography 
(EtOAc/pentane 1/1) to yield the lactone 2.63 (17 mg, 47%). 
The analytical data matched those reported in the literature: M. S. Lall, C. Karvellas, J. C. 
Vederas, Org. Lett. 1999, 1, 803–806. 
1H-NMR (400 MHz, CDCl3) δ 7.40–7.29 (m, 5H), 5.41 (br s, 1H), 5.13 (s, 2H), 4.42 (q, J = 
14.0, 11.5 Hz, 2H), 4.24 (ddd, J = 10.3, 9.6, 6.0 Hz, 1H), 2.85–2.70 (m, 1H), 2.21 (qd, J = 
11.7, 9.1 Hz, 1H); 13C-NMR (101 MHz, CDCl3) δ 174.9, 156.1, 135.9, 128.6 (2C), 128.3, 
128.2 (2C), 67.4, 65.8, 50.5, 30.5; HRMS ESI calcd. for [C12H13NO4Na]+ [M+Na]+: 
258.0737; found: 258.0737. 
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benzyl (1-(diethylamino)-4-hydroxybutan-2-yl)carbamate (2.64) 
To a solution of the iminium ether 2.62 (49.2 mg, 0.13 mmol) in MeOH 
(1 mL) at RT, sodium borohydride (9.8 mg, 0.26 mmol) was added and the 
colourless solution was stirred for 16 h before it was poured into aq. sat. 
NaHCO3 (8 mL). The aq. layer was extracted with EtOAc (3x4 mL), and the combined org. 
layers were dried (MgSO4), filtered and evaporated under reduced pressure. The residue was 
dissolved in a minimum amount of CH2Cl2. Then, tBME was added and the CH2Cl2 was 
evaporated under reduced pressure to give a white suspension. The suspension was filtered, 
washed with tBME and the filtrate was evaporated under reduced pressure to give the tertiary 
amine 2.64 (31 mg, 81%) as a colourless oil. 
Rƒ = 0.28 (CH2Cl2/MeOH 20/1); 1H-NMR (400 MHz, CDCl3) δ 7.40–7.27(m, 5H), 5.51 (br s, 
1H), 5.15–5.0 (m, 1H), 5.09 (q, J = 12.2 Hz, 2H), 3.89–3.75 (m, 1H), 3.72–3.56 (m, J = 4.6 
Hz, 2H), 2.65 (dq, J = 14.2, 7.2 Hz, 2H), 2.59–2.47 (m, 3H), 2.46–2.34 (m, 1H), 1.83–1.66 
(m, 2H), 1.03 (t, J = 7.2 Hz, 6H); 13C-NMR (101 MHz, CDCl3) δ 156.5, 136.5, 128.6 (2C), 
128.3, 128.2 (2C), 66.9, 59.6, 58.2, 48.8, 47.1 (2C), 39.1, 11.1 (2C); HRMS ESI calcd. for 
[C16H27N2O3]+ [M+H]+: 295.2016; found: 295.2018; IR ν = 3314, 2967, 2927, 2849, 1695, 
1531, 1455, 1377, 1309, 1244, 1214, 1138, 1055, 1028, 736, 696 cm-1. 
 
benzyl (4-azido-1-(diethylamino)-1-oxobutan-2-yl)carbamate (2.65) 
To a solution of iminium ether 2.62 (45.0 mg, 0.12 mmol) in MeCN 
(0.8 mL) at RT, sodium azide (15.6 mg, 0.24 mmol) was added and the 
suspension was stirred for 24 h at RT. The resulting milky, thick suspension 
suspension was diluted with EtOAc (2 mL), filtered over Celite and evaporated under reduced 
pressure. Purification by column chromatography (tBME/cHex 1/1) gave the desired azide 
2.65 (14 mg, 35%) as colourless solid. 
Rƒ = 0.28 (tBME/cHex 1/1); M.p. = 62.2°C; 1H-NMR (400 MHz, CDCl3) δ 7.37–7.29 (m, 
5H), 5.70 (d, J = 8.9 Hz, 1H), 5.18–5.02 (m, 2H), 4.73 (td, J = 8.6, 4.0 Hz, 1H), 3.52 (tt, J = 
12.7, 6.3 Hz, 1H), 3.47–3.31 (m, 4H), 3.23 (dq, J = 14.0, 7.1 Hz, 1H), 1.97–1.82 (m, 1H), 
1.86–1.72 (m, 1H), 1.25 (t, J = 7.1 Hz, 3H), 1.12 (t, J = 7.1 Hz, 3H); 13C-NMR (101 MHz, 
CDCl3) δ 170.5, 156.2, 136.4, 128.7 (2C), 128.3, 128.2 (2C), 67.1, 48.6, 48.0, 42.0, 40.6, 
N
H
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33.6, 14.7, 13.0; HRMS ESI calcd. for [C16H24N5O3]+ [M+H]+: 334.1874; found: 334.1871; 
IR ν = 3310, 3224, 3062, 3034, 2981, 2360, 2342, 2086, 1777, 1703, 1633, 1542, 1497, 1454, 
1441, 1385, 1254, 1170, 1098, 1073, 1024, 980, 946, 908, 848, 823, 779, 743, 694, 669 cm-1. 
 
benzyl (2-(hydroxyimino)tetrahydrofuran-3-yl)carbamate (2.66) 
To the reaction mixture of the freshly prepared imium ether 2.62 (55 mg, 
0.15 mmol) in MeCN (1 mL) at RT, aq. hydroxylamine (50 wt.%, 45 µL, 
0.73 mmol) was added and the mixture was stirred for 24 h. The reaction was quenched with 
aq. HCl (1M, 5 mL), extracted with EtOAc (3x5 mL) and the org. layers were dried (MgSO4), 
filtered and evaporated under reduced pressure. Purification by column chromatography 
(tBME) gave product 2.66 (8.0 mg, 22%) as a white solid and homoserine lactone 2.63 
(6.0 mg, 18%). 
Rƒ = 0.36 (tBME); M.p. = 141.5 °C; 1H-NMR (400 MHz, CD3OD) δ 7.44–7.24 (m, 5H), 5.10 
(s, 2H), 4.75 (t, J = 8.2 Hz, 1H), 4.41 (td, J = 8.3, 3.9 Hz, 1H), 4.25 (td, J = 8.8, 6.5 Hz, 1H), 
2.47 (dddd, J = 12.2, 8.0, 6.5, 4.1 Hz, 1H), 2.08 (dtd, J = 12.5, 8.6, 8.0 Hz, 1H); 13C-NMR 
(101 MHz, CDCl3) δ 158.0, 156.1, 136.2, 128.7 (2C), 128.4, 128.3 (2C), 69.8, 67.4, 50.7, 
32.5; HRMS ESI calcd. for [C12H15N2O4]+ [M+H]+: 251.1026; found: 251.1025; IR ν = 
3341, 3034, 2911, 1703, 1650, 1540, 1455, 1392, 1361, 1308, 1292, 1254, 1225, 1176, 1080, 
1013, 987, 958, 935, 880, 848, 828, 788, 743, 691, 651 cm-1. 
 
benzyl (2-((benzyloxy)imino)tetrahydrofuran-3-yl)carbamate (2.67) 
and  
benzyl (4-oxo-1,10-diphenyl-2,9-dioxa-3,8-diazadecan-5-yl)carbamate (2.68) 
To a solution of iminium ether 2.62 (45.0 mg, 0.12 mmol) in MeCN (0.8 mL) at RT, O-
benzylhydroxylamine (30 µl, 0.24 mmol) was added and the suspension was stirred for 48 h 
at RT. The mixture was quenched with aq. HCl (1M, 3 mL), extracted with EtOAc (3x5 mL) 
and the org. layers were dried (MgSO4), filtered and evaporated under reduced pressure. 
N
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Purification by column chromatography (tBME/cHex) gave a inseparable mixture of the 
products 2.67 (14 mg, 36%, calc. from NMR) and 2.68 (20 mg, 35%, calc. from NMR).  
For sake of characterization the two products were separated by recrystallization from hot 
cHex to give pure 2.67 (12 mg). The filtrate was evaporated and purified further by column 
chromatography (toluene/EtOAc 3/1) to give product 2.68 (9 mg). 
2.67: Rƒ = 0.23 (tBME/cHex 1/1), 0.35 (toluene/EtOAc 3/1); M.p. = 
105.7 °C; 1H-NMR (400 MHz, CDCl3) δ 7.41–7.27 (m, 10H), 5.25–
5.15 (m, 1H), 5.12 (s, 2H), 4.99 (s, 2H), 4.66 (q, J = 7.2, 6.5 Hz, 1H), 
4.45 (td, J = 8.6, 2.5 Hz, 1H), 4.23 (td, J = 9.7, 5.8 Hz, 1H), 2.78–2.63 
(m, 1H), 2.04 (dtd, J = 12.4, 10.1, 8.4 Hz, 1H); 13C-NMR (101 MHz, CDCl3) δ 156.6, 156.0, 
137.5, 136.2, 128.7 (2C), 128.6 (2C), 128.49 (2C), 128.45, 128.4 (2C), 128.1, 80.1, 69.9, 
67.3, 51.0, 32.7; HRMS ESI calcd. for [C19H21N2O4]+ [M+H]+: 341.1496; found: 341.1493; 
IR ν = 3285, 3031, 2964, 2927, 2361, 2341, 1683, 1537, 1454, 1389, 1357, 1288, 1248, 1225, 
1178, 1081, 1043, 983, 917, 883, 834, 781, 753, 741, 694 cm-1. 
2.68: Rƒ = 0.23 (tBME/cHex 1/1), 0.22 (toluene/EtOAc 3/1); 1H-
NMR (400 MHz, CDCl3, major rotamer) δ7.77 (s, 1H), 7.41–7.27 
(m, 15H), 5.56 (d, J = 8.7 Hz, 1H), 5.14 (d, J = 12.3 Hz, 1H), 5.11 
(d, J = 12.3 Hz, 1H), 5.0–4.91 (m, 1H), 4.95 (s, 2H), 4.82 (d, J = 
11.1 Hz, 1H), 4.78 (d, J = 11.1 Hz, 1H), 3.72–3.59 (m, 2H), 2.98 
(t, J = 6.8 Hz, 1H), 2.17–2.06 (m, 1H), 1.71–1.61 (m, 1H); 13C-NMR (101 MHz, CDCl3) δ 
156.9, 155.5, 137.3, 136.4, 135.2, 129.4, 128.9, 128.8, 128.7, 128.5, 128.5, 128.4, 128.3, 
128.2, 78.9, 76.5, 67.3, 58.7, 46.4, 37.7; HRMS ESI calcd. for [C26H30N3O5]+ [M+H]+: 
464.2180; found: 464.2177; IR ν = 3406, 3304, 3062, 3032, 2928, 2877, 2362, 2342, 1704, 
1627, 1498, 1454, 1363, 1227, 1144, 1046, 1026, 910, 735, 696 cm-1. 
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benzyl (1-(diethylamino)-4-(1,3-dioxoisoindolin-2-yl)-1-oxobutan-2-yl)carbamate (2.69) 
To a solution of iminium ether 2.62 (45.0 mg, 0.12 mmol) in MeCN 
(0.8 mL) at RT, potassium phtalimide (44.1 mg, 0.24 mmol) was added. 
The suspension was stirred for 2 h at RT quickly turning into a orange, thick 
suspension. The reaction was quenched with water (4 mL), extracted with 
EtOAc (3x3 mL), dried (MgSO4) and evaporated under reduced pressure. 
Purification by column chromatography (tBME/cHex 1/1) gave the product 2.69 (10 mg, 
19%) as a colourless resin. 
Rƒ = 0.15 (tBME/cHex 1/1); 1H-NMR (400 MHz, CDCl3) δ 7.83 (dd, J = 5.4, 3.1 Hz, 2H), 
7.70 (dd, J = 5.5, 3.0 Hz, 2H), 7.40–7.28 (m, 5H), 5.77 (d, J = 8.7 Hz, 1H), 5.10 (s, 2H), 4.71 
(td, J = 8.5, 4.1 Hz, 1H), 3.88–3.73 (m, 2H), 3.50 (dq, J = 14.3, 7.2 Hz, 1H), 3.37 (dp, J = 
22.4, 7.6 Hz, 2H), 3.17 (dq, J = 14.0, 7.0 Hz, 1H), 2.20–2.06 (m, 1H), 2.04–1.90 (m, 1H), 
1.24 (t, J = 7.1 Hz, 3H), 1.09 (t, J = 7.1 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 170.2, 
168.3, 156.2, 136.5, 134.1, 132.3, 128.6, 128.2, 128.1, 123.4, 67.1, 49.3, 42.0, 40.6, 34.7, 
31.9, 14.6, 13.0; HRMS ESI calcd. for [C24H28N3O5]+ [M+H]+: 438.2024; found: 438.2031; 
IR ν = 3286, 2973, 2934, 2360, 2341, 1772, 1706, 1633, 1525, 1498, 1446, 1396, 1372, 1242, 
1217, 1117, 1047, 966, 869, 718, 697 cm-1. 
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5 Appendices 
5.1 List of Abbreviations, Acronyms and Symbols  
Ac    acetyl 
AcOH   acetic acid 
AIBN   azaisobutyronitrile 
Ala    alanine 
ap    appearing  
aq.    aqueous 
BDA    butane-1,2-diacetal 
Bn     benzyl 
brsm    based on recovered starting material 
BOP  (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium 
hexafluorophosphate 
Boc    tert-butyloxycarbonyl 
br    broad 
BSP    1-(Phenylsulfinyl)piperidine 
Bu    butyl 
Bz    benzoyl 
°C    degrees Celsius 
c    concentration (g/100 mL) 
calc.    calculated 
CAM    ceric ammonium molybdate 
cat.    catalytic 
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Cbz    carboxybenzyl 
CDI    clostridium difficile infection 
cHex    cyclohexane 
conc.    concentrated 
δ    chemical shift 
d    doublet 
DABCO   1,4-diazabicyclo[2.2.2]octane 
DAST   diethlaminosulfur trifluoride 
d.r.    diastereomeric ratio 
DBU    1,8-diazabicyclo[5,6]undec-7-ene 
DCC    N,N’-diclohexylcarbodiimide 
DCE    1,2-dichloroethane 
DEAD   Diethyl azodicarboxylate 
DIBAL-H   diisobutylaluminium hydride 
DMAP   4-dimethylaminopyridine 
DMF    dimethylformamide 
DMS    dimethylsulfide 
DNA    desoxyribonucleic acid 
DTMBP   2,5-di-tert-butyl-4-methylpyridine 
e.g.    exempli gratia 
EDC    1-(3-dimethylaminopropyl)-3-ethylcarbodiimid 
ee    enantiomeric excess 
ESI    electrospray ionization 
Et    ethyl 
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Et3N    triethylamine 
Et2O    diethylether 
EtOAc   ethylacetate 
EtOH   ethanol 
equiv    equivalent 
FDA    U.S. food and drug administration 
g    gram(s) 
Gly    glycine 
h    hour(s) 
HPLC   high-performance liquid chromatography 
HRMS   high resolution mass spectrometry 
hv    high vacuum 
Hz    hertz (s-1) 
imid.    imidazole 
Ipc    isopinocampheyl 
iPr    isopropyl 
IR    infra red 
J    coupling constant 
L    liter(s) 
LDA    lithium diisopropylamide 
M    molarity (mol/L) 
m    multiplett 
mCPBA   meta-chloroperoxybenzoic acid 
MDR    multi drug resistant 
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Me    methyl 
MeCN   acetonitrile 
MEG    methylene ethylene glycol 
MeOH   methanol 
Met    methionine 
MIC    minimal inhibitory concentration 
min    minute(s) 
MOM   methoxymethylene 
M.p.    melting point 
MRSA   methicillin resistant Streptococcus aureus 
m.s.    molecular sieves 
MTB    mycobacterium tuberculosis 
µw    microwave 
m/z    mass per charge 
NaHMDS   sodium hexamethyl disilazane 
n.d.    not determined 
NBS    N-bromosuccinimide 
NIS    N-iodosuccinimide 
NMO   N-methylmorpholine-N-oxide 
NMR    nuclear magnetic resonance spectroscopy 
NOE    nuclear Overhauser effect 
NP    normal phase 
org.    organic 
Ph    phenyl 
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Phe    phenylalanine 
PKS    polyketide synthase 
PMP    para-methoxyphenyl 
PMB    para-methoxybenzoyl 
PPh3    triphenylphosphine 
ppm    parts per million 
PTFAI   N-phenyltrifluoroacetimidate 
q    quartet 
quant.   quantitative 
RCM    ring closing metathesis 
RT    room temperature 
Rƒ    retention factor 
RP    reverse phase 
Rt    retention time 
RNA     ribonucleic acid 
RNAP   RNA polymerase 
s    singlet 
SAR    structure activity relationship 
sat.    saturated 
SEM    2-(trimethylsilyl)ethoxymethyl 
soln.    solution 
t    triplet 
TBAF   tetrabutylammonium fluoride 
tBME   tert-butylmethylether 
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TBS    tert-butyldimethylsilyl 
TES    triethylsilyl 
Tf    trifluoromethanesulfonyl 
TFA    trifluoroacetic acid 
THF    tetrahydrofuran 
TLC    thin layer chromatography 
TMS    trimethylsilyl 
Trt    trityl 
Ts    tosyl 
TTBP   2,4,6-tri-tert-butylpyridine 
tol.    toluene 
tr    retention time 
UHPLC   ultra high performance liquid chromatography 
UV     ultra violet 
ν    wavenumber 
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5.2 Crystal Structures 
 
 
 
 
Table 5.1 Crystal data for β-1.102 
 
Formula      C13H20O7 
Formula weight      288.30 g · Mol-1 
Z, calculated density     2, 1.375 Mg · m-3 
F(000)       308 
Description and size of crystal     colourless needle, 
0.020 · 0.030 · 0.190 mm3 
Absorption coefficient     0.950 mm-1 
Min/max transmission     0.97 / 0.98 
Temperature      123K 
Radiation(wavelength)     Cu Kα (λ = 1.54178 Å) 
Crystal system, space group    monoclinic, P 21 
a       7.6012(6) Å 
b       6.2321(4) Å 
c       14.7178(10) Å 
α       90° 
β       92.593(5)° 
γ       90° 
V       696.49(5) Å3 
Min/max Θ      5.827° / 68.854° 
Number of collected reflections    5345 
Number of independent refections    2359 (merging r = 0.033) 
Number of observed reflections    2130 (I>2.0σ(I)) 
Number of refined parameters    182 
r       0.0334 
rW       0.0427 
 
Goodness of fit      1.1118  
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Table 5.2 Crystal data for 1.134 
 
Formula      C12H12Cl2O4 
Formula weight      291.12 g · Mol-1 
Z, calculated density     2, 1.574 Mg · m-3 
F(000)       300 
Description and size of crystal   colourless prism,  
0.13 · 0.20 · 0.25 mm3 
Absorption coefficient     0.531 mm-1 
Min/max transmission     0.822 / 0.936 
Temperature      160(1)K 
Radiation(wavelength)     Mo Kα (λ = 0.71073 Å) 
Crystal system, space group    ???, ??? 
a       7.6060(2) Å 
b       8.7708(2) Å 
c       9.6095(2) Å 
α       100.2589(12)° 
β       100.4269(14)° 
γ       96.0635(13)° 
V       614.06(3) Å3 
Min/max Θ      2.384° / 30.039° 
Number of collected reflections    17761 
Number of independent refections    3594 (merging r = 0.0403) 
Number of observed reflections    3593 (I > 2σ(I)) 
Number of refined parameters    170 
r       0.0314 
rW       0.0820 
 
Goodness of fit      1.045 
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Table 5.3 Crystal data for 2.35 
 
Formula      C17H25I1N2O2 
Formula weight       416.30 g · Mol-1 
Z, calculated density      4, 1.519 Mg · m-3 
F(000)       840 
Description and size of crystal    colourless plate,  
0.030 · 0.110 · 0.190 mm3 
Absorption coefficient     1.768 mm-1 
Min/max transmission     0.82 / 0.95 
Temperature      123K 
Radiation(wavelength)     Mo Kα (λ = 0.71073 Å) 
Crystal system, space group    monoclinic, P 21/c 
a       11.7141(3) Å 
b       14.6710(5) Å 
c       11.1342(4) Å 
α       90° 
β       107.929(2)° 
γ       90° 
V       1820.57(10) Å3 
Min/max Θ      1.827° / 32.578° 
Number of collected reflections    22730 
Number of independent refections    6575 (merging r = 0.056) 
Number of observed reflections    4261 (I>2.0σ(I)) 
Number of refined parameters    199 
r       0.0368 
rW       0.0403 
Goodness of fit      1.0047 
!
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5.3 NMR Spectra 
5.3.1 Total Synthesis of Fidaxomicin 
(3aS,4S,7S,7aS)-4-methoxy-6,6-dimethyl-2-oxotetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-
7-yl isobutyrate (α-1.102) 
 
1H-NMR (400 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3)   
O
O
O
OMe
O
O
O
iPr
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(3aS,4S,7S,7aS)-4-methoxy-6,6-dimethyl-2-oxotetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-
7-yl isobutyrate (β-1.102) 
 
1H-NMR (400 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3 
  
O
O
O
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O
O
O
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 (3S,4S,5S)-6-methoxy-2,2-dimethyltetrahydro-2H-pyran-3,4,5-triol (1.103) 
 
1H-NMR (400 MHz, CD3OD, α:β 2:1)  
13C-NMR (101 MHz, CD3OD, α:β 2:1)   
O
HO
OH
HO
OMe
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(2S,3S,4S, 5S, 6S)-2-(iodomethyl)-6-methoxytetrahydro-2H-pyran-3,4,5-triol (1.105) 
 
1H-NMR (400 MHz, D2O)  
(3aS,4S,6S,73aS,7aS)-6-(iodomethyl)-4-methoxy-2,2-dimethyltetrahydro-4H-
[1,3]dioxolo[4,5-c]pyran-7-ol (1.106) 
1H-NMR (400 MHz, CDCl3)  
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13C-NMR (101 MHz, CDCl3)  
(3aS, 4S, 6R,6aS)-2,2-dimethyl-6-vinyltetrahydrofuro[3,4-d][1,3]dioxol-4-ol (1.107) 
 
 
1H-NMR (400 MHz, CDCl3)  
O
O O
OH
H
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13C-NMR (101 MHz, CDCl3) 
 (3aS,4S,6R,6aS)-4-methoxy-2,2-dimethyl-6-vinyltetrahydrofuro[3,4-d][1,3]dioxole 
(1.108) 
 
1H-NMR (400 MHz, CDCl3)  
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O O
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H
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13C-NMR (101 MHz, CDCl3)  
methyl (3aR,4S, 6S, 6aS)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-
carboxylate (1.109)  
 
1H-NMR (400 MHz, CDCl3)  
O
O O
OMe
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H
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13C-NMR (101 MHz, CDCl3)  
(3aS,4S,6S,6aS)-6-methoxy-2-oxotetrahydrofuro[3,4-d][1,3]dioxole-4-carbaldehyde 
(1.110) 
 
1H-NMR (400 MHz, CDCl3)  
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13C-NMR (101 MHz, CDCl3) 
2-((3aS,4S,6S,6aS)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-
propan-2-ol (1.112) 
 
1H-NMR (400 MHz, CDCl3)  
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O
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H
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13C-NMR (101 MHz, CDCl3) 
(3aS,7S,7aS)-4-methoxy-6,6-dimethyl-2-oxotetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-7-yl 
acetate (α-1.116) 
 
1H-NMR (400 MHz, CDCl3 
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O
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13C-NMR (63 MHz, CDCl3 
(3aS,7S,7aS)-4-methoxy-6,6-dimethyl-2-oxotetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-7-yl 
acetate (β-1.116) 
 
1H-NMR (400 MHz, CDCl3) 
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O
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13C-NMR (101 MHz, CDCl3)  
(3aS,4R,7S,7aS)-4-(cyclohexyloxy)-6,6-dimethyl-2-oxotetrahydro-4H-[1,3]dioxolo[4,5-
c]pyran-7-yl isobutyrate (β-1.176) 
 
1H-NMR (400 MHz, CDCl3)  
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(3aS,4S,7S,7aS)-4-(cyclohexyloxy)-6,6-dimethyl-2-oxotetrahydro-4H-[1,3]dioxolo[4,5-
c]pyran-7-yl isobutyrate (α-1.176) 
 
1H-NMR (500 MHz, CDCl3)  
13C-NMR (126 MHz, CDCl3 
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O
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COSY (500 MHz, CDCl3)  
 
NOESY (500 MHz, CDCl3)  
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HSQC (500 MHz, CDCl3)  
 
HMBC (500 MHz, CDCl3)  
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(3aS,7S,7aS)-4-hydroxy-6,6-dimethyl-2-oxotetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-7-yl 
isobutyrate (1.178) 
 
1H-NMR (400 MHz, CDCl3, major/minor anomer 2/1) 
13C-NMR (126 MHz, CDCl3)   
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(3aS,7S,7aS)-4-fluoro-6,6-dimethyl-2-oxotetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-7-yl 
isobutyrate (1.179) 
 
1H-NMR (400 MHz, CDCl3) 
(3aS,4S,7S,7aS)-6,6-dimethyl-2-oxo-4-((E)-2,2,2-trifluoro-1-(phenylimino)ethoxy)-
tetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-7-yl isobutyrate (α-1.181) 
1H-NMR (400 MHz, CDCl3) 
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(3aS,4R,7S,7aS)-6,6-dimethyl-2-oxo-4-((E)-2,2,2-trifluoro-1-(phenylimino)ethoxy)-
tetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-7-yl isobutyrate (β-1.181) 
 
1H-NMR (400 MHz, Acetone-d6)  
COSY (400 MHz, Acetone-d6)  
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NOESY (400 MHz, Acetone-d6)  
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7-(allyloxy)-6,8-dichloro-5-ethyl-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (1.128)  
 
1H-NMR (400 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3)  
OAllyl
O
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2R,3R,4S,5S,6R)-4-((tert-butyldimethylsilyl)oxy)-5-methoxy-2-methyl-6-
(phenylthio)tetrahydro-2H-pyran-3-ol (1.129) 
 
 
1H-NMR (400 MHz, CDCl3) 
13C-NMR (101 MHz, CDCl3  
OHO
SPh
OMe
TBSO
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5-ethyl-7-hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (1.133) 
 
1H-NMR (400 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3  
OH
O
O
O
Et
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6,8-dichloro-5-ethyl-7-hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (1.134) 
 
1H-NMR (400 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3)  
Cl
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OH
O
O
O
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(2R,4aR,6S,7S,8R,8aS)-6-methoxy-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-7,8-diol 
(1.135) 
 
1H-NMR (400 MHz, CDCl3) 
13C-NMR (101 MHz, CDCl3)   
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(2R,4aR,6S,7S,8R,8aR)-8-((tert-butyldimethylsilyl)oxy)-6-methoxy-2-
phenylhexahydropyrano[3,2-d][1,3]dioxin-7-ol (1.135b) 
 
1H-NMR (400 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3)   
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tert-butyl(((2R,4aR,6S,7S,8S,8aR)-6,7-dimethoxy-2-phenylhexahydropyrano[3,2-
d][1,3]dioxin-8-yl)oxy)dimethylsilane (1.136) 
 
1H-NMR (400 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3) 
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((2R,3R,4S,5S,6S)-3-(benzyloxy)-4-((tert-butyldimethylsilyl)oxy)-5,6-
dimethoxytetrahydro-2H-pyran-2-yl)methanol (1.137) 
 
1H-NMR (400 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3)  
O
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OMe
TBSO
 Appendices 223  
(((2S,3R,4S,5S,6S)-3-(benzyloxy)-2-(iodomethyl)-5,6-dimethoxytetrahydro-2H-pyran-4-
yl)oxy)(tert-butyl)dimethylsilane (1.137b) 
 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)  
O
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(((2R,3R,4S,5S,6S)-3-(benzyloxy)-5,6-dimethoxy-2-methyltetrahydro-2H-pyran-4-
yl)oxy)(tert-butyl)dimethylsilane (1.138) 
 
1H-NMR (400 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3)  
OBnO
OMe
OMe
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 Appendices 225  
(((2R,3R,4S,5S,6R)-3-(benzyloxy)-5-methoxy-2-methyl-6-(phenylthio)tetrahydro-2H-
pyran-4-yl)oxy)(tert-butyl)dimethylsilane (1.139) 
 
1H-NMR (400 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3)  
OBnO
SPh
OMe
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(2R,3R,4R,5S,6R)-3-((tert-butyldimethylsilyl)oxy)-5-methoxy-2-methyl-6-(phenylthio)-
tetrahydro-2H-pyran-4-yl 4-(allyloxy)-3,5-dichloro-2-ethyl-6-hydroxybenzoate (1.140) 
 
1H-NMR (400 MHz, CDCl3)  
 
COSY (500 MHz, CDCl3) 
OTBSO
O
OMe
SPh
O
Et
OH
Cl
AllylO
Cl
 Appendices 227  
NOESY (500 MHz, CDCl3) 
(2R,3R,4S,5S,6R)-4-((tert-butyldimethylsilyl)oxy)-5-methoxy-2-methyl-6-(phenylthio)-
tetrahydro-2H-pyran-3-yl 4-(allyloxy)-3,5-dichloro-2-ethyl-6-hydroxybenzoate (1.127) 
 
1H-NMR (400 MHz, CDCl3 
O
O
OTBS
OMe
SPh
O
Et
OH
Cl
AllylO
Cl
228  Appendices 
(2R,3R,4S,5S,6R)-3-hydroxy-5-methoxy-2-methyl-6-(phenylthio)tetrahydro-2H-pyran-4-
yl 4-(allyloxy)-3,5-dichloro-2-ethyl-6-hydroxybenzoate (1.141) 
 
1H-NMR (400 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3)  
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(2R,3S,4S,5S,6R)-4-hydroxy-5-methoxy-2-methyl-6-(phenylthio)tetrahydro-2H-pyran-3-
yl 4-(allyloxy)-3,5-dichloro-2-ethyl-6-hydroxybenzoate (1.142) 
 
1H-NMR (400 MHz, CDCl3 
13C-NMR (101 MHz, CDCl3)   
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(2R,3S,4S,5S,6S)-2-(hydroxymethyl)-5,6-dimethoxytetrahydro-2H-pyran-3,4-diol (1.143) 
 
1H-NMR (400 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3)  
O
OMe
HO OMe
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(2S,3S,4S,5S,6S)-2-(iodomethyl)-5,6-dimethoxytetrahydro-2H-pyran-3,4-diol (1.143b) 
 
1H-NMR (400 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3)  
O
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 (2R,3S,4S,5S,6S)-5,6-dimethoxy-2-methyltetrahydro-2H-pyran-3,4-diol (1.144) 
 
1H-NMR (400 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3) 
O
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(2R,3S,4S,5S,6R)-5-methoxy-2-methyl-6-(phenylthio)tetrahydro-2H-pyran-3,4-diol 
(1.145) 
 
1H-NMR (400 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3) 
O
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(2R,3R,4S,5S,6S)-3-hydroxy-5,6-dimethoxy-2-methyltetrahydro-2H-pyran-4-yl 
4-(allyloxy)-3,5-dichloro-2-ethyl-6-hydroxybenzoate (1.146) 
1H-NMR (250 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3) 
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(2R,3S,4S,5S,6S)-4-hydroxy-5,6-dimethoxy-2-methyltetrahydro-2H-pyran-3-yl 
4-(allyloxy)-3,5-dichloro-2-ethyl-6-hydroxybenzoate (1.147) 
 
1H-NMR (250 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3) 
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(2S,3S,4S,5S,6R)-2-methoxy-6-methyltetrahydro-2H-pyran-3,4,5-triol (1.148)  
 
1H-NMR (400 MHz, CD3OD)  
13C-NMR (101 MHz, CD3OD)   
O
HO
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OMe
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(2R,3S,4S,5S,6R)-4-hydroxy-5-methoxy-2-methyl-6-((S)-phenylsulfinyl)tetrahydro-2H-
pyran-3-yl 4-(allyloxy)-3,5-dichloro-2-ethyl-6-hydroxybenzoate (1.156) 
 
1H-NMR (400 MHz, CDCl3)  
4-((TBS)oxy)-5-methoxy-2-methyl-6-(phenylthio)-tetrahydro-2H-pyran-3-yl 4-(allyloxy)-
2-((tert-butyldimethylsilyl)oxy)-3,5-dichloro-6-ethylbenzoate (1.162) 
1H-NMR (400 MHz, CDCl3)  
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13C-NMR (101 MHz, C6D6)  
 
COSY (101 MHz, C6D6)  
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HSQC (101 MHz, C6D6)  
 HMBC (101 MHz, C6D6)  
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5-methoxy-2-methyl-6-(phenylthio)-4-((2-(trimethylsilyl)ethoxy)-methoxy)tetrahydro-
2H-pyran-3-yl 4-(allyloxy)-3,5-dichloro-2-ethyl-6-(2-SEM)methoxy)benzoate (1.163) 
 
1H-NMR (400 MHz, CDCl3)  
13C-NMR (126 MHz, CDCl3)  
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(2R,3S,4S,5S,6R)-4-hydroxy-5-methoxy-2-methyl-6-(phenylthio)tetrahydro-2H-pyran-3-
yl 2,4-bis(allyloxy)-3,5-dichloro-6-ethylbenzoate (1.164) 
 
1H-NMR (400 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3) 
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(2R,3R,4S,5S,6R)-4-((tert-butyldimethylsilyl)oxy)-5-methoxy-2-methyl-6-(phenylthio)-
tetrahydro-2H-pyran-3-yl 2,4-bis(allyloxy)-3,5-dichloro-6-ethylbenzoate (1.165) 
 
1H-NMR (400 MHz, CDCl3) 
4-((tert-butyldimethylsilyl)oxy)-5-methoxy-2-methyl-6-((S)-phenylsulfinyl)tetrahydro-
2H-pyran-3-yl 4-(allyloxy)-2-((TBS)oxy)-3,5-dichloro-6-ethylbenzoate (1.166) 
 
1H-NMR (400 MHz, CDCl3)  
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5-methoxy-2-methyl-6-((R)-phenylsulfinyl)-4-((2-(SEM)methoxy)tetrahydro-2H-pyran-
3-yl 4-(allyloxy)-3,5-dichloro-2-ethyl-6-((2-SEM)methoxy)benzoate (1.167) 
 
1H-NMR (400 MHz, CDCl3)  
(2R,3S,4S,5S,6R)-4-hydroxy-5-methoxy-2-methyl-6-((S)-phenylsulfinyl)tetrahydro-2H-
pyran-3-yl 2,4-bis(allyloxy)-3,5-dichloro-6-ethylbenzoate (1.168) 
 
1H-NMR (400 MHz, CDCl3)  
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13C-NMR (101 MHz, CDCl3)  
COSY (500 MHz, CDCl3)  
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 HSQC (500 MHz, CDCl3)  
 
 
HMBC (500 MHz, CDCl3)   
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(2R,3S,4S,5S,6R)-4-hydroxy-5-methoxy-2-methyl-6-((E)-2,2,2-trifluoro-1-(phenylimino)-
ethoxy)tetrahydro-2H-pyran-3-yl 2,4-bis(allyloxy)-3,5-dichloro-6-ethylbenzoate (1.169) 
1H-NMR (400 MHz, Acetone-d6 
(2R,3S,4S,5S,6R)-4-hydroxy-5-methoxy-2-methyl-6-(phenylthio)tetrahydro-2H-pyran-3-
yl 2,4-bis(allyloxy)-3,5-dichloro-6-ethylbenzoate (1.172) 
 
1H-NMR (400 MHz, CDCl3)  
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13C-NMR (101 MHz, CDCl3)  
(2R,3S,4S,5S)-4,6-dihydroxy-5-methoxy-2-methyltetrahydro-2H-pyran-3-yl 
2,4-bis(allyloxy)-3,5-dichloro-6-ethylbenzoate (1.173) 
 
1H-NMR (400 MHz, CDCl3)  
OO
HO
OMe
OHO
Et
AllylO
Cl
AllylO
Cl
248  Appendices 
13C-NMR (101 MHz, CDCl3) 
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(2R,3S,4S,5S,6S)-6-((2-(ethoxycarbonyl)allyl)oxy)-4-hydroxy-5-methoxy-2-methyl-
tetrahydro-2H-pyran-3-yl 4-(allyloxy)-3,5-dichloro-2-ethyl-6-hydroxybenzoate (α-1.158) 
1H-NMR (400 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3) 
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COSY (500 MHz, CDCl3)  
 
HSQC (500 MHz, CDCl3)  
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HMBC (500 MHz, CDCl3)  
(2R,3S,4S,5S,6R)-6-((2-(ethoxycarbonyl)allyl)oxy)-4-hydroxy-5-methoxy-2-methyl-
tetrahydro-2H-pyran-3-yl 4-(allyloxy)-3,5-dichloro-2-ethyl-6-hydroxybenzoate (β-1.158) 
 
1H-NMR (500 MHz, CDCl3)  
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13C-NMR (101 MHz, CDCl3)  
 HSQC (500 MHz, CDCl3)  
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 HMBC (500 MHz, CDCl3)  
 
NOESY (500 MHz, CDCl3)  
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(2R,3S,4S,5S,6S)-6-((2-(ethoxycarbonyl)allyl)oxy)-4-hydroxy-5-methoxy-2-methyl-
tetrahydro-2H-pyran-3-yl 2,4-bis(allyloxy)-3,5-dichloro-6-ethylbenzoate (α-1.164b) 
 
1H-NMR (500 MHz, CDCl3) 
13C-NMR (101 MHz, CDCl3) 
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COSY (500 MHz, CDCl3)  
 
HSQC (500 MHz, CDCl3)  
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HMBC (500 MHz, CDCl3)  
 
NOESY (500 MHz, CDCl3)  
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(2R,3S,4S,5S,6R)-6-((2-(ethoxycarbonyl)allyl)oxy)-4-hydroxy-5-methoxy-2-methyl-
tetrahydro-2H-pyran-3-yl 2,4-bis(allyloxy)-3,5-dichloro-6-ethylbenzoate (β-1.164b) 
1H-NMR (500 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3  
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COSY (500 MHz, CDCl3)  
 
HSQC (500 MHz, CDCl3)  
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HMBC (500 MHz, CDCl3)  
 
NOESY (500 MHz, CDCl3)  
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4-(((1E,3R,4S,5E,7S)-7-((TBS)oxy)-4-ethyl-1-iodo-2,6-dimethyldeca-1,5,9-trien-3-yl)oxy)-
6,6-dimethyl-2-oxotetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-7-yl isobutyrate (β-1.185) 
1H-NMR (400 MHz, CDCl3)  
 
13C-NMR (101 MHz, CDCl3 
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NOESY (500 MHz, CDCl3)  
4-(((1E,3R,4S,5E,7S)-7-((TBS)oxy)-4-ethyl-1-iodo-2,6-dimethyldeca-1,5,9-trien-3-yl)oxy)-
6,6-dimethyl-2-oxotetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-7-yl isobutyrate (α-1.185) 
1H-NMR (400 MHz, CDCl3)  
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13C-NMR (101 MHz, CDCl3)  
 
NOESY (500 MHz, CDCl3)  
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(2R,3S,Z)-2-((tert-butyldimethylsilyl)oxy)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)hept-5-en-3-ol (1.41)  
1H-NMR (500 MHz, CDCl3) 
13C-NMR (126 MHz, CDCl3) 
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O
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11B-NMR (128 MHz, CDCl3)  
(2R,3S,Z)-2-((tert-butyldimethylsilyl)oxy)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)hept-5-en-3-yl (E)-2-(((tert-butyldimethylsilyl)oxy)methyl)penta-2,4-dienoate (1.186) 
1H-NMR (500 MHz, CDCl3)  
O
O
OTBS
OTBS
BO
O
 Appendices 265  
13C-NMR (126 MHz, CDCl3)  
11B-NMR (128 MHz, CDCl3)  
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RCM precursor (1.187) 
1H-NMR (500 MHz, CDCl3) 
 
13C-NMR (126 MHz, CDCl3)  
 
O
O
OTBS
TBSO
O
OTBS
O
O
O
O
O
O
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E-Macrolide (1.188) 
 
1H-NMR (500 MHz, CDCl3)  
13C-NMR (126 MHz, CDCl3)  
O
O
OTBS
TBSO
O
OTBS
O
O
O
O
O
O
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Fully Protected Fidaxomicin (1.189). 
 
1H-NMR (400 MHz, acetone-d6)  
13C-NMR (101 MHz, acetone-d6)  
TBSO
O
O O
O
O
O
O
OTBS
O
O
HO OMeO
Et
OAllylCl
AllylO
Cl
O
O
O
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HSQC (500 MHz, acetone-d6)  
 
HMBC (500 MHz, acetone-d6)  
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Allyl, Carbonate-protected Fidaxomicin (1.190). 
 
1H-NMR (400 MHz, acetone-d6)  
13C-NMR (101 MHz, acetone-d6)   
HO
O
O O
O
O
O
O
OH
O
O
HO OMeO
Et
OAllylCl
AllylO
Cl
O
O
O
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Allyl-protected Fidaxomicin (1.191) 
1H-NMR (400 MHz, acetone-d6)  
Fidaxomicin (Tiacumicin B, Lipiarmycin A3) 
1H-NMR (400 MHz, acetone-d6)  
HO
O
O O
O
O
O
O
OH
O
O
HO OMeO
Et
OAllylCl
AllylO
Cl
OH
OH
HO
O
O O
O
O
O
O
OH
O
O
HO OMeO
Et
OHCl
HO
Cl
OH
OH
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1H-NMR (400 MHz, CD3OD)  
 
13C-NMR (101 MHz, CD3OD); 
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5.3.2 Methionine-Derived Iminium Lactones 
N-(1-(diethylamino)-4-(methylthio)-1-oxobutan-2-yl)benzamide (2.23) 
1H-NMR (400 MHz, CDCl3) 
13C-NMR (101 MHz, CDCl3)  
NH
S
O
N
O
Ph
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N-(4-(methylthio)-1-oxo-1-(piperidin-1-yl)butan-2-yl)benzamide (2.24) 
 
1H-NMR (400 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3)   
NH
S
O
N
O
Ph
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N-(4-(methylthio)-1-oxo-1-(pyrrolidin-1-yl)butan-2-yl)benzamide (2.25) 
 
1H-NMR (400 MHz, CDCl3) 
N-(4-(methylthio)-1-morpholino-1-oxobutan-2-yl)benzamide (2.26) 
1H-NMR (400 MHz, CDCl3)  
NH
S
O
N
O
Ph
O
NH
S
O
N
O
Ph
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13C-NMR (101 MHz, CDCl3) 
4-methoxy-N-(4-(methylthio)-1-oxo-1-(piperidin-1-yl)butan-2-yl)benzamide (2.27) 
1H-NMR (400 MHz, CDCl3)  
NH
S
O
N
O
O
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13C-NMR (101 MHz, CDCl3) 
(S)-2-amino-N,N-diisopropyl-4-(methylthio)butanamide (2.29) 
1H-NMR (400 MHz, CDCl3)  
NH2
S
O
N
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(S)-N-(1-(diisopropylamino)-4-(methylthio)-1-oxobutan-2-yl)benzamide (2.30) 
 
1H-NMR (400 MHz, CDCl3) 
13C-NMR (101 MHz, CDCl3)   
NH
S
O
N
O
Ph
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tert-butyl (3-(methylthio)propyl)carbamate (2.40) 
 
1H-NMR (400 MHz, CDCl3)  
N-(3-(methylthio)propyl)benzamide (2.42) 
1H-NMR (400 MHz, CDCl3)   
MeS NHBoc
MeS N
H
Ph
O
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N-(1-(benzyl(methyl)amino)-4-(methylthio)-1-oxobutan-2-yl)benzamide (2.49) 
 
1H-NMR (400 MHz, CDCl3)  
N-(1-(methoxy(methyl)amino)-4-(methylthio)-1-oxobutan-2-yl)benzamide (2.50) 
1H-NMR (400 MHz, CDCl3)  
NH
S
O
N
O
Ph
O
NH
S
O
N
O
Ph
Ph
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13C-NMR (101 MHz, CDCl3) 
tert-butyl N-(benzoylmethionyl)-N-methylglycinate (2.51) 
 
 1H-NMR (400 MHz, CDCl3)  
NH
S
O
N
O
Ph
O
O
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13C-NMR (101 MHz, CDCl3)  
tert-butyl (S)-(1-(diethylamino)-4-(methylthio)-1-oxobutan-2-yl)carbamate (2.52) 
 
1H-NMR (400 MHz, CDCl3) 
NH
S
O
N
Boc
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tert-butyl (S)-(1-(diethylamino)-4-(methylthio)-1-oxobutan-2-yl)(methyl)carbamate 
(2.53) 
 
1H-NMR (400 MHz, CDCl3) 
benzyl (S)-(1-(diethylamino)-4-(methylthio)-1-oxobutan-2-yl)carbamate (2.54) 
 
1H-NMR (400 MHz, CDCl3)  
N
S
O
N
Boc
NH
S
O
N
Cbz
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13C-NMR (101 MHz, CDCl3)  
benzyl (S)-(1-(methyl((trimethylsilyl)methyl)amino)-4-(methylthio)-1-oxobutan-2-yl)-
carbamate (2.76) 
 
1H-NMR (400 MHz, CDCl3)  
S
N
H
N
O
SiMe3O
O
Ph
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13C-NMR (101 MHz, CDCl3)  
methyl benzoylmethioninate (2.37) 
 
1H-NMR (400 MHz, CDCl3)  
  
NH
S
O
O
O
Ph
286  Appendices 
N-(3-benzamidodihydrofuran-2(3H)-ylidene)-N-ethylethanaminium iodide (2.31) 
 
1H-NMR (400 MHz, CD3CN) 
 
COSY (400 MHz, CD3CN) 
O
N+
N
H
O
Ph I
-
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1-(3-benzamidodihydrofuran-2(3H)-ylidene)piperidin-1-ium iodide (2.32) 
 
1H-NMR (400 MHz, CD3CN)  
 
13C-NMR (63 MHz, CD3CN)  
O
N+
N
H
O
Ph I-
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COSY (400 MHz, CD3CN) 
 
HSQC (400 MHz, CD3CN) 
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HMBC(400 MHz, CD3CN) 
N-(3-benzamidodihydrofuran-2(3H)-ylidene)-N-isopropylpropan-2-aminium 
iodide (2.35) 
1H-NMR (400 MHz, CD3CN)  
 
O
N+
N
H
O
Ph I-
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13C-NMR (101 MHz, CD3CN)  
 
HSQC (500 MHz, CD3CN) 
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 HMBC (500 MHz, CD3CN) 
N-(3-benzamidodihydrofuran-2(3H)-ylidene)-N-ethylethanaminium tetrafluoroborate 
(2.55) 
 
1H-NMR (400 MHz, CD3CN)  
O
N+
N
H
BF4-
O
Ph
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13C-NMR (101 MHz, CD3CN)  
19F-NMR (376 MHz, CD3CN)  
 Appendices 293  
11B-NMR (128 MHz, CD3CN)  
1-(3-benzamidodihydrofuran-2(3H)-ylidene)piperidin-1-ium tetrafluoroborate (2.56) 
 
1H-NMR (400 MHz, CD3CN)  
O
N+
N
H
BF4-
O
Ph
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13C-NMR (63 MHz, CD3CN)  
19F-NMR (376 MHz, CD3CN)  
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N-(3-((tert-butoxycarbonyl)amino)dihydrofuran-2(3H)-ylidene)-N-ethylethanaminium 
tetrafluoroborate (2.60) 
 
1H-NMR (400 MHz, CD3CN)  
13C-NMR (101 MHz, CD3CN) 
O
N+
BocHN BF4
-
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19F-NMR (376 MHz, CD3CN) 
11B-NMR (128 MHz, CD3CN)  
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N-(3-((tert-butoxycarbonyl)(methyl)amino)dihydrofuran-2(3H)-ylidene)-N-ethylethan-
aminium tetrafluoroborate (2.61) 
 
1H-NMR (400 MHz, CD3CN)  
N-(3-(((benzyloxy)carbonyl)amino)dihydrofuran-2(3H)-ylidene)-N-ethylethanaminium 
tetrafluoroborate (2.62) 
 
O
N+
CbzHN BF4
-
O
N+
BocN BF4
-
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1H-NMR (400 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3)  
19F-NMR (376 MHz, CDCl3)  
 Appendices 299  
11B-NMR (128 MHz, CDCl3)  
(E,Z)-N-(3-(((benzyloxy)carbonyl)amino)dihydrofuran-2(3H)-ylidene)-N-methyl-1-
(trimethylsilyl)methanaminium tetrafluoroborate (2.77) 
 
1H-NMR (400 MHz, CD3CN)  
CbzHN
O
N+
BF4-
SiMe3
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13C-NMR (101 MHz, CD3CN 
19F-NMR (376 MHz, CD3CN 
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benzyl (2-oxotetrahydrofuran-3-yl)carbamate (2.63) 
 
1H-NMR (400 MHz, CDCl3) 
13C-NMR (101 MHz, CDCl3)  
CbzHN
O
O
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benzyl (1-(diethylamino)-4-hydroxybutan-2-yl)carbamate (2.64) 
 
1H-NMR (400 MHz, CDCl3) 
13C-NMR (101 MHz, CDCl3)  
N
H
Cbz N
OH
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benzyl (4-azido-1-(diethylamino)-1-oxobutan-2-yl)carbamate (2.65) 
 
1H-NMR (400 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3)  
N
H
Cbz N
N3
O
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benzyl (2-(hydroxyimino)tetrahydrofuran-3-yl)carbamate (2.66) 
 
1H-NMR (400 MHz, CD3OD) 
13C-NMR (101 MHz, CDCl3)   
N
H
Cbz O
N OH
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benzyl (2-((benzyloxy)imino)tetrahydrofuran-3-yl)carbamate (2.67) 
 
1H-NMR (400 MHz, CDCl3) 
13C-NMR (101 MHz, CDCl3) 
N
H
Cbz O
N O
306  Appendices 
benzyl (4-oxo-1,10-diphenyl-2,9-dioxa-3,8-diazadecan-5-yl)carbamate (2.68) 
 
1H-NMR (400 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3)   
N
H
Cbz
H
N O
NH
O
O
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benzyl (1-(diethylamino)-4-(1,3-dioxoisoindolin-2-yl)-1-oxobutan-2-yl)carbamate (2.69) 
 
1H-NMR (400 MHz, CDCl3)  
 
13C-NMR (101 MHz, CDCl3)  
CbzHN N
O
NO O
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